Diagnosis	I
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
:	O
role	O
of	O
clinical	I
Doppler	I
echocardiography	I
.	O

In	O
developed	O
countries	O
,	O
at	O
least	O
38–54	O
%	O
of	O
patients	I
with	O
heart	I
failure	I
show	O
preserved	I
left	I
ventricular	I
(	O
LV	I
)	O
ejection	I
fraction	I
.	O

The	O
prevalence	I
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFPEF	I
)	O
is	O
steadily	O
increasing	O
and	O
its	O
prognosis	I
is	O
poor	O
.	O

LV	I
diastolic	I
dysfunction	I
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
factors	O
(	O
figure	O
1	O
)	O
,	O
is	O
the	O
major	O
underlying	O
mechanism	O
of	O
HFPEF	I
.	O

In	O
the	O
general	O
population	O
,	O
the	O
presence	O
of	O
even	O
mild	O
clinical	I
diastolic	I
dysfunction	I
has	O
been	O
associated	O
with	O
pronounced	O
increases	O
in	O
all	O
cause	O
mortality	I
.	O

Hence	O
,	O
the	O
diagnosis	I
of	O
clinical	I
(	O
prognostic	I
)	O
diastolic	I
dysfunction	I
leading	O
to	O
HFPEF	I
is	O
of	O
critical	O
importance	O
.	O

The	O
European	O
Society	O
of	O
Cardiology	I
guidelines	O
based	O
definition	O
of	O
HFPEF	I
requires	O
a	O
presence	O
of	O
signs	O
and	O
symptoms	I
of	O
heart	I
failure	I
,	O
preserved	I
LV	I
ejection	I
fraction	I
of	O
a	O
non-dilated	I
left	I
ventricle	I
,	O
and	O
evidence	O
of	O
diastolic	I
dysfunction	I
(	O
impaired	O
LV	I
relaxation	I
or	O
increased	O
LV	I
diastolic	I
stiffness	I
)	O
with	O
elevated	O
LV	I
filling	I
pressures	I
.	O

LV	I
diastolic	I
dysfunction	I
and	O
filling	I
pressures	I
can	O
be	O
assessed	O
non-invasively	I
using	O
Doppler	I
echocardiography	I
.	O

Soluble	O
ST2	I
in	O
ambulatory	I
patients	I
with	O
heart	I
failure	I
:	O
Association	O
with	O
functional	I
capacity	I
and	O
long-term	O
outcomes	I
.	O

BACKGROUND	O
:	O

ST2	I
is	O
involved	O
in	O
cardioprotective	I
signaling	I
in	O
the	O
myocardium	I
and	O
has	O
been	O
identified	O
as	O
a	O
potentially	O
promising	O
biomarker	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

We	O
evaluated	O
ST2	I
levels	O
and	O
their	O
association	O
with	O
functional	I
capacity	I
and	O
long-term	O
clinical	I
outcomes	I
in	O
a	O
cohort	O
of	O
ambulatory	I
patients	I
with	O
HF	I
enrolled	O
in	O
the	O
Heart	I
Failure	I
:	O
A	O
Controlled	O
Trial	O
Investigating	O
Outcomes	I
of	O
Exercise	O
Training	O
(	O
HF-ACTION	I
)	O
study-a	O
multicenter	O
,	O
randomized	I
study	O
of	O
exercise	O
training	O
in	O
HF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

HF-ACTION	I
randomized	I
2331	O
patients	I
with	O
left	I
ventricular	I
ejection	I
fraction	I
<	O
0.35	O
and	O
New	I
York	I
Heart	I
Association	I
class	I
II	I
to	O
IV	I
HF	I
to	O
either	O
exercise	O
training	O
or	O
usual	O
care	O
.	O

ST2	I
was	O
analyzed	O
in	O
a	O
subset	O
of	O
910	O
patients	I
with	O
evaluable	O
plasma	I
samples	O
.	O

Correlations	I
and	O
Cox	I
models	I
were	O
used	O
to	O
assess	O
the	O
relationship	O
among	O
ST2	I
,	O
functional	I
capacity	I
,	O
and	O
long-term	O
outcomes	I
.	O

The	O
median	O
baseline	I
ST2	I
level	O
was	O
23.7	O
ng	O
/	O
mL	O
(	O
interquartile	I
range	I
,	O
18.6	O
-	O
31.8	O
)	O
.	O

ST2	I
was	O
modestly	O
associated	O
with	O
measures	O
of	O
functional	I
capacity	I
.	O

In	O
univariable	I
analysis	I
,	O
ST2	I
was	O
significantly	I
associated	O
with	O
death	I
or	O
hospitalization	I
(	O
hazard	I
ratio	I
,	O
1.48	O
;	O
P	I
<	O
0.0001	O
)	O
,	O
cardiovascular	I
death	I
or	O
HF	I
hospitalization	I
(	O
hazard	I
ratio	I
,	O
2.14	O
;	O
P	I
<	O
0.0001	O
)	O
,	O
and	O
all-cause	I
mortality	I
(	O
hazard	I
ratio	I
,	O
2.33	O
;	O
P	I
<	O
0.0001	O
;	O
all	O
hazard	I
ratios	I
for	O
log2	O
ng	O
/	O
mL	O
)	O
.	O

In	O
multivariable	I
models	I
,	O
ST2	I
remained	O
independently	O
associated	O
with	O
outcomes	I
after	O
adjustment	O
for	O
clinical	I
variables	O
and	O
amino-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
.	O

However	O
,	O
ST2	I
did	O
not	O
add	O
significantly	I
to	O
reclassification	O
of	O
risk	O
as	O
assessed	O
by	O
changes	O
in	O
the	O
C	I
statistic	I
,	O
net	I
reclassification	I
improvement	I
,	O
and	O
integrated	I
discrimination	I
improvement	I
.	O

CONCLUSIONS	O
:	O

ST2	I
was	O
modestly	O
associated	O
with	O
functional	I
capacity	I
and	O
was	O
significantly	I
associated	O
with	O
outcomes	I
in	O
a	O
well-treated	O
cohort	O
of	O
ambulatory	I
patients	I
with	O
HF	I
although	O
it	O
did	O
not	O
significantly	I
affect	O
reclassification	O
of	O
risk	O
.	O

Age-dependent	O
effect	O
of	O
left	I
ventricular	I
ejection	I
fraction	I
on	O
long-term	O
mortality	I
in	O
patients	I
with	O
heart	I
failure	I
(	O
from	O
the	O
Heart	I
Failure	I
Survey	O
in	O
ISrael	O
)	O
.	O

Contemporary	O
heart	I
failure	I
(	O
HF	I
)	O
therapies	I
have	O
not	O
resulted	O
in	O
improved	O
outcomes	I
among	O
patients	I
with	O
HF	I
and	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
(	O
LVEF	I
)	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
differential	I
effect	I
of	O
LVEF	I
on	O
long-term	O
mortality	I
after	O
hospitalization	I
for	O
acute	I
decompensated	I
HF	I
in	O
a	O
real-world	O
setting	O
.	O

All-cause	I
mortality	I
at	O
4	O
years	O
after	O
hospitalization	I
for	O
HF	I
was	O
assessed	O
by	O
LVEF	I
(	O
categorized	O
as	O
preserved	O
[	O
≥50	O
%	O
]	O
,	O
mildly	O
[	O
40	O
%	O
to	O
49	O
%	O
]	O
,	O
moderately	O
[	O
30	O
%	O
to	O
39	O
%	O
]	O
,	O
and	O
severely	O
[	O
<	O
30	O
%	O
]	O
reduced	O
)	O
among	O
1,620	O
patients	I
enrolled	O
in	O
the	O
Heart	I
Failure	I
Survey	O
in	O
ISrael	O
.	O

Among	O
the	O
study	O
patients	I
,	O
30	O
%	O
had	O
preserved	I
LVEF	I
and	O
20	O
%	O
,	O
25	O
%	O
,	O
and	O
25	O
%	O
,	O
had	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
reductions	O
in	O
LVEF	I
,	O
respectively	O
.	O

Multivariate	I
analysis	I
showed	O
that	O
patients	I
with	O
preserved	I
LVEF	I
had	O
a	O
similar	O
risk	O
of	O
long-term	O
mortality	I
as	O
patients	I
with	O
mild	O
or	O
moderate	O
reduction	O
in	O
LVEF	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
0.92	O
[	O
p	I
=	O
0.40	O
]	O
and	O
1.01	O
[	O
p	I
=	O
0.90	O
]	O
,	O
respectively	O
)	O
while	O
severely	O
reduced	O
LVEF	I
conferred	O
increased	O
increase	O
rate	O
compared	O
with	O
preserved	I
LVEF	I
(	O
HR	I
1.20	O
,	O
p	I
=	O
0.04	O
)	O
.	O

Interaction	I
term	I
analysis	I
showed	O
that	O
the	O
risk	O
associated	O
with	O
severely	O
reduced	O
LVEF	I
was	O
evident	O
only	O
among	O
patients	I
≤75	O
years	O
(	O
HR	I
1.49	O
,	O
p	I
=	O
0.003	O
)	O
,	O
whereas	O
among	O
older	O
patients	I
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
long-term	O
mortality	I
between	O
those	O
with	O
preserved	I
versus	O
severely	O
reduced	O
LVEF	I
(	O
HR	I
1.02	O
[	O
p	I
=	O
0.86	O
]	O
;	O
p	I
value	I
for	O
age-by-LVEF	I
interaction	O
=	O
0.03	O
)	O
.	O

In	O
conclusion	O
,	O
patients	I
hospitalized	I
for	O
HF	I
who	O
have	O
preserved	I
LVEF	I
experience	O
similar	O
long-term	O
mortality	I
as	O
patients	I
with	O
mild	O
or	O
moderate	O
reductions	O
in	O
LVEF	I
,	O
whereas	O
severely	O
reduced	O
LVEF	I
remains	O
an	O
independent	O
predictor	O
of	O
long-term	O
mortality	I
in	O
this	O
population	O
.	O

The	O
differential	I
effect	I
of	O
LVEF	I
on	O
long-term	O
mortality	I
is	O
significantly	I
attenuated	O
in	O
the	O
older	O
age	O
group	O
.	O

Study	O
PARADIGM-HF	I
-	O
a	O
paradigm	O
shift	O
in	O
the	O
treatment	O
of	O
chronic	I
heart	I
failure	I

Chronic	I
heart	I
failure	I
is	O
a	O
crucial	O
problem	O
of	O
current	O
cardiology	I
.	O

Despite	O
that	O
,	O
no	O
major	O
development	O
has	O
occurred	O
in	O
the	O
therapy	I
in	O
recent	O
years	O
.	O

In	O
this	O
regard	O
,	O
first	O
results	O
of	O
studies	O
with	O
ARNI	I
inhibitors	I
(	O
angiotensin-receptor	I
neprilysin	I
inhibitors	I
)	O
may	O
be	O
considered	O
hopeful	O
.	O

Dual	O
inhibition	O
of	O
AT1	I
receptors	I
and	O
neprilysin	I
blocks	O
renin-angiotensin-aldosteron	I
(	O
RAS	I
)	O
axis	O
and	O
concurrently	O
supports	O
natural	O
vasodilatory	I
and	O
diuretic	I
effect	O
of	O
natriuretic	I
peptides	I
.	O

Large-scale	O
prospective	I
randomized	I
multicenter	O
trial	O
PARADIGM-HF	I
with	O
more	O
than	O
8000	O
individuals	O
with	O
stabilized	O
chronic	I
heart	I
failure	I
with	O
systolic	I
dysfunction	I
(	O
LV	I
EF	I
40	O
%	O
,	O
later	O
35	O
%	O
)	O
,	O
mostly	O
in	O
functional	I
class	I
NYHA	O
II-III	O
with	O
elevated	O
BNP	I
/	O
NT-pro	I
BNP	I
has	O
shown	O
20	O
%	O
decrease	O
in	O
primary	I
endpoint	I
(	O
cardiovascular	I
death	I
or	O
hospitalization	I
for	O
heart	I
failure	I
)	O
in	O
a	O
group	O
treated	O
by	O
ARNI	I
(	O
LCZ696	I
;	O
sacubiltril	I
-	O
valsartan	I
)	O
.	O

Beneficial	O
effect	O
of	O
ARNI	I
was	O
consistent	O
also	O
for	O
total	O
and	O
cardiovascular	I
mortality	I
,	O
for	O
hospitalization	I
for	O
heart	I
failure	I
and	O
in	O
other	O
pre-specified	O
subgroup	O
analyses	O
,	O
including	O
quality	I
of	I
life	I
.	O

The	O
treatment	O
was	O
safe	O
,	O
typical	O
adverse	I
event	I
was	O
hypotension	I
,	O
however	O
without	O
a	O
need	O
to	O
interrupt	O
the	O
treatment	O
.	O

Dual	O
RAS	I
and	O
neprilysin	I
inhibition	I
might	O
thus	O
after	O
long	O
time	O
become	O
a	O
change	O
in	O
stable	I
chronic	I
heart	I
failure	I
with	O
systolic	I
dysfunction	I
treatment	O
paradigm	O
.	O

Czech	O
Republic	O
significantly	I
contributed	O
to	O
this	O
study	O
and	O
all	O
study	O
sites	O
should	O
be	O
congratulated	O
and	O
thanked	O
for	O
their	O
high-quality	O
work	O
provided	O
.	O

Contemporary	O
use	O
of	O
devices	O
in	O
heart	I
failure	I
.	O

Devices	O
have	O
become	O
a	O
cornerstone	O
of	O
heart	I
failure	I
(	O
HF	I
)	O
therapy	I
.	O

Implantable	I
cardioverter-defibrillators	I
(	O
ICDs	I
)	O
decrease	O
mortality	I
,	O
and	O
cardiac	I
resynchronization	I
therapy	I
(	O
CRT	I
)	O
improves	O
symptoms	I
and	O
mortality	I
.	O

Most	O
data	O
have	O
been	O
collected	O
in	O
patients	I
with	O
systolic	I
dysfunction	I
.	O

Data	O
in	O
patients	I
with	O
preserved	O
systolic	I
function	I
are	O
scarce	O
,	O
but	O
interesting	O
therapeutic	I
concepts	O
are	O
evolving	O
.	O

Besides	O
therapeutic	I
functions	O
,	O
devices	O
can	O
have	O
add-on	O
diagnostic	I
features	O
such	O
as	O
early	O
detection	O
of	O
fluid	I
overload	I
.	O

In	O
addition	O
,	O
stand-alone	O
diagnostic	I
devices	O
are	O
now	O
also	O
being	O
developed	O
for	O
HF	I
.	O

Soluble	O
concentrations	O
of	O
the	O
interleukin	I
receptor	I
family	O
member	O
ST2	I
and	O
beta-blocker	I
therapy	I
in	O
chronic	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Concentrations	O
of	O
soluble	O
(	O
s	I
)	O
ST2	I
predict	O
prognosis	I
in	O
heart	I
failure	I
.	O

We	O
recently	O
found	O
changing	O
doses	O
of	O
β-blocker	I
(	O
BB	I
)	O
may	O
affect	O
sST2	I
concentrations	O
.	O

It	O
remains	O
unclear	O
whether	O
sST2	I
concentrations	O
identify	O
benefit	O
of	O
BB	I
therapy	I
,	O
however	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

A	O
total	O
of	O
151	O
subjects	O
with	O
heart	I
failure	I
attributable	O
to	O
left	I
ventricular	I
systolic	I
dysfunction	I
were	O
examined	O
in	O
this	O
post	I
hoc	I
analysis	I
;	O
>	O
96	O
%	O
were	O
taking	O
BB	I
at	O
enrollment	O
.	O

Medication	I
regimen	O
and	O
sST2	I
values	O
were	O
obtained	O
during	O
10	O
months	O
.	O

Cardiovascular	I
events	I
were	O
examined	O
as	O
a	O
function	O
of	O
baseline	I
sST2	I
status	O
(	O
low	O
≤35	O
versus	O
high	O
>	O
35	O
ng	O
/	O
mL	O
)	O
and	O
final	O
achieved	O
BB	I
dose	O
(	O
high	O
≥50	O
versus	O
low	O
<	O
50	O
mg	O
daily	O
equivalent	O
dose	O
of	O
metoprolol	I
succinate	I
)	O
.	O

Patients	I
with	O
low	O
sST2	I
titrated	I
to	O
high-dose	O
BB	I
had	O
the	O
lowest	O
cardiovascular	I
event	I
rate	O
at	O
0.53	O
events	O
(	O
P=0.001	I
)	O
,	O
and	O
lowest	O
cumulative	O
hazard	O
(	O
P=0.003	I
)	O
.	O

Those	O
with	O
low	O
sST2	I
/	O
low-dose	O
BB	I
,	O
or	O
high	O
sST2	I
/	O
high-dose	O
BB	I
had	O
intermediate	O
outcomes	I
(	O
0.92	O
and	O
1.19	O
events	O
)	O
.	O

Patients	I
with	O
high	O
sST2	I
treated	O
with	O
low-dose	O
BB	I
had	O
the	O
highest	O
cardiovascular	I
event	I
rate	O
(	O
2.08	O
events	O
)	O
and	O
the	O
highest	O
cumulative	O
hazard	O
.	O

Compared	O
with	O
low	O
sST2	I
/	O
high-dose	O
BB	I
,	O
those	O
with	O
high	O
sST2	I
treated	O
with	O
low-dose	O
BB	I
had	O
an	O
odds	I
ratio	I
of	O
6.77	O
(	O
P	I
<	O
0.001	O
)	O
for	O
a	O
cardiovascular	I
event	I
.	O

Patients	I
with	O
low	O
sST2	I
/	O
low-dose	O
BB	I
or	O
high	O
sST2	I
/	O
high-dose	O
BB	I
had	O
intermediate	O
odds	I
ratios	I
for	O
cardiovascular	I
events	I
(	O
P=0.18	I
and	O
0.02	O
)	O
.	O

Similar	O
results	O
were	O
found	O
for	O
heart	I
failure	I
hospitalization	I
and	O
cardiovascular	I
death	I
.	O

CONCLUSIONS	O
:	O

Although	O
BB	I
therapy	I
exerted	O
dose-related	O
benefits	O
across	O
all	O
study	O
participants	O
,	O
sST2	I
measurement	O
identifies	O
patients	I
with	O
chronic	I
heart	I
failure	I
who	O
may	O
particularly	O
benefit	O
from	O
higher	O
BB	I
doses	O
.	O

Management	O
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
.	O

Heart	I
failure	I
affects	O
nearly	O
one	O
million	O
people	O
in	O
the	O
UK	O
.	O

Half	O
of	O
these	O
patients	I
have	O
normal	O
,	O
or	O
near	O
normal	O
,	O
left	I
ventricular	I
ejection	I
fraction	I
and	O
are	O
classified	O
as	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
.	O

Newer	O
imaging	O
techniques	O
have	O
confirmed	O
that	O
systolic	I
function	I
in	O
HFpEF	I
patients	I
is	O
not	O
completely	O
normal	O
,	O
with	O
reduced	O
long	I
axis	I
function	I
and	O
extensive	O
but	O
subtle	O
changes	O
on	O
exercise	O
.	O

Patients	I
are	O
likely	O
to	O
be	O
older	O
women	O
with	O
a	O
history	O
of	O
hypertension	I
.	O

Other	O
cardiovascular	I
risk	O
factors	O
,	O
such	O
as	O
diabetes	I
mellitus	I
,	O
atrial	I
fibrillation	I
and	O
coronary	I
artery	I
disease	I
are	O
prevalent	O
in	O
the	O
HFpEF	I
population	O
.	O

Clinical	I
symptoms	I
and	O
signs	O
in	O
HFpEF	I
are	O
often	O
nonspecific	O
although	O
the	O
primary	O
symptoms	I
are	O
breathlessness	I
,	O
fatigue	O
and	O
fluid	I
retention	I
.	O

There	O
is	O
still	O
no	O
single	O
diagnostic	I
test	O
for	O
HFpEF	I
and	O
the	O
cornerstone	O
in	O
the	O
assessment	O
remains	O
a	O
thorough	O
medical	I
history	I
and	O
physical	I
examination	I
.	O

The	O
duration	O
and	O
extent	O
of	O
the	O
symptoms	I
are	O
relevant	O
and	O
it	O
is	O
useful	O
to	O
classify	O
patients	I
according	O
to	O
the	O
NYHA	O
functional	O
assessment	O
.	O

Physical	I
examination	I
should	O
include	O
the	O
patient	I
's	O
BMI	I
and	O
weight	O
,	O
heart	I
rate	I
and	O
rhythm	I
,	O
lying	O
and	O
standing	O
blood	I
pressure	I
and	O
auscultation	I
to	O
rule	O
out	O
valvular	I
disease	I
and	O
pulmonary	I
congestion	I
.	O

Estimating	O
the	O
jugular	I
venous	I
pressure	I
and	O
the	O
presence	O
of	O
peripheral	I
oedema	I
allows	O
assessment	O
of	O
the	O
patient	I
's	O
volume	O
status	O
.	O

Patients	I
with	O
heart	I
failure	I
should	O
be	O
referred	O
to	O
heart	I
failure	I
nurses	I
and	O
have	O
follow-up	I
with	O
local	O
cardiology	I
services	O
as	O
these	O
have	O
both	O
been	O
shown	O
to	O
reduce	O
mortality	I
.	O

Effect	O
of	O
Caloric	O
Restriction	O
or	O
Aerobic	O
Exercise	O
Training	O
on	O
Peak	I
Oxygen	I
Consumption	I
and	O
Quality	I
of	I
Life	I
in	O
Obese	I
Older	O
Patients	I
With	O
Heart	I
Failure	I
With	I
Preserved	I
Ejection	I
Fraction	I
:	O
A	O
Randomized	I
Clinical	I
Trial	O
.	O

IMPORTANCE	O
:	O

More	O
than	O
80	O
%	O
of	O
patients	I
with	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFPEF	I
)	O
,	O
the	O
most	O
common	O
form	O
of	O
heart	I
failure	I
among	O
older	O
persons	O
,	O
are	O
overweight	O
or	O
obese	I
.	O

Exercise	I
intolerance	I
is	O
the	O
primary	O
symptom	I
of	O
chronic	I
HFPEF	I
and	O
a	O
major	O
determinant	O
of	O
reduced	O
quality	I
of	I
life	I
(	O
QOL	I
)	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
caloric	O
restriction	O
(	O
diet	O
)	O
or	O
aerobic	O
exercise	O
training	O
(	O
exercise	O
)	O
improves	O
exercise	I
capacity	I
and	O
QOL	I
in	O
obese	I
older	O
patients	I
with	O
HFPEF	I
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O

Randomized	I
,	O
attention-controlled	O
,	O
2	O
×	O
2	O
factorial	O
trial	O
conducted	O
from	O
February	O
2009	O
through	O
November	O
2014	O
in	O
an	O
urban	O
academic	O
medical	I
center	O
.	O

Of	O
577	O
initially	O
screened	O
participants	O
,	O
100	O
older	O
obese	I
participants	O
(	O
mean	O
[	O
SD	I
]	O
:	O
age	O
,	O
67	O
years	O
[	O
5	O
]	O
;	O
body	I
mass	I
index	I
,	O
39.3	O
[	O
5.6	O
]	O
)	O
with	O
chronic	I
,	O
stable	I
HFPEF	I
were	O
enrolled	O
(	O
366	O
excluded	O
by	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
31	O
for	O
other	O
reasons	O
,	O
and	O
80	O
declined	O
participation	O
)	O
.	O

INTERVENTIONS	O
:	O

Twenty	O
weeks	O
of	O
diet	O
,	O
exercise	O
,	O
or	O
both	O
;	O
attention	O
control	O
consisted	O
of	O
telephone	O
calls	O
every	O
2	O
weeks	O
.	O

MAIN	O
OUTCOMES	I
AND	O
MEASURES	O
:	O

Exercise	I
capacity	I
measured	O
as	O
peak	I
oxygen	I
consumption	I
(	O
VO2	I
,	O
mL	O
/	O
kg	O
/	O
min	O
;	O
co-primary	I
outcome	I
)	O
and	O
QOL	I
measured	O
by	O
the	O
Minnesota	O
Living	O
with	O
Heart	I
Failure	I
(	O
MLHF	O
)	O
Questionnaire	O
(	O
score	O
range	O
:	O
0	O
-	O
105	O
,	O
higher	O
scores	O
indicate	O
worse	O
heart	I
failure-related	I
QOL	I
;	O
co-primary	I
outcome	I
)	O
.	O

RESULTS	O
:	O

Of	O
the	O
100	O
enrolled	O
participants	O
,	O
26	O
participants	O
were	O
randomized	I
to	O
exercise	O
;	O
24	O
to	O
diet	O
;	O
25	O
to	O
exercise	O
+	O
diet	O
;	O
25	O
to	O
control	O
.	O

Of	O
these	O
,	O
92	O
participants	O
completed	O
the	O
trial	O
.	O

Exercise	O
attendance	O
was	O
84	O
%	O
(	O
SD	I
,	O
14	O
%	O
)	O
and	O
diet	O
adherence	O
was	O
99	O
%	O
(	O
SD	I
,	O
1	O
%	O
)	O
.	O

By	O
main	O
effects	O
analysis	O
,	O
peak	I
VO2	I
was	O
increased	O
significantly	I
by	O
both	O
interventions	O
:	O
exercise	O
,	O
1.2	O
mL	O
/	O
kg	O
body	O
mass	O
/	O
min	O
(	O
95	O
%	O
CI	I
,	O
0.7	O
to	O
1.7	O
)	O
,	O
P	I
<	O
.001	O
;	O
diet	O
,	O
1.3	O
mL	O
/	O
kg	O
body	O
mass	O
/	O
min	O
(	O
95	O
%	O
CI	I
,	O
0.8	O
to	O
1.8	O
)	O
,	O
P	I
<	O
.001	O
.	O

The	O
combination	O
of	O
exercise	O
+	O
diet	O
was	O
additive	O
(	O
complementary	O
)	O
for	O
peak	I
VO2	I
(	O
joint	O
effect	O
,	O
2.5	O
mL	O
/	O
kg	O
/	O
min	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	I
change	O
in	O
MLHF	O
total	O
score	O
with	O
exercise	O
and	O
with	O
diet	O
(	O
main	O
effect	O
:	O
exercise	O
,	O
-	O
1	O
unit	O
[	O
95	O
%	O
CI	I
,	O
-	O
8	O
to	O
5	O
]	O
,	O
P	I
=	O
.70	O
;	O
diet	O
,	O
-	O
6	O
units	O
[	O
95	O
%	O
CI	I
,	O
-	O
12	O
to	O
1	O
]	O
,	O
P	I
=	O
.08	O
)	O
.	O

The	O
change	O
in	O
peak	I
VO2	I
was	O
positively	O
correlated	I
with	O
the	O
change	O
in	O
percent	O
lean	I
body	I
mass	I
(	O
r	I
=	O
0.32	O
;	O
P	I
=	O
.003	O
)	O
and	O
the	O
change	O
in	O
thigh	O
muscle	I
:	O
intermuscular	O
fat	O
ratio	O
(	O
r	I
=	O
0.27	O
;	O
P	I
=	O
.02	O
)	O
.	O

There	O
were	O
no	O
study-related	O
serious	O
adverse	I
events	I
.	O

Body	O
weight	O
decreased	O
by	O
7	O
%	O
(	O
7	O
kg	O
[	O
SD	I
,	O
1	O
]	O
)	O
in	O
the	O
diet	O
group	O
,	O
3	O
%	O
(	O
4	O
kg	O
[	O
SD	I
,	O
1	O
]	O
)	O
in	O
the	O
exercise	O
group	O
,	O
10	O
%	O
(	O
11	O
kg	O
[	O
SD	I
,	O
1	O
]	O
in	O
the	O
exercise	O
+	O
diet	O
group	O
,	O
and	O
1	O
%	O
(	O
1	O
kg	O
[	O
SD	I
,	O
1	O
]	O
)	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
AND	O
RELEVANCE	O
:	O

Among	O
obese	I
older	O
patients	I
with	O
clinically	I
stable	I
HFPEF	I
,	O
caloric	O
restriction	O
or	O
aerobic	O
exercise	O
training	O
increased	O
peak	I
VO2	I
,	O
and	O
the	O
effects	O
may	O
be	O
additive	O
.	O

Neither	O
intervention	O
had	O
a	O
significant	I
effect	O
on	O
quality	I
of	I
life	I
as	O
measured	O
by	O
the	O
MLHF	O
Questionnaire	O
.	O

Reduced	O
hospitalizations	I
in	O
severe	O
,	O
refractory	I
congestive	I
heart	I
failure	I
with	O
peritoneal	I
dialysis	I
:	O
a	O
consecutive	O
case	O
series	O
.	O

BACKGROUND	O
:	O

Peritoneal	I
dialysis	I
(	O
PD	I
)	O
for	O
long-term	O
management	O
of	O
diuretic	I
resistant	O
volume	I
overload	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
may	O
provide	O
potential	O
benefit	O
with	O
few	O
adverse	O
consequences	O
.	O

We	O
examined	O
the	O
impact	O
of	O
PD	I
on	O
clinical	I
status	O
hospitalizations	I
,	O
and	O
complications	I
of	O
therapy	I
in	O
severe	O
end-stage	I
HF	I
.	O

METHODS	O
:	O

A	O
consecutive	O
case	O
series	O
of	O
10	O
transplant	I
ineligible	O
patients	I
receiving	O
PD	I
solely	O
for	O
HF	I
volume	O
management	O
between	O
2007	O
and	O
2011	O
was	O
evaluated	O
with	O
clinical	I
data	O
reviewed	O
pre	O
-	O
and	O
post-PD	I
initiation	O
.	O

RESULTS	O
:	O

The	O
mean	O
ejection	I
fraction	I
(	O
EF	I
)	O
pre-PD	I
was	O
24.5	O
±	O
6.0	O
%	O
with	O
the	O
majority	O
of	O
patients	I
having	O
NYHA	I
class	I
IIIB	I
symptoms	I
and	O
moderate-severe	O
right	I
ventricular	I
dysfunction	I
.	O

9	O
/	O
10	O
patients	I
were	O
Stage	O
3	O
chronic	I
kidney	I
disease	I
(	O
CKD	I
)	O
or	O
worse	O
.	O

After	O
PD	I
initiation	O
,	O
average	O
weight	O
loss	O
was	O
almost	O
7	O
kg	O
(	O
p	I
=	O
0.016	O
)	O
with	O
improvement	O
in	O
diuretic	I
response	O
,	O
peripheral	I
edema	I
,	O
and	O
functional	I
class	I
.	O

There	O
was	O
a	O
significant	I
decrease	O
in	O
re-hospitalization	I
from	O
an	O
average	O
of	O
3.2	O
±	O
2.5	O
to	O
0.1	O
±	O
0.3	O
admissions	I
per	O
patient	I
(	O
p	I
=	O
0.007	O
)	O
and	O
reduced	O
average	O
length	O
of	O
stay	O
from	O
37	O
±	O
36.7	O
to	O
0.78	O
±	O
2.3	O
days	O
(	O
p	I
=	O
0.019	O
)	O
.	O

SUMMARY	O
:	O

Objective	O
criteriabased	O
institution	O
of	O
PD	I
for	O
the	O
treatment	O
of	O
diuretic	I
refractory	O
severe-end-stage	I
HF	I
was	O
well	O
tolerated	O
and	O
demonstrated	O
favorable	O
outcomes	I
;	O
these	O
included	O
improved	O
clinical	I
status	O
,	O
reduced	O
hospitalizations	I
and	O
length	O
of	O
stay	O
,	O
with	O
very	O
few	O
and	O
easily	O
treatable	O
PDrelated	I
complications	I
.	O

PD	I
appears	O
to	O
be	O
a	O
viable	O
option	O
in	O
refractory	O
,	O
end-stage	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
.	O

Changes	O
in	O
circulating	I
progenitor	I
cells	I
are	O
associated	O
with	O
outcome	I
in	O
heart	I
failure	I
patients	I
:	O
a	O
longitudinal	I
study	O
.	O

BACKGROUND	O
:	O

Circulating	I
progenitor	I
cells	I
(	O
CPCs	I
)	O
are	O
involved	O
in	O
the	O
process	O
of	O
endothelial	I
repair	O
and	O
are	O
a	O
prognostic	I
factor	O
in	O
cardiovascular	I
diseases	I
.	O

We	O
evaluated	O
the	O
association	O
between	O
serial	O
measurements	O
of	O
CPCs	I
and	O
functional	I
capacity	I
and	O
outcomes	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

METHODS	O
:	O

We	O
included	O
156	O
consecutive	O
consenting	O
ambulatory	I
HF	I
patients	I
(	O
left	I
ventricular	I
ejection	I
fraction	I
<	O
40	O
%	O
)	O
.	O

We	O
evaluated	O
CPCs	I
and	O
functional	I
capacity	I
(	O
peak	I
VO2	I
)	O
every	O
6	O
months	O
for	O
up	O
to	O
2	O
years	O
.	O

CPCs	I
were	O
measured	O
as	O
early-outgrowth	I
colony-forming	I
units	I
(	O
EO-CFUs	I
)	O
and	O
circulating	O
CD34	I
+	I
,	O
VEGFR2	I
+	I
and	O
/	O
or	O
CD133	I
+	I
cells	I
.	O

We	O
recorded	O
mortality	I
,	O
HF	I
hospital	I
admissions	I
,	O
transplant	I
,	O
and	O
ventricular	I
assist	I
device	I
.	O

RESULTS	O
:	O

The	O
mean	O
age	O
was	O
55	O
±	O
15	O
years	O
.	O

A	O
decrease	O
in	O
CD34+VEGFR2	I
+	I
cells	I
was	O
independently	O
associated	O
with	O
increased	O
functional	I
capacity	I
;	O
a	O
10-cell	I
decrease	O
in	O
CD34+VEGFR2	I
+	I
cells	I
was	O
associated	O
with	O
an	O
increase	O
of	O
0.2	O
mL	O
/	O
kg	O
/	O
min	O
in	O
peak	I
VO2	I
(	O
P	I
<	O
0.05	O
)	O
.	O

We	O
found	O
an	O
interaction	O
effect	O
(	O
P	I
=	O
0.02	O
)	O
between	O
EO-CFUs	I
and	O
diabetes	I
:	O
in	O
patients	I
without	O
diabetes	I
,	O
a	O
10-EO-CFU	I
increase	O
was	O
independently	O
associated	O
with	O
increased	O
peak	I
VO2	I
of	O
0.28	O
mL	O
/	O
kg	O
/	O
min	O
(	O
P	I
=	O
0.01	O
)	O
,	O
and	O
in	O
patients	I
with	O
diabetes	I
,	O
a	O
decrease	O
in	O
EO-CFUs	I
was	O
associated	O
with	O
an	O
increased	O
peak	I
VO2	I
(	O
P	I
<	O
0.05	O
)	O
.	O

Higher	O
EO-CFUs	I
were	O
associated	O
with	O
reduced	O
mortality	I
(	O
hazard	I
ratio	I
,	O
0.25	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.09	O
-	O
0.69	O
)	O
.	O

CONCLUSIONS	O
:	O

We	O
noted	O
differential	O
relations	O
between	O
CPCs	I
and	O
outcomes	I
in	O
patients	I
with	O
vs	O
without	O
diabetes	I
.	O

Higher	O
EO-CFUs	I
and	O
lower	O
CD34+VEGFR2	I
+	I
cells	I
were	O
associated	O
with	O
improved	O
functional	I
capacity	I
and	O
reduced	O
mortality	I
in	O
nondiabetic	I
patients	I
.	O

In	O
patients	I
with	O
diabetes	I
,	O
lower	O
EO-CFUs	I
were	O
associated	O
with	O
improved	O
functional	I
capacity	I
.	O

The	O
basis	O
for	O
these	O
differences	O
requires	O
further	O
examination	O
.	O

Composite	O
quality	O
measures	O
for	O
common	O
inpatient	I
medical	I
conditions	I
.	O

BACKGROUND	O
:	O

Public	O
reporting	O
on	O
quality	O
aims	O
to	O
help	O
patients	I
select	O
better	O
hospitals	I
.	O

However	O
,	O
individual	O
quality	O
measures	O
are	O
suboptimal	O
in	O
identifying	O
superior	O
and	O
inferior	O
hospitals	I
based	O
on	O
outcome	I
performance	O
.	O

OBJECTIVE	O
:	O

To	O
combine	O
structure	O
,	O
process	O
,	O
and	O
outcome	I
measures	O
into	O
an	O
empirically	O
derived	O
composite	O
quality	O
measure	O
for	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
acute	I
myocardial	I
infarction	I
(	O
AMI	I
)	O
,	O
and	O
pneumonia	I
(	O
PNA	I
)	O
.	O

To	O
assess	O
how	O
well	O
the	O
composite	O
measure	O
predicts	O
future	O
high	O
and	O
low	O
performers	O
,	O
and	O
explains	O
variance	O
in	O
future	O
hospital	I
mortality	I
.	O

RESEARCH	O
DESIGN	O
:	O

Using	O
national	O
Medicare	O
data	O
,	O
we	O
created	O
a	O
cohort	O
of	O
older	O
patients	I
treated	O
at	O
an	O
acute	I
care	O
hospital	I
for	O
HF	I
(	O
n=1,203,595	O
)	O
,	O
AMI	I
(	O
n=625,595	O
)	O
,	O
or	O
PNA	I
(	O
n=1,234,299	O
)	O
.	O

We	O
ranked	O
hospitals	I
on	O
the	O
basis	O
of	O
their	O
July	O
2005	O
to	O
June	O
2008	O
performance	O
on	O
the	O
composite	O
.	O

We	O
then	O
estimated	O
the	O
odds	O
of	O
future	O
(	O
July	O
to	O
December	O
2009	O
)	O
30-day	O
,	O
risk-adjusted	O
mortality	I
at	O
the	O
worst	O
versus	O
best	O
quintile	O
of	O
hospitals	I
.	O

We	O
repeated	O
this	O
analysis	O
using	O
2005	O
-	O
2008	O
performance	O
on	O
existing	O
quality	O
indicators	O
,	O
including	O
mortality	I
.	O

RESULTS	O
:	O

The	O
composite	O
(	O
vs.	O
Hospital	I
Compare	O
)	O
explained	O
68	O
%	O
(	O
vs.	O
39	O
%	O
)	O
of	O
variation	O
in	O
future	O
AMI	I
mortality	I
rates	O
.	O

In	O
2009	O
,	O
if	O
an	O
AMI	I
patient	I
had	O
chosen	O
a	O
hospital	I
in	O
the	O
worst	O
versus	O
best	O
quintile	O
of	O
performance	O
using	O
2005	O
-	O
2008	O
composite	O
(	O
vs.	O
Hospital	I
Compare	O
)	O
rankings	O
,	O
he	O
or	O
she	O
would	O
have	O
had	O
1.61	O
(	O
vs.	O
1.39	O
)	O
times	O
the	O
odds	O
of	O
dying	O
in	O
30	O
days	O
(	O
P-value	I
for	O
difference	O
<	O
0.001	O
)	O
.	O

Results	O
were	O
similar	O
for	O
HF	I
and	O
PNA	I
.	O

CONCLUSIONS	O
:	O

Composite	O
measures	O
of	O
quality	O
for	O
HF	I
,	O
AMI	I
,	O
and	O
PNA	I
performed	O
better	O
than	O
existing	O
measures	O
at	O
explaining	O
variation	O
in	O
future	O
mortality	I
and	O
predicting	O
future	O
high	O
and	O
low	O
performers	O
.	O

Remote	I
monitoring	I
after	O
recent	O
hospital	I
discharge	I
in	O
patients	I
with	O
heart	I
failure	I
:	O
a	O
systematic	O
review	O
and	O
network	O
meta-analysis	I
.	O

CONTEXT	O
:	O

Readmission	I
to	O
hospital	I
for	O
heart	I
failure	I
is	O
common	O
after	O
recent	O
discharge	I
.	O

Remote	I
monitoring	I
(	O
RM	I
)	O
strategies	O
have	O
the	O
potential	O
to	O
deliver	O
specialised	O
care	O
and	O
management	O
and	O
may	O
be	O
one	O
way	O
to	O
meet	O
the	O
growing	O
needs	O
of	O
the	O
heart	I
failure	I
population	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
RM	I
strategies	O
improve	O
outcomes	I
for	O
adults	O
who	O
have	O
been	O
recently	O
discharged	I
(	O
<	O
28	O
days	O
)	O
following	O
an	O
unplanned	O
admission	I
due	O
to	O
heart	I
failure	I
.	O

STUDY	O
DESIGN	O
:	O

Systematic	O
review	O
and	O
network	O
meta-analysis	I
.	O

DATA	O
SOURCES	O
:	O

Fourteen	O
electronic	O
databases	O
(	O
including	O
MEDLINE	O
,	O
EMBASE	O
and	O
PsycINFO	O
)	O
were	O
searched	O
to	O
January	O
2012	O
,	O
and	O
supplemented	O
by	O
hand-searching	O
relevant	O
articles	O
.	O

STUDY	O
SELECTION	O
:	O

All	O
randomised-controlled	I
trials	I
(	O
RCTs	I
)	O
or	O
observational	I
cohort	I
studies	I
with	O
a	O
contemporaneous	I
control	I
group	I
were	O
included	O
.	O

RM	I
interventions	O
included	O
home	O
telemonitoring	I
(	O
TM	I
)	O
(	O
including	O
implanted	I
monitoring	O
devices	O
)	O
with	O
medical	I
support	O
provided	O
during	O
office	O
hours	O
or	O
24	O
/	O
7	O
and	O
structured	I
telephone	I
support	I
(	O
STS	I
)	O
programmes	O
delivered	O
via	O
human-to-human	I
contact	I
(	O
HH	I
)	O
or	O
human-to-machine	I
interface	I
(	O
HM	I
)	O
.	O

DATA	O
EXTRACTION	O
:	O

Data	O
were	O
extracted	O
and	O
validity	O
was	O
assessed	O
independently	O
by	O
two	O
reviewers	O
.	O

RESULTS	O
:	O

Twenty-one	O
RCTs	I
that	O
enrolled	O
6317	O
patients	I
were	O
identified	O
(	O
11	O
studies	O
evaluated	O
STS	I
(	O
10	O
of	O
which	O
were	O
HH	I
,	O
while	O
1	O
was	O
HM	I
)	O
,	O
9	O
studies	O
assessed	O
TM	I
,	O
and	O
1	O
study	O
assessed	O
both	O
STS	I
and	O
TM	I
)	O
.	O

No	O
trial	O
of	O
implanted	I
monitoring	O
devices	O
met	O
the	O
inclusion	O
criteria	O
.	O

Compared	O
with	O
usual	O
care	O
,	O
although	O
not	O
reaching	O
statitistical	O
significance	I
,	O
RM	I
trended	O
to	O
reduce	O
all-cause	I
mortality	I
for	O
STS	I
HH	I
(	O
HR	I
:	O
0.77	O
,	O
95	O
%	O
credible	O
interval	O
(	O
CrI	I
)	O
:	O
0.55	O
,	O
1.08	O
)	O
,	O
TM	I
during	O
office	O
hours	O
(	O
HR	I
:	O
0.76	O
,	O
95	O
%	O
CrI	I
:	O
0.49	O
,	O
1.18	O
)	O
and	O
TM24	I
/	I
7	I
(	O
HR	I
:	O
0.49	O
,	O
95	O
%	O
CrI	I
:	O
0.20	O
,	O
1.18	O
)	O
.	O

Exclusion	O
of	O
one	O
trial	O
that	O
provided	O
better-than-usual	O
support	O
to	O
the	O
control	O
group	O
rendered	O
each	O
of	O
the	O
above	O
comparisons	O
statistically	O
significant	I
.	O

No	O
beneficial	O
effect	O
on	O
mortality	I
was	O
observed	O
with	O
STS	I
HM	I
.	O

Reductions	O
were	O
also	O
observed	O
in	O
all-cause	I
hospitalisations	I
for	O
TM	I
interventions	O
but	O
not	O
for	O
STS	I
interventions	O
.	O

Care	O
packages	O
generally	O
improved	O
health-related	I
quality-of-life	I
and	O
were	O
acceptable	O
to	O
patients	I
.	O

CONCLUSIONS	O
:	O

STS	I
HH	I
and	O
TM	I
with	O
medical	I
support	O
provided	O
during	O
office	O
hours	O
showed	O
beneficial	O
trends	O
,	O
particularly	O
in	O
reducing	O
all-cause	I
mortality	I
for	O
recently	O
discharged	I
patients	I
with	O
heart	I
failure	I
.	O

Where	O
'	O
usual	O
'	O
care	O
is	O
less	O
good	O
,	O
the	O
impact	O
of	O
RM	I
is	O
likely	O
to	O
be	O
greater	O
.	O

A	O
CLCNKA	I
polymorphism	I
(	O
rs10927887	I
;	O
p	I
.	I

Arg83Gly	I
)	O
previously	O
linked	O
to	O
heart	I
failure	I
is	O
associated	O
with	O
the	O
estimated	I
glomerular	I
filtration	I
rate	I
in	O
the	O
RENASTUR	O
cohort	O
.	O

A	O
total	O
of	O
569	O
individuals	O
aged	O
55	O
-	O
85	O
and	O
Caucasian	O
were	O
genotyped	I
for	O
SNP	I
rs10927887	I
in	O
the	O
Ka	I
renal	I
chloride	I
channel	I
gene	I
(	O
CLCNKA	I
)	O
.	O

The	O
following	O
variables	O
were	O
significantly	I
associated	O
with	O
an	O
estimated	I
glomerular	I
filtration	I
rate	I
of	O
(	O
eGFR	I
)	O
<	O
60	O
ml	O
/	O
min	O
.	O

/	O
1.73	O
m	O
(	O
2	O
)	O
:	O
age	O
,	O
type	I
2	I
diabetes	I
,	O
total	O
cholesterol	I
,	O
LDL-cholesterol	I
,	O
and	O
the	O
CLCNKA	I
GG	O
genotype	I
(	O
p=0.03	I
;	O
OR=1.65	I
,	O
95	O
%	O
CI=1.04-2.62	I
)	O
.	O

This	O
novel	O
finding	O
could	O
partly	O
explain	O
the	O
reported	O
greater	O
risk	O
of	O
heart	I
failure	I
linked	O
to	O
the	O
CLCNKA	I
SNP	I
,	O
but	O
requires	O
confirmation	O
on	O
other	O
populations	O
.	O

Within-day	O
test-retest	O
reliability	O
of	O
the	O
Timed	I
Up	I
&	I
Go	I
test	I
in	O
patients	I
with	O
advanced	O
chronic	I
organ	I
failure	I
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
within-day	O
test-retest	O
reliability	O
of	O
the	O
Timed	I
Up	I
&	I
Go	I
(	O
TUG	I
)	O
test	I
in	O
patients	I
with	O
advanced	O
chronic	I
obstructive	I
pulmonary	I
disease	I
(	O
COPD	I
)	O
,	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
,	O
and	O
chronic	I
renal	I
failure	I
(	O
CRF	I
)	O
.	O

DESIGN	O
:	O

Cross-sectional	O
.	O

SETTING	O
:	O

Patients	I
'	O
home	O
environment	O
.	O

PARTICIPANTS	O
:	O

Subjects	O
(	O
N=235	O
,	O
64	O
%	O
men	O
;	O
median	O
age	O
,	O
70y	O
[	O
interquartile	I
range	I
,	O
61-77y	O
]	O
;	O
median	O
body	I
mass	I
index	I
,	O
25.6	O
kg	O
/	O
m	O
(	O
2	O
)	O
[	O
interquartile	I
range	I
,	O
22.8	O
-	O
29.4	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
)	O
with	O
advanced	O
COPD	I
(	O
n=95	O
)	O
,	O
CHF	I
(	O
n=68	O
)	O
,	O
or	O
CRF	I
(	O
n=72	O
)	O
.	O

INTERVENTIONS	O
:	O

Not	O
applicable	O
.	O

MAIN	O
OUTCOME	I
MEASURE	O
:	O

Time	O
to	O
complete	O
the	O
TUG	I
test	I
.	O

Three	O
trials	O
were	O
performed	O
on	O
the	O
same	O
day	O
and	O
by	O
the	O
same	O
assessors	O
.	O

The	O
intraclass	I
correlation	I
coefficient	I
(	O
ICC	I
)	O
,	O
kappa	I
coefficient	I
,	O
standard	I
error	I
of	I
measurement	I
,	O
and	O
absolute	O
and	O
relative	O
minimal	I
detectable	I
change	I
(	O
MDC	I
)	O
values	O
were	O
calculated	O
.	O

RESULTS	O
:	O

Good	O
agreement	O
was	O
observed	O
,	O
in	O
general	O
,	O
for	O
both	O
the	O
total	O
sample	O
and	O
subgroups	O
(	O
COPD	I
,	O
CHF	I
,	O
CRF	I
)	O
,	O
with	O
ICC	I
values	O
ranging	O
from	O
.85	O
to	O
.98	O
,	O
and	O
kappa	I
coefficients	I
from	O
.49	O
to	O
1.00	O
.	O

However	O
,	O
statistical	O
improvement	O
occurred	O
in	O
the	O
total	O
sample	O
from	O
the	O
first	O
to	O
the	O
second	O
trial	O
with	O
large	O
limits	O
of	O
agreement	O
(	O
mean	O
difference	O
,	O
-	O
.97s	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
3.00	O
to	O
-	O
4.94s	O
;	O
P	I
<	O
.01	O
)	O
.	O

The	O
third	O
trial	O
added	O
little	O
or	O
no	O
information	O
to	O
the	O
first	O
2	O
trials	O
.	O

For	O
the	O
total	O
sample	O
,	O
a	O
standard	I
error	I
of	I
measurement	I
value	O
of	O
approximately	O
1.6	O
seconds	O
,	O
an	O
absolute	O
value	O
of	O
MDC	I
at	O
the	O
95	O
%	O
confidence	O
level	O
(	O
MDC95	I
%	O
)	O
of	O
approximately	O
4.5	O
seconds	O
,	O
and	O
a	O
relative	O
value	O
of	O
MDC	I
at	O
the	O
95	O
%	O
confidence	O
level	O
(	O
MDC95	I
%	O
%	O
)	O
of	O
approximately	O
35	O
%	O
were	O
found	O
between	O
the	O
first	O
2	O
trials	O
,	O
with	O
similar	O
values	O
found	O
for	O
the	O
subgroups	O
.	O

CONCLUSIONS	O
:	O

The	O
TUG	I
test	I
is	O
reliable	O
in	O
patients	I
with	O
advanced	O
COPD	I
,	O
CHF	I
,	O
or	O
CRF	I
after	O
2	O
trials	O
.	O

Values	O
of	O
standard	I
error	I
of	I
measurement	I
and	O
MDC	I
may	O
be	O
used	O
in	O
daily	O
clinical	I
practice	O
with	O
these	O
populations	O
to	O
define	O
what	O
is	O
expected	O
and	O
what	O
represents	O
true	O
change	O
in	O
repeated	O
measures	O
.	O

Assessing	O
the	O
link	O
between	O
air	O
pollution	O
and	O
heart	I
failure	I
.	O

Ambient	O
air	O
pollution	O
is	O
a	O
well-recognised	O
risk	O
factor	O
for	O
cardiovascular	I
health	I
,	O
and	O
it	O
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
trigger	O
of	O
acute	I
myocardial	I
infarction	I
.	O

In	O
The	O
Lancet	O
,	O
Anoop	O
Shah	O
and	O
colleagues	O
provide	O
a	O
new	O
systematic	O
review	O
of	O
the	O
effects	O
of	O
air	O
pollution	O
on	O
heart	I
failure	I
,	O
a	O
common	O
disorder	O
associated	O
with	O
high	O
morbidity	I
and	O
mortality	I
,	O
especially	O
in	O
elderly	O
people	O
.	O

Physicians	I
and	O
professionals	O
in	O
public	O
health	I
should	O
be	O
aware	O
that	O
the	O
air	O
pollution	O
experienced	O
in	O
most	O
urban	O
and	O
industrial	O
areas	O
can	O
aggravate	O
cardiovascular	I
health	I
and	O
lead	O
to	O
hospitalisation	I
and	O
death	I
.	O

Tricuspid	I
annular	I
plane	I
systolic	I
excursion	I
and	O
pulmonary	I
arterial	I
systolic	I
pressure	I
relationship	O
in	O
heart	I
failure	I
:	O
an	O
index	O
of	O
right	I
ventricular	I
contractile	I
function	I
and	O
prognosis	I
.	O

Abstract	O

Echo-derived	I
pulmonary	I
arterial	I
systolic	I
pressure	I
(	O
PASP	I
)	O
and	O
right	I
ventricular	I
(	O
RV	I
)	O
tricuspid	I
annular	I
plane	I
systolic	I
excursion	I
(	O
TAPSE	I
;	O
from	O
the	O
end	O
of	O
diastole	I
to	O
end-systole	I
)	O
are	O
of	O
basic	O
relevance	O
in	O
the	O
clinical	I
follow-up	I
of	O
heart	I
failure	I
(	O
HF	I
)	O
patients	I
,	O
carrying	O
two	O
-	O
to	O
threefold	O
increase	O
in	O
cardiac	I
risk	O
when	O
increased	O
and	O
reduced	O
,	O
respectively	O
.	O

We	O
hypothesized	O
that	O
the	O
relationship	O
between	O
TAPSE	I
(	O
longitudinal	I
RV	I
fiber	I
shortening	I
)	O
and	O
PASP	I
(	O
force	O
generated	O
by	O
the	O
RV	I
)	O
provides	O
an	O
index	O
of	O
in	I
vivo	I
RV	I
length-force	O
relationship	O
,	O
with	O
their	O
ratio	O
better	O
disclosing	O
prognosis	I
.	O

Two	O
hundred	O
ninety-three	O
HF	I
patients	I
with	O
reduced	I
(	O
HFrEF	I
,	O
n	O
=	O
247	O
)	O
or	O
with	O
preserved	I
left	I
ventricular	I
(	I
LV	I
)	I
ejection	I
fraction	I
(	O
HFpEF	I
,	O
n	O
=	O
46	O
)	O
underwent	O
echo-Doppler	I
studies	O
and	O
N-terminal	I
pro-brain-type	I
natriuretic	I
peptide	I
assessment	O
and	O
were	O
tracked	O
for	O
adverse	I
events	I
.	O

The	O
median	O
follow-up	I
duration	I
was	O
20.8	O
mo	O
.	O

TAPSE	I
vs.	O
PASP	I
relationship	O
showed	O
a	O
downward	O
regression	I
line	I
shift	O
in	O
nonsurvivors	O
who	O
were	O
more	O
frequently	O
presenting	O
with	O
higher	O
PASP	I
and	O
lower	O
TAPSE	I
.	O

HFrEF	I
and	O
HFpEF	I
patients	I
exhibited	O
a	O
similar	O
distribution	O
along	O
the	O
regression	I
line	I
.	O

Given	O
the	O
TAPSE	I
,	O
PASP	I
,	O
and	O
TAPSE-to-PASP	I
ratio	O
(	O
TAPSE	I
/	O
PASP	I
)	O
collinearity	O
,	O
separate	O
Cox	I
regression	I
and	O
Kaplan-Meier	I
analyses	I
were	O
performed	O
:	O
one	O
with	O
TAPSE	I
and	O
PASP	I
as	O
individual	O
measures	O
,	O
and	O
the	O
other	O
combining	O
them	O
in	O
ratio	O
form	O
.	O

Hazard	I
ratios	I
for	O
variables	O
retained	O
in	O
the	O
multivariate	I
regression	I
were	O
as	O
follows	O
:	O
TAPSE	I
/	O
PASP	I
<	O
/	O
≥	O
0.36	O
mm	O
/	O
mmHg	O
[	O
hazard	I
ratio	I
(	O
HR	I
)	O
:	O
10.4	O
,	O
P	I
<	O
0.001	O
]	O
;	O
TAPSE	I
<	O
/	O
≥	O
16	O
mm	O
(	O
HR	I
:	O
5.1	O
,	O
P	I
<	O
0.01	O
)	O
;	O
New	I
York	I
Heart	I
Association	I
functional	I
class	I
<	O
/	O
≥	O
3	O
(	O
HR	I
:	O
4.4	O
,	O
P	I
<	O
0.001	O
)	O
;	O
E	I
/	I
e	I
'	I
(	O
HR	I
:	O
4.1	O
,	O
P	I
<	O
0.001	O
)	O
.	O

This	O
study	O
shows	O
that	O
the	O
TAPSE	I
vs.	O
PASP	I
relationship	O
is	O
shifted	O
downward	O
in	O
nonsurvivors	O
with	O
a	O
similar	O
distribution	O
in	O
HFrEF	I
and	O
HFpEF	I
,	O
and	O
their	O
ratio	O
improves	O
prognostic	I
resolution	O
.	O

The	O
TAPSE	I
vs.	O
PASP	I
relationship	O
as	O
a	O
possible	O
index	O
of	O
the	O
length-force	O
relationship	O
may	O
be	O
a	O
step	O
forward	O
for	O
a	O
more	O
efficient	O
RV	I
function	I
evaluation	O
and	O
is	O
not	O
affected	O
by	O
the	O
quality	O
of	O
LV	I
dysfunction	I
.	O

Global	O
proteomics	I
and	O
pathway	O
analysis	O
of	O
pressure-overload-induced	I
heart	I
failure	I
and	O
its	O
attenuation	O
by	O
mitochondrial-targeted	I
peptides	I
.	O

BACKGROUND	O
:	O

We	O
investigated	O
the	O
protective	O
effects	O
of	O
mitochondrial-targeted	I
antioxidant	O
and	O
protective	O
peptides	I
,	O
Szeto-Schiller	I
(	O
SS	I
)	O
31	I
and	O
SS20	I
,	O
on	O
cardiac	I
function	I
,	O
proteomic	I
remodeling	I
,	O
and	O
signaling	I
pathways	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
applied	O
an	O
improved	O
label-free	O
shotgun	O
proteomics	I
approach	O
to	O
evaluate	O
the	O
global	O
proteomics	I
changes	O
in	O
transverse	I
aortic	I
constriction	I
(TAC)-induced	I
heart	I
failure	I
and	O
the	O
associated	O
signaling	I
pathway	I
changes	O
using	O
ingenuity	I
pathway	I
analysis	I
.	O

We	O
found	O
that	O
538	O
proteins	I
significantly	I
changed	O
after	O
TAC	I
,	O
which	O
mapped	O
to	O
53	O
pathways	O
.	O

The	O
top	O
pathways	O
were	O
in	O
the	O
categories	O
of	O
actin	I
cytoskeleton	I
,	O
mitochondrial	I
function	I
,	O
intermediate	O
metabolism	I
,	O
glycolysis	I
/	O
gluconeogenesis	I
,	O
and	O
citrate	I
cycle	I
.	O

Concomitant	O
treatment	O
with	O
SS31	I
ameliorated	O
the	O
congestive	I
heart	I
failure	I
phenotypes	I
and	O
mitochondrial	I
damage	O
induced	O
by	O
TAC	I
,	O
in	O
parallel	O
with	O
global	O
attenuation	O
of	O
mitochondrial	I
proteome	I
changes	O
,	O
with	O
an	O
average	O
of	O
84	O
%	O
protection	O
of	O
mitochondrial	I
and	O
69	O
%	O
of	O
nonmitochondrial	I
protein	I
changes	O
.	O

This	O
included	O
significant	I
amelioration	O
of	O
all	O
the	O
ingenuity	I
pathway	I
analysis	I
noted	O
above	O
.	O

SS20	I
had	O
only	O
modest	O
effects	O
on	O
heart	I
failure	I
and	O
this	O
tracked	O
with	O
only	O
partial	O
attenuation	O
of	O
global	O
proteomics	I
changes	O
;	O
furthermore	O
,	O
actin	I
cytoskeleton	I
pathways	O
were	O
significantly	I
protected	O
in	O
SS20	I
,	O
whereas	O
mitochondrial	I
and	O
metabolic	I
pathways	I
essentially	O
were	O
not	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
elucidates	O
the	O
signaling	I
pathways	I
significantly	I
changed	O
in	O
pressure-overload-induced	I
heart	I
failure	I
.	O

The	O
global	O
attenuation	O
of	O
TAC-induced	I
proteomic	I
alterations	O
by	O
the	O
mitochondrial-targeted	I
peptide	I
SS31	I
suggests	O
that	O
perturbed	O
mitochondrial	I
function	I
may	O
be	O
an	O
upstream	O
signal	O
to	O
many	O
of	O
the	O
pathway	O
alterations	O
in	O
TAC	I
and	O
supports	O
the	O
potential	O
clinical	I
application	O
of	O
mitochondrial-targeted	I
peptide	I
drugs	I
for	O
the	O
treatment	O
heart	I
failure	I
.	O

Xanthine	I
oxidase	I
inhibition	I
preserves	O
left	I
ventricular	I
systolic	I
but	O
not	O
diastolic	I
function	I
in	O
cardiac	I
volume	I
overload	I
.	O

Xanthine	I
oxidase	I
(	O
XO	I
)	O
is	O
increased	O
in	O
human	O
and	O
rat	O
left	I
ventricular	I
(	O
LV	I
)	O
myocytes	I
with	O
volume	I
overload	I
(	O
VO	I
)	O
of	O
mitral	I
regurgitation	I
and	O
aortocaval	I
fistula	I
(	O
ACF	I
)	O
.	O

In	O
the	O
setting	O
of	O
increased	O
ATP	I
demand	O
,	O
XO-mediated	I
ROS	I
can	O
decrease	O
mitochondrial	I
respiration	I
and	O
contractile	I
function	I
.	O

Thus	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
XO	I
inhibition	I
improves	O
cardiomyocyte	I
bioenergetics	I
and	O
LV	I
function	I
in	O
chronic	I
ACF	I
in	O
the	O
rat	O
.	O

Sprague-Dawley	O
rats	O
were	O
randomized	I
to	O
either	O
sham	O
or	O
ACF	I
±	O
allopurinol	I
(	O
100	O
mg·kg(-1)·day(-1)	O
,	O
n	O
≥7	O
rats	O
/	O
group	O
)	O
.	O

Echocardiography	I
at	O
8	O
wk	O
demonstrated	O
a	O
similar	O
37	O
%	O
increase	O
in	O
LV	I
end-diastolic	I
dimension	I
(	O
P	I
<	O
0.001	O
)	O
,	O
a	O
twofold	O
increase	O
in	O
LV	I
end-diastolic	I
pressure	I
/	O
wall	I
stress	I
(	O
P	I
<	O
0.05	O
)	O
,	O
and	O
a	O
twofold	O
increase	O
in	O
lung	I
weight	O
(	O
P	I
<	O
0.05	O
)	O
in	O
treated	O
and	O
untreated	O
ACF	I
groups	O
versus	O
the	O
sham	O
group	O
.	O

LV	I
ejection	I
fraction	I
,	O
velocity	O
of	O
circumferential	O
shortening	O
,	O
maximal	O
systolic	I
elastance	I
,	O
and	O
contractile	I
efficiency	I
were	O
significantly	I
depressed	O
in	O
ACF	I
and	O
significantly	I
improved	O
in	O
ACF	I
+	O
allopurinol	I
rats	O
,	O
all	O
of	O
which	O
occurred	O
in	O
the	O
absence	O
of	O
changes	O
in	O
the	O
maximum	O
O2	O
consumption	O
rate	O
measured	O
in	O
isolated	O
cardiomyocytes	I
using	O
the	O
extracellular	I
flux	I
analyzer	I
.	O

However	O
,	O
the	O
improvement	O
in	O
contractile	I
function	I
is	O
not	O
paralleled	O
by	O
any	O
attenuation	O
in	O
LV	I
dilatation	I
,	O
LV	I
end-diastolic	I
pressure	I
/	O
wall	I
stress	I
,	O
and	O
lung	I
weight	O
.	O

In	O
conclusion	O
,	O
allopurinol	I
improves	O
LV	I
contractile	I
function	I
and	O
efficiency	I
possibly	O
by	O
diminishing	O
the	O
known	O
XO-mediated	I
ROS	I
effects	O
on	O
myofilament	I
Ca	I
(	I
2	I
+	I
)	I
sensitivity	I
.	O

However	O
,	O
LV	I
remodeling	I
and	O
diastolic	I
properties	O
are	O
not	O
improved	O
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
XO	I
inhibition	I
to	O
improve	O
symptoms	I
and	O
hospitalizations	I
in	O
patients	I
with	O
severe	I
heart	I
failure	I
.	O

Remote	I
ischemic	I
conditioning	I
for	O
patients	I
with	O
heart	I
failure	I
?	O

Management	O
of	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
stemming	O
from	O
ischemic	I
and	O
nonischemic	I
cardiomyopathies	I
,	O
continues	O
to	O
be	O
problematic	O
,	O
despite	O
the	O
inroads	O
made	O
in	O
the	O
pharmacological	I
armamentarium	O
,	O
by	O
implantable	I
cardioverter	I
defibrillators	I
,	O
cardiac	I
resynchronization	I
therapy	I
,	O
and	O
the	O
eventual	O
resort	O
to	O
cardiac	I
transplantation	I
,	O
and	O
left	I
and	O
/	O
or	O
right	I
ventricular	I
assist	I
devices	I
.	O

Both	O
patients	I
with	O
low	O
left	I
ventricular	I
ejection	I
fraction	I
and	O
patients	I
with	O
HF	I
with	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
are	O
admitted	O
to	O
the	O
hospital	I
frequently	O
and	O
serially	O
and	O
keep	O
physicians	I
busy	O
,	O
in	O
the	O
acute	I
and	O
outpatient	I
settings	O
,	O
for	O
their	O
management	O
,	O
also	O
prompting	O
them	O
to	O
search	O
for	O
better	O
ways	O
to	O
deal	O
with	O
this	O
worldwide	O
epidemic	I
and	O
its	O
impact	O
on	O
medical	I
resources	O
and	O
financial	O
costs	O
.	O

Exercise	I
intolerance	I
in	O
heart	I
failure	I
:	O
update	O
on	O
exercise	O
parameters	O
for	O
diagnosis	I
,	O
prognosis	I
and	O
therapeutic	I
interventions	O
.	O

Exercise	I
intolerance	I
is	O
a	O
hallmark	O
feature	O
of	O
chronic	I
heart	I
failure	I
and	O
is	O
associated	O
with	O
poor	O
prognosis	I
.	O

This	O
review	O
provides	O
an	O
update	O
on	O
cardiopulmonary	I
exercise	O
variables	O
,	O
proven	O
to	O
be	O
prognostically	I
important	O
in	O
heart	I
failure	I
.	O

Besides	O
the	O
widely	O
accepted	O
peak	I
oxygen	I
consumption	I
(	O
peak	I
VO2	I
)	O
and	O
VEN	I
/	I
VCO2	I
slope	I
,	O
other	O
exercise	O
variables	O
-	O
exercise	I
oscillatory	I
ventilation	I
(	O
EOV	I
)	O
and	O
partial	I
pressure	I
of	I
end-tidal	I
CO2	I
,	O
(	O
PETCO2	I
)	O
-	O
should	O
gain	O
attention	O
in	O
the	O
interpretation	O
of	O
cardiopulmonary	I
exercise	I
testing	I
.	O

In	O
addition	O
to	O
prognosis	I
,	O
the	O
pathophysiological	I
origin	O
is	O
also	O
discussed	O
.	O

Different	O
mechanisms	O
underlie	O
these	O
exercise	O
variables	O
with	O
an	O
important	O
contribution	O
of	O
haemodynamic	I
,	O
pulmonary	I
and	O
peripheral	O
abnormalities	O
.	O

Given	O
the	O
different	O
pathophysiological	I
origin	O
,	O
a	O
multivariate	O
assessment	O
with	O
the	O
inclusion	O
of	O
all	O
the	O
aforementioned	O
parameters	O
should	O
be	O
encouraged	O
,	O
not	O
only	O
for	O
diagnostic	I
and	O
prognostic	I
purposes	O
but	O
also	O
for	O
evaluating	O
the	O
effect	O
of	O
interventions	O
.	O

Heart	I
Failure	I
:	O
Pathophysiology	I
,	O
Diagnosis	I
,	O
Medical	I
Treatment	I
Guidelines	O
,	O
and	O
Nursing	I
Management	O
.	O

Heart	I
failure	I
(	O
HF	I
)	O
is	O
a	O
debilitating	O
chronic	I
disease	I
and	O
is	O
expected	O
to	O
increase	O
in	O
upcoming	O
years	O
due	O
to	O
demographic	O
changes	O
.	O

Nurses	I
in	O
all	O
settings	O
have	O
an	O
essential	O
role	O
in	O
supporting	O
patients	I
in	O
managing	O
this	O
disease	I
.	O

This	O
article	O
describes	O
the	O
pathophysiology	I
of	O
HF	I
,	O
diagnosis	I
,	O
medical	I
management	O
,	O
and	O
nursing	I
interventions	O
.	O

It	O
is	O
crucial	O
for	O
nurses	I
to	O
understand	O
the	O
pathophysiology	I
of	O
HF	I
and	O
the	O
importance	O
that	O
nursing	I
actions	O
have	O
on	O
enhancing	O
medical	I
management	O
to	O
alleviate	O
symptoms	I
and	O
to	O
deter	O
the	O
advancement	O
of	O
the	O
pathophysiologic	I
state	O
.	O

Such	O
an	O
understanding	O
can	O
ultimately	O
reduce	O
morbidity	I
and	O
mortality	I
and	O
optimize	O
quality	I
of	I
life	I
in	O
patients	I
with	O
HF	I
.	O

Renin-angiotensin-aldosterone	I
system	I
inhibitors	I
in	O
heart	I
failure	I
.	O

Heart	I
failure	I
(	O
HF	I
)	O
is	O
a	O
very	O
common	O
condition	I
that	O
,	O
despite	O
advances	O
in	O
treatment	O
,	O
carries	O
significant	O
morbidity	I
and	O
mortality	I
.	O

Although	O
there	O
is	O
good	O
evidence	O
for	O
the	O
treatment	O
of	O
HF	I
with	I
reduced	I
ejection	I
fraction	I
(	O
HFrEF	I
)	O
,	O
the	O
treatment	O
for	O
HF	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
is	O
not	O
well	O
defined	O
.	O

The	O
renin-angiotensin-aldosterone	I
system	I
(	O
RAAS	I
)	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
target	O
in	O
the	O
treatment	O
of	O
HFrEF	I
using	O
angiotensin-converting	I
enzyme	I
inhibitors	I
,	O
angiotensin	I
receptor	I
blockers	I
,	O
and	O
aldosterone	I
blockade	I
,	O
although	O
the	O
evidence	O
in	O
HFpEF	I
is	O
less	O
clear	O
.	O

This	O
review	O
aims	O
to	O
look	O
first	O
at	O
the	O
evidence	O
for	O
these	O
drugs	I
,	O
and	O
second	O
at	O
the	O
newer	O
drugs	I
that	O
act	O
on	O
the	O
RAAS	I
,	O
namely	O
,	O
direct	O
renin	I
inhibitors	I
,	O
neutral	O
endopeptidase	I
inhibitors	I
,	O
vasopeptidase	I
inhibitors	I
,	O
and	O
angiotensin	I
receptor	I
blockers	I
.	O

Reversal	O
of	O
cardiac	I
dysfunction	I
and	O
subcellular	I
alterations	O
by	O
metoprolol	I
in	O
heart	I
failure	I
due	O
to	O
myocardial	I
infarction	I
.	O

In	O
order	O
to	O
examine	O
the	O
reversibility	O
of	O
heart	I
failure	I
due	O
to	O
myocardial	I
infarction	I
(	O
MI	I
)	O
by	O
β-adrenoceptor	I
blockade	I
,	O
12	O
weeks	O
infarcted	I
rats	O
were	O
treated	O
with	O
or	O
without	O
metoprolol	I
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
8	O
weeks	O
.	O

The	O
depressed	O
left	I
ventricular	I
(	O
LV	I
)	O
systolic	I
pressure	I
,	O
positive	O
and	O
negative	O
rates	O
of	O
changes	O
in	O
pressure	O
development	O
,	O
ejection	I
fraction	I
,	O
fractional	I
shortening	I
and	O
cardiac	I
output	I
,	O
as	O
well	O
as	O
increased	O
LV	I
end-diastolic	I
pressure	I
in	O
20	O
weeks	O
MI	I
animals	O
were	O
partially	O
reversed	O
by	O
metoprolol	I
.	O

MI-induced	I
decreases	O
in	O
septum	I
(	O
systolic	I
)	O
thickness	O
as	O
well	O
as	O
increase	O
in	O
LV	I
posterior	I
wall	I
thickness	O
and	O
LV	I
internal	I
diameter	I
were	O
partially	O
or	O
fully	O
reversible	O
by	O
metoprolol	I
.	O

Treatment	O
of	O
MI	I
animals	O
with	O
metoprolol	I
partially	O
reversed	O
the	O
elevated	O
levels	O
of	O
plasma	I
norepinephrine	I
and	O
dopamine	I
without	O
affecting	O
the	O
elevated	O
levels	O
of	O
epinephrine	I
.	O

Although	O
sarcoplasmic	I
reticular	I
(	O
SR	I
)	O
Ca	I
(	I
2+)-uptake	I
,	O
as	O
well	O
as	O
protein	I
content	O
for	O
SR	I
Ca	I
(	I
2+)-pump	I
and	O
phospholamban	I
,	O
were	O
reduced	O
in	O
the	O
infarcted	I
hearts	I
;	O
these	O
changes	O
were	O
partially	O
reversible	O
with	O
metoprolol	I
.	O

Depressed	O
myofibrillar	I
Ca	I
(	I
2+)-stimulated	I
ATPase	I
activity	O
,	O
as	O
well	O
as	O
mRNA	I
levels	O
for	O
SR	I
Ca	I
(	I
2+)-pump	I
,	O
phospholamban	I
and	O
α-myosin	I
heavy	I
chain	I
,	O
were	O
unaffected	O
whereas	O
increased	O
mRNA	I
level	O
for	O
β-myosin	I
heavy	I
chain	I
was	O
partially	O
reversed	O
by	O
metoprolol	I
.	O

The	O
results	O
suggest	O
that	O
partial	O
improvement	O
of	O
cardiac	I
performance	O
by	O
β-adrenoceptor	I
blockade	I
at	O
advanced	O
stages	O
of	O
heart	I
failure	I
may	O
be	O
due	O
to	O
partial	O
reversal	O
of	O
changes	O
in	O
SR	I
Ca	I
(	I
2+)-pump	I
function	O
whereas	O
partial	O
to	O
complete	O
reverse	O
cardiac	I
remodeling	I
may	O
be	O
due	O
to	O
partial	O
reduction	O
in	O
the	O
elevated	O
levels	O
of	O
plasma	I
catecholamines	I
.	O

Should	O
eligibility	O
for	O
heart	I
transplantation	I
be	O
a	O
requirement	O
for	O
left	I
ventricular	I
assist	I
device	I
use	O
?	O

Recommendations	O
based	O
on	O
a	O
systematic	O
review	O
.	O

Left	I
ventricular	I
assist	I
devices	I
(	O
LVADs	I
)	O
are	O
used	O
in	O
chronic	I
end-stage	I
heart	I
failure	I
as	O
bridge	I
to	I
transplantation	I
(	O
BTT	I
)	O
and	O
,	O
more	O
recently	O
,	O
for	O
transplant-ineligible	I
patients	I
as	O
destination	I
therapy	I
(	O
DT	I
)	O
.	O

We	O
reviewed	O
the	O
evidence	O
on	O
clinical	I
effects	O
and	O
cost-effectiveness	O
of	O
2	O
types	O
of	O
continuous-flow	I
LVADs	I
(	O
HeartMate	O
II	O
[	O
HM	O
II	O
]	O
and	O
HeartWare	O
)	O
,	O
for	O
BTT	I
and	O
DT	I
patients	I
.	O

We	O
systematically	O
searched	O
the	O
scientific	O
literature	O
(	O
January	O
2008-June	O
2012	O
)	O
and	O
identified	O
14	O
clinical	I
studies	O
(	O
approximately	O
2900	O
HM	O
II	O
and	O
approximately	O
200	O
HeartWare	O
patients	I
)	O
,	O
and	O
3	O
economic	O
evaluations	O
(	O
HM	O
II	O
)	O
using	O
simulation	O
models	O
.	O

Data	O
were	O
,	O
however	O
,	O
limited	O
to	O
2	O
-	O
3	O
studies	O
per	O
outcome	I
.	O

We	O
made	O
policy	O
recommendations	O
on	O
the	O
basis	O
of	O
our	O
systematic	O
review	O
.	O

Although	O
complications	I
after	O
implantation	I
are	O
frequent	O
,	O
LVAD	I
therapy	I
is	O
often	O
highly	O
effective	O
across	O
transplantation	I
eligibility	O
status	O
and	O
device	O
,	O
with	O
1-year	O
survival	O
reaching	O
86	O
%	O
for	O
BTT	I
and	O
78	O
%	O
for	O
DT	I
(	O
compared	O
with	O
25	O
%	O
for	O
medical	I
therapy	I
)	O
.	O

Neither	O
BTT	I
nor	O
DT	I
currently	O
meet	O
traditional	O
cost-effectiveness	O
limits	O
in	O
models	O
using	O
historical	O
data	O
,	O
although	O
BTT	I
is	O
standard	O
practice	O
for	O
a	O
limited	O
number	O
of	O
patients	I
in	O
many	O
regions	O
.	O

We	O
found	O
that	O
BTT	I
and	O
DT	I
as	O
implantation	I
strategies	O
tend	O
to	O
be	O
no	O
longer	O
mutually	O
exclusive	O
.	O

We	O
conclude	O
that	O
evidence	O
is	O
sufficient	O
to	O
support	O
LVAD	I
use	O
,	O
regardless	O
of	O
transplantation	I
eligibility	O
status	O
,	O
as	O
long	O
as	O
patients	I
are	O
carefully	O
selected	O
and	O
program	O
infrastructure	O
and	O
budget	O
are	O
adequate	O
.	O

However	O
,	O
evidence	O
gaps	O
,	O
limitations	O
in	O
economic	O
models	O
,	O
and	O
the	O
lack	O
of	O
Canadian	O
data	O
point	O
to	O
the	O
importance	O
of	O
mandatory	O
,	O
systematic	O
monitoring	O
of	O
LVAD	I
use	O
and	O
outcomes	I
.	O

Chronic	I
heart	I
failure	I
is	O
associated	O
with	O
transforming	O
growth	O
factor	O
beta-dependent	O
yield	O
and	O
functional	O
decline	O
in	O
atrial	I
explant-derived	I
c-Kit	I
+	I
cells	I
.	O

BACKGROUND	O
:	O

Cardiac	I
c-Kit	I
+	I
cells	I
isolated	O
from	O
cardiac	I
explant-derived	I
cells	I
modestly	O
improve	O
cardiac	I
functions	I
after	O
myocardial	I
infarction	I
;	O
however	O
,	O
their	O
full	O
potential	O
has	O
not	O
yet	O
been	O
realized	O
.	O

For	O
instance	O
,	O
the	O
majority	O
of	O
potential	O
candidates	O
for	O
cell	I
therapy	I
suffer	O
from	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
,	O
and	O
it	O
is	O
unclear	O
how	O
this	O
disease	I
affects	O
the	O
explant-derived	I
progenitor	I
cells	I
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
CHF	I
on	O
the	O
number	O
and	O
phenotype	I
of	O
cardiac	I
explant	I
c-Kit	I
+	I
progenitors	I
and	O
elucidate	O
mechanisms	O
of	O
their	O
regulation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Myocardial	I
infarction	I
was	O
created	O
by	O
left	I
anterior	I
descending	I
coronary	I
artery	I
occlusion	I
.	O

Sham-operated	O
animals	O
were	O
used	O
as	O
a	O
control	O
group	O
.	O

CHF-developed	I
infarcted	I
animals	O
were	O
selected	O
on	O
the	O
basis	O
of	O
left	I
ventricle	I
end-diastolic	I
pressure	I
≥	O
20	O
mm	O
Hg	O
and	O
scar	O
size	O
≥	O
30	O
%	O
.	O

Here	O
,	O
we	O
found	O
that	O
CHF	I
atrial	I
explants	I
produced	O
less	O
c-Kit	I
+	I
cells	I
than	O
sham	O
explants	I
.	O

CHF-derived	I
c-Kit	I
+	I
cells	I
exhibited	O
upregulated	O
transforming	I
growth	I
factor-β	I
(	O
TGF-β	I
)	O
signaling	I
,	O
increased	O
level	O
of	O
epithelial	I
to	O
mesenchymal	I
transition	O
markers	O
,	O
and	O
diminished	O
expression	I
of	O
pluripotency	I
markers	I
compared	O
with	O
shams	O
.	O

We	O
show	O
that	O
intervention	O
with	O
TGF-β	I
signaling	I
by	O
inhibiting	O
TGF-β	I
receptor	I
type	I
I	I
or	O
Smad	I
2	I
/	I
3	I
using	O
small-molecule	O
inhibitors	O
improved	O
c-Kit	I
+	I
cell	I
yield	O
,	O
attenuated	O
epithelial	I
to	O
mesenchymal	I
transition	O
markers	O
,	O
stimulated	O
the	O
pluripotency	I
marker	I
Nanog	I
,	O
and	O
improved	O
efficiency	O
of	O
c-Kit	I
+	I
cell	I
differentiation	O
toward	O
cardiomyocyte-like	I
cells	I
in	I
vitro	I
.	O

CONCLUSIONS	O
:	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
TGF-β	I
inhibition	O
positively	O
modulates	O
c-Kit	I
+	I
cell	I
phenotype	I
and	O
function	O
in	I
vitro	I
,	O
and	O
this	O
strategy	O
may	O
be	O
considered	O
in	O
optimizing	O
cardiac	I
progenitor	I
function	I
and	O
cell	I
expansion	O
protocols	O
for	O
clinical	I
application	O
.	O

Acute	I
care	I
surgery	I
in	O
heart	I
transplant	I
recipients	O
.	O

Orthotopic	I
heart	I
transplantation	I
(	O
OHT	I
)	O
is	O
the	O
optimal	O
treatment	O
for	O
end-stage	I
heart	I
failure	I
.	O

We	O
reviewed	O
our	O
institutional	O
experience	O
between	O
2008	O
and	O
2012	O
with	O
acute	I
care	I
surgery	I
(	O
ACS	I
)	O
consultations	I
and	O
procedures	O
within	O
1	O
year	O
of	O
OHT	I
in	O
recipients	O
bridged	O
to	O
transplantation	I
with	O
medical	I
therapy	I
(	O
MT	O
,	O
n	O
=	O
169	O
)	O
,	O
including	O
intravenous	I
inotropes	I
,	O
and	O
ventricular	I
assist	I
devices	I
(	O
VADs	I
,	O
n	O
=	O
74	O
)	O
.	O

In	O
total	O
,	O
28	O
consultations	I
were	O
required	O
in	O
21	O
patients	I
(	O
9	O
%	O
)	O
and	O
16	O
procedures	O
were	O
performed	O
in	O
11	O
patients	I
(	O
5	O
%	O
)	O
.	O

The	O
interval	O
from	O
transplantation	I
to	O
consultation	I
was	O
shorter	O
for	O
the	O
MT	O
group	O
(	O
50	O
vs	O
82	O
days	O
;	O
P	I
=	O
0.015	O
)	O
,	O
whereas	O
the	O
interval	O
from	O
consultation	I
to	O
operation	I
was	O
longer	O
(	O
5	O
vs	O
1	O
day	O
;	O
P	I
=	O
0.03	O
)	O
.	O

Patients	I
undergoing	O
MT	O
were	O
more	O
likely	O
to	O
require	O
consultation	I
for	O
abdominal	I
problems	O
(	O
88	O
vs	O
27	O
%	O
;	O
P	I
=	O
0.004	O
)	O
.	O

All	O
but	O
one	O
of	O
the	O
seven	O
ischemic	I
/	O
inflammatory	I
abdominal	I
problems	O
occurred	O
in	O
the	O
MT	O
group	O
.	O

Complications	I
occurred	O
after	O
five	O
ACS	I
procedures	O
(	O
31	O
%	O
)	O
in	O
two	O
patients	I
undergoing	O
MT	O
and	O
three	O
patients	I
undergoing	O
VAD	I
.	O

Mortality	I
was	O
24	O
per	O
cent	O
with	O
five	O
deaths	I
occurring	O
within	O
30	O
days	O
of	O
ACS	I
consultation	I
and	O
/	O
or	O
operation	I
.	O

In	O
summary	O
,	O
this	O
is	O
one	O
of	O
the	O
largest	O
series	O
of	O
ACS	I
problems	O
in	O
patients	I
undergoing	O
OHT	I
bridged	O
to	O
transplant	I
with	O
MT	O
or	O
VAD	I
.	O

With	O
similar	O
incidence	I
in	O
MT	O
and	O
VAD	I
groups	O
,	O
ACS	I
consultations	I
and	O
operations	I
are	O
infrequent	O
with	O
high	O
mortality	I
and	O
morbidity	I
.	O

Unilateral	I
renal	I
denervation	I
improves	O
autonomic	I
balance	I
in	O
conscious	O
rabbits	O
with	O
chronic	I
heart	I
failure	I
.	O

A	O
hallmark	O
of	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
is	O
an	O
increased	O
sympathetic	I
tone	I
resulting	O
in	O
autonomic	I
imbalance	I
.	O

Renal	I
denervation	I
(	O
DNx	I
)	O
in	O
CHF	I
patients	I
has	O
resulted	O
in	O
symptomatic	I
improvement	O
,	O
but	O
the	O
protective	O
mechanisms	O
remain	O
unclear	O
.	O

We	O
hypothesized	O
in	O
CHF	I
,	O
unilateral	I
renal	I
DNx	I
would	O
improve	O
cardiac	I
autonomic	I
balance	I
.	O

The	O
present	O
study	O
used	O
conscious	O
,	O
chronically	O
instrumented	O
New	O
Zealand	O
White	O
rabbits	O
undergoing	O
renal	I
DNx	I
prior	O
to	O
pacing-induced	I
CHF	I
.	O

Four	O
treatment	O
groups	O
were	O
used	O
:	O
nonpace	O
,	O
non-DNx	I
[	O
Sham-Innervated	O
(	O
Sham-INV	O
)	O
]	O
,	O
nonpace	O
DNx	I
(	O
sham-DNx	I
)	O
,	O
pace	O
non-DNx	I
(	O
CHF-INV	I
)	O
or	O
pace	O
DNx	I
(	O
CHF-DNx	I
)	O
.	O

We	O
examined	O
several	O
markers	O
indicative	O
of	O
autonomic	I
balance	I
.	O

Baroreflex	I
sensitivity	I
and	O
time	O
domain	O
heart	I
rate	I
variability	I
(	O
HRV	I
)	O
were	O
both	O
decreased	O
in	O
the	O
CHF-INV	I
group	O
compared	O
with	O
sham-INV	O
and	O
were	O
restored	O
to	O
sham	O
levels	O
by	O
renal	I
DNx	I
.	O

Power	I
spectral	I
analysis	I
indicated	O
an	O
increase	O
in	O
low-frequency	O
/	O
high-frequency	O
(	O
LF	O
/	O
HF	O
)	O
ratio	O
in	O
the	O
CHF-INV	I
compared	O
with	O
the	O
sham-INV	O
,	O
which	O
was	O
normalized	O
to	O
sham	O
levels	O
by	O
DNx	I
.	O

To	O
assess	O
whether	O
this	O
was	O
due	O
to	O
a	O
withdrawal	O
of	O
sympathetic	I
tone	I
or	O
an	O
increase	O
in	O
parasympathetic	I
tone	I
,	O
the	O
heart	I
rate	I
response	O
was	O
measured	O
after	O
an	O
intravenous	I
bolus	I
of	O
metoprolol	I
or	O
atropine	I
.	O

Bradycardia	I
induced	O
by	O
intravenous	I
metoprolol	I
(	O
indicative	O
of	O
cardiac	I
sympathetic	I
tone	I
)	O
was	O
exacerbated	O
in	O
CHF-INV	I
rabbits	O
compared	O
with	O
sham-INV	O
but	O
was	O
normalized	O
in	O
CHF-DNx	I
.	O

Conversely	O
,	O
the	O
tachycardia	I
in	O
response	O
to	O
intravenous	I
atropine	I
(	O
indicative	O
of	O
cardiac	I
vagal	I
tone	I
)	O
was	O
not	O
improved	O
in	O
CHF-DNx	I
vs.	O
CHF-INV	I
animals	O
.	O

Renal	I
DNx	I
also	O
prevented	O
the	O
increase	O
in	O
circulating	O
plasma	I
NE	O
seen	O
in	O
CHF-INV	I
rabbits	O
.	O

These	O
results	O
suggest	O
renal	I
DNx	I
improves	O
cardiac	I
autonomic	I
balance	I
in	O
CHF	I
by	O
a	O
reduction	O
of	O
sympathetic	I
tone	I
.	O

Nitroxyl	I
(	O
HNO	I
)	O
:	O
A	O
novel	O
approach	O
for	O
the	O
acute	I
treatment	O
of	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

The	O
nitroxyl	I
(	O
HNO	I
)	O
donor	I
,	O
Angeli	I
's	I
salt	I
,	O
exerts	O
positive	O
inotropic	I
,	O
lusitropic	I
,	O
and	O
vasodilator	I
effects	O
in	I
vivo	I
that	O
are	O
cAMP	I
independent	O
.	O

Its	O
clinical	I
usefulness	O
is	O
limited	O
by	O
chemical	O
instability	O
and	O
cogeneration	O
of	O
nitrite	I
which	O
itself	O
has	O
vascular	I
effects	O
.	O

Here	O
,	O
we	O
report	O
on	O
effects	O
of	O
a	O
novel	O
,	O
stable	O
,	O
pure	O
HNO	I
donor	I
(	O
CXL-1020	I
)	O
in	O
isolated	O
myoctyes	I
and	O
intact	O
hearts	I
in	O
experimental	O
models	O
and	O
in	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

CXL-1020	I
converts	O
solely	O
to	O
HNO	I
and	O
inactive	O
CXL-1051	I
with	O
a	O
t1	O
/	O
2	O
of	O
2	O
minutes	O
.	O

In	O
adult	O
mouse	O
ventricular	I
myocytes	I
,	O
it	O
dose	O
dependently	O
increased	O
sarcomere	I
shortening	O
by	O
75	O
%	O
to	O
210	O
%	O
(	O
50	O
-	O
500	O
μmol	O
/	O
L	O
)	O
,	O
with	O
a	O
≈30	O
%	O
rise	O
in	O
the	O
peak	O
Ca	I
(	I
2	I
+	I
)	I
transient	O
only	O
at	O
higher	O
doses	O
.	O

Neither	O
inhibition	O
of	O
protein	I
kinase	I
A	I
nor	O
soluble	O
guanylate	I
cyclase	I
altered	O
this	O
contractile	I
response	I
.	O

Unlike	O
isoproterenol	I
,	O
CXL-1020	I
was	O
equally	O
effective	O
in	O
myocytes	I
from	O
normal	O
or	O
failing	O
hearts	I
.	O

In	O
anesthetized	I
dogs	O
with	O
coronary	I
microembolization-induced	I
HF	I
,	O
CXL-1020	I
reduced	O
left	I
ventricular	I
end-diastolic	I
pressure	I
and	O
myocardial	I
oxygen	I
consumption	I
while	O
increasing	O
ejection	I
fraction	I
from	O
27	O
%	O
to	O
40	O
%	O
and	O
maximal	I
ventricular	I
power	I
index	I
by	O
42	O
%	O
(	O
both	O
P	I
<	O
0.05	O
)	O
.	O

In	O
conscious	O
dogs	O
with	O
tachypacing-induced	I
HF	I
,	O
CXL-1020	I
increased	O
contractility	I
assessed	O
by	O
end-systolic	I
elastance	I
and	O
provided	O
venoarterial	I
dilation	I
.	O

Heart	I
rate	I
was	O
minimally	O
altered	O
.	O

In	O
patients	I
with	O
systolic	I
HF	I
,	O
CXL-1020	I
reduced	O
both	O
left	I
and	O
right	I
heart	I
filling	I
pressures	I
and	O
systemic	I
vascular	I
resistance	I
,	O
while	O
increasing	O
cardiac	I
and	O
stroke	I
volume	I
index	I
.	O

Heart	I
rate	I
was	O
unchanged	O
,	O
and	O
arterial	I
pressure	I
declined	O
modestly	O
.	O

CONCLUSIONS	O
:	O

These	O
data	O
show	O
the	O
functional	O
efficacy	O
of	O
a	O
novel	O
pure	O
HNO	I
donor	I
to	O
enhance	O
myocardial	I
function	I
and	O
present	O
first-in-man	O
evidence	O
for	O
its	O
potential	O
usefulness	O
in	O
HF	I
.	O

Treatment	O
of	O
anemia	I
in	O
patients	I
with	O
heart	I
disease	I
:	O
a	O
clinical	I
practice	I
guideline	I
from	O
the	O
American	O
College	O
of	O
Physicians	I
.	O

Description	O
:	O
The	O
American	O
College	O
of	O
Physicians	I
(	O
ACP	O
)	O
developed	O
this	O
guideline	O
to	O
present	O
the	O
evidence	O
and	O
provide	O
clinical	I
recommendations	O
on	O
the	O
treatment	O
of	O
anemia	I
and	O
iron	O
deficiency	O
in	O
adult	O
patients	I
with	O
heart	I
disease	I
.	O

Methods	O
:	O
This	O
guideline	O
is	O
based	O
on	O
published	O
literature	O
in	O
the	O
English	O
language	O
on	O
anemia	I
and	O
iron	O
deficiency	O
from	O
1947	O
to	O
July	O
2012	O
that	O
was	O
identified	O
using	O
MEDLINE	O
and	O
the	O
Cochrane	O
Library	O
.	O

Literature	O
was	O
reassessed	O
in	O
April	O
2013	O
,	O
and	O
additional	O
studies	O
were	O
included	O
.	O

Outcomes	I
evaluated	O
for	O
this	O
guideline	O
included	O
mortality	I
;	O
hospitalization	I
;	O
exercise	I
tolerance	I
;	O
quality	I
of	I
life	I
;	O
and	O
cardiovascular	I
events	I
(	O
defined	O
as	O
myocardial	I
infarction	I
,	O
congestive	I
heart	I
failure	I
exacerbation	O
,	O
arrhythmia	I
,	O
or	O
cardiac	I
death	I
)	O
and	O
harms	O
,	O
including	O
hypertension	I
,	O
venous	I
thromboembolic	I
events	I
,	O
and	O
ischemic	I
cerebrovascular	I
events	I
.	O

The	O
target	O
audience	O
for	O
this	O
guideline	O
includes	O
all	O
clinicians	I
,	O
and	O
the	O
target	O
patient	I
population	O
is	O
anemic	I
or	O
iron-deficient	O
adult	O
patients	I
with	O
heart	I
disease	I
.	O

This	O
guideline	O
grades	O
the	O
evidence	O
and	O
recommendations	O
using	O
the	O
ACP	O
's	O
clinical	I
practice	I
guidelines	I
grading	O
system	O
.	O

Recommendation	O
1	O
:	O
ACP	O
recommends	O
using	O
a	O
restrictive	O
red	I
blood	I
cell	I
transfusion	I
strategy	O
(	O
trigger	O
hemoglobin	I
threshold	O
of	O
7	O
to	O
8	O
g	O
/	O
dL	O
compared	O
with	O
higher	O
hemoglobin	I
levels	O
)	O
in	O
hospitalized	I
patients	I
with	O
coronary	I
heart	I
disease	I
.	O

(	O
Grade	O
:	O
weak	O
recommendation	O
;	O
low-quality	O
evidence	O
)	O

Recommendation	O
2	O
:	O
ACP	O
recommends	O
against	O
the	O
use	O
of	O
erythropoiesis-stimulating	I
agents	I
in	O
patients	I
with	O
mild	O
to	O
moderate	O
anemia	I
and	O
congestive	I
heart	I
failure	I
or	O
coronary	I
heart	I
disease	I
.	O

(	O
Grade	O
:	O
strong	O
recommendation	O
;	O
moderate-quality	O
evidence	O
)	O

Therapeutic	I
implications	O
of	O
biomarkers	I
in	O
chronic	I
heart	I
failure	I
.	O

Understanding	O
of	O
chronic	I
heart	I
failure	I
(	O
HF	I
)	O
has	O
progressed	O
from	O
the	O
concept	O
of	O
a	O
purely	O
hemodynamic	I
disorder	O
to	O
that	O
of	O
a	O
syndrome	I
that	O
results	O
from	O
dysfunction	I
in	O
interconnected	O
molecular	I
pathways	I
.	O

As	O
a	O
result	O
,	O
the	O
focus	O
of	O
research	O
investigations	O
and	O
clinical	I
care	O
has	O
shifted	O
to	O
measurement	O
and	O
modification	O
of	O
maladaptive	O
molecular	O
processes	O
.	O

Accumulating	O
evidence	O
shows	O
that	O
molecular	O
biomarkers	I
provide	O
a	O
window	O
into	O
the	O
pathophysiology	I
of	O
chronic	I
HF	I
and	O
therefore	O
have	O
important	O
therapeutic	I
implications	O
.	O

However	O
,	O
the	O
use	O
of	O
biomarkers	I
in	O
the	O
treatment	O
of	O
HF	I
remains	O
in	O
its	O
infancy	O
.	O

This	O
is	O
partly	O
a	O
result	O
of	O
shortcomings	O
in	O
research	O
studies	O
and	O
a	O
dearth	O
of	O
biomarker-guided	I
clinical	I
trials	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
potential	O
therapeutic	I
implications	O
of	O
promising	O
biomarkers	I
that	O
uniquely	O
capture	O
the	O
molecular	I
dysfunction	I
that	O
occurs	O
in	O
chronic	I
HF	I
.	O

We	O
discuss	O
the	O
need	O
for	O
strict	O
statistical	O
standards	O
in	O
biomarker	I
studies	O
,	O
provide	O
an	O
overview	O
of	O
biomarker-guided	I
clinical	I
trial	O
design	O
,	O
and	O
discuss	O
the	O
therapeutic	I
potential	O
of	O
a	O
multimarker-based	O
strategy	O
.	O

A	O
simple	O
validated	O
clinical	I
tool	O
to	O
predict	O
the	O
absence	O
of	O
coronary	I
artery	I
disease	I
in	O
patients	I
with	O
systolic	I
heart	I
failure	I
of	O
unclear	O
etiology	I
.	O

Coronary	I
artery	I
disease	I
(	O
CAD	I
)	O
is	O
a	O
major	O
cause	O
of	O
systolic	I
heart	I
failure	I
(	O
HF	I
)	O
.	O

Identifying	O
CAD	I
as	O
a	O
cause	O
of	O
systolic	I
HF	I
has	O
prognostic	I
and	O
treatment	O
implications	O
.	O

Whether	O
all	O
patients	I
with	O
systolic	I
HF	I
of	O
unclear	O
etiology	I
should	O
undergo	O
coronary	I
angiography	I
has	O
been	O
controversial	O
.	O

We	O
sought	O
to	O
derive	O
and	O
validate	O
a	O
clinical	I
prediction	O
rule	O
to	O
exclude	O
CAD	I
as	O
a	O
cause	O
of	O
systolic	I
HF	I
.	O

A	O
derivation	O
cohort	O
was	O
formed	O
of	O
consecutive	O
patients	I
who	O
had	O
undergone	O
coronary	I
angiography	I
with	O
a	O
primary	O
diagnosis	I
of	O
systolic	I
HF	I
of	O
unclear	O
etiology	I
(	O
ejection	I
fraction	I
<	O
50	O
%	O
)	O
.	O

Using	O
multivariate	I
logistic	I
regression	I
analysis	I
,	O
we	O
derived	O
a	O
prediction	O
rule	O
for	O
severe	O
CAD	I
(	O
≥50	O
%	O
diameter	O
stenosis	I
in	O
the	O
left	O
main	O
,	O
3-vessel	I
CAD	I
,	O
and	O
2-vessel	I
CAD	I
involving	O
the	O
proximal	O
left	I
anterior	I
descending	I
artery	I
)	O
.	O

The	O
diagnostic	I
performance	O
of	O
the	O
defined	O
prediction	O
rule	O
was	O
prospectively	I
validated	O
in	O
a	O
separate	O
cohort	O
recruited	O
from	O
2	O
institutions	O
.	O

Of	O
the	O
124	O
patients	I
in	O
the	O
derivation	O
cohort	O
,	O
27	O
%	O
had	O
CAD	I
,	O
including	O
15	O
%	O
with	O
severe	O
CAD	I
.	O

The	O
independent	O
predictors	O
of	O
severe	O
CAD	I
included	O
diabetes	I
(	O
odds	I
ratio	I
5.1	O
,	O
p	I
=	O
0.005	O
)	O
,	O
electrocardiographic	I
Q	I
waves	I
or	O
left	I
bundle	I
branch	I
block	I
(	O
odds	I
ratio	I
3.8	O
,	O
p	I
=	O
0.02	O
)	O
,	O
and	O
≥2	O
nondiabetes	I
risk	O
factors	O
:	O
age	O
(	O
men	O
≥55	O
or	O
women	O
≥65	O
years	O
)	O
,	O
dyslipidemia	I
,	O
hypertension	I
,	O
and	O
tobacco	O
use	O
(	O
odds	I
ratio	I
4.8	O
,	O
p	I
=	O
0.02	O
)	O
.	O

A	O
prediction	O
rule	O
of	O
having	O
≥1	O
independent	O
predictor	O
identified	O
97	O
%	O
of	O
the	O
patients	I
with	O
CAD	I
and	O
100	O
%	O
of	O
the	O
patients	I
with	O
severe	O
CAD	I
.	O

In	O
the	O
prospective	I
validation	O
cohort	O
of	O
143	O
patients	I
,	O
the	O
prediction	O
rule	O
had	O
98	O
%	O
sensitivity	I
and	O
18	O
%	O
specificity	I
for	O
CAD	I
but	O
100	O
%	O
sensitivity	I
for	O
severe	O
CAD	I
.	O

In	O
conclusion	O
,	O
a	O
simple	O
clinical	I
prediction	O
rule	O
can	O
accurately	O
identify	O
patients	I
with	O
CAD	I
and	O
eliminate	O
the	O
need	O
for	O
angiography	I
in	O
a	O
substantial	O
proportion	O
of	O
patients	I
with	O
systolic	I
HF	I
,	O
with	O
potentially	O
significant	I
cost	O
savings	O
and	O
risk	O
avoidance	O
.	O

Change	O
in	O
readmissions	I
and	O
follow-up	I
visits	O
as	O
part	O
of	O
a	O
heart	I
failure	I
readmission	I
quality	O
improvement	O
initiative	O
.	O

OBJECTIVES	O
:	O

The	O
study	O
objectives	O
were	O
to	O
quantify	O
the	O
change	O
in	O
7-day	O
follow-up	I
visits	O
and	O
30-day	O
readmissions	I
as	O
part	O
of	O
a	O
hospital	I
quality	O
improvement	O
initiative	O
and	O
to	O
characterize	O
events	O
at	O
7-day	O
follow-up	I
visits	O
.	O

Some	O
data	O
suggest	O
that	O
outpatient	I
assessments	O
of	O
patients	I
with	O
heart	I
failure	I
within	O
7	O
days	O
of	O
hospital	I
discharge	I
may	O
prevent	O
readmissions	I
,	O
although	O
little	O
is	O
known	O
about	O
patient	I
needs	O
at	O
7-day	O
follow-up	I
visits	O
.	O

METHODS	O
:	O

We	O
performed	O
a	O
single-center	O
,	O
retrospective	O
chart	O
review	O
of	O
all	O
heart	I
failure	I
discharges	I
at	O
the	O
University	O
of	O
Connecticut	O
Health	I
Center	O
(	O
398	O
patients	I
)	O
the	O
year	O
before	O
(	O
2008	O
)	O
and	O
the	O
year	O
after	O
(	O
2011	O
)	O
a	O
quality	O
improvement	O
initiative	O
that	O
included	O
mandatory	O
7-day	O
follow-up	I
visits	O
.	O

We	O
quantified	O
the	O
change	O
in	O
30-day	O
readmission	I
rate	O
after	O
the	O
initiative	O
,	O
frequency	O
of	O
7-day	O
follow-up	I
visits	O
,	O
and	O
events	O
at	O
follow-up	I
visits	O
.	O

RESULTS	O
:	O

The	O
average	O
age	O
of	O
patients	I
with	O
heart	I
failure	I
was	O
79.9	O
years	O
in	O
2011	O
,	O
with	O
45.9	O
%	O
having	O
systolic	I
heart	I
failure	I
.	O

Thirty-day	O
all-cause	I
readmissions	I
decreased	O
from	O
27.5	O
%	O
to	O
19.1	O
%	O
after	O
our	O
quality	O
improvement	O
initiative	O
(	O
P	I
=	O
.024	O
)	O
.	O

Frequency	O
of	O
7-day	O
follow-up	I
visits	O
increased	O
from	O
19.6	O
%	O
to	O
46.9	O
%	O
(	O
P	I
<	O
.01	O
)	O
.	O

Eighty-one	O
percent	O
of	O
7-day	O
visits	O
occurred	O
in	O
the	O
University	O
of	O
Connecticut	O
Heart	I
Failure	I
Center	O
with	O
a	O
cardiologist	O
or	O
heart	I
failure	I
nurse	I
practitioner	I
.	O

Fifty-one	O
percent	O
of	O
patients	I
had	O
blood	I
work	O
drawn	O
,	O
and	O
26	O
%	O
had	O
a	O
medication	I
dose	O
changed	O
.	O

Only	O
13	O
%	O
of	O
patients	I
had	O
no	O
discrepancy	O
between	O
the	O
discharge	I
and	O
follow-up	I
medication	I
lists	O
.	O

CONCLUSIONS	O
:	O

Our	O
hospital	I
's	O
30-day	O
readmission	I
rate	O
for	O
patients	I
with	O
heart	I
failure	I
decreased	O
in	O
parallel	O
with	O
an	O
increase	O
in	O
7-day	O
follow-up	I
visits	O
.	O

Patients	I
with	O
heart	I
failure	I
were	O
complex	O
and	O
often	O
had	O
diagnostic	I
testing	O
and	O
medication	I
changes	O
at	O
follow-up	I
visits	O
.	O

Mitral	I
stenosis	I
reversed	O
by	O
medical	I
treatment	I
for	O
heart	I
failure	I
.	O

It	O
is	O
reported	O
that	O
functional	I
mitral	I
stenosis	I
frequently	O
develops	O
after	O
ring	I
annuloplasty	I
for	O
ischemic	I
mitral	I
regurgitation	I
.	O

The	O
mechanism	O
is	O
a	O
combination	O
of	O
annular	O
size	O
reduction	O
by	O
surgery	I
and	O
diastolic	I
mitral	I
valve	I
tethering	I
,	O
restricting	O
the	O
anterior	I
leaflet	I
opening	O
due	O
to	O
posteriorly	O
displaced	O
papillary	I
muscles	I
with	O
left	I
ventricular	I
dilatation	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
57-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
successful	O
mitral	I
valve	I
plasty	I
for	O
degenerative	I
mitral	I
regurgitation	I
.	O

Four	O
years	O
later	O
he	O
developed	O
heart	I
failure	I
,	O
severe	O
hypertension	I
,	O
mild	O
mitral	I
regurgitation	I
,	O
and	O
significant	I
mitral	I
stenosis	I
,	O
which	O
were	O
reversed	O
by	O
aggressive	O
medical	I
treatment	I
for	O
heart	I
failure	I
.	O

Functional	I
mitral	I
stenosis	I
(	O
MS	I
)	O
frequently	O
develops	O
after	O
ring	I
annuloplasty	I
for	O
ischemic	I
mitral	I
regurgitation	I
(	O
MR	I
)	O
.	O

The	O
mechanism	O
is	O
a	O
combination	O
of	O
annular	O
size	O
reduction	O
by	O
surgery	I
and	O
diastolic	I
mitral	I
valve	I
tethering	I
,	O
restricting	O
the	O
anterior	I
leaflet	I
opening	O
due	O
to	O
posteriorly	O
displaced	O
papillary	I
muscles	I
with	O
left	I
ventricular	I
(	O
LV	I
)	O
dilatation	I
.	O

Functional	I
MS	I
has	O
not	O
been	O
reported	O
in	O
patients	I
with	O
degenerative	I
MR	I
.	O

However	O
,	O
functional	I
MS	I
could	O
develop	O
even	O
in	O
patients	I
with	O
a	O
history	O
of	O
successful	O
valve	I
plasty	I
and	O
annular	O
size	O
reduction	O
for	O
degenerative	I
MR	I
if	O
the	O
LV	I
were	O
dilated	I
by	O
another	O
disease	I
.	O

In	O
addition	O
,	O
because	O
functional	I
MS	I
is	O
dynamic	O
and	O
proportional	O
to	O
LV	I
dilatation	I
,	O
treatment	O
for	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
acting	O
to	O
reduce	O
the	O
LV	I
size	O
,	O
can	O
potentially	O
improve	O
such	O
functional	I
MS	I
.	O

A	O
52-year-old	O
man	O
had	O
HF	I
with	O
severe	O
MR	I
due	O
to	O
prolapse	I
of	O
a	O
degenerative	I
mitral	I
valve	I
in	O
2008	O
.	O

He	O
had	O
grade	I
4	I
/	I
6	I
holosystolic	I
murmur	I
and	O
a	O
third	I
heart	I
sound	I
in	O
the	O
apex	I
.	O

His	O
blood	I
pressure	I
was	O
120	O
/	O
70	O
mm	O
Hg	O
,	O
he	O
underwent	O
mitral	I
valve	I
plasty	I
for	O
degenerative	I
MR	I
,	O
he	O
had	O
P3	I
prolapse	I
with	O
2	O
chordal	I
ruptures	I
and	O
he	O
underwent	O
triangular	I
resection	I
,	O
edge-to-edge	I
anastomosis	I
,	O
and	O
ring	I
annuloplasty	I
with	O
a	O
Physio	O
Ring	O
30	O
(	O
Edwards	O
Lifesciences	O
,	O
Irvine	O
,	O
CA	O
)	O
of	O
just	O
size	O
.	O

After	O
the	O
surgery	I
,	O
HF	I
disappeared	O
and	O
postoperative	I
echocardiography	I
confirmed	O
a	O
normal	O
sized	O
LV	I
with	O
an	O
end-diastolic	I
volume	I
index	I
of	O
71	O
mL	O
/	O
m2	O
,	O
normal	O
LV	I
ejection	I
fraction	I
of	O
0.70	O
,	O
no	O
MR	I
and	O
preserved	O
mitral	I
valve	I
opening	I
with	O
a	O
mitral	I
valve	I
area	I
(	O
MVA	I
)	O
of	O
1.8	O
cm2	O
,	O
and	O
a	O
mean	O
pressure	O
gradient	O
of	O
4.4	O
mm	O
Hg	O
(	O
Fig	O
1A	O
)	O
.	O

The	O
MVA	I
was	O
obtained	O
by	O
a	O
continuity	I
equation	I
(	O
LV	I
end-diastolic	I
volume	I
-	O
LV	I
end-systolic	I
volume	I
=	O
mitral	I
filling	I
flow	I
volume	O
=	O
MVA	I
×	O
velocity	O
time	O
integral	O
of	O
mitral	I
filling	I
flow	I
by	O
continuous	I
wave	I
Doppler	I
echocardiography	I
)	O
,	O
which	O
can	O
be	O
utilized	O
even	O
in	O
the	O
presence	O
of	O
MR	I
.	O

His	O
mitral	I
valve	I
plasty	I
was	O
successfully	O
performed	O
without	O
major	O
concerns	O
.	O

He	O
developed	O
HF	I
again	O
4	O
years	O
later	O
.	O

This	O
time	O
,	O
he	O
had	O
severe	O
hypertension	I
of	O
191	O
/	O
104	O
mm	O
Hg	O
,	O
diabetes	I
mellitus	I
,	O
and	O
grade	O
2	O
to	O
3	O
/	O
6	O
systolic	I
as	O
well	O
as	O
diastolic	I
murmurs	I
were	O
audible	O
at	O
the	O
apex	I
.	O

Echocardiography	I
demonstrated	O
moderately	O
dilated	I
LV	I
with	O
an	O
end-diastolic	I
volume	I
index	I
of	O
84	O
mL	O
/	O
m2	O
,	O
reduced	O
LV	I
ejection	I
fraction	I
of	O
0.40	O
,	O
mild	O
MR	I
,	O
and	O
limited	O
mitral	I
valve	I
opening	I
,	O
resulting	O
in	O
a	O
significant	I
MS	I
with	O
an	O
MVA	I
of	O
1.2	O
cm2	O
and	O
a	O
mean	O
pressure	O
gradient	O
of	O
8.4	O
mm	O
Hg	O
(	O
Fig	O
1B	O
)	O
.	O

Coronary	I
angiography	I
revealed	O
no	O
significant	I
lesions	I
in	O
the	O
major	O
branches	O
.	O

The	O
patient	I
was	O
diagnosed	I
as	O
hypertensive	I
LV	I
dysfunction	I
with	O
mild	O
MR	I
and	O
significant	I
MS	I
.	O

Both	O
systolic	I
and	O
diastolic	I
mitral	I
leaflet	I
motions	I
were	O
restricted	O
without	O
any	O
clear	O
organic	I
lesion	I
.	O

The	O
etiology	I
of	O
the	O
MR	I
and	O
MS	I
was	O
diagnosed	I
as	O
functional	O
.	O

As	O
significant	I
MS	I
was	O
associated	O
with	O
HF	I
,	O
surgical	I
indication	O
for	O
MS	I
was	O
discussed	O
.	O

The	O
possibility	O
of	O
MS	I
to	O
improve	O
after	O
medical	I
treatment	I
for	O
HF	I
was	O
considered	O
because	O
functional	I
MS	I
is	O
highly	O
dynamic	O
and	O
can	O
potentially	O
respond	O
to	O
medical	I
treatment	I
.	O

Consequently	O
,	O
surgery	I
was	O
not	O
performed	O
and	O
aggressive	O
medical	I
treatment	I
for	O
HF	I
and	O
hypertension	I
with	O
vasodilators	I
and	O
diuretics	I
was	O
started	O
.	O

His	O
HF	I
symptom	I
as	O
well	O
as	O
cardiac	I
murmurs	I
disappeared	O
with	O
a	O
reduction	O
in	O
blood	I
pressure	I
to	O
140	O
/	O
80	O
mm	O
Hg	O
.	O

Repeated	O
echocardiography	I
4	O
months	O
later	O
demonstrated	O
a	O
reduction	O
in	O
LV	I
end-diastolic	I
volume	I
of	O
66	O
mL	O
/	O
m2	O
,	O
disappearance	O
of	O
MR	I
,	O
improvement	O
of	O
the	O
mitral	I
valve	I
opening	I
to	O
an	O
MVA	I
of	O
1.7	O
cm2	O
,	O
and	O
a	O
mean	O
pressure	O
gradient	O
of	O
4.6	O
mm	O
Hg	O
(	O
Fig	O
1	O
C	O
)	O
.	O

In	O
this	O
patient	I
there	O
was	O
no	O
MS	I
before	O
the	O
surgery	I
by	O
echocardiography	I
.	O

Direct	O
observation	O
at	O
the	O
time	O
of	O
surgery	I
also	O
confirmed	O
no	O
findings	O
of	O
rheumatic	I
or	O
other	O
causes	O
of	O
MS	I
.	O

After	O
the	O
surgery	I
,	O
MVA	I
was	O
reduced	O
but	O
only	O
modestly	O
.	O

Possible	O
reasons	O
for	O
the	O
modest	O
reduction	O
in	O
MVA	I
could	O
be	O
annular	O
size	O
reduction	O
by	O
the	O
surgical	I
ring	O
implantation	I
and	O
mild	O
restriction	O
of	O
leaflet	I
motion	O
by	O
the	O
leaflet	I
resection	O
and	O
edge-to-edge	I
anastomosis	I
.	O

However	O
,	O
the	O
degree	O
of	O
MS	I
early	O
after	O
surgery	I
was	O
not	O
significant	I
,	O
with	O
an	O
MVA	I
of	O
1.8	O
cm2	O
.	O

Mitral	I
regurgitation	I
as	O
well	O
as	O
HF	I
symptoms	I
disappeared	O
after	O
the	O
surgery	I
.	O

Therefore	O
,	O
the	O
surgery	I
was	O
successful	O
.	O

However	O
,	O
this	O
patient	I
developed	O
HF	I
4	O
years	O
later	O
.	O

At	O
this	O
time	O
,	O
he	O
had	O
severe	O
hypertension	I
,	O
moderate	O
LV	I
dilatation	I
,	O
LV	I
dysfunction	I
,	O
mild	O
MR	I
,	O
and	O
significant	I
MS	I
.	O

As	O
the	O
mitral	I
valve	I
demonstrated	O
restricted	O
closure	O
and	O
opening	O
without	O
any	O
clear	O
organic	I
lesion	I
,	O
being	O
consistent	O
with	O
systolic	I
and	O
diastolic	I
tethering	I
,	O
a	O
functional	O
etiology	I
of	O
MR	I
and	O
MS	I
was	O
considered	O
.	O

There	O
have	O
been	O
reports	O
demonstrating	O
development	O
of	O
functional	I
MS	I
following	O
ring	I
annuloplasty	I
for	O
ischemic	I
MR	I
with	O
LV	I
dilatation	I
.	O

This	O
patient	I
showed	O
that	O
functional	I
MS	I
could	O
develop	O
even	O
in	O
a	O
patient	I
with	O
successful	O
valve	I
plasty	I
for	O
degenerative	I
MR	I
,	O
if	O
the	O
LV	I
is	O
dilated	I
by	O
another	O
disease	I
.	O

Because	O
functional	I
MS	I
is	O
dynamic	O
and	O
proportional	O
to	O
LV	I
dilatation	I
,	O
the	O
degree	O
of	O
functional	I
MS	I
can	O
potentially	O
vary	O
considerably	O
.	O

At	O
the	O
time	O
of	O
second	O
HF	I
4	O
years	O
after	O
valve	I
plasty	I
,	O
MS	I
was	O
significant	I
with	O
an	O
MVA	I
of	O
1.2	O
cm2	O
.	O

According	O
to	O
the	O
guideline	O
,	O
the	O
MS	I
at	O
that	O
time	O
could	O
be	O
considered	O
indicative	O
for	O
surgery	I
.	O

After	O
aggressive	O
medical	I
treatment	I
for	O
HF	I
,	O
the	O
HF	I
symptom	I
disappeared	O
and	O
the	O
MS	I
was	O
reversed	O
to	O
an	O
MVA	I
of	O
1.7	O
cm2	O
.	O

At	O
this	O
point	O
,	O
insignificant	O
MS	I
can	O
be	O
considered	O
as	O
not	O
indicative	O
for	O
surgery	I
.	O

Therefore	O
,	O
the	O
surgical	I
indications	O
need	O
to	O
be	O
carefully	O
evaluated	O
in	O
patients	I
with	O
functional	I
MS	I
.	O

In	O
addition	O
to	O
the	O
leaflet	I
configurations	O
,	O
the	O
serial	O
evaluation	O
strongly	O
suggested	O
that	O
the	O
MS	I
in	O
this	O
patient	I
was	O
subvalvular	I
and	O
therefore	O
dynamic	O
,	O
as	O
opposed	O
to	O
annular	I
MS	I
with	O
a	O
fixed	O
ring	O
size	O
.	O

This	O
case	O
report	O
demonstrates	O
that	O
functional	I
MS	I
could	O
develop	O
even	O
in	O
a	O
patient	I
with	O
a	O
history	O
of	O
successful	O
valve	I
plasty	I
for	O
degenerative	I
MR	I
,	O
if	O
the	O
LV	I
is	O
dilated	I
by	O
another	O
disease	I
.	O

Functional	I
MS	I
can	O
potentially	O
be	O
reversed	O
by	O
medical	I
treatment	I
and	O
thus	O
requires	O
careful	O
evaluation	O
of	O
the	O
surgical	I
indications	O
.	O

Myocardial	I
loss	O
of	O
IRS1	I
and	O
IRS2	I
causes	O
heart	I
failure	I
and	O
is	O
controlled	O
by	O
p38alpha	I
MAPK	I
during	O
insulin	I
resistance	I
.	O

Cardiac	I
failure	I
is	O
a	O
major	O
cause	O
of	O
death	I
in	O
patients	I
with	O
type	I
2	I
diabetes	I
,	O
but	O
the	O
molecular	O
mechanism	O
that	O
links	O
diabetes	I
to	O
heart	I
failure	I
remains	O
unclear	O
.	O

Insulin	I
resistance	I
is	O
a	O
hallmark	O
of	O
type	I
2	I
diabetes	I
,	O
and	O
insulin	I
receptor	I
substrates	I
1	I
and	O
2	I
(	O
IRS1	I
and	O
IRS2	I
)	O
are	O
the	O
major	O
insulin-signaling	I
components	O
regulating	O
cellular	I
metabolism	I
and	O
survival	O
.	O

To	O
determine	O
the	O
role	O
of	O
IRS1	I
and	O
IRS2	I
in	O
the	O
heart	I
and	O
examine	O
whether	O
hyperinsulinemia	I
causes	O
myocardial	I
insulin	I
resistance	I
and	O
cellular	I
dysfunction	I
via	O
IRS1	I
and	O
IRS2	I
,	O
we	O
generated	O
heart-specific	I
IRS1	I
and	I
IRS2	I
gene	I
double-knockout	I
(	O
H-DKO	I
)	O
mice	O
and	O
liver-specific	I
IRS1	I
and	I
IRS2	I
double-knockout	I
(	O
L-DKO	I
)	O
mice	O
.	O

H-DKO	I
mice	O
had	O
reduced	O
ventricular	I
mass	I
;	O
developed	O
cardiac	I
apoptosis	I
,	O
fibrosis	I
,	O
and	O
failure	I
;	O
and	O
showed	O
diminished	O
Akt→forkhead	I
box	I
class	I
O-1	I
signaling	I
that	O
was	O
accompanied	O
by	O
impaired	O
cardiac	I
metabolic	I
gene	I
expression	I
and	O
reduced	O
ATP	I
content	O
.	O

L-DKO	I
mice	O
had	O
decreased	O
cardiac	I
IRS1	I
and	O
IRS2	I
proteins	I
and	O
exhibited	O
features	O
of	O
heart	I
failure	I
,	O
with	O
impaired	O
cardiac	I
energy	I
metabolism	I
gene	I
expression	I
and	O
activation	O
of	O
p38α	I
mitogen-activated	I
protein	I
kinase	I
(	O
p38	I
)	O
.	O

Using	O
neonatal	O
rat	O
ventricular	I
cardiomyocytes	I
,	O
we	O
further	O
found	O
that	O
chronic	I
insulin	I
exposure	O
reduced	O
IRS1	I
and	O
IRS2	I
proteins	I
and	O
prevented	O
insulin	I
action	O
through	O
activation	O
of	O
p38	I
,	O
revealing	O
a	O
fundamental	O
mechanism	O
of	O
cardiac	I
dysfunction	I
during	O
insulin	I
resistance	I
and	O
type	I
2	I
diabetes	I
.	O

The	O
high-risk	O
patient	I
with	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
:	O
treatment	O
options	O
and	O
challenges	O
.	O

An	O
estimated	O
5.1	O
million	O
Americans	O
aged	O
20	O
years	O
and	O
older	O
have	O
heart	I
failure	I
.	O
(	O

1	O
)	O
With	O
therapies	I
ranging	O
from	O
medication	I
and	O
physical	I
therapy	I
to	O
implantable	I
defibrillators	I
and	O
circulatory	I
support	I
,	O
and	O
possibly	O
transplantation	I
,	O
accurate	O
risk	I
stratification	I
of	O
patient	I
with	O
heart	I
failure	I
and	O
delivery	O
of	O
therapies	I
appropriate	O
to	O
the	O
level	O
of	O
their	O
disease	I
severity	O
is	O
becoming	O
increasingly	O
important	O
.	O

Determination	O
of	O
risk	O
and	O
associated	O
treatment	O
strategies	O
is	O
the	O
subject	O
of	O
this	O
brief	O
review	O
.	O

Right	I
atrial	I
myxoma	I
complicated	O
by	O
pulmonary	I
embolism	I
and	O
revealed	O
by	O
right	I
heart	I
failure	I
.	O

Myxomas	I
are	O
the	O
most	O
common	O
type	O
of	O
cardiac	I
benign	I
tumors	I
and	O
most	O
of	O
them	O
are	O
located	O
in	O
the	O
left	I
atrium	I
,	O
followed	O
by	O
the	O
right	I
atrium	I
.	O

Myxomas	I
in	O
the	O
right	I
atrium	I
may	O
rarely	O
embolize	I
to	O
the	O
pulmonary	I
arterial	I
vasculature	I
.	O

Here	O
,	O
we	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	I
with	O
right	I
atrial	I
myxoma	I
and	O
massive	I
embolism	I
to	O
the	O
pulmonary	I
arteries	I
treated	O
surgically	I
with	O
right	I
atrial	I
mass	O
removal	O
and	O
pulmonary	I
embolectomy	I
.	O

The	O
right	I
atrium	I
mass	O
presented	O
with	O
prolapse	I
through	O
the	O
tricuspid	I
valve	I
causing	O
a	O
stenotic	I
physiology	I
.	O

The	O
left	I
pulmonary	I
artery	I
was	O
completed	O
occluded	O
and	O
the	O
right	I
pulmonary	I
artery	I
was	O
partially	O
obstructed	O
.	O

Surgical	I
tactics	O
included	O
a	O
brief	O
hypothermic	I
circulatory	I
arrest	I
.	O

The	O
patient	I
had	O
an	O
uneventful	O
recovery	O
and	O
was	O
asymptomatic	I
after	O
6	O
months	O
of	O
follow-up	I
.	O

Practice-level	O
variation	O
in	O
use	O
of	O
recommended	O
medications	I
among	O
outpatients	I
with	O
heart	I
failure	I
:	O
Insights	O
from	O
the	O
NCDR	O
PINNACLE	O
program	O
.	O

BACKGROUND	O
:	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
examine	O
practice-level	O
variation	O
in	O
rates	O
of	O
guideline-recommended	O
treatment	O
for	O
outpatients	I
with	O
heart	I
failure	I
and	I
reduced	I
ejection	I
fraction	I
,	O
and	O
to	O
examine	O
the	O
association	O
between	O
treatment	O
variation	O
and	O
practice	O
site	O
,	O
independent	O
of	O
patient	I
factors	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Cardiology	I
practices	O
participating	O
in	O
the	O
National	O
Cardiovascular	I
Disease	I
Registry	O
Practice	O
Innovation	O
and	O
Clinical	I
Excellence	O
registry	O
from	O
July	O
2008	O
to	O
December	O
2010	O
were	O
evaluated	O
.	O

Practice	O
rates	O
of	O
treatment	O
with	O
angiotensin-converting	I
enzyme	I
inhibitors	I
/	O
angiotensin	I
receptor	I
blockers	I
and	O
β-blockers	I
and	O
an	O
optimal	O
combined	O
treatment	O
measure	O
were	O
determined	O
for	O
patients	I
with	O
heart	I
failure	I
and	I
reduced	I
ejection	I
fraction	I
and	O
no	O
documented	O
contraindications	O
.	O

Multivariable	O
hierarchical	O
regression	I
models	I
were	O
adjusted	O
for	O
demographics	O
,	O
insurance	O
status	O
,	O
and	O
comorbidities	I
.	O

A	O
median	O
rate	I
ratio	I
was	O
calculated	O
for	O
each	O
therapy	I
,	O
which	O
describes	O
the	O
likelihood	O
that	O
the	O
treatment	O
of	O
a	O
patient	I
with	O
given	O
comorbidities	I
would	O
differ	O
at	O
2	O
randomly	O
selected	O
practices	O
.	O

We	O
identified	O
12	O
556	O
patients	I
from	O
45	O
practices	O
.	O

The	O
unadjusted	O
practice-level	O
prescription	I
rates	O
ranged	O
from	O
44	O
%	O
to	O
100	O
%	O
for	O
angiotensin-converting	I
enzyme	I
inhibitors	I
/	O
angiotensin	I
receptor	I
blockers	I
(	O
median	O
,	O
85	O
%	O
;	O
interquartile	I
range	I
,	O
75%-89	O
%	O
)	O
,	O
from	O
49	O
%	O
to	O
100	O
%	O
for	O
β-blockers	I
(	O
median	O
,	O
92	O
%	O
;	O
interquartile	I
range	I
,	O
83%-95	O
%	O
)	O
,	O
and	O
from	O
37	O
%	O
to	O
100	O
%	O
for	O
optimal	O
combined	O
treatment	O
(	O
median	O
,	O
79	O
%	O
;	O
interquartile	I
range	I
,	O
66%-85	O
%	O
)	O
.	O

The	O
adjusted	O
median	O
rate	I
ratio	I
was	O
1.11	O
(	O
95	O
%	O
confidence	I
interval	I
,	O
1.08	O
-	O
1.18	O
)	O
for	O
angiotensin-converting	I
enzyme	I
inhibitors	I
/	O
angiotensin	I
receptor	I
blockers	I
therapy	I
,	O
1.08	O
(	O
95	O
%	O
confidence	I
interval	I
,	O
1.05	O
-	O
1.15	O
)	O
for	O
β-blockers	I
therapy	I
,	O
and	O
1.17	O
(	O
1.13	O
-	O
1.26	O
)	O
for	O
optimal	O
combined	O
treatment	O
.	O

CONCLUSIONS	O
:	O

Variation	O
in	O
the	O
use	O
of	O
guideline-recommended	O
medications	I
for	O
patients	I
with	O
heart	I
failure	I
and	I
reduced	I
ejection	I
fraction	I
exists	O
in	O
the	O
outpatient	I
setting	O
.	O

Addressing	O
practice-level	O
differences	O
may	O
be	O
an	O
important	O
component	O
of	O
improving	O
quality	O
of	O
care	O
for	O
patients	I
with	O
heart	I
failure	I
and	I
reduced	I
ejection	I
fraction	I
.	O

Experience	O
of	O
a	O
vasopressin	I
receptor	I
antagonist	I
,	O
tolvaptan	I
,	O
under	O
the	O
unique	O
indication	O
in	O
Japanese	O
heart	I
failure	I
patients	I
.	O

Tolvaptan	I
is	O
a	O
vasopressin	I
type	I
2	I
receptor	I
antagonist	I
.	O

Currently	O
,	O
tolvaptan	I
is	O
indicated	O
for	O
the	O
treatment	O
of	O
severe	O
hyponatremia	I
in	O
most	O
countries	O
,	O
including	O
the	O
United	O
States	O
,	O
but	O
in	O
Japan	O
the	O
indication	O
is	O
broader	O
;	O
it	O
can	O
be	O
used	O
in	O
congestive	I
heart	I
failure	I
patients	I
in	O
addition	O
to	O
standard	O
or	O
optimal	O
diuretic	I
therapy	I
,	O
regardless	O
of	O
their	O
serum	I
sodium	I
levels	O
or	O
systolic	I
function	I
.	O

Our	O
review	O
of	O
this	O
newly	O
introduced	O
drug	I
is	O
based	O
on	O
our	O
experience	O
in	O
Japan	O
.	O

Heart	I
failure	I
in	O
the	O
young	O
.	O

Heart	I
failure	I
is	O
an	O
enormous	O
clinical	I
burden	O
in	O
adult	O
medicine	I
,	O
largely	O
because	O
of	O
the	O
prevalence	I
of	O
atheromatous	O
coronary	I
disease	I
.	O

In	O
children	O
,	O
where	O
coronary	I
disease	I
is	O
not	O
the	O
leading	O
cause	O
of	O
heart	I
failure	I
,	O
it	O
is	O
less	O
common	O
.	O

It	O
is	O
,	O
however	O
,	O
an	O
important	O
disease	I
,	O
accounting	O
for	O
10	O
%	O
of	O
paediatric	O
cardiac	I
transplants	I
in	O
children	O
.	O

Cardiac	I
symptoms	I
in	O
children	O
are	O
usually	O
the	O
result	O
of	O
congenital	I
lesions	I
.	O

Most	O
of	O
these	O
lesions	I
,	O
such	O
as	O
septal	I
defects	O
,	O
are	O
amenable	O
to	O
surgical	I
intervention	O
.	O

It	O
is	O
not	O
appropriate	O
to	O
expand	O
on	O
the	O
management	O
of	O
congenital	I
heart	I
lesions	I
in	O
this	O
review	O
.	O

There	O
is	O
a	O
small	O
subgroup	O
of	O
children	O
that	O
have	O
diastolic	I
failure	I
from	O
cardiomyopathic	I
restriction	O
to	O
flow	O
.	O

The	O
remaining	O
patients	I
,	O
which	O
will	O
be	O
focused	O
on	O
below	O
,	O
have	O
heart	I
failure	I
that	O
is	O
principally	O
related	O
to	O
poor	O
myocardial	I
function	I
and	O
largely	O
comprise	O
those	O
children	O
with	O
dilated	I
poorly	O
contracting	I
ventricles	I
,	O
which	O
can	O
be	O
related	O
to	O
specific	O
aetiologies	I
in	O
some	O
cases	O
.	O

Particular	O
topics	O
of	O
debate	O
in	O
paediatric	O
heart	I
failure	I
concern	O
:	O

the	O
diagnosis	I
and	O
management	O
of	O
myocarditis	I
versus	O
dilated	I
cardiomyopathy	I

the	O
most	O
appropriate	O
investigations	O
for	O
new	O
onset	O
heart	I
failure	I

cellular	O
responses	O
to	O
heart	I
failure	I

the	O
increasing	O
population	O
of	O
anthracycline	I
treated	O
survivors	O
of	O
childhood	O
malignant	O
disease	I

treatment	O
strategies	O
.	O

Periodic	I
breathing	I
with	O
no	O
heart	I
beat	I
.	O

A	O
protocol	O
was	O
originally	O
designed	O
to	O
study	O
breathing	I
control	O
during	O
and	O
following	O
cardiac	I
arrest	I
in	O
humans	O
,	O
taking	O
advantage	O
of	O
the	O
period	O
of	O
pulseless	I
ventricular	I
fibrillation	I
(	O
PVF	I
)	O
produced	O
while	O
testing	O
a	O
newly	O
implanted	I
cardioverter-defibrillator	I
device	I
.	O

A	O
patient	I
aged	O
in	O
his	O
60s	O
with	O
New	I
York	I
Heart	I
Association	I
class	I
III	I
heart	I
failure	I
(	O
HF	I
)	O
(	O
left	I
ventricular	I
ejection	I
fraction	I
of	O
25	O
%	O
)	O
who	O
was	O
originally	O
part	O
of	O
this	O
study	O
displayed	O
permanent	O
periodic	I
breathing	I
(	O
PB	I
)	O
and	O
was	O
then	O
excluded	O
from	O
the	O
final	O
data	O
analysis	O
;	O
his	O
response	O
is	O
presented	O
in	O
this	O
report	O
.	O

The	O
8	O
-	O
to	O
9-s	O
PVF	I
was	O
incidentally	O
produced	O
during	O
the	O
ascending	O
phase	O
of	O
a	O
PB	I
cycle	O
,	O
followed	O
by	O
another	O
12-s	O
recovery	O
period	O
of	O
low	O
BP	I
.	O

PVF	I
and	O
its	O
recovery	O
had	O
no	O
effect	O
on	O
PB	I
characteristics	O
(	O
period	O
or	O
amplitude	O
)	O
.	O

This	O
occurred	O
despite	O
a	O
profound	O
change	O
in	O
Paco2	I
,	O
cerebral	I
blood	I
flow	I
,	O
and	O
perfusion	I
of	O
the	O
carotid	I
bodies	O
.	O

It	O
is	O
concluded	O
that	O
PB	I
in	O
patients	I
with	O
HF	I
could	O
be	O
produced	O
by	O
primary	O
oscillations	O
originating	O
from	O
the	O
central	O
pattern	O
generator	O
.	O

Effectiveness	O
of	O
Chinese	O
herbal	O
medicine	I
as	O
an	O
adjunctive	O
treatment	O
for	O
dilated	I
cardiomyopathy	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

OBJECTIVES	O
:	O

To	O
evaluate	O
the	O
effectiveness	O
and	O
safety	O
of	O
Chinese	O
herbal	O
medicine	I
(	O
CHM	O
)	O
as	O
an	O
adjunctive	O
treatment	O
for	O
patients	I
with	O
dilated	I
cardiomyopathy	I
(	O
DCM	I
)	O
and	O
heart	I
failure	I
.	O

DESIGN	O
:	O

Studies	O
on	O
biomedical	I
treatment	O
plus	O
CHM	O
versus	O
biomedical	I
treatment	O
alone	O
in	O
treating	O
patients	I
with	O
DCM	I
and	O
heart	I
failure	I
were	O
retrieved	O
from	O
PubMed	O
and	O
other	O
major	O
databases	O
(	O
1980	O
-	O
2011	O
)	O
.	O

Meta-analysis	I
was	O
performed	O
on	O
the	O
overall	O
effects	O
on	O
effective	O
rate	O
,	O
left	I
ventricular	I
ejection	I
fraction	I
,	O
left	I
ventricular	I
diastolic	I
end	I
diameter	I
,	O
and	O
other	O
outcome	I
measures	O
.	O

RESULTS	O
:	O

Twenty-seven	O
studies	O
with	O
1887	O
patients	I
were	O
included	O
.	O

Compared	O
with	O
biomedical	I
treatment	O
alone	O
,	O
biomedical	I
treatment	O
plus	O
CHM	O
showed	O
significant	I
improvement	O
in	O
effective	O
rate	O
(	O
relative	I
risk	I
,	O
1.26	O
;	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
,	O
1.19	O
-	O
1.34	O
)	O
,	O
left	I
ventricular	I
ejection	I
fraction	I
(	O
%	O
)	O
(	O
mean	O
difference	O
,	O
5.88	O
;	O
95	O
%	O
CI	I
,	O
3.92	O
-	O
7.85	O
)	O
,	O
left	I
ventricular	I
diastolic	I
end	I
diameter	I
(	O
mm	O
)	O
(	O
mean	O
difference	O
,	O
-	O
2.78	O
;	O
95	O
%	O
CI	I
,	O
-	O
5.15	O
to	O
-	O
0.42	O
)	O
,	O
and	O
other	O
outcome	I
measures	O
.	O

Most	O
adverse	I
events	I
observed	O
in	O
the	O
studies	O
were	O
not	O
severe	O
and	O
resolved	O
without	O
special	O
treatment	O
.	O

CONCLUSIONS	O
:	O

This	O
meta-analysis	I
indicated	O
that	O
biomedical	I
treatment	O
plus	O
CHM	O
is	O
more	O
effective	O
than	O
biomedical	I
treatment	O
alone	O
in	O
treating	O
patients	I
with	O
DCM	I
and	O
heart	I
failure	I
.	O

However	O
,	O
further	O
studies	O
with	O
long-term	O
follow-up	I
,	O
systemic	I
adverse	I
events	I
evaluation	O
,	O
and	O
other	O
ethnic	O
groups	O
are	O
still	O
required	O
to	O
verify	O
the	O
efficacy	O
and	O
safety	O
of	O
CHM	O
as	O
an	O
adjunctive	O
treatment	O
in	O
all	O
patients	I
with	O
DCM	I
and	O
heart	I
failure	I
.	O

beta1-adrenergic	I
receptor	I
and	O
sphingosine-1-phosphate	I
receptor	I
1	I
(	O
S1PR1	I
)	O
reciprocal	O
downregulation	I
influences	O
cardiac	I
hypertrophic	I
response	O
and	O
progression	O
to	O
heart	I
failure	I
:	O
protective	O
role	O
of	O
S1PR1	I
cardiac	I
gene	I
therapy	I
.	O

BACKGROUND	O
:	O

The	O
sphingosine-1-phosphate	I
receptor	I
1	I
(	O
S1PR1	I
)	O
and	O
β1-adrenergic	I
receptor	I
(	O
β1AR	I
)	O
are	O
G-protein-coupled	I
receptors	I
expressed	O
in	O
the	O
heart	I
.	O

These	O
2	O
receptors	I
have	O
opposing	O
actions	O
on	O
adenylyl	I
cyclase	I
because	O
of	O
differential	O
G-protein	I
coupling	I
.	O

Importantly	O
,	O
both	O
of	O
these	O
receptors	I
can	O
be	O
regulated	O
by	O
the	O
actions	O
of	O
G-protein-coupled	I
receptor	I
kinase-2	I
,	O
which	O
triggers	O
desensitization	O
and	O
downregulation	I
processes	O
.	O

Although	O
classic	O
signaling	O
paradigms	O
suggest	O
that	O
simultaneous	O
activation	O
of	O
β1ARs	I
and	O
S1PR1s	I
in	O
a	O
myocyte	I
would	O
simply	O
result	O
in	O
opposing	O
action	O
on	O
cAMP	I
production	O
,	O
in	O
this	O
report	O
we	O
have	O
uncovered	O
a	O
direct	O
interaction	O
between	O
these	O
2	O
receptors	I
,	O
with	O
regulatory	O
involvement	O
of	O
G-protein-coupled	I
receptor	I
kinase-2	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

In	O
HEK	I
(	O
human	I
embryonic	I
kidney	I
)	O
293	O
cells	I
overexpressing	O
both	O
β1AR	I
and	O
S1PR1	I
,	O
we	O
demonstrated	O
that	O
β1AR	I
downregulation	I
can	O
occur	O
after	O
stimulation	O
with	O
sphingosine-1-phosphate	I
(	O
an	O
S1PR1	I
agonist	I
)	O
,	O
whereas	O
S1PR1	I
downregulation	I
can	O
be	O
triggered	O
by	O
isoproterenol	I
(	O
a	O
β-adrenergic	I
receptor	I
agonist	I
)	O
treatment	O
.	O

This	O
cross	I
talk	I
between	O
these	O
2	O
distinct	O
G-protein-coupled	I
receptors	I
appears	O
to	O
have	O
physiological	I
significance	I
,	O
because	O
they	O
interact	O
and	O
show	O
reciprocal	O
regulation	O
in	O
mouse	O
hearts	I
undergoing	O
chronic	I
β-adrenergic	I
receptor	I
stimulation	O
and	O
in	O
a	O
rat	O
model	O
of	O
postischemic	I
heart	I
failure	I
.	O

CONCLUSIONS	O
:	O

We	O
demonstrate	O
that	O
restoration	O
of	O
cardiac	I
plasma	I
membrane	I
levels	O
of	O
S1PR1	I
produces	O
beneficial	O
effects	O
that	O
counterbalance	O
the	O
deleterious	O
β1AR	I
overstimulation	O
in	O
heart	I
failure	I
.	O

Impact	O
of	O
ejection	I
fraction	I
on	O
the	O
clinical	I
response	O
to	O
cardiac	I
resynchronization	I
therapy	I
in	O
mild	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Current	O
guidelines	O
recommend	O
cardiac	I
resynchronization	I
therapy	I
(	O
CRT	I
)	O
in	O
mild	I
heart	I
failure	I
(	O
HF	I
)	O
patients	I
with	O
QRS	I
prolongation	I
and	O
ejection	I
fraction	I
(	O
EF	I
)	O
≤30	O
%	O
.	O

To	O
assess	O
the	O
effect	O
of	O
CRT	I
in	O
less	O
severe	O
systolic	I
dysfunction	I
,	O
outcomes	I
in	O
the	O
REsynchronization	I
reVErses	O
Remodeling	I
in	O
Systolic	I
left	I
vEntricular	I
dysfunction	I
(	O
REVERSE	O
)	O
study	O
were	O
evaluated	O
in	O
which	O
patients	I
with	O
left	I
ventricular	I
(	O
LV	I
)	O
ejection	I
fraction	I
(	O
LVEF	I
)	O
>	O
30	O
%	O
were	O
included	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

The	O
results	O
of	O
patients	I
with	O
baseline	I
EF	I
>	O
30	O
%	O
(	O
n=177	O
)	O
and	O
those	O
with	O
EF	I
≤30	O
%	O
(	O
n=431	O
)	O
,	O
as	O
determined	O
by	O
a	O
blinded	O
core	O
laboratory	O
,	O
were	O
compared	O
.	O

In	O
the	O
LVEF	I
>	O
30	O
%	O
subgroup	O
,	O
there	O
was	O
a	O
trend	O
for	O
improvement	O
in	O
the	O
clinical	I
composite	O
response	O
with	O
CRT	I
ON	O
versus	O
CRT	I
OFF	O
(	O
P=0.06	I
)	O
and	O
significant	I
reductions	O
in	O
LV	I
end	O
systolic	I
volume	I
index	I
(	O
-	O
6.7	O
±	O
21.1	O
versus	O
2.1	O
±	O
17.6	O
mL	O
/	O
m	O
(	O
2	O
)	O
;	O
P=0.01	I
)	O
and	O
LV	I
mass	I
(	O
-	O
20.6	O
±	O
50.5	O
versus	O
5.0	O
±	O
42.4	O
g	O
;	O
P=0.04	I
)	O
after	O
12	O
months	O
.	O

The	O
time	O
to	O
death	I
or	O
first	O
HF	I
hospitalization	I
was	O
significantly	I
prolonged	O
with	O
CRT	I
(	O
hazard	I
ratio	I
,	O
0.26	O
;	O
P=0.012	I
)	O
.	O

In	O
the	O
LVEF	I
<	O
30	O
%	O
subgroup	O
,	O
significant	I
improvements	O
in	O
clinical	I
composite	O
response	O
(	O
P=0.02	I
)	O
,	O
reverse	I
remodeling	I
parameters	O
,	O
and	O
time	O
to	O
death	I
or	O
first	O
HF	I
hospitalization	I
(	O
hazard	I
ratio	I
,	O
0.58	O
;	O
P=0.047	I
)	O
were	O
observed	O
.	O

After	O
adjusting	O
for	O
important	O
covariates	I
,	O
the	O
CRT	I
ON	O
assignment	O
remained	O
independently	O
associated	O
with	O
improved	O
time	O
to	O
death	I
or	O
first	O
HF	I
hospitalization	I
(	O
hazard	I
ratio	I
,	O
0.54	O
;	O
P=0.035	I
)	O
,	O
whereas	O
there	O
was	O
no	O
significant	I
interaction	O
with	O
LVEF	I
.	O

CONCLUSIONS	O
:	O

Among	O
subjects	O
with	O
mild	I
HF	I
,	O
QRS	I
prolongation	I
,	O
and	O
LVEF	I
>	O
30	O
%	O
,	O
CRT	I
produced	O
reverse	I
remodeling	I
and	O
similar	O
clinical	I
benefit	O
compared	O
with	O
subjects	O
with	O
more	O
severe	O
LV	I
systolic	I
dysfunction	I
.	O

Presence	O
of	O
diastolic	I
dysfunction	I
in	O
patients	I
with	O
peripheral	I
artery	I
disease	I
.	O

Peripheral	I
artery	I
disease	I
(	O
PAD	I
)	O
and	O
heart	I
failure	I
(	O
HF	I
)	O
share	O
many	O
risk	O
factors	O
;	O
however	O
,	O
the	O
prevalence	I
and	O
characteristics	O
of	O
HF	I
in	O
patients	I
with	O
PAD	I
have	O
not	O
been	O
fully	O
examined	O
.	O

We	O
investigated	O
120	O
consecutive	O
patients	I
with	O
PAD	I
,	O
defined	O
by	O
an	O
ankle-brachial	I
index	I
≤	O
0.9	O
.	O

In	O
all	O
,	O
36	O
(	O
30	O
%	O
)	O
patients	I
had	O
brain	I
natriuretic	I
peptide	I
(	O
BNP	I
)	O
levels	O
≥	O
100	O
pg	O
/	O
mL	O
(	O
high	O
BNP	I
group	O
)	O
,	O
and	O
84	O
(	O
70	O
%	O
)	O
patients	I
had	O
BNP	I
levels	O
<	O
100	O
pg	O
/	O
mL	O
(	O
low	O
BNP	I
group	O
)	O
.	O

Univariate	I
analysis	I
showed	O
that	O
high	O
BNP	I
was	O
associated	O
with	O
age	O
,	O
estimated	I
glomerular	I
filtration	I
rate	I
,	O
hypertension	I
,	O
and	O
transmitral	I
E-wave	I
/	O
early	O
diastolic	I
mitral	I
annular	I
velocity	I
(	O
E	I
/	I
e	I
'	I
)	O
ratio	O
.	O

Multivariate	I
logistic	I
regression	I
analysis	I
established	O
that	O
a	O
high	O
BNP	I
was	O
strongly	O
and	O
independently	O
associated	O
with	O
the	O
highest	O
quartile	O
of	O
E	I
/	I
e	I
'	I
,	O
highlighting	O
these	O
patients	I
'	O
diastolic	I
dysfunction	I
.	O

The	O
prevalence	I
of	O
high	O
BNP	I
levels	O
in	O
patients	I
with	O
PAD	I
suggests	O
that	O
routine	O
BNP	I
measurements	O
might	O
be	O
useful	O
to	O
detect	O
HF	I
.	O

Do	O
anticoagulants	I
or	O
antiplatelet	I
drugs	I
have	O
a	O
role	O
in	O
treating	O
heart	I
failure	I
in	O
the	O
absence	O
of	O
atrial	I
fibrillation	I
?	O

Patients	I
with	O
atrial	I
fibrillation	I
(	O
AF	I
)	O
and	O
heart	I
failure	I
(	O
HF	I
)	O
are	O
at	O
risk	O
for	O
stroke	I
,	O
and	O
progress	O
in	O
anticoagulation	I
has	O
led	O
to	O
new	O
options	O
for	O
these	O
patients	I
.	O

Patients	I
in	O
sinus	I
rhythm	I
may	O
benefit	O
from	O
antiplatelet	I
agents	I
or	O
anticoagulants	I
,	O
but	O
much	O
work	O
remains	O
to	O
establish	O
efficacy	O
and	O
safety	O
.	O

Additional	O
progress	O
is	O
needed	O
,	O
including	O
better	O
tools	O
for	O
risk	I
stratification	I
and	O
clarity	O
regarding	O
the	O
need	O
for	O
antiplatelet	I
agents	I
in	O
combination	O
with	O
anticoagulants	I
for	O
those	O
with	O
other	O
vascular	I
diseases	I
.	O

Psychometric	I
testing	O
of	O
the	O
Self-Care	O
of	O
Heart	I
Failure	I
Index	O
Version	O
6.2	O
.	O

The	O
Self-Care	O
of	O
Heart	I
Failure	I
Index	O
Version	O
6.2	O
(	O
SCHFI	O
v.6.2	O
)	O
is	O
widely	O
used	O
,	O
but	O
its	O
psychometric	I
profile	O
is	O
still	O
questioned	O
.	O

In	O
a	O
sample	O
of	O
659	O
heart	I
failure	I
patients	I
from	O
Italy	O
,	O
we	O
performed	O
confirmatory	I
factor	I
analysis	I
(	O
CFA	I
)	O
to	O
test	O
the	O
original	O
construct	O
of	O
the	O
SCHFI	O
v.6.2	O
scales	O
(	O
Self-Care	O
Maintenance	O
,	O
Self-Care	O
Management	O
,	O
and	O
Self-Care	O
Confidence	O
)	O
,	O
with	O
limited	O
success	O
.	O

We	O
then	O
used	O
exploratory	I
factor	I
analysis	I
to	O
determine	O
the	O
presence	O
of	O
separate	O
scale	O
dimensions	O
,	O
followed	O
by	O
CFA	I
in	O
a	O
separate	O
sub-sample	O
.	O

Construct	O
validity	O
of	O
individual	O
scales	O
showed	O
excellent	O
fit	O
indices	O
:	O
CFI	I
=	O
.92	O
,	O
RMSEA	I
=	O
.05	O
for	O
the	O
Self-Care	O
Maintenance	O
Scale	O
;	O
CFI	I
=	O
.95	O
,	O
RMSEA	I
=	O
.07	O
for	O
the	O
Self-Care	O
Management	O
Scale	O
;	O
CFI	I
=	O
.99	O
,	O
RMSEA	I
=	O
.02	O
for	O
the	O
Self-Care	O
Confidence	O
scale	O
.	O

Contrasting	O
groups	O
validity	O
,	O
internal	O
consistency	O
,	O
and	O
test-retest	O
reliability	O
were	O
supported	O
as	O
well	O
.	O

This	O
evidence	O
provides	O
a	O
new	O
understanding	O
of	O
the	O
structure	O
of	O
the	O
SCHFI	O
v.6.2	O
and	O
supports	O
its	O
use	O
in	O
clinical	I
practice	O
and	O
research	O
.	O

Human	O
resistin	I
in	O
chemotherapy-induced	I
heart	I
failure	I
in	O
humanized	O
male	O
mice	O
and	O
in	O
women	O
treated	O
for	O
breast	I
cancer	I
.	O

Resistin	I
is	O
a	O
circulating	O
mediator	O
of	O
insulin	I
resistance	I
mainly	O
expressed	O
in	O
human	O
monocytes	I
and	O
responsive	O
to	O
inflammatory	I
stimuli	O
.	O

Recent	O
clinical	I
studies	O
have	O
connected	O
elevated	O
resistin	I
levels	O
with	O
the	O
development	O
and	O
severity	O
of	O
heart	I
failure	I
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
role	O
of	O
human	O
resistin	I
in	O
heart	I
failure	I
,	O
we	O
studied	O
a	O
humanized	O
mouse	O
model	O
lacking	O
murine	I
resistin	I
but	O
transgenic	I
for	O
the	O
human	O
Retn	I
gene	I
(	O
Hum-Retn	I
mice	O
)	O
,	O
which	O
exhibits	O
basal	O
and	O
inflammation-stimulated	I
resistin	I
levels	O
similar	O
to	O
humans	O
.	O

Specifically	O
,	O
we	O
explored	O
whether	O
resistin	I
underlies	O
acute	I
anthracycline-induced	I
cardiotoxicity	I
.	O

Remarkably	O
,	O
doxorubicin	I
(	O
25mg	O
/	O
kg	O
ip	O
)	O
led	O
to	O
a	O
4-fold	O
induction	O
of	O
serum	O
resistin	I
levels	O
in	O
Hum-Retn	I
mice	O
.	O

Moreover	O
,	O
doxorubicin-induced	I
cardiotoxicity	I
was	O
greater	O
in	O
the	O
Hum-Retn	I
mice	O
than	O
in	O
littermate	O
controls	O
not	O
expressing	O
human	O
resistin	I
(	O
Retn	I
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Hum-Retn	I
mice	O
showed	O
increased	O
cardiac	I
mRNA	I
levels	O
of	O
inflammatory	I
and	O
cell	I
adhesion	I
genes	I
compared	O
with	O
Retn	I
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Macrophages	I
,	O
but	O
not	O
cardiomyocytes	I
,	O
from	O
Hum-Retn	I
mice	O
treated	O
with	O
doxorubicin	I
in	I
vitro	I
showed	O
dramatic	O
induction	O
of	O
hRetn	O
(	O
human	O
resistin	I
)	O
mRNA	I
and	O
protein	I
expression	I
.	O

We	O
also	O
examined	O
resistin	I
levels	O
in	O
anthracycline-treated	I
breast	I
cancer	I
patients	I
with	O
and	O
without	O
cardiotoxicity	I
.	O

Intriguingly	O
,	O
serum	O
resistin	I
levels	O
in	O
women	O
undergoing	O
anthracycline-containing	I
chemotherapy	I
increased	O
significantly	I
at	O
3	O
months	O
and	O
remained	O
elevated	O
at	O
6	O
months	O
in	O
those	O
with	O
subsequent	O
cardiotoxicity	I
.	O

Further	O
,	O
elevation	O
in	O
resistin	I
correlated	I
with	O
decline	O
in	O
ejection	I
fraction	I
in	O
these	O
women	O
.	O

These	O
results	O
suggest	O
that	O
elevated	O
resistin	I
is	O
a	O
biomarker	I
of	O
anthracycline-induced	I
cardiotoxicity	I
and	O
may	O
contribute	O
in	O
the	O
development	O
of	O
heart	I
failure	I
via	O
its	O
direct	O
effects	O
on	O
macrophages	I
.	O

These	O
results	O
further	O
implicate	O
resistin	I
as	O
a	O
link	O
between	O
inflammation	I
,	O
metabolism	I
,	O
and	O
heart	I
disease	I
.	O

Phosphodiesterase-2	I
is	O
up-regulated	O
in	O
human	O
failing	O
hearts	I
and	O
blunts	O
beta-adrenergic	I
responses	I
in	O
cardiomyocytes	I
.	O

OBJECTIVES	O
:	O

This	O
study	O
investigated	O
whether	O
myocardial	I
phosphodiesterase-2	I
(	O
PDE2	I
)	O
is	O
altered	O
in	O
heart	I
failure	I
(	O
HF	I
)	O
and	O
determined	O
PDE2-mediated	I
effects	O
on	O
beta-adrenergic	I
receptor	I
(	O
β-AR	I
)	O
signaling	I
in	O
healthy	I
and	O
diseased	I
cardiomyocytes	I
.	O

BACKGROUND	O
:	O

Diminished	O
cyclic	I
adenosine	I
monophosphate	I
(	O
cAMP	I
)	O
and	O
augmented	O
cyclic	I
guanosine	I
monophosphate	I
(	O
cGMP	I
)	O
signaling	I
is	O
characteristic	O
for	O
failing	O
hearts	I
.	O

Among	O
the	O
PDE	I
superfamily	O
,	O
PDE2	I
has	O
the	O
unique	O
property	O
of	O
being	O
able	O
to	O
be	O
stimulated	O
by	O
cGMP	I
,	O
thus	O
leading	O
to	O
a	O
remarkable	O
increase	O
in	O
cAMP	I
hydrolysis	I
mediating	O
a	O
negative	O
cross	I
talk	I
between	O
cGMP	I
and	O
cAMP	I
signaling	I
.	O

However	O
,	O
the	O
role	O
of	O
PDE2	I
in	O
HF	I
is	O
poorly	O
understood	O
.	O

METHODS	O
:	O

Immunoblotting	I
,	O
radioenzymatic	I
-	O
and	O
fluorescence	I
resonance	I
energy	I
transfer-based	I
assays	I
,	O
video	I
edge	I
detection	I
,	O
epifluorescence	I
microscopy	I
,	O
and	O
L-type	I
Ca2	I
(	I
+	I
)	I
current	I
measurements	O
were	O
performed	O
in	O
myocardial	I
tissues	I
and	O
/	O
or	O
isolated	O
cardiomyocytes	I
from	O
human	O
and	O
/	O
or	O
experimental	O
HF	I
,	O
respectively	O
.	O

RESULTS	O
:	O

Myocardial	I
PDE2	I
expression	I
and	O
activity	O
were	O
~	O
2-fold	O
higher	O
in	O
advanced	O
human	O
HF	I
.	O

Chronic	I
β-AR	I
stimulation	O
via	O
catecholamine	I
infusions	I
in	O
rats	O
enhanced	O
PDE2	I
expression	I
~	O
2-fold	O
and	O
cAMP	I
hydrolytic	O
activity	O
~	O
4-fold	O
,	O
which	O
correlated	I
with	O
blunted	O
cardiac	I
β-AR	I
responsiveness	I
.	O

In	O
diseased	I
cardiomyocytes	I
,	O
higher	O
PDE2	I
activity	O
could	O
be	O
further	O
enhanced	O
by	O
stimulation	O
of	O
cGMP	I
synthesis	I
via	O
nitric	I
oxide	I
donors	I
,	O
whereas	O
specific	O
PDE2	I
inhibition	I
partially	O
restored	O
β-AR	I
responsiveness	I
.	O

Accordingly	O
,	O
PDE2	I
overexpression	O
in	O
healthy	I
cardiomyocytes	I
reduced	O
the	O
rise	O
in	O
cAMP	I
levels	O
and	O
L-type	I
Ca2	I
(	I
+	I
)	I
current	I
amplitude	O
,	O
and	O
abolished	O
the	O
inotropic	I
effect	I
following	O
acute	I
β-AR	I
stimulation	O
,	O
without	O
affecting	O
basal	O
contractility	I
.	O

Importantly	O
,	O
PDE2-overexpressing	I
cardiomyocytes	I
showed	O
marked	O
protection	O
from	O
norepinephrine-induced	I
hypertrophic	I
responses	O
.	O

CONCLUSIONS	O
:	O

PDE2	I
is	O
markedly	O
up-regulated	O
in	O
failing	O
hearts	I
and	O
desensitizes	O
against	O
acute	I
β-AR	I
stimulation	O
.	O

This	O
may	O
constitute	O
an	O
important	O
defense	O
mechanism	O
during	O
cardiac	I
stress	I
,	O
for	O
example	O
,	O
by	O
antagonizing	O
excessive	O
β-AR	I
drive	O
.	O

Thus	O
,	O
activating	O
myocardial	I
PDE2	I
may	O
represent	O
a	O
novel	O
intracellular	I
antiadrenergic	I
therapeutic	I
strategy	O
in	O
HF	I
.	O

National	O
trends	O
in	O
patient	I
safety	O
for	O
four	O
common	O
conditions	I
,	O
2005	O
-	O
2011	O
.	O

The	O
effects	O
of	O
more	O
than	O
a	O
decade	O
of	O
national	O
efforts	O
dedicated	O
to	O
improve	O
patient	I
safety	O
remain	O
largely	O
unclear	O
.	O

This	O
study	O
used	O
the	O
Medicare	O
Patient	I
Safety	O
Monitoring	O
System	O
(	O
MPSMS	O
)	O
database	O
to	O
assess	O
national	O
trends	O
in	O
adverse	I
event	I
rates	O
between	O
2005	O
through	O
2011	O
for	O
patients	I
hospitalized	I
with	O
acute	I
myocardial	I
infarction	I
,	O
congestive	I
heart	I
failure	I
,	O
pneumonia	I
,	O
or	O
conditions	I
requiring	O
surgery	I
.	O

The	O
analysis	O
included	O
a	O
large	O
study	O
sample	O
with	O
more	O
than	O
60,000	O
patients	I
across	O
4372	O
hospitals	I
.	O

The	O
results	O
show	O
a	O
significant	I
decline	O
in	O
adverse	I
event	I
rates	O
for	O
acute	I
myocardial	I
infarction	I
and	O
congestive	I
heart	I
failure	I
,	O
translating	O
to	O
an	O
estimated	O
81,000	O
in-hospital	I
adverse	I
events	I
averted	O
in	O
2010–2011	O
.	O

However	O
,	O
there	O
were	O
no	O
measurable	O
overall	O
improvements	O
for	O
patients	I
admitted	O
with	O
pneumonia	I
or	O
surgical	I
conditions	I
.	O

Some	O
events	O
,	O
such	O
as	O
pressure	I
ulcers	I
in	O
surgical	I
patients	I
,	O
actually	O
increased	O
despite	O
considerable	O
national	O
attention	O
to	O
these	O
problems	O
.	O

This	O
study	O
suggests	O
that	O
national	O
patient	I
safety	O
initiatives	O
have	O
led	O
to	O
real	O
progress	O
in	O
some	O
areas	O
but	O
have	O
not	O
created	O
across-the-board	O
improvements	O
.	O

Heart	I
rate	I
reduction	I
and	O
exercise	O
performance	O
in	O
recent	O
onset	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
:	O
arguments	O
for	O
beta-blocker	I
hypo-response	O
.	O

OBJECTIVE	O
:	O

Beta	I
blockers	I
reduce	O
all-cause	I
mortality	I
and	O
readmissions	I
in	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
(	O
HFrEF	I
)	O
,	O
which	O
may	O
be	O
explained	O
by	O
their	O
effect	O
on	O
heart	I
rate	I
(	O
HR	I
)	O
.	O

This	O
study	O
assessed	O
the	O
impact	O
of	O
HR	I
reduction	I
with	O
beta	I
blockers	I
on	O
exercise	I
capacity	I
in	O
recent	O
onset	O
HFrEF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Fifty	O
consecutive	O
patients	I
with	O
recent	O
onset	O
HFrEF	I
(	O
<	O
30	O
days	O
)	O
performed	O
a	O
standardized	O
exercise	O
protocol	O
with	O
respiratory	I
gas	I
analysis	I
at	O
baseline	I
as	O
well	O
as	O
after	O
6	O
and	O
12	O
months	O
.	O

Patients	I
participated	O
in	O
a	O
quality	O
of	O
care	O
programme	O
aiming	O
to	O
achieve	O
guideline-recommended	O
target	O
doses	O
for	O
beta-blocker	I
therapy	I
.	O

At	O
baseline	I
,	O
6	O
and	O
12	O
months	O
,	O
36	O
%	O
,	O
70	O
%	O
and	O
62	O
%	O
of	O
patients	I
,	O
respectively	O
,	O
had	O
a	O
resting	I
HR	I
<	O
70	O
bpm	I
.	O

Beta-blocker	I
dose	O
after	O
12	O
months	O
was	O
comparable	O
in	O
patients	I
with	O
resting	I
HR	I
<	O
70	O
versus	O
≥70	O
bpm	I
(	O
P	I
value=0.631	I
)	O
.	O

However	O
,	O
with	O
similar	O
dose	O
uptitration	I
,	O
the	O
former	O
versus	O
the	O
latter	O
had	O
a	O
significantly	I
larger	O
HR	I
reduction	I
(	O
17±22	O
versus	O
4±15	O
bpm	I
;	O
P	I
value=0.027	I
)	O
.	O

Peak	I
oxygen	I
consumption	I
(	O
VO2max	I
)	O
was	O
significantly	I
higher	O
when	O
resting	I
HR	I
was	O
<	O
70	O
versus	O
≥70	O
bpm	I
(	O
17.5±5.5	O
versus	O
14.4±3.3	O
mL	O
/	O
min	O
/	O
kg	O
,	O
respectively	O
;	O
P	I
value=0.038	I
)	O
.	O

Similar	O
results	O
were	O
observed	O
after	O
6	O
months	O
.	O

Patients	I
in	O
whom	O
resting	I
HR	I
decreased	O
at	O
follow-up	I
compared	O
to	O
baseline	I
had	O
a	O
2.0±3.2	O
mL	O
/	O
min	O
/	O
kg	O
increase	O
in	O
VO2max	I
compared	O
to	O
a	O
1.2±7.7	O
mL	O
/	O
min	O
/	O
kg	O
increase	O
in	O
patients	I
who	O
did	O
not	O
demonstrate	O
a	O
lower	O
resting	I
HR	I
(	O
P	I
value=0.033	I
)	O
.	O

CONCLUSIONS	O
:	O

In	O
recent	O
onset	O
HFrEF	I
,	O
exercise	O
performance	O
was	O
better	O
when	O
resting	I
HR	I
was	O
controlled	O
<	O
70	O
bpm	I
with	O
beta-blocker	I
therapy	I
.	O

However	O
,	O
despite	O
aggressive	O
dose	O
uptitration	I
,	O
many	O
patients	I
did	O
not	O
achieve	O
this	O
target	O
as	O
they	O
had	O
little	O
HR	I
reduction	I
with	O
beta-blocker	I
therapy	I
.	O

Investigation	O
of	O
apoptosis	I
in	O
a	O
canine	O
model	O
of	O
chronic	I
heart	I
failure	I
induced	O
by	O
tachycardia	I
.	O

Participation	O
of	O
apoptosis	I
during	O
the	O
development	O
of	O
pacing-induced	I
dilated	I
cardiomyopathy	I
is	O
not	O
fully	O
understood	O
.	O

After	O
7	O
weeks	O
rapid	O
right	I
ventricular	I
pacing	I
,	O
gene	I
expressions	I
of	O
Bax	I
,	O
Bcl-2	I
and	O
Caspase-3	I
were	O
measured	O
by	O
RTQ-PCR	I
from	O
interventricular	I
septum	I
biopsies	I
that	O
were	O
taken	O
weekly	O
in	O
21	O
beagle	O
dogs	O
during	O
the	O
development	O
of	O
heart	I
failure	I
.	O

We	O
evaluated	O
protein	I
levels	O
of	O
these	O
genes	I
by	O
Western	I
blot	I
and	O
DNA	I
fragmentation	I
by	O
TUNEL	I
method	O
from	O
autopsy	O
samples	O
.	O

Gene	I
expression	I
of	O
Bax	I
remained	O
unchanged	O
during	O
the	O
pacing	O
period	O
;	O
Bcl-2	I
mRNA	I
expression	I
transiently	O
decreased	O
in	O
moderate	O
heart	I
failure	I
and	O
their	O
ratio	O
(	O
Bcl-2	I
/	O
Bax	I
)	O
was	O
not	O
significantly	I
altered	O
.	O

Caspase-3	I
gene	I
expression	I
increased	O
in	O
heart	I
failure	I
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
expression	I
of	O
Bax	I
and	O
Bcl-2	I
proteins	I
and	O
their	O
ratio	O
were	O
increased	O
in	O
dogs	O
only	O
after	O
4	O
weeks	O
of	O
pacing	O
.	O

No	O
band	O
of	O
activated	O
Caspase	I
was	O
found	O
in	O
the	O
normal	O
nor	O
in	O
the	O
paced	O
myocardium	I
.	O

In	O
the	O
TUNEL	I
assay	O
there	O
was	O
no	O
significant	I
difference	O
between	O
numbers	O
of	O
apoptotic	I
cells	I
in	O
any	O
of	O
the	O
groups	O
,	O
although	O
a	O
few	O
TUNEL-positive	I
cells	I
were	O
detected	O
in	O
the	O
paced	O
groups	O
.	O

Our	O
results	O
are	O
not	O
in	O
favour	O
of	O
apoptosis	I
in	O
the	O
pathogenesis	I
of	O
heart	I
failure	I
in	O
this	O
model	O
and	O
may	O
be	O
it	O
could	O
be	O
attributed	O
to	O
activation	O
of	O
other	O
systems	O
.	O

Genetic	I
susceptibility	O
to	O
anthracycline-related	I
congestive	I
heart	I
failure	I
in	O
survivors	O
of	O
haematopoietic	I
cell	I
transplantation	I
.	O

Haematopoietic	I
cell	I
transplantation	I
(	O
HCT	I
)	O
survivors	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
,	O
primarily	O
due	O
to	O
pre-HCT	I
exposure	O
to	O
anthracyclines	I
.	O

We	O
examined	O
the	O
association	O
between	O
the	O
development	O
of	O
CHF	I
after	O
HCT	I
and	O
polymorphisms	I
in	O
16	O
candidate	O
genes	I
involved	O
in	O
anthracycline	I
metabolism	I
,	O
iron	I
homeostasis	I
,	O
anti-oxidant	I
defence	I
,	O
and	O
myocardial	I
remodelling	I
.	O

A	O
nested	O
case-control	O
study	O
design	O
was	O
used	O
.	O

Cases	O
(	O
post-HCT	I
CHF	I
)	O
were	O
identified	O
from	O
2950	O
patients	I
who	O
underwent	O
HCT	I
between	O
1988	O
and	O
2007	O
at	O
City	O
of	O
Hope	O
and	O
had	O
survived	O
≥1	O
year	O
.	O

This	O
cohort	O
formed	O
the	O
sampling	O
frame	O
for	O
selecting	O
controls	O
(	O
without	O
CHF	I
)	O
matched	O
on	O
:	O
age	O
,	O
race	O
/	O
ethnicity	O
,	O
cumulative	O
anthracycline	I
exposure	O
,	O
stem	I
cell	I
source	O
(	O
allogeneic	I
,	O
autologous	I
)	O
,	O
and	O
length	O
of	O
follow-up	I
.	O

Seventy-seven	O
cases	O
with	O
pre-HCT	I
germline	O
DNA	I
and	O
178	O
controls	O
were	O
genotyped	I
.	O

Multivariate	I
analysis	I
revealed	O
that	O
the	O
odds	O
of	O
CHF	I
was	O
higher	O
in	O
females	O
[	O
Odds	I
Ratio	I
(	O
OR	I
)	O
=	O
2·9	O
,	O
P	I
<	O
0·01	O
]	O
,	O
individuals	O
with	O
pre-HCT	I
chest	I
radiation	O
(	O
OR	I
=	O
4·7	O
,	O
P	I
=	O
0·05	O
)	O
,	O
hypertension	I
(	O
OR	I
=	O
2·9	O
,	O
P	I
=	O
0·01	O
)	O
,	O
and	O
with	O
variants	O
of	O
genes	I
coding	O
for	O
the	O
NAD(P)	I
H-oxidase	I
subunit	O
RAC2	I
(	O
rs13058338	O
,	O
7508T→A	O
;	O
OR	I
=	O
2·8	O
,	O
P	I
<	O
0·01	O
)	O
,	O
HFE	O
(	O
rs1799945	O
,	O
63C→G	O
;	O
OR	I
=	O
2·5	O
,	O
P	I
=	O
0·05	O
)	O
or	O
the	O
doxorubicin	I
efflux	I
transporter	I
ABCC2	I
(	O
rs8187710	O
,	O
1515G→A	O
;	O
OR	I
=	O
4·3	O
,	O
P	I
<	O
0·01	O
)	O
.	O

A	O
combined	O
(	O
clinical	I
and	O
genetic	I
)	O
CHF	I
predictive	O
model	O
performed	O
better	O
[	O
area	I
under	I
the	I
curve	I
(	O
AUC	I
)	O
,	O
0·79	O
]	O
than	O
the	O
genetic	I
(	O
AUC	I
=	O
0·67	O
)	O
or	O
the	O
clinical	I
(	O
AUC	I
=	O
0·69	O
)	O
models	O
alone	O
.	O

Differential	O
effects	O
of	O
nonselective	I
versus	O
selective	I
beta-blockers	I
on	O
cardiac	I
sympathetic	I
activity	I
and	O
hemostasis	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

Carvedilol	I
,	O
a	O
nonselective	I
β-blocker	I
,	O
may	O
be	O
more	O
effective	O
than	O
the	O
selective	I
β-blocker	I
metoprolol	I
in	O
reducing	O
the	O
risk	O
of	O
thromboembolic	I
events	I
in	O
heart	I
failure	I
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
,	O
first	O
,	O
to	O
assess	O
whether	O
there	O
is	O
a	O
differential	O
response	O
in	O
cardiac	I
sympathetic	I
activity	I
by	O
(123)I-meta-iodobenzylguanidine	I
((123)I-MIBG	I
)	O
imaging	O
when	O
either	O
β-blocker	I
is	O
used	O
.	O

Second	O
,	O
we	O
assessed	O
whether	O
that	O
response	O
correlates	I
with	O
levels	O
of	O
various	O
serum	O
factors	O
that	O
serve	O
as	O
markers	O
for	O
coagulability	I
.	O

METHODS	O
:	O

In	O
this	O
prospective	I
,	O
randomized	I
,	O
open-label	O
crossover	I
study	I
with	O
masked	O
outcome	I
assessments	O
,	O
stable	I
heart	I
failure	I
patients	I
(	O
left	I
ventricular	I
ejection	I
fraction	I
<	O
40	O
%	O
)	O
homozygous	I
for	O
the	O
Arg16	I
/	I
Gln27	I
(	O
n	O
=	O
13	O
)	O
or	O
Gly16	I
/	I
Glu27	I
haplotype	I
(	O
n	O
=	O
8	O
)	O
of	O
the	O
β2-receptor	I
were	O
randomized	I
to	O
equipotent	O
dosages	O
of	O
carvedilol	I
or	O
metoprolol	I
for	O
two	O
6-wk	O
periods	O
.	O

Primary	I
outcome	I
was	O
sympathetic	I
activity	I
as	O
measured	O
by	O
(123)I-MIBG	I
myocardial	I
washout	I
.	O

Secondary	I
outcomes	I
included	O
markers	O
of	O
hemostasis	I
.	O

RESULTS	O
:	O

(123)I-MIBG	I
cardiac	I
washout	I
was	O
lower	O
during	O
carvedilol	I
than	O
metoprolol	I
treatment	O
(	O
12.9	O
%	O
±	O
3.9	O
%	O
vs.	O
22.1	O
%	O
±	O
2.8	O
%	O
,	O
respectively	O
,	O
P	I
=	O
0.003	O
)	O
,	O
irrespective	O
of	O
β2-adrenergic	I
receptor	I
haplotype	I
.	O

In	O
addition	O
,	O
treatment	O
with	O
carvedilol	I
resulted	O
in	O
a	O
lower	O
von	I
Willebrand	I
factor	I
than	O
did	O
metoprolol	I
(	O
149	O
%	O
±	O
13	O
%	O
vs.	O
157	O
%	O
±	O
13	O
%	O
,	O
respectively	O
,	O
P	I
=	O
0.01	O
)	O
,	O
irrespective	O
of	O
β2-adrenergic	I
receptor	I
haplotype	I
.	O

CONCLUSION	O
:	O

Compared	O
with	O
metoprolol	I
,	O
carvedilol	I
resulted	O
in	O
greater	O
reduction	O
of	O
sympathetic	I
activity	I
after	O
6	O
wk	O
of	O
treatment	O
and	O
lower	O
von	I
Willebrand	I
factor	I
concentrations	O
in	O
both	O
Arg16	I
/	I
Gln27	I
and	O
Gly16	I
/	I
Glu27	I
individuals	O
.	O

Therefore	O
,	O
carvedilol	I
may	O
reduce	O
the	O
risk	O
of	O
thromboembolic	I
events	I
in	O
patients	I
with	O
heart	I
failure	I
,	O
irrespective	O
of	O
β2-receptor	I
haplotype	I
status	O
.	O

Unidirectional	O
left-to-right	O
interatrial	I
shunting	I
for	O
treatment	O
of	O
patients	I
with	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
:	O
a	O
safety	O
and	O
proof-of-principle	I
cohort	I
study	I
.	O

BACKGROUND	O
:	O

In	O
patients	I
with	O
heart	I
failure	I
,	O
interventions	O
to	O
reduce	O
elevated	O
left	I
atrial	I
pressure	I
improve	O
symptoms	I
and	O
reduce	O
the	O
risk	O
of	O
hospital	I
admission	I
.	O

We	O
aimed	O
to	O
assess	O
the	O
safety	O
and	O
potential	O
efficacy	O
of	O
therapeutic	I
left-to-right	O
interatrial	I
shunting	I
in	O
patients	I
with	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
.	O

METHODS	O
:	O

We	O
did	O
this	O
proof-of-principle	I
cohort	I
study	I
at	O
one	O
centre	O
in	O
Canada	O
.	O

Patients	I
(	O
aged	O
≥18	O
years	O
)	O
with	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	O
)	O
class	I
III	I
chronic	I
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
were	O
enrolled	O
under	O
the	O
Canadian	O
special	O
access	O
programme	O
.	O

Shunt	I
implants	I
were	O
done	O
after	O
transseptal	I
catheterisation	I
with	O
transoesophageal	I
echocardiographic	I
guidance	O
under	O
general	I
anaesthesia	I
.	O

Patients	I
had	O
clinical	I
and	O
echocardiography	I
evaluations	O
at	O
baseline	I
and	O
months	O
1	O
and	O
3	O
after	O
shunt	I
implantation	I
.	O

FINDINGS	O
:	O

Between	O
Oct	O
10	O
,	O
2013	O
,	O
and	O
March	O
27	O
,	O
2015	O
,	O
we	O
enrolled	O
ten	O
patients	I
.	O

The	O
device	O
was	O
successfully	O
implanted	I
in	O
all	O
patients	I
;	O
no	O
device-related	O
or	O
procedural	O
adverse	I
events	I
occurred	O
during	O
follow-up	I
.	O

Transoesophageal	I
echocardiography	I
at	O
1	O
month	O
showed	O
that	O
all	O
shunts	I
were	O
patent	O
,	O
with	O
no	O
thrombosis	I
or	O
migration	O
.	O

From	O
baseline	I
to	O
3	O
month	O
follow-up	I
,	O
we	O
recorded	O
improvements	O
in	O
NYHA	I
classification	I
(	O
from	O
class	O
III	O
to	O
class	O
II	O
in	O
seven	O
[	O
78	O
%	O
]	O
of	O
nine	O
patients	I
,	O
from	O
class	O
III	O
to	O
class	O
I	O
in	O
one	O
[	O
11	O
%	O
]	O
patient	I
,	O
and	O
no	O
change	O
in	O
one	O
[	O
11	O
%	O
]	O
patient	I
;	O
p=0·0004	I
)	O
;	O
quality	I
of	I
life	I
,	O
as	O
assessed	O
by	O
the	O
Duke	O
Activity	O
Status	O
Index	O
(	O
from	O
a	O
mean	O
score	O
of	O
13	O
[	O
SD	I
6·2	O
]	O
to	O
24·8	O
[	O
12·9	O
]	O
;	O
p=0·016	I
)	O
and	O
the	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
(	O
from	O
a	O
mean	O
score	O
of	O
44·3	O
[	O
SD	I
9·8	O
]	O
to	O
79·1	O
[	O
13·0	O
]	O
;	O
p=0·0001	I
)	O
;	O
and	O
6	I
min	I
walk	I
test	I
distance	O
(	O
from	O
a	O
mean	O
of	O
244	O
m	O
[	O
SD	I
112	O
]	O
to	O
318	O
m	O
[	O
134	O
]	O
;	O
p=0·016	I
)	O
.	O

Pulmonary	I
capillary	I
wedge	I
pressure	I
was	O
reduced	O
from	O
a	O
mean	O
of	O
23	O
mm	O
Hg	O
(	O
SD	I
5	O
)	O
at	O
baseline	I
to	O
17	O
mm	O
Hg	O
(	O
8	O
)	O
at	O
3	O
months	O
(	O
p=0·035	I
)	O
,	O
with	O
no	O
changes	O
in	O
right	I
atrial	I
pressure	I
,	O
pulmonary	I
arterial	I
pressure	I
,	O
or	O
pulmonary	I
resistance	I
.	O

No	O
patient	I
was	O
admitted	O
to	O
hospital	I
for	O
worsening	O
heart	I
failure	I
.	O

One	O
(	O
10	O
%	O
)	O
patient	I
was	O
admitted	O
to	O
hospital	I
with	O
gastrointestinal	I
bleeding	I
at	O
month	O
1	O
;	O
one	O
(	O
10	O
%	O
)	O
patient	I
died	O
after	O
incessant	O
ventricular	I
tachycardia	I
storm	O
,	O
which	O
led	O
to	O
terminal	I
heart	I
failure	I
2	O
months	O
post-procedure	O
.	O

INTERPRETATION	O
:	O

This	O
first-in-man	O
experience	O
with	O
an	O
implanted	I
left-to-right	O
interatrial	I
shunt	I
demonstrates	O
initial	O
safety	O
and	O
early	O
beneficial	O
clinical	I
and	O
haemodynamic	I
outcomes	I
in	O
patients	I
with	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
.	O

Further	O
large-scale	O
randomised	I
studies	O
are	O
warranted	O
.	O

Race	O
,	O
exercise	O
training	O
,	O
and	O
outcomes	I
in	O
chronic	I
heart	I
failure	I
:	O
findings	O
from	O
Heart	I
Failure	I
-	O
a	O
Controlled	O
Trial	O
Investigating	O
Outcomes	I
in	O
Exercise	O
TraiNing	O
(	O
HF-ACTION	I
)	O
.	O

BACKGROUND	O
:	O

The	O
strength	O
of	O
race	O
as	O
an	O
independent	O
predictor	O
of	O
long-term	O
outcomes	I
in	O
a	O
contemporary	O
chronic	I
heart	I
failure	I
(	O
HF	I
)	O
population	O
and	O
its	O
association	O
with	O
exercise	O
training	O
response	O
have	O
not	O
been	O
well	O
established	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
race	O
and	O
outcomes	I
and	O
to	O
explore	O
interactions	O
with	O
exercise	O
training	O
in	O
patients	I
with	O
ambulatory	I
HF	I
.	O

METHODS	O
:	O

We	O
performed	O
an	O
analysis	O
of	O
HF-ACTION	I
,	O
which	O
randomized	I
2331	O
patients	I
with	O
HF	I
having	O
an	O
ejection	I
fraction	I
≤35	O
%	O
to	O
usual	O
care	O
with	O
or	O
without	O
exercise	O
training	O
.	O

We	O
examined	O
characteristics	O
and	O
outcomes	I
(	O
mortality	I
/	O
hospitalization	I
,	O
mortality	I
,	O
and	O
cardiovascular	I
mortality	I
/	O
HF	I
hospitalization	I
)	O
by	O
race	O
using	O
adjusted	O
Cox	I
models	I
and	O
explored	O
an	O
interaction	O
with	O
exercise	O
training	O
.	O

RESULTS	O
:	O

There	O
were	O
749	O
self-identified	O
black	O
patients	I
(	O
33	O
%	O
)	O
.	O

Blacks	O
were	O
younger	O
with	O
significantly	I
more	O
hypertension	I
and	O
diabetes	I
,	O
less	O
ischemic	I
etiology	I
,	O
and	O
lower	O
socioeconomic	O
status	O
versus	O
whites	O
.	O

Blacks	O
had	O
shorter	O
6-minute	I
walk	I
distance	I
and	O
lower	O
peak	I
VO2	I
at	O
baseline	I
.	O

Over	O
a	O
median	O
follow-up	I
of	O
2.5	O
years	O
,	O
black	O
race	O
was	O
associated	O
with	O
increased	O
risk	O
for	O
all	O
outcomes	I
except	O
mortality	I
.	O

After	O
multivariable	I
adjustment	I
,	O
black	O
race	O
was	O
associated	O
with	O
increased	O
mortality	I
/	O
hospitalization	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
1.16	O
,	O
95	O
%	O
CI	I
1.01	O
-	O
1.33	O
)	O
and	O
cardiovascular	I
mortality	I
/	O
HF	I
hospitalization	I
(	O
HR	I
1.46	O
,	O
95	O
%	O
CI	I
1.20	O
-	O
1.77	O
)	O
.	O

The	O
hazard	O
associated	O
with	O
black	O
race	O
was	O
largely	O
caused	O
by	O
increased	O
HF	I
hospitalization	I
(	O
HR	I
1.58	O
,	O
95	O
%	O
CI	I
1.27	O
-	O
1.96	O
)	O
,	O
given	O
similar	O
cardiovascular	I
mortality	I
.	O

There	O
was	O
no	O
interaction	O
between	O
race	O
and	O
exercise	O
training	O
on	O
outcomes	I
(	O
P	I
>	O
.5	O
)	O
.	O

CONCLUSIONS	O
:	O

Black	O
race	O
in	O
patients	I
with	O
chronic	I
HF	I
was	O
associated	O
with	O
increased	O
prevalence	I
of	O
modifiable	O
risk	O
factors	O
,	O
lower	O
exercise	O
performance	O
,	O
and	O
increased	O
HF	I
hospitalization	I
,	O
but	O
not	O
increased	O
mortality	I
or	O
a	O
differential	O
response	O
to	O
exercise	O
training	O
.	O

Hospital-to-Home	I
:	O
a	O
hospital	I
readmission	I
reduction	O
program	O
for	O
congestive	I
heart	I
failure	I
.	O

OBJECTIVE	O
:	O

To	O
decrease	O
the	O
30-day	O
readmission	I
rate	O
following	O
hospital	I
stay	O
for	O
congestive	I
heart	I
failure	I
,	O
which	O
in	O
the	O
United	O
States	O
approaches	O
30	O
percent	O
nationally	O
.	O

In	O
addition	O
to	O
indicating	O
possible	O
suboptimal	O
care	O
of	O
patients	I
with	O
this	O
condition	I
,	O
there	O
are	O
significant	O
economic	O
considerations	O
.	O

DESIGN	O
:	O

Prospective	I
,	O
non-randomized	I
,	O
two-center	O
pilot	O
project	O
.	O

SETTING	O
:	O

General	O
hospital	I
and	O
cardiac	I
specialty	O
hospital	I
,	O
both	O
located	O
in	O
a	O
community	O
of	O
150,000	O
population	O
in	O
predominantly	O
rural	O
South	O
Dakota	O
.	O

PARTICIPANTS	O
:	O

All	O
patients	I
admitted	O
between	O
June	O
7	O
,	O
2010	O
and	O
June	O
6	O
,	O
2011	O
with	O
a	O
diagnosis	I
of	O
congestive	I
heart	I
failure	I
.	O

INTERVENTION	O
:	O

An	O
intensive	O
transitions	O
of	O
care	O
program	O
was	O
implemented	O
to	O
ensure	O
adequate	O
self-management	O
training	O
of	O
patients	I
and	O
appropriate	O
out-patient	I
follow-up	I
and	O
monitoring	O
of	O
the	O
patient	I
by	O
the	O
health	I
care	I
system	O
.	O

MAIN	O
OUTCOME	I
MEASURE	O
:	O

30-day	O
all-cause	I
readmissions	I
.	O

RESULTS	O
:	O

A	O
statistically	O
significant	I
42	O
percent	O
relative	O
reduction	O
in	O
30-day	O
readmission	I
rate	O
was	O
documented	O
for	O
those	O
patients	I
participating	O
in	O
the	O
pilot	O
program	O
.	O

This	O
represented	O
a	O
net	O
economic	O
savings	O
,	O
even	O
accounting	O
for	O
the	O
added	O
cost	O
of	O
the	O
intervention	O
.	O

CONCLUSIONS	O
:	O

An	O
intensive	O
transitions	O
of	O
care	O
program	O
decreases	O
the	O
30-day	O
readmission	I
rate	O
for	O
patients	I
with	O
congestive	I
heart	I
failure	I
in	O
a	O
non-urbanized	O
Midwestern	O
state	O
like	O
South	O
Dakota	O
.	O

Contemporary	O
trends	O
in	O
heart	I
failure	I
with	I
reduced	I
and	O
preserved	I
ejection	I
fraction	I
after	O
myocardial	I
infarction	I
:	O
a	O
community	O
study	O
.	O

Major	O
changes	O
have	O
recently	O
occurred	O
in	O
the	O
epidemiology	I
of	O
myocardial	I
infarction	I
(	O
MI	I
)	O
that	O
could	O
possibly	O
affect	O
outcomes	I
such	O
as	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

Data	O
describing	O
trends	O
in	O
HF	I
after	O
MI	I
are	O
scarce	O
and	O
conflicting	O
and	O
do	O
not	O
distinguish	O
between	O
preserved	I
and	O
reduced	I
ejection	I
fraction	I
(	O
EF	I
)	O
.	O

We	O
evaluated	O
temporal	O
trends	O
in	O
HF	I
after	O
MI	I
.	O

All	O
residents	O
of	O
Olmsted	O
County	O
,	O
Minnesota	O
(	O
n	O
=	O
2,596	O
)	O
who	O
had	O
a	O
first-ever	O
MI	I
diagnosed	I
in	O
1990	O
-	O
2010	O
and	O
no	O
prior	O
HF	I
were	O
followed-up	I
through	O
2012	O
.	O

Framingham	O
Heart	I
Study	O
criteria	O
were	O
used	O
to	O
define	O
HF	I
,	O
which	O
was	O
further	O
classified	O
according	O
to	O
EF	I
.	O

Both	O
early-onset	O
(	O
0	O
-	O
7	O
days	O
after	O
MI	I
)	O
and	O
late-onset	O
(	O
8	O
days	O
to	O
5	O
years	O
after	O
MI	I
)	O
HF	I
were	O
examined	O
.	O

Changes	O
in	O
patient	I
presentation	O
were	O
noted	O
,	O
including	O
fewer	O
ST-segment-elevation	I
MIs	I
,	O
lower	O
Killip	I
class	I
,	O
and	O
more	O
comorbid	I
conditions	I
.	O

Over	O
the	O
5-year	O
follow-up	I
period	O
,	O
715	O
patients	I
developed	O
HF	I
,	O
475	O
of	O
whom	O
developed	O
it	O
during	O
the	O
first	O
week	O
.	O

The	O
age	O
-	O
and	O
sex-adjusted	O
risk	O
declined	O
from	O
1990	O
-	O
1996	O
to	O
2004	O
-	O
2010	O
,	O
with	O
hazard	I
ratios	I
of	O
0.67	O
(	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
:	O
0.54	O
,	O
0.85	O
)	O
for	O
early-onset	O
HF	I
and	O
0.63	O
(	O
95	O
%	O
CI	I
:	O
0.45	O
,	O
0.86	O
)	O
for	O
late-onset	O
HF	I
.	O

Further	O
adjustment	O
for	O
patient	I
and	O
MI	I
characteristics	O
yielded	O
hazard	I
ratios	I
of	O
0.86	O
(	O
95	O
%	O
CI	I
:	O
0.66	O
,	O
1.11	O
)	O
and	O
0.63	O
(	O
95	O
%	O
CI	I
:	O
0.45	O
,	O
0.88	O
)	O
for	O
early	O
-	O
and	O
late-onset	O
HF	I
,	O
respectively	O
.	O

Declines	O
in	O
early-onset	O
and	O
late-onset	O
HF	I
were	O
observed	O
for	O
HF	I
with	I
reduced	I
EF	I
(	O
<	O
50	O
%	O
)	O
but	O
not	O
for	O
HF	I
with	I
preserved	I
EF	I
,	O
indicating	O
a	O
change	O
in	O
the	O
case	O
mix	O
of	O
HF	I
after	O
MI	I
that	O
requires	O
new	O
prevention	O
strategies	O
.	O

Echocardiographic	I
predictors	O
of	O
reverse	I
remodeling	I
after	O
cardiac	I
resynchronization	I
therapy	I
and	O
subsequent	O
events	O
.	O

BACKGROUND	O
:	O

Studies	O
of	O
echocardiographic	I
predictors	O
of	O
response	O
after	O
cardiac	I
resynchronization	I
therapy	I
(	O
CRT	I
)	O
have	O
largely	O
involved	O
single	O
parameters	O
.	O

We	O
hypothesized	O
that	O
combining	O
parameters	O
would	O
be	O
more	O
robust	O
and	O
sought	O
to	O
develop	O
a	O
multiparametric	O
echocardiographic	I
score	O
for	O
predicting	O
CRT	I
response	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Global	O
longitudinal	O
strain	I
of	O
left	I
ventricle	I
was	O
added	O
to	O
standard	O
echocardiographic	I
measurements	O
in	O
334	O
consecutive	O
patients	I
(	O
224	O
men	O
;	O
mean	O
,	O
65±12	O
years	O
)	O
who	O
underwent	O
baseline	I
echocardiography	I
before	O
CRT	I
and	O
underwent	O
follow-up	I
echocardiograms	I
at	O
1	O
year	O
.	O

Regression	I
analysis	I
was	O
performed	O
to	O
create	O
an	O
echocardiographic	I
score	O
for	O
prediction	O
of	O
LV	I
reverse	I
remodeling	I
(	O
defined	O
as	O
≥15	O
%	O
reduction	O
in	O
the	O
LV	I
end-systolic	I
volume	I
)	O
.	O

Cox	I
proportional	I
hazards	I
models	I
were	O
used	O
to	O
identify	O
the	O
association	O
of	O
the	O
score	O
with	O
death	I
,	O
transplantation	I
or	O
LV	I
assist	I
device	I
implantation	I
,	O
and	O
heart	I
failure	I
hospitalization	I
during	O
57±22	O
months	O
of	O
follow-up	I
.	O

LV	I
reverse	I
remodeling	I
(	O
n=161	O
;	O
48	O
%	O
)	O
was	O
associated	O
with	O
pre-CRT	I
LV	I
end-diastolic	I
dimension	I
index	O
<	O
3.1	O
cm	O
/	O
m	O
(	O
2	O
)	O
,	O
global	O
longitudinal	O
strain	I
of	O
left	I
ventricle	I
<	O
-	O
7	O
%	O
,	O
left	I
atrial	I
area	I
<	O
26	O
cm	O
(	O
2	O
)	O
,	O
right	I
ventricular	I
end-diastolic	I
area	I
index	I
<	O
10.0	O
cm(2)	O
/	O
m	O
(	O
2	O
)	O
,	O
right	I
atrial	I
area	O
<	O
20	O
cm	O
(	O
2	O
)	O
,	O
and	O
right	I
ventricular	I
fractional	I
area	I
change	O
≥35	O
%	O
.	O

Combination	O
of	O
these	O
into	O
an	O
echocardiographic	I
score	O
allowed	O
prediction	O
of	O
LV	I
reverse	I
remodeling	I
with	O
a	O
sensitivity	I
of	O
84	O
%	O
and	O
a	O
specificity	I
of	O
79	O
%	O
.	O

During	O
follow-up	I
,	O
there	O
were	O
134	O
deaths	I
,	O
18	O
heart	I
transplantations	I
/	O
LV	I
assist	I
device	I
implantations	I
,	O
and	O
93	O
heart	I
failure	I
admissions	I
.	O

The	O
score	O
was	O
associated	O
with	O
heart	I
failure	I
admission	I
,	O
heart	I
transplantation	I
/	O
LV	I
assist	I
device	I
,	O
or	O
death	I
(	O
hazard	I
ratio	I
,	O
0.97	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.95	O
-	O
0.98	O
;	O
P	I
<	O
0.001	O
)	O
and	O
all-cause	O
death	I
(	O
hazard	I
ratio	I
,	O
0.97	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.96	O
-	O
0.98	O
;	O
P	I
<	O
0.001	O
)	O
,	O
independent	O
of	O
age	O
,	O
sex	O
,	O
ischemic	I
cause	O
,	O
and	O
initial	O
functional	I
class	I
.	O

CONCLUSIONS	O
:	O

A	O
multiparametric	O
echocardiographic	I
score	O
is	O
helpful	O
in	O
selecting	O
patients	I
likely	O
to	O
undergo	O
reverse	I
remodeling	I
after	O
CRT	I
and	O
predicts	O
clinical	I
outcomes	I
.	O

Effects	O
of	O
care	O
management	O
and	O
telehealth	I
:	O
a	O
longitudinal	I
analysis	O
using	O
medicare	O
data	O
.	O

OBJECTIVES	O
:	O

To	O
evaluate	O
mortality	I
and	O
healthcare	I
utilization	O
effects	O
of	O
an	O
intervention	O
that	O
combined	O
care	O
management	O
and	O
telehealth	I
,	O
targeting	O
individuals	O
with	O
congestive	I
heart	I
failure	I
,	O
chronic	I
obstructive	I
pulmonary	I
disease	I
,	O
or	O
diabetes	I
mellitus	I
.	O

DESIGN	O
:	O

Retrospective	I
matched	I
cohort	I
study	I
.	O

SETTING	O
:	O

Northwest	O
United	O
States	O
.	O

PARTICIPANTS	O
:	O

High-cost	O
Medicare	O
fee-for-service	O
beneficiaries	O
(	O
N	O
=	O
1,767	O
)	O
enrolled	O
in	O
two	O
Centers	O
for	O
Medicare	O
and	O
Medicaid	O
Services	O
demonstration	O
participating	O
clinics	I
and	O
a	O
propensity-score	I
matched	O
control	O
group	O
.	O

INTERVENTION	O
:	O

The	O
Health	I
Buddy	O
Program	O
,	O
which	O
integrates	O
a	O
content-driven	O
telehealth	I
system	O
with	O
care	O
management	O
.	O

MEASUREMENTS	O
:	O

Mortality	I
,	O
inpatient	I
admissions	I
,	O
hospital	I
days	O
,	O
and	O
emergency	I
department	I
(	O
ED	I
)	O
visits	O
during	O
the	O
2-year	O
study	O
period	O
were	O
measured	O
.	O

Cox-proportional	I
hazard	I
models	I
and	O
negative	I
binomial	I
regression	I
models	I
were	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
the	O
intervention	O
and	O
survival	O
and	O
utilization	O
,	O
controlling	O
for	O
demographic	O
and	O
health	I
characteristics	O
that	O
were	O
statistically	O
different	O
between	O
groups	O
after	O
matching	O
.	O

RESULTS	O
:	O

At	O
2	O
years	O
,	O
participants	O
offered	O
the	O
Health	I
Buddy	O
Program	O
had	O
15	O
%	O
lower	O
risk-adjusted	O
all-cause	I
mortality	I
(	O
hazard	I
ratio	I
(	O
HR	I
)	O
=	O
0.85	O
,	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
=	O
0.74	O
-	O
0.98	O
;	O
P	I
=	O
.03	O
)	O
and	O
had	O
reductions	O
in	O
the	O
number	O
of	O
quarterly	O
inpatient	I
admissions	I
from	O
baseline	I
to	O
the	O
study	O
period	O
that	O
were	O
18	O
%	O
greater	O
than	O
those	O
of	O
matched	O
controls	O
during	O
this	O
same	O
time	O
period	O
(	O
-	O
0.035	O
vs	O
-	O
0.003	O
;	O
difference-in-differences	O
=	O
-	O
0.032	O
,	O
95	O
%	O
CI	I
=	O
-	O
0.054	O
to	O
-	O
0.010	O
,	O
P	I
=	O
.005	O
)	O
.	O

No	O
relationship	O
was	O
found	O
between	O
the	O
Health	I
Buddy	O
Program	O
and	O
ED	I
use	O
or	O
number	O
of	O
hospital	I
days	O
for	O
participants	O
who	O
were	O
hospitalized	I
.	O

The	O
Health	I
Buddy	O
Program	O
was	O
most	O
strongly	O
associated	O
with	O
fewer	O
admissions	I
for	O
individuals	O
with	O
chronic	I
obstructive	I
pulmonary	I
disease	I
and	O
mortality	I
for	O
those	O
with	O
congestive	I
heart	I
failure	I
.	O

CONCLUSION	O
:	O

Care	O
management	O
coupled	O
with	O
content-driven	O
telehealth	I
technology	O
has	O
potential	O
to	O
improve	O
health	I
outcomes	I
in	O
high-cost	O
Medicare	O
beneficiaries	O
.	O

Usefulness	O
of	O
tissue	I
Doppler	I
imaging	O
for	O
assessing	O
left	I
ventricular	I
filling	I
pressure	I
in	O
patients	I
with	O
stable	I
severe	I
systolic	I
heart	I
failure	I
.	O

The	O
ratio	O
of	O
early	O
transmitral	I
blood	I
flow	I
velocity	I
over	O
tissue	I
Doppler	I
early	O
diastolic	I
mitral	I
annulus	I
velocity	I
(	O
E	I
/	I
e	I
'	I
)	O
was	O
found	O
unreliable	O
for	O
estimating	O
pulmonary	I
capillary	I
wedge	I
pressure	I
(	O
PCWP	I
)	O
in	O
patients	I
with	O
decompensated	I
systolic	I
heart	I
failure	I
(	O
HF	I
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
its	O
reliability	O
in	O
stable	I
HF	I
.	O

Therefore	O
,	O
130	O
consecutive	O
patients	I
with	O
a	O
left	I
ventricular	I
(	O
LV	I
)	O
ejection	I
fraction	I
of	O
<	O
35	O
%	O
and	O
stable	I
HF	I
underwent	O
right-sided	I
cardiac	I
catheterization	I
and	O
transthoracic	I
echocardiography	I
with	O
measurement	O
of	O
transmitral	I
flow	I
velocities	O
(	O
E	O
,	O
A	O
)	O
and	O
mitral	I
annulus	I
velocities	I
during	O
systole	I
(	O
s	I
'	I
)	O
and	O
diastole	I
(	O
e	O
'	O
)	O
.	O

Mean	O
age	O
was	O
56	O
±	O
11	O
years	O
and	O
mean	O
LV	I
ejection	I
fraction	I
was	O
28	O
±	O
8	O
%	O
;	O
48	O
%	O
had	O
PCWP	I
of	O
>	O
15	O
mm	O
Hg	O
.	O

E	I
/	I
e'septal	I
correlated	I
more	O
strongly	O
with	O
PCWP	I
(	O
r	I
=	O
0.53	O
)	O
compared	O
with	O
E	I
/	I
e'lateral	I
(	O
r	I
=	O
0.41	O
)	O
and	O
E	I
/	I
e'mean	I
(	O
r	I
=	O
0.50	O
;	O
all	O
p	I
values	I
<	O
0.001	O
)	O
.	O

The	O
area	I
under	I
the	I
receiver	I
operating	I
characteristic	I
curve	I
(	O
AUC	I
)	O
of	O
E	I
/	I
e	I
'	I
ratios	O
for	O
PCWP	I
estimation	O
was	O
0.79	O
(	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
0.70	O
to	O
0.87	O
)	O
for	O
E	I
/	I
e'septal	I
,	O
0.72	O
(	O
95	O
%	O
CI	I
0.63	O
to	O
0.82	O
)	O
for	O
E	O
/	O
elateral	O
,	O
and	O
0.79	O
(	O
95	O
%	O
CI	I
0.70	O
to	O
0.87	O
)	O
for	O
E	O
/	O
emean	O
(	O
all	O
p	I
values	I
<	O
0.0001	O
)	O
.	O

AUCs	I
of	O
E	O
/	O
eseptal	O
and	O
E	O
/	O
emean	O
did	O
not	O
vary	O
with	O
s'septal	I
,	O
QRS	I
width	O
,	O
or	O
resynchronization	I
.	O

Using	O
a	O
cutoff	O
of	O
8	O
,	O
negative	O
predictive	O
value	O
of	O
E	I
/	I
e'septal	I
was	O
89	O
%	O
and	O
negative	O
likelihood	I
ratio	I
of	O
0.15	O
.	O

E	I
/	I
e'lateral	I
showed	O
good	O
diagnostic	I
performance	O
only	O
in	O
patients	I
with	O
s'lateral	I
of	O
>	O
4.5	O
cm	O
/	O
s	O
(	O
n	O
=	O
77	O
,	O
59	O
%	O
;	O
AUC	I
=	O
0.82	O
;	O
95	O
%	O
CI	I
0.71	O
to	O
0.92	O
;	O
s'lateral	I
of	O
≤4.5	O
cm	O
/	O
s	O
:	O
AUC	I
=	O
0.54	O
;	O
95	O
%	O
CI	I
0.38	O
to	O
0.70	O
;	O
p	I
=	O
0.005	O
)	O
.	O

In	O
conclusion	O
,	O
e	O
'	O
is	O
useful	O
for	O
estimating	O
LV	I
filling	I
pressure	I
in	O
stable	I
severe	I
systolic	I
HF	I
.	O

E	I
/	I
e'septal	I
showed	O
good	O
diagnostic	I
performance	O
for	O
detecting	O
normal	O
filling	I
pressures	I
.	O

Functional	I
electrical	I
stimulation	I
of	O
peripheral	I
muscles	I
improves	O
endothelial	I
function	I
and	O
clinical	I
and	O
emotional	O
status	O
in	O
heart	I
failure	I
patients	I
with	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
.	O

BACKGROUND	O
:	O

Functional	I
electrical	I
stimulation	I
(	O
FES	I
)	O
improves	O
exercise	I
capacity	I
,	O
quality	I
of	I
life	I
,	O
emotional	O
stress	O
,	O
and	O
endothelial	I
function	I
in	O
chronic	I
heart	I
failure	I
with	O
impaired	O
systolic	I
function	I
.	O

We	O
sought	O
to	O
investigate	O
the	O
effects	O
of	O
FES	I
on	O
the	O
above	O
parameters	O
in	O
patients	I
with	O
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
.	O

METHODS	O
:	O

Thirty	O
HFpEF	I
patients	I
,	O
18	O
female	O
and	O
12	O
male	O
,	O
aged	O
69	O
±	O
8	O
years	O
,	O
in	O
New	I
York	I
Heart	I
Association	I
class	I
II	I
or	O
III	I
and	O
with	O
mean	O
ejection	I
fraction	I
63	O
%	O
±	O
6	O
%	O
,	O
were	O
randomly	O
(	O
1:1	O
)	O
assigned	O
to	O
a	O
6-week	O
FES	I
program	O
or	O
placebo	I
.	O

Assessment	O
was	O
performed	O
at	O
baseline	I
and	O
after	O
completion	O
of	O
training	O
protocol	O
and	O
included	O
6-minute	I
walked	I
distance	I
,	O
quality	I
of	I
life	I
(	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
and	O
Minnesota	O
Living	O
with	O
Heart	I
Failure	I
Questionnaire	O
)	O
,	O
depressive	O
symptoms	I
(	O
Beck	O
Depression	O
Inventory	O
and	O
Zung	O
self-rated	O
depression	O
scores	O
)	O
,	O
B-type	I
natriuretic	I
peptide	I
,	O
endothelial	I
function	I
(	O
flow-mediated	I
dilatation	I
)	O
,	O
and	O
left	I
ventricular	I
diastolic	I
function	I
.	O

RESULTS	O
:	O

A	O
significant	I
improvement	O
in	O
6-minute	I
walked	I
distance	I
(	O
F	O
=	O
21.61	O
,	O
P	I
=	O
.001	O
)	O
,	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
summary	O
(	O
F	O
=	O
8.68	O
,	O
P	I
=	O
.006	O
)	O
,	O
Minnesota	O
Living	O
with	O
Heart	I
Failure	I
Questionnaire	O
(	O
F	O
=	O
6.43	O
,	O
P	I
=	O
.017	O
)	O
,	O
Beck	O
Depression	O
Inventory	O
(	O
F	O
=	O
6.66	O
,	O
P	I
=	O
.015	O
)	O
,	O
Zung	O
(	O
F	O
=	O
6.25	O
,	O
P	I
=	O
.019	O
)	O
,	O
and	O
flow-mediated	I
dilatation	I
diameter	O
(	O
F	O
=	O
11.98	O
,	O
P	I
=	O
.002	O
)	O
was	O
observed	O
in	O
the	O
FES	I
group	O
compared	O
with	O
placebo	I
group	O
;	O
B-type	I
natriuretic	I
peptide	I
also	O
declined	O
but	O
not	O
significantly	I
(	O
F	O
=	O
0.249	O
,	O
P	I
=	O
.622	O
)	O
,	O
and	O
there	O
was	O
a	O
tendency	O
toward	O
lower	O
mitral	I
E	I
/	I
e	I
'	I
wave	O
ratio	O
(	O
F	O
=	O
3.066	O
,	O
P	I
=	O
.091	O
)	O
.	O

CONCLUSION	O
:	O

As	O
in	O
heart	I
failure	I
and	O
reduced	I
left	I
ventricular	I
ejection	I
fraction	I
,	O
FES	I
also	O
improves	O
exercise	I
capacity	I
,	O
quality	I
of	I
life	I
,	O
emotional	O
status	O
,	O
and	O
endothelial	I
function	I
in	O
HFpEF	I
.	O

Given	O
the	O
lack	O
of	O
effective	O
evidence-based	I
therapies	I
in	O
these	O
patients	I
,	O
FES	I
warrants	O
further	O
investigation	O
.	O

Systems	I
proteomics	I
of	O
cardiac	I
chromatin	I
identifies	O
nucleolin	I
as	O
a	O
regulator	O
of	O
growth	O
and	O
cellular	I
plasticity	I
in	O
cardiomyocytes	I
.	O

Myocyte	I
hypertrophy	I
antecedent	O
to	O
heart	I
failure	I
involves	O
changes	O
in	O
global	I
gene	I
expression	I
,	O
although	O
the	O
preceding	O
mechanisms	O
to	O
coordinate	O
DNA	I
accessibility	O
on	O
a	O
genomic	I
scale	O
are	O
unknown	O
.	O

Chromatin-associated	I
proteins	I
alter	O
chromatin	I
structure	I
by	O
changing	O
their	O
association	O
with	O
DNA	I
,	O
thereby	O
altering	O
the	O
gene	I
expression	I
profile	I
.	O

Little	O
is	O
known	O
about	O
the	O
global	O
changes	O
in	O
chromatin	I
subproteomes	I
that	O
accompany	O
heart	I
failure	I
,	O
and	O
the	O
mechanisms	O
by	O
which	O
these	O
proteins	I
alter	O
chromatin	I
structure	I
.	O

The	O
present	O
study	O
tests	O
the	O
fundamental	O
hypothesis	O
that	O
cardiac	I
growth	I
and	O
plasticity	I
in	O
the	O
setting	O
of	O
disease	I
recapitulates	O
conserved	O
developmental	O
chromatin	I
remodeling	I
events	O
.	O

We	O
used	O
quantitative	O
proteomics	I
to	O
identify	O
chromatin-associated	I
proteins	I
extracted	O
via	O
detergent	O
and	O
to	O
quantify	O
changes	O
in	O
their	O
abundance	O
during	O
disease	I
.	O

Our	O
study	O
identified	O
321	O
proteins	I
in	O
this	O
subproteome	I
,	O
demonstrating	O
it	O
to	O
have	O
modest	O
conservation	O
(	O
37	O
%	O
)	O
with	O
that	O
revealed	O
using	O
strong	O
acid	O
.	O

Of	O
these	O
proteins	I
,	O
176	O
exhibited	O
altered	O
expression	I
during	O
cardiac	I
hypertrophy	I
and	O
failure	I
;	O
we	O
conducted	O
extensive	O
functional	O
characterization	O
of	O
one	O
of	O
these	O
proteins	I
,	O
Nucleolin	I
.	O

Morpholino-based	I
knockdown	O
of	O
nucleolin	I
nearly	O
abolished	O
protein	I
expression	I
but	O
surprisingly	O
had	O
little	O
impact	O
on	O
gross	O
morphological	O
development	O
.	O

However	O
,	O
hearts	I
of	O
fish	O
lacking	O
Nucleolin	I
displayed	O
severe	O
developmental	O
impairment	O
,	O
abnormal	O
chamber	I
patterning	I
and	O
functional	O
deficits	O
,	O
ostensibly	O
due	O
to	O
defects	O
in	O
cardiac	I
looping	I
and	O
myocyte	I
differentiation	I
.	O

The	O
mechanisms	O
underlying	O
these	O
defects	O
involve	O
perturbed	O
bone	I
morphogenetic	I
protein	I
4	I
expression	I
,	O
decreased	O
rRNA	I
transcription	I
,	O
and	O
a	O
shift	O
to	O
more	O
heterochromatic	I
chromatin	I
.	O

This	O
study	O
reports	O
the	O
quantitative	O
analysis	O
of	O
a	O
new	O
chromatin	I
subproteome	I
in	O
the	O
normal	O
and	O
diseased	I
mouse	O
heart	I
.	O

Validation	O
studies	O
in	O
the	O
complementary	O
model	O
system	O
of	O
zebrafish	O
examine	O
the	O
role	O
of	O
Nucleolin	I
to	O
orchestrate	O
genomic	I
reprogramming	I
events	O
shared	O
between	O
development	O
and	O
disease	I
.	O

Mechanistic	O
insight	O
into	O
prolonged	O
electromechanical	I
delay	I
in	O
dyssynchronous	I
heart	I
failure	I
:	O
a	O
computational	O
study	O
.	O

In	O
addition	O
to	O
the	O
left	I
bundle	I
branch	I
block	I
type	O
of	O
electrical	O
activation	O
,	O
there	O
are	O
further	O
remodeling	I
aspects	O
associated	O
with	O
dyssynchronous	I
heart	I
failure	I
(	O
HF	I
)	O
that	O
affect	O
the	O
electromechanical	O
behavior	O
of	O
the	O
heart	I
.	O

Among	O
the	O
most	O
important	O
are	O
altered	O
ventricular	I
structure	O
(	O
both	O
geometry	O
and	O
fiber	O
/	O
sheet	O
orientation	O
)	O
,	O
abnormal	O
Ca	I
(	I
2	I
+	I
)	I
handling	I
,	O
slowed	O
conduction	O
,	O
and	O
reduced	O
wall	I
stiffness	I
.	O

In	O
dyssynchronous	I
HF	I
,	O
the	O
electromechanical	I
delay	I
(	O
EMD	I
)	O
,	O
the	O
time	O
interval	O
between	O
local	O
myocyte	I
depolarization	I
and	O
myofiber	I
shortening	I
onset	O
,	O
is	O
prolonged	O
.	O

However	O
,	O
the	O
contributions	O
of	O
the	O
four	O
major	O
HF	I
remodeling	I
aspects	O
in	O
extending	O
EMD	I
in	O
the	O
dyssynchronous	I
failing	I
heart	I
remain	O
unknown	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
individual	O
and	O
combined	O
contributions	O
of	O
HF-induced	I
remodeling	I
aspects	O
to	O
EMD	I
prolongation	O
.	O

We	O
used	O
MRI-based	I
models	O
of	O
dyssynchronous	I
nonfailing	I
and	O
HF	I
canine	O
electromechanics	O
and	O
constructed	O
additional	O
models	O
in	O
which	O
varying	O
combinations	O
of	O
the	O
four	O
remodeling	I
aspects	O
were	O
represented	O
.	O

A	O
left	I
bundle	I
branch	I
block	I
electrical	O
activation	O
sequence	O
was	O
simulated	O
in	O
all	O
models	O
.	O

The	O
simulation	O
results	O
revealed	O
that	O
deranged	O
Ca	I
(	I
2	I
+	I
)	I
handling	I
is	O
the	O
primary	O
culprit	O
in	O
extending	O
EMD	I
in	O
dyssynchronous	I
HF	I
,	O
with	O
the	O
other	O
aspects	O
of	O
remodeling	I
contributing	O
insignificantly	I
.	O

Mechanistically	O
,	O
we	O
found	O
that	O
abnormal	O
Ca	I
(	I
2	I
+	I
)	I
handling	I
in	O
dyssynchronous	I
HF	I
slows	O
myofiber	I
shortening	I
velocity	O
at	O
the	O
early-activated	O
septum	I
and	O
depresses	O
both	O
myofiber	I
shortening	I
and	O
stretch	O
rate	O
at	O
the	O
late-activated	O
lateral	O
wall	O
.	O

These	O
changes	O
in	O
myofiber	I
dynamics	I
delay	O
the	O
onset	O
of	O
myofiber	I
shortening	I
,	O
thus	O
giving	O
rise	O
to	O
prolonged	O
EMD	I
in	O
dyssynchronous	I
HF	I
.	O

Relationship	O
between	O
sex	O
,	O
ejection	I
fraction	I
,	O
and	O
B-type	I
natriuretic	I
peptide	I
levels	O
in	O
patients	I
hospitalized	I
with	O
heart	I
failure	I
and	O
associations	O
with	O
inhospital	I
outcomes	I
:	O
findings	O
from	O
the	O
Get	O
With	O
The	O
Guideline-Heart	I
Failure	I
Registry	O
.	O

BACKGROUND	O
:	O

In	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
there	O
are	O
known	O
differences	O
in	O
plasma	I
B-type	I
natriuretic	I
peptide	I
(	O
BNP	I
)	O
levels	O
between	O
reduced	I
and	O
preserved	I
ejection	I
fraction	I
(	O
EF	I
)	O
,	O
but	O
few	O
HF	I
studies	O
have	O
explored	O
sex	O
differences	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
relationship	O
between	O
sex	O
,	O
EF	I
,	O
and	O
BNP	I
in	O
HF	I
patients	I
and	O
determine	O
prognostic	I
significance	I
of	O
BNP	I
as	O
it	O
relates	O
to	O
sex	O
and	O
EF	I
.	O

METHODS	O
:	O

We	O
included	O
hospitals	I
in	O
Get	O
With	O
The	O
Guidelines-Heart	I
Failure	I
that	O
admitted	O
99,930	O
HF	I
patients	I
with	O
reduced	I
(	O
EF	I
<	O
40	O
%	O
)	O
,	O
borderline	O
(	O
EF	I
40%-49	O
%	O
)	O
,	O
or	O
preserved	I
(	O
EF	I
≥50	O
%	O
)	O
EF	I
.	O

The	O
primary	I
end	I
point	I
was	O
inhospital	I
mortality	I
.	O

Multivariate	I
models	I
were	O
used	O
to	O
compute	O
odds	I
ratios	I
while	O
accounting	O
for	O
hospital	I
clustering	O
.	O

RESULTS	O
:	O

There	O
were	O
47,025	O
patients	I
with	O
reduced	I
(	O
37	O
%	O
female	O
)	O
,	O
13,950	O
with	O
borderline	O
(	O
48	O
%	O
female	O
)	O
,	O
and	O
38,955	O
with	O
preserved	I
(	O
65	O
%	O
female	O
)	O
EF	I
.	O

Women	O
compared	O
with	O
men	O
had	O
higher	O
admission	I
median	O
BNP	I
levels	O
with	O
the	O
greatest	O
difference	O
among	O
reduced	I
EF	I
and	O
smallest	O
difference	O
among	O
preserved	I
EF	I
(	O
median	O
BNP	I
in	O
women	O
vs	O
men	O
:	O
EF	I
reduced	O
1,259	O
vs	O
1,113	O
pg	O
/	O
mL	O
,	O
borderline	O
821	O
vs	O
732	O
pg	O
/	O
mL	O
,	O
and	O
preserved	O
559	O
vs	O
540	O
pg	O
/	O
mL	O
;	O
P	I
<	O
.001	O
all	O
comparisons	O
)	O
.	O

Ejection	I
fraction	I
and	O
sex	O
were	O
independently	O
associated	O
with	O
BNP	I
.	O

Inhospital	I
mortality	I
was	O
2.7	O
%	O
,	O
and	O
patients	I
above	O
the	O
median	O
BNP	I
level	O
had	O
higher	O
mortality	I
than	O
those	O
below	O
.	O

After	O
adjusting	O
for	O
over	O
20	O
clinical	I
variables	O
,	O
the	O
ability	O
of	O
BNP	I
to	O
predict	O
inhospital	I
mortality	I
was	O
similar	O
among	O
all	O
subgroups	O
(	O
P	I
for	O
heterogeneity	O
=	O
.47	O
)	O
.	O

CONCLUSIONS	O
:	O

In	O
a	O
large	O
registry	O
,	O
we	O
found	O
that	O
despite	O
sex	O
/	O
EF	I
differences	O
in	O
BNP	I
values	O
,	O
there	O
was	O
no	O
significant	I
difference	O
in	O
the	O
ability	O
of	O
BNP	I
to	O
predict	O
inhospital	I
mortality	I
among	O
these	O
subgroups	O
.	O

Implications	O
of	O
metric	O
choice	O
for	O
common	O
applications	O
of	O
readmission	I
metrics	O
.	O

OBJECTIVE	O
:	O

To	O
quantify	O
the	O
differential	O
impact	O
on	O
hospital	I
performance	O
of	O
three	O
readmission	I
metrics	O
:	O
all-cause	I
readmission	I
(	O
ACR	I
)	O
,	O
3M	O
Potential	O
Preventable	O
Readmission	I
(	O
PPR	O
)	O
,	O
and	O
Centers	O
for	O
Medicare	O
and	O
Medicaid	O
30-day	O
readmission	I
(	O
CMS	O
)	O
.	O

DATA	O
SOURCES	O
:	O

2000	O
-	O
2009	O
California	O
Office	O
of	O
Statewide	O
Health	I
Planning	O
and	O
Development	O
Patient	I
Discharge	I
Data	O
Nonpublic	O
file	O
.	O

STUDY	O
DESIGN	O
:	O

We	O
calculated	O
30-day	O
readmission	I
rates	O
using	O
three	O
metrics	O
,	O
for	O
three	O
disease	I
groups	O
:	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
acute	I
myocardial	I
infarction	I
(	O
AMI	I
)	O
,	O
and	O
pneumonia	I
.	O

Using	O
each	O
metric	O
,	O
we	O
calculated	O
the	O
absolute	O
change	O
and	O
correlation	I
between	O
performance	O
;	O
the	O
percent	O
of	O
hospitals	I
remaining	O
in	O
extreme	O
deciles	O
and	O
level	O
of	O
agreement	O
;	O
and	O
differences	O
in	O
longitudinal	I
performance	O
.	O

PRINCIPAL	O
FINDINGS	O
:	O

Average	O
hospital	I
rates	O
for	O
HF	I
patients	I
and	O
the	O
CMS	O
metric	O
were	O
generally	O
higher	O
than	O
for	O
other	O
conditions	I
and	O
metrics	O
.	O

Correlations	I
between	O
the	O
ACR	I
and	O
CMS	O
metrics	O
were	O
highest	O
(	O
r	I
=	O
0.67	O
-	O
0.84	O
)	O
.	O

Rates	O
calculated	O
using	O
the	O
PPR	O
and	O
either	O
ACR	I
or	O
CMS	O
metrics	O
were	O
moderately	O
correlated	I
(	O
r	I
=	O
0.50	O
-	O
0.67	O
)	O
.	O

Between	O
47	O
and	O
75	O
percent	O
of	O
hospitals	I
in	O
an	O
extreme	O
decile	O
according	O
to	O
one	O
metric	O
remained	O
when	O
using	O
a	O
different	O
metric	O
.	O

Correlations	I
among	O
metrics	O
were	O
modest	O
when	O
measuring	O
hospital	I
longitudinal	I
change	O
.	O

CONCLUSIONS	O
:	O

Different	O
approaches	O
to	O
computing	O
readmissions	I
can	O
produce	O
different	O
hospital	I
rankings	O
and	O
impact	O
pay-for-performance	O
.	O

Careful	O
consideration	O
should	O
be	O
placed	O
on	O
readmission	I
metric	O
choice	O
for	O
these	O
applications	O
.	O

The	O
reality	O
of	O
heart	I
failure	I
in	O
Latin	O
America	O
.	O

Heart	I
failure	I
(	O
HF	I
)	O
data	O
in	O
Latin	O
America	O
(	O
LA	O
)	O
were	O
reviewed	O
to	O
guide	O
health	I
service	O
planning	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
HF	I
.	O

The	O
HF	I
epidemiology	I
and	O
the	O
adequacy	O
of	O
relevant	O
health	I
service	O
provision	O
related	O
to	O
HF	I
in	O
LA	O
are	O
not	O
well	O
delineated	O
.	O

A	O
systematic	O
search	O
of	O
the	O
electronic	O
databases	O
and	O
the	O
World	O
Health	I
Organization	O
website	O
was	O
undertaken	O
for	O
HF	I
in	O
LA	O
.	O

LA	O
countries	O
have	O
reduced	O
gross	O
income	O
and	O
lower	O
total	O
expenditure	O
on	O
health	I
per	O
capita	O
.	O

LA	O
is	O
a	O
heterogeneous	O
region	O
with	O
HF	I
risk	O
factors	O
of	O
developed	O
and	O
nondeveloped	O
countries	O
,	O
including	O
lower	O
risk	O
of	O
raised	O
blood	I
glucose	I
levels	O
,	O
obesity	I
,	O
tobacco	O
,	O
and	O
aging	O
,	O
whereas	O
systemic	I
hypertension	I
(	O
SH	I
)	O
,	O
rheumatic	I
fever	I
,	O
and	O
Chagas	I
'	I
disease	I
(	O
C	I
'D	I
)	O
are	O
higher	O
in	O
LA	O
.	O

Main	O
etiologies	I
of	O
HF	I
in	O
LA	O
are	O
idiopathic	I
dilated	I
cardiomyopathy	I
(	O
from	O
1.3	O
%	O
to	O
37	O
%	O
)	O
,	O
C	I
'D	I
(	O
from	O
1.3	O
%	O
to	O
21	O
%	O
)	O
,	O
ischemic	I
(	O
from	O
68	O
%	O
to	O
17	O
%	O
)	O
,	O
SH	I
(	O
from	O
14	O
%	O
to	O
76	O
%	O
)	O
,	O
valvular	I
(	O
from	O
3	O
%	O
to	O
22	O
%	O
)	O
,	O
and	O
alcohol	O
related	O
(	O
from	O
1.1	O
%	O
to	O
8	O
%	O
)	O
.	O

The	O
prognosis	I
of	O
C	I
'D	I
HF	I
is	O
worse	O
than	O
for	O
other	O
etiologies	I
.	O

Chronic	I
HF	I
is	O
the	O
cause	O
of	O
death	I
in	O
6.3	O
%	O
of	O
cases	O
.	O

Decompensated	I
HF	I
is	O
the	O
main	O
cause	O
of	O
cardiovascular	I
hospitalization	I
.	O

The	O
prevalence	I
of	O
systolic	I
HF	I
varies	O
from	O
64	O
%	O
to	O
69	O
%	O
.	O

LA	O
is	O
under	O
the	O
awful	O
paradox	O
of	O
having	O
the	O
HF	I
risk	O
factors	O
and	O
HF	I
epidemiology	I
of	O
developed	O
countries	O
with	O
the	O
added	O
factors	O
of	O
SH	I
,	O
C	I
'D	I
,	O
and	O
rheumatic	I
fever	I
.	O

Overall	O
,	O
in	O
the	O
scenario	O
of	O
lower	O
total	O
expenditure	O
on	O
health	I
per	O
capita	O
and	O
lower	O
gross	O
national	O
income	O
per	O
capita	O
,	O
new	O
strategies	O
are	O
essential	O
for	O
prevention	O
and	O
treatment	O
of	O
HF	I
in	O
LA	O
.	O

First-in-class	O
angiotensin	I
receptor	I
neprilysin	I
inhibitor	I
in	O
heart	I
failure	I
.	O

Neprilysin	I
inhibitors	I
augment	O
the	O
natriuretic	I
peptide	I
system	O
by	O
preventing	O
the	O
breakdown	O
of	O
atrial	I
natriuretic	I
peptide	I
and	O
B-type	I
natriuretic	I
peptide	I
.	O

LCZ696	I
,	O
an	O
angiotensin	I
receptor	I
neprilysin	I
inhibitor	I
composed	O
of	O
a	O
neprilysin	I
inhibitor	I
prodrug	I
and	O
the	O
angiotensin	I
receptor	I
antagonist	I
valsartan	I
,	O
has	O
proven	O
effective	O
in	O
hypertension	I
,	O
has	O
shown	O
promise	O
in	O
a	O
pilot	O
trial	O
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
,	O
and	O
is	O
being	O
tested	O
in	O
a	O
large	O
outcomes	I
trial	O
of	O
heart	I
failure	I
with	I
reduced	I
ejection	I
fraction	I
.	O

A	O
preserved	I
ejection	I
fraction	I
outcomes	I
trial	O
is	O
beginning	O
.	O

Learning	O
from	O
recent	O
trials	O
and	O
shaping	O
the	O
future	O
of	O
acute	I
heart	I
failure	I
trials	O
.	O

The	O
last	O
decade	O
of	O
acute	I
heart	I
failure	I
(	O
HF	I
)	O
research	O
is	O
characterized	O
by	O
disappointments	O
in	O
large	O
phase	O
2	O
and	O
3	O
pharmacologic	I
studies	O
of	O
therapeutics	I
including	O
calcium-sensitizing	I
agents	I
and	O
antagonists	I
of	O
endothelin	I
,	O
vasopressin	I
,	O
and	O
adenosine	I
.	O

As	O
a	O
result	O
,	O
pharmacologic	I
management	O
for	O
acute	I
HF	I
has	O
changed	O
little	O
in	O
recent	O
years	O
,	O
and	O
adverse	I
event	I
rates	O
remain	O
higher	O
than	O
in	O
chronic	I
HF	I
.	O

Despite	O
neutral	O
results	O
in	O
many	O
acute	I
HF	I
trials	O
,	O
recent	O
studies	O
including	O
RELAX-AHF	I
,	O
ASTRONAUT	O
,	O
and	O
PRONTO	O
have	O
highlighted	O
the	O
role	O
of	O
appropriate	O
timing	O
of	O
patient	I
enrollment	O
,	O
targeting	O
the	O
right	O
patients	I
,	O
and	O
selecting	O
appropriate	O
end	I
points	I
and	O
sites	O
.	O

We	O
describe	O
lessons	O
learned	O
from	O
recent	O
trials	O
in	O
acute	I
HF	I
and	O
outline	O
strategies	O
to	O
improve	O
the	O
potential	O
for	O
success	O
in	O
future	O
trials	O
.	O

Ten-year	O
experience	O
with	O
extended	I
criteria	I
cardiac	I
transplantation	I
.	O

BACKGROUND	O
:	O

Extended	I
criteria	I
cardiac	I
transplant	I
(	O
ECCT	I
)	O
programs	O
expand	O
the	O
transplant	I
pool	O
by	O
matching	O
donors	I
and	O
recipients	O
typically	O
excluded	O
from	O
the	O
transplant	I
process	O
because	O
of	O
age	O
or	O
comorbidity	I
.	O

There	O
is	O
a	O
paucity	I
of	O
data	O
examining	O
long-term	O
outcomes	I
with	O
this	O
strategy	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Between	O
January	O
2000	O
and	O
December	O
2009	O
,	O
adult	O
patients	I
undergoing	O
isolated	O
heart	I
transplant	I
were	O
prospectively	I
classified	O
as	O
ECCT	I
based	O
on	O
prespecified	O
criteria	O
.	O

Baseline	I
characteristics	O
and	O
outcomes	I
were	O
compared	O
between	O
ECCT	I
and	O
standard	O
criteria	O
cardiac	I
transplant	I
recipients	O
.	O

Two	O
Cox	I
proportional	I
hazards	I
models	I
were	O
developed	O
.	O

The	O
first	O
to	O
identify	O
clinical	I
variables	O
contributing	O
to	O
survival	O
between	O
the	O
2	O
groups	O
,	O
and	O
the	O
second	O
to	O
determine	O
the	O
additional	O
risk	O
associated	O
with	O
assignment	O
to	O
ECCT	I
.	O

Among	O
the	O
454	O
patients	I
who	O
underwent	O
heart	I
transplant	I
,	O
84	O
(	O
18.5	O
%	O
)	O
were	O
ECCT	I
.	O

Compared	O
with	O
the	O
patients	I
who	O
underwent	O
standard	O
criteria	O
cardiac	I
transplant	I
,	O
ECCT	I
patients	I
were	O
older	O
(	O
median	O
,	O
66.6	O
years	O
versus	O
53.2	O
years	O
;	O
P	I
<	O
0.001	O
)	O
,	O
with	O
higher	O
frequency	O
of	O
diabetes	I
mellitus	I
(	O
46.4	O
%	O
versus	O
24.6	O
%	O
;	O
P	I
<	O
0.001	O
)	O
and	O
chronic	I
kidney	I
disease	I
(	O
median	O
estimated	I
glomerular	I
filtration	I
rate	I
,	O
55	O
versus	O
61.6	O
mL	O
/	O
min	O
;	O
P=0.001	I
)	O
.	O

After	O
adjustment	O
for	O
baseline	I
characteristics	O
,	O
standard	O
criteria	O
cardiac	I
transplant	I
survival	O
was	O
higher	O
than	O
ECCT	I
at	O
1	O
(	O
89	O
%	O
versus	O
86	O
%	O
;	O
P=0.18	I
)	O
and	O
5	O
(	O
77	O
%	O
versus	O
66	O
%	O
;	O
P=0.035	I
)	O
years	O
.	O

In	O
a	O
multivariate	I
model	I
that	O
included	O
listing	O
criteria	O
,	O
creatinine	I
(	O
hazard	I
ratio	I
,	O
1.05	O
per	O
0.1	O
mg	O
/	O
dL	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
1.02	O
-	O
1.09	O
;	O
P=0.001	I
)	O
was	O
a	O
significant	I
predictor	O
of	O
post-transplant	I
mortality	I
.	O

CONCLUSIONS	O
:	O

ECCT	I
is	O
an	O
acceptable	O
alternative	O
for	O
advanced	O
heart	I
failure	I
therapy	I
in	O
select	O
patients	I
.	O

Age	O
and	O
renal	I
dysfunction	I
are	O
important	O
determinants	O
of	O
long-term	O
survival	O
and	O
post-transplant	I
morbidity	I
.	O

Nicorandil	I
ameliorates	O
mitochondrial	I
dysfunction	I
in	O
doxorubicin-induced	I
heart	I
failure	I
in	O
rats	O
:	O
possible	O
mechanism	O
of	O
cardioprotection	I
.	O

Despite	O
of	O
its	O
known	O
cardiotoxicity	I
,	O
doxorubicin	I
is	O
still	O
a	O
highly	O
effective	O
anti-neoplastic	I
agent	I
in	O
the	O
treatment	O
of	O
several	O
cancers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
cardioprotective	I
effect	O
of	O
nicorandil	I
was	O
investigated	O
on	O
hemodynamic	I
alterations	O
and	O
mitochondrial	I
dysfunction	I
induced	O
by	O
cumulative	O
administration	O
of	O
doxorubicin	I
in	O
rats	O
.	O

Doxorubicin	I
was	O
injected	I
i.p.	O
over	O
2	O
weeks	O
to	O
obtain	O
a	O
cumulative	O
dose	O
of	O
18	O
mg	O
/	O
kg	O
.	O

Nicorandil	I
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
given	O
orally	I
with	O
or	O
without	O
doxorubicin	I
treatment	O
.	O

Heart	I
rate	I
and	O
aortic	I
blood	I
flow	I
were	O
recorded	O
24	O
h	O
after	O
receiving	O
the	O
last	O
dose	O
of	O
doxorubicin	I
.	O

Rats	O
were	O
then	O
sacrificed	O
and	O
hearts	I
were	O
rapidly	O
excised	O
for	O
estimation	O
of	O
caspase-3	I
activity	O
,	O
phosphocreatine	I
and	O
adenine	I
nucleotides	I
contents	O
in	O
addition	O
to	O
cytochrome	I
c	I
,	O
Bcl2	I
,	O
Bax	I
and	O
caspase	I
3	I
expression	I
.	O

Moreover	O
,	O
mitochondrial	I
oxidative	I
phosphorylation	I
capacity	I
,	O
creatine	I
kinase	I
activity	O
and	O
oxidative	I
stress	I
markers	O
were	O
measured	O
together	O
with	O
the	O
examination	O
of	O
DNA	I
fragmentation	I
and	O
ultrastructural	O
changes	O
.	O

Nicorandil	I
was	O
effective	O
in	O
alleviating	O
the	O
decrement	O
of	O
heart	I
rate	I
and	O
aortic	I
blood	I
flow	I
and	O
the	O
state	O
of	O
mitochondrial	I
oxidative	I
stress	I
induced	O
by	O
doxorubicin	I
cardiotoxicity	I
.	O

Nicorandil	I
also	O
preserved	O
phosphocreatine	I
and	O
adenine	I
nucleotides	I
contents	O
by	O
restoring	O
mitochondrial	I
oxidative	I
phosphorylation	I
capacity	I
and	O
creatine	I
kinase	I
activity	O
.	O

Moreover	O
,	O
nicorandil	I
provided	O
a	O
significant	I
cardioprotection	I
via	O
inhibition	O
of	O
apoptotic	I
signaling	I
pathway	I
,	O
DNA	I
fragmentation	I
and	O
mitochondrial	I
ultrastructural	O
changes	O
.	O

Interestingly	O
,	O
nicorandil	I
did	O
not	O
interfere	O
with	O
cytotoxic	I
effect	O
of	O
doxorubicin	I
against	O
the	O
growth	O
of	O
solid	O
Ehrlich	I
carcinoma	I
.	O

In	O
conclusion	O
,	O
nicorandil	I
was	O
effective	O
against	O
the	O
development	O
of	O
doxorubicin-induced	I
heart	I
failure	I
in	O
rats	O
as	O
indicated	O
by	O
improvement	O
of	O
hemodynamic	I
perturbations	O
,	O
mitochondrial	I
dysfunction	I
and	O
ultrastructural	O
changes	O
without	O
affecting	O
its	O
antitumor	I
activity	O
.	O

Relationships	O
between	O
right	I
ventricular	I
function	I
,	O
body	O
composition	O
,	O
and	O
prognosis	I
in	O
advanced	O
heart	I
failure	I
.	O

OBJECTIVES	O
:	O

This	O
study	O
sought	O
to	O
examine	O
the	O
relationships	O
between	O
right	I
ventricular	I
(	O
RV	I
)	O
function	I
,	O
body	O
composition	O
,	O
and	O
prognosis	I
in	O
patients	I
with	O
advanced	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

BACKGROUND	O
:	O

Previous	O
studies	O
investigating	O
HF-related	I
cachexia	I
have	O
not	O
examined	O
the	O
impact	O
of	O
RV	I
function	I
on	O
body	O
composition	O
.	O

We	O
hypothesized	O
that	O
RV	I
dysfunction	I
is	O
linked	O
to	O
weight	O
loss	O
,	O
abnormal	O
body	O
composition	O
,	O
and	O
worsened	O
prognosis	I
in	O
advanced	O
HF	I
.	O

METHODS	O
:	O

Subjects	O
with	O
advanced	O
HF	I
(	O
n	O
=	O
408	O
)	O
underwent	O
prospective	I
assessment	O
of	O
body	O
composition	O
(	O
skinfold	O
thickness	O
,	O
dual-energy	I
X-ray	I
absorptiometry	I
)	O
,	O
comprehensive	O
echocardiography	I
,	O
and	O
blood	I
testing	O
.	O

Subjects	O
were	O
followed	I
up	I
for	O
adverse	I
events	I
(	O
defined	O
as	O
death	I
,	O
transplantation	I
,	O
or	O
circulatory	I
assist	I
device	I
)	O
.	O

RESULTS	O
:	O

Subjects	O
with	O
RV	I
dysfunction	I
(	O
51	O
%	O
)	O
had	O
lower	O
body	I
mass	I
index	I
,	O
lower	O
fat	I
mass	I
index	O
,	O
and	O
were	O
more	O
likely	O
to	O
display	O
cachexia	I
(	O
19	O
%	O
)	O
.	O

The	O
extent	O
of	O
RV	I
dysfunction	I
correlated	I
with	O
greater	O
antecedent	O
weight	O
loss	O
and	O
a	O
lower	O
fat	O
/	O
lean	I
body	I
mass	I
ratio	O
.	O

Over	O
a	O
median	O
follow-up	I
of	O
541	O
days	O
,	O
there	O
were	O
150	O
events	O
(	O
37	O
%	O
)	O
.	O

Risk	O
of	O
event	O
was	O
greater	O
in	O
subjects	O
with	O
RV	I
dysfunction	I
(	O
hazard	I
ratio	I
:	O
3.09	O
[	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
:	O
2.18	O
to	O
4.45	O
]	O
)	O
and	O
cachexia	I
(	O
hazard	I
ratio	I
:	O
2.90	O
[	O
95	O
%	O
CI	I
:	O
2.00	O
to	O
4.12	O
]	O
)	O
in	O
univariate	I
and	O
multivariate	I
analyses	I
.	O

Increased	O
body	I
mass	I
index	I
was	O
associated	O
with	O
a	O
lower	O
event	O
rate	O
(	O
HR	I
per	O
kg	O
/	O
m	O
(	O
2	O
)	O
:	O
0.92	O
[	O
95	O
%	O
CI	I
:	O
0.88	O
to	O
0.96	O
]	O
)	O
,	O
and	O
this	O
protection	O
was	O
mediated	O
by	O
a	O
higher	O
fat	I
mass	I
(	O
0.91	O
[	O
95	O
%	O
CI	I
:	O
0.87	O
to	O
0.96	O
]	O
)	O
but	O
not	O
a	O
fat-free	I
mass	I
index	O
(	O
0.97	O
[	O
95	O
%	O
CI	I
:	O
0.92	O
to	O
1.03	O
]	O
)	O
.	O

CONCLUSIONS	O
:	O

RV	I
dysfunction	I
and	O
cardiac	I
cachexia	I
often	O
coexist	O
,	O
have	O
additive	O
adverse	O
impact	O
,	O
and	O
might	O
be	O
mechanistically	O
interrelated	O
.	O

Wasting	O
of	O
fat	O
but	O
not	O
of	O
lean	I
mass	I
was	O
predictive	O
of	O
adverse	I
outcome	I
,	O
suggesting	O
that	O
fat	O
loss	O
is	O
either	O
a	O
surrogate	O
of	O
enhanced	O
catabolism	O
or	O
adipose	I
tissue	I
is	O
cardioprotective	I
in	O
the	O
context	O
of	O
HF	I
.	O

B-type	I
natriuretic	I
peptide	I
and	O
N-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
–	O
Diagnostic	I
role	O
in	O
stable	I
coronary	I
artery	I
disease	I

B-type	I
natriuretic	I
peptide	I
(	O
BNP	I
)	O
and	O
its	O
N-terminal	O
fragment	O
(	O
NT-proBNP	I
)	O
are	O
released	O
from	O
ventricular	I
cardiomyocytes	I
in	O
response	O
to	O
an	O
increase	O
in	O
ventricular	I
wall	I
stress	I
and	O
to	O
myocardial	I
ischemia	I
.	O

Both	O
BNP	I
and	O
NT-proBNP	I
have	O
proven	O
to	O
be	O
reliable	O
diagnostic	I
and	O
prognostic	I
biomarkers	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

Recently	O
,	O
the	O
diagnostic	I
roles	O
of	O
BNP	I
and	O
NT-proBNP	I
in	O
patients	I
with	O
coronary	I
artery	I
disease	I
(	O
CAD	I
)	O
have	O
been	O
investigated	O
.	O

For	O
patients	I
with	O
acute	I
coronary	I
syndromes	I
,	O
data	O
have	O
been	O
derived	O
from	O
a	O
great	O
number	O
of	O
studies	O
,	O
whereas	O
in	O
patients	I
with	O
stable	I
CAD	I
,	O
only	O
a	O
limited	O
amount	O
of	O
recent	O
data	O
is	O
available	O
;	O
although	O
limited	O
,	O
these	O
data	O
show	O
that	O
elevations	O
in	O
BNP	I
and	O
NT-proBNP	I
levels	O
are	O
associated	O
with	O
the	O
extent	O
of	O
CAD	I
,	O
thus	O
providing	O
prognostic	I
information	O
for	O
an	O
unfavourable	O
clinical	I
outcome	I
.	O

However	O
,	O
clinical	I
and	O
therapeutic	I
implications	O
are	O
indistinct	O
and	O
need	O
to	O
be	O
elucidated	O
in	O
further	O
studies	O
.	O

Prevalence	I
,	O
clinical	I
characteristics	O
,	O
and	O
outcomes	I
associated	O
with	O
eccentric	I
versus	O
concentric	I
left	I
ventricular	I
hypertrophy	I
in	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
.	O

Although	O
concentric	I
remodeling	I
(	O
CR	I
)	O
and	O
concentric	I
hypertrophy	I
(	O
CH	I
)	O
are	O
common	O
forms	O
of	O
left	I
ventricular	I
(	O
LV	I
)	O
remodeling	I
in	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
,	O
eccentric	I
hypertrophy	I
(	O
EH	I
)	O
can	O
also	O
occur	O
in	O
these	O
patients	I
.	O

However	O
,	O
clinical	I
characteristics	O
and	O
outcomes	I
of	O
EH	I
have	O
not	O
been	O
well	O
described	O
in	O
HFpEF	I
.	O

We	O
prospectively	I
studied	O
402	O
patients	I
with	O
HFpEF	I
,	O
divided	O
into	O
4	O
groups	O
based	O
on	O
LV	I
structure	O
:	O
normal	O
geometry	O
(	O
no	O
LV	I
hypertrophy	I
[	O
LVH	I
]	O
and	O
relative	I
wall	I
thickness	I
[	O
RWT	I
]	O
≤0.42	O
)	O
;	O
CR	I
(	O
no	O
LVH	I
and	O
RWT	I
>	O
0.42	O
)	O
;	O
CH	I
(	O
LVH	I
and	O
RWT	I
>	O
0.42	O
)	O
;	O
and	O
EH	I
(	O
LVH	I
and	O
RWT	I
≤0.42	O
)	O
.	O

We	O
compared	O
clinical	I
,	O
laboratory	O
,	O
echocardiographic	I
,	O
invasive	I
hemodynamic	I
,	O
and	O
outcome	I
data	O
among	O
groups	O
.	O

Of	O
402	O
patients	I
,	O
48	O
(	O
12	O
%	O
)	O
had	O
EH	I
.	O

Compared	O
with	O
CH	I
,	O
patients	I
with	O
EH	I
had	O
lower	O
systolic	I
blood	I
pressure	I
and	O
less	O
renal	I
impairment	I
despite	O
similar	O
rates	O
of	O
hypertension	I
.	O

After	O
adjustment	O
for	O
covariates	I
,	O
EH	I
was	O
associated	O
with	O
reduced	O
LV	I
contractility	I
compared	O
with	O
CH	I
:	O
lower	O
LVEF	I
(	O
β	I
coefficient	I
=	O
-	O
3.2	O
;	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
-	O
5.4	O
to	O
-	O
1.1	O
%	O
)	O
and	O
ratio	O
of	O
systolic	I
blood	I
pressure	I
to	O
end-systolic	I
volume	I
(	O
β	I
coefficient	I
=	O
-	O
1.0	O
;	O
95	O
%	O
CI	I
-	O
1.5	O
to	O
-	O
0.5	O
mm	O
Hg	O
/	O
ml	O
)	O
.	O

EH	I
was	O
also	O
associated	O
with	O
increased	O
LV	I
compliance	I
compared	O
with	O
CH	I
(	O
LV	I
end-diastolic	I
volume	I
at	O
an	O
idealized	O
LV	I
end-diastolic	I
pressure	I
of	O
20	O
mm	O
Hg	O
β	I
coefficient	I
=	O
14.2	O
;	O
95	O
%	O
CI	I
9.4	O
to	O
19.1	O
ml	O
)	O
.	O

Despite	O
these	O
differences	O
,	O
EH	I
and	O
CH	I
had	O
similarly	O
elevated	O
cardiac	I
filling	I
pressures	I
and	O
equivalent	O
adverse	I
outcomes	I
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
EH	I
denotes	O
a	O
distinct	O
subset	O
of	O
HFpEF	I
that	O
is	O
pathophysiologically	I
similar	O
to	O
HF	I
with	I
reduced	I
EF	I
(	O
HFrEF	I
)	O
and	O
may	O
benefit	O
from	O
HFrEF	I
therapy	I
.	O

Heart	I
failure	I
risk	O
among	O
patients	I
with	O
rheumatoid	I
arthritis	I
starting	O
a	O
TNF	I
antagonist	I
.	O

BACKGROUND	O
:	O

While	O
heart	I
failure	I
(	O
HF	I
)	O
is	O
associated	O
with	O
elevations	O
in	O
tumor	I
necrosis	I
factor	I
(	O
TNF)α	I
,	O
several	O
trials	O
of	O
TNF	I
antagonists	I
showed	O
no	O
benefit	O
and	O
possibly	O
worsening	O
of	O
disease	I
in	O
those	O
with	O
known	O
severe	I
HF	I
.	O

We	O
studied	O
the	O
risk	O
of	O
new	O
or	O
recurrent	O
HF	I
among	O
a	O
group	O
of	O
patients	I
receiving	O
these	O
agents	O
to	O
treat	O
rheumatoid	I
arthritis	I
(	O
RA	I
)	O
.	O

METHODS	O
:	O

We	O
used	O
data	O
from	O
four	O
different	O
US	O
healthcare	I
programmes	O
.	O

Subjects	O
with	O
RA	I
receiving	O
methotrexate	I
were	O
eligible	O
to	O
enter	O
the	O
study	O
cohort	O
if	O
they	O
added	O
or	O
switched	O
to	O
a	O
TNF	I
antagonist	I
or	O
another	O
non-biological	I
disease	I
modifying	I
antirheumatic	I
drug	I
(	O
nbDMARD	I
)	O
.	O

These	O
groups	O
were	O
compared	O
in	O
Cox	I
regression	I
models	I
stratified	O
by	O
propensity	I
score	I
decile	O
and	O
adjusted	O
for	O
oral	I
glucocorticoid	I
dosage	O
,	O
prior	O
HF	I
hospitalisations	I
,	O
and	O
the	O
use	O
of	O
loop	I
diuretics	I
.	O

RESULTS	O
:	O

We	O
compared	O
8656	O
new	O
users	O
of	O
a	O
nbDMARD	I
with	O
11	O
587	O
new	O
users	O
of	O
a	O
TNF	I
antagonist	I
with	O
similar	O
baseline	I
covariates	I
.	O

The	O
HR	I
for	O
the	O
TNF	I
antagonists	I
compared	O
with	O
nbDMARD	I
was	O
0.85	O
(	O
95	O
%	O
CI	I
0.63	O
to	O
1.14	O
)	O
.	O

The	O
HR	I
was	O
also	O
not	O
elevated	O
in	O
subjects	O
with	O
a	O
history	O
of	O
HF	I
.	O

But	O
,	O
it	O
was	O
elevated	O
prior	O
to	O
2002	O
(	O
HR	I
2.17	O
,	O
95	O
%	O
CI	I
0.45	O
to	O
10.50	O
,	O
test	O
for	O
interaction	O
p=0.036	I
)	O
.	O

Oral	I
glucocorticoids	I
were	O
associated	O
with	O
a	O
dose-related	O
gradient	O
of	O
HF	I
risk	O
:	O
compared	O
with	O
no	O
use	O
,	O
1≤5	O
mg	O
HR	I
1.30	O
(	O
95	O
%	O
CI	I
0.91	O
to	O
1.85	O
)	O
,	O
≥5	O
mg	O
HR	I
1.54	O
(	O
95	O
%	O
CI	I
1.09	O
to	O
2.19	O
)	O
.	O

CONCLUSIONS	O
:	O

TNF	I
antagonists	I
were	O
not	O
associated	O
with	O
a	O
risk	O
of	O
HF	I
hospital	I
admissions	I
compared	O
with	O
nbDMARDs	I
in	O
this	O
RA	I
population	O
.	O

Relation	O
between	O
preoperative	I
renal	I
dysfunction	I
and	O
cardiovascular	I
events	I
(	O
stroke	I
,	O
myocardial	I
infarction	I
,	O
or	O
heart	I
failure	I
or	O
death	I
)	O
within	O
three	O
months	O
of	O
isolated	I
coronary	I
artery	I
bypass	I
grafting	I
.	O

Renal	I
dysfunction	I
is	O
related	O
to	O
long-term	O
mortality	I
and	O
myocardial	I
infarction	I
after	O
coronary	I
artery	I
bypass	I
grafting	I
(	O
CABG	I
)	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
preoperative	I
renal	I
dysfunction	I
and	O
early	O
risk	O
of	O
stroke	I
,	O
myocardial	I
infarction	I
,	O
or	O
heart	I
failure	I
after	O
CABG	I
.	O

From	O
the	O
Swedish	O
Web-system	O
for	O
Enhancement	O
and	O
Development	O
of	O
Evidence-based	I
care	O
in	O
Heart	I
disease	I
Evaluated	O
According	O
to	O
Recommended	O
Therapies	I
registry	O
,	O
we	O
included	O
all	O
36,284	O
patients	I
who	O
underwent	O
primary	O
isolated	O
CABG	I
from	O
2000	O
to	O
2008	O
in	O
Sweden	O
.	O

The	O
Swedish	O
National	O
Inpatient	I
Registry	O
was	O
used	O
to	O
obtain	O
the	O
primary	I
end	I
point	I
,	O
which	O
was	O
rehospitalization	I
for	O
stroke	I
,	O
myocardial	I
infarction	I
,	O
or	O
heart	I
failure	I
≤90	O
days	O
after	O
CABG	I
.	O

Logistic	I
regression	I
models	I
were	O
used	O
to	O
estimate	O
the	O
risk	O
for	O
the	O
primary	I
outcome	I
and	O
the	O
secondary	I
outcome	I
of	O
death	I
from	O
any	O
cause	O
,	O
while	O
adjusting	O
for	O
confounders	O
.	O

During	O
90	O
days	O
of	O
follow-up	I
,	O
there	O
were	O
2,462	O
cardiovascular	I
events	I
and	O
617	O
deaths	I
.	O

In	O
total	O
,	O
17	O
%	O
of	O
patients	I
developed	O
acute	I
kidney	I
injury	I
postoperatively	I
.	O

Odds	I
ratios	I
with	O
95	O
%	O
confidence	I
intervals	I
for	O
cardiovascular	I
events	I
after	O
adjustment	O
for	O
age	O
,	O
gender	O
,	O
atrial	I
fibrillation	I
,	O
left	I
ventricular	I
ejection	I
fraction	I
,	O
diabetes	I
mellitus	I
,	O
peripheral	I
vascular	I
disease	I
,	O
and	O
history	O
of	O
myocardial	I
infarction	I
,	O
heart	I
failure	I
,	O
or	O
stroke	I
was	O
1.24	O
(	O
1.06	O
to	O
1.45	O
)	O
in	O
patients	I
with	O
an	O
estimated	I
glomerular	I
filtration	I
rate	I
of	O
15	O
to	O
45	O
ml	O
/	O
min	O
/	O
1.73	O
m	O
(	O
2	O
)	O
but	O
became	O
nonsignificant	I
after	O
acute	I
kidney	I
injury	I
was	O
introduced	O
into	O
the	O
statistical	O
model	O
.	O

The	O
risk	O
of	O
death	I
was	O
significantly	I
increased	O
in	O
patients	I
with	O
estimated	I
glomerular	I
filtration	I
rate	I
of	O
15	O
to	O
45	O
ml	O
/	O
min	O
/	O
1.73	O
m	O
(	O
2	O
)	O
(	O
odds	I
ratio	I
1.76	O
,	O
95	O
%	O
confidence	I
interval	I
1.38	O
to	O
2.25	O
)	O
even	O
after	O
adjustment	O
for	O
all	O
confounders	O
.	O

Renal	I
dysfunction	I
was	O
associated	O
with	O
all-cause	I
mortality	I
but	O
not	O
with	O
cardiovascular	I
events	I
during	O
the	O
first	O
3	O
postoperative	I
months	O
after	O
primary	O
isolated	O
CABG	I
.	O

Perturbations	O
in	O
skeletal	I
muscle	I
sarcomere	I
structure	O
in	O
patients	I
with	O
heart	I
failure	I
and	O
type	I
2	I
diabetes	I
:	O
restorative	O
effects	O
of	O
(-)-epicatechin-rich	I
cocoa	I
.	O

HF	I
(	O
heart	I
failure	I
)	O
and	O
T2D	I
(	O
Type	I
2	I
diabetes	I
)	O
associate	O
with	O
detrimental	O
alterations	O
in	O
SkM	I
(	O
skeletal	I
muscle	I
)	O
structure	O
/	O
function	O
.	O

We	O
have	O
demonstrated	O
recently	O
that	O
(-)-ERC	I
(	O
epicatechin-rich	I
cocoa	I
)	O
improves	O
SkM	I
mitochondrial	I
structure	I
[	O
Taub	O
,	O
Ramirez-Sanchez	O
,	O
Ciaraldi	O
,	O
Perkins	O
,	O
Murphy	O
,	O
Naviaux	O
,	O
Hogan	O
,	O
Ceballos	O
,	O
Maisel	O
,	O
Henry	O
et	O
al	O
.	O

(	O
2012	O
)	O
Clin	O
.	O

Trans	O
.	O

Sci	O
.	O

5	O
,	O
43	O
-	O
47	O
]	O
.	O

We	O
hypothesized	O
that	O
an	O
improved	O
mitochondrial	I
structure	I
may	O
facilitate	O
the	O
reversal	O
of	O
detrimental	O
alterations	O
in	O
sarcomeric	I
microstructure	I
.	O

In	O
a	O
pilot	O
study	O
,	O
five	O
patients	I
with	O
HF	I
and	O
T2D	I
consumed	O
ERC	I
for	O
3	O
months	O
;	O
treadmill	O
testing	O
[	O
VO2max	I
(	O
maximum	I
oxygen	I
consumption	I
)	O
]	O
and	O
SkM	I
biopsies	I
were	O
performed	O
.	O

Western	I
blot	I
analysis	O
,	O
immunohistochemistry	I
and	O
electron	I
microscopy	I
were	O
used	O
.	O

We	O
report	O
severe	O
perturbations	O
in	O
components	O
of	O
the	O
DAPC	I
(	O
dystrophin-associated	I
protein	I
complex	I
)	O
as	O
well	O
as	O
sarcomeric	I
microstructure	I
at	O
baseline	I
.	O

ERC	I
induced	O
recovery	O
/	O
enhancement	O
of	O
DAPC	I
protein	I
levels	O
,	O
sarcomeric	I
microstructure	I
and	O
,	O
in	O
a	O
co-ordinated	O
fashion	O
,	O
alterations	O
in	O
markers	O
of	O
SkM	I
growth	O
/	O
differentiation	O
consistent	O
with	O
myofibre	I
regeneration	I
.	O

VO2max	I
increased	O
(	O
~	O
24	O
%	O
)	O
but	O
did	O
not	O
reach	O
statistical	O
significance	I
.	O

These	O
initial	O
results	O
warrant	O
further	O
rigorous	O
investigation	O
,	O
since	O
the	O
use	O
of	O
ERC	I
(	O
or	O
pure	O
epicatechin	I
)	O
may	O
represent	O
a	O
safe	O
and	O
novel	O
means	O
of	O
improving	O
muscle	I
function	O
.	O

Effect	O
of	O
If-channel	I
inhibition	I
on	O
hemodynamic	I
status	O
and	O
exercise	I
tolerance	I
in	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
:	O
a	O
randomized	I
trial	O
.	O

OBJECTIVES	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
effects	O
of	O
treatment	O
with	O
ivabradine	I
on	O
exercise	I
capacity	I
and	O
left	I
ventricular	I
filling	I
in	O
patients	I
with	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
.	O

BACKGROUND	O
:	O

Because	O
symptoms	I
of	O
HFpEF	I
are	O
typically	O
exertional	O
,	O
optimization	O
of	O
diastolic	I
filling	I
time	I
by	O
controlling	O
heart	I
rate	I
may	O
delay	O
the	O
onset	O
of	O
symptoms	I
.	O

METHODS	O
:	O

Sixty-one	O
patients	I
with	O
HFpEF	I
were	O
randomly	O
assigned	O
to	O
ivabradine	I
5	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
30	O
)	O
or	O
placebo	I
(	O
n	O
=	O
31	O
)	O
for	O
7	O
days	O
in	O
this	O
double-blind	I
trial	O
.	O

Cardiopulmonary	I
exercise	I
testing	I
with	O
echocardiographic	I
assessment	O
of	O
myocardial	I
function	I
and	O
left	I
ventricular	I
filling	I
were	O
undertaken	O
at	O
rest	O
and	O
after	O
exercise	O
.	O

RESULTS	O
:	O

The	O
ivabradine	I
group	O
demonstrated	O
significant	I
improvement	O
between	O
baseline	I
and	O
follow-up	I
exercise	I
capacity	I
(	O
4.2	O
±	O
1.8	O
METs	I
vs.	O
5.7	O
±	O
1.9	O
METs	I
,	O
p	I
=	O
0.001	O
)	O
and	O
peak	I
oxygen	I
uptake	I
(	O
14.0	O
±	O
6.1	O
ml	O
/	O
min	O
/	O
kg	O
vs.	O
17.0	O
±	O
3.3	O
ml	O
/	O
min	O
/	O
kg	O
,	O
p	I
=	O
0.001	O
)	O
,	O
with	O
simultaneous	O
reduction	O
in	O
exercise-induced	O
increase	O
in	O
the	O
ratio	O
of	O
peak	I
early	I
diastolic	I
mitral	I
flow	I
velocity	I
to	O
peak	I
early	I
diastolic	I
mitral	I
annular	I
velocity	I
(	O
3.1	O
±	O
2.7	O
vs.	O
1.3	O
±	O
2.0	O
,	O
p	I
=	O
0.004	O
)	O
.	O

Work	O
load-corrected	O
chronotropic	I
response	I
(	O
the	O
difference	O
in	O
heart	I
rate	I
at	O
the	O
same	O
exercise	O
time	O
at	O
the	O
baseline	I
and	O
follow-up	I
tests	O
)	O
showed	O
a	O
slower	O
increase	O
in	O
heart	I
rate	I
during	O
exercise	O
than	O
in	O
the	O
placebo-treated	I
group	O
.	O

Therapy	I
with	O
ivabradine	I
(	O
β	O
=	O
0.34	O
,	O
p	I
=	O
0.04	O
)	O
and	O
change	O
with	O
treatment	O
in	O
exertional	O
increase	O
in	O
the	O
ratio	O
of	O
peak	I
early	I
diastolic	I
mitral	I
flow	I
velocity	I
to	O
peak	I
early	I
diastolic	I
mitral	I
annular	I
velocity	I
(	O
β	O
=	O
-	O
0.30	O
,	O
p	I
=	O
0.02	O
)	O
were	O
independent	O
correlates	I
of	O
increase	O
in	O
exercise	I
capacity	I
,	O
and	O
therapy	I
with	O
ivabradine	I
(	O
β	O
=	O
0.32	O
,	O
p	I
=	O
0.007	O
)	O
was	O
independently	O
correlated	I
with	O
increase	O
in	O
peak	I
oxygen	I
uptake	I
.	O

CONCLUSIONS	O
:	O

In	O
patients	I
with	O
HFpEF	I
,	O
short-term	O
treatment	O
with	O
ivabradine	I
increased	O
exercise	I
capacity	I
,	O
with	O
a	O
contribution	O
from	O
improved	O
left	I
ventricular	I
filling	I
pressure	I
response	O
to	O
exercise	O
as	O
reflected	O
by	O
the	O
ratio	O
of	O
peak	I
early	I
diastolic	I
mitral	I
flow	I
velocity	I
to	O
peak	I
early	I
diastolic	I
mitral	I
annular	I
velocity	I
.	O

Because	O
this	O
patient	I
population	O
is	O
symptomatic	I
on	O
exertion	O
,	O
therapeutic	I
treatments	O
targeting	O
abnormal	O
exercise	O
hemodynamic	I
status	O
may	O
prove	O
useful	O
.	O

(	O
Use	O
of	O
Exercise	O
and	O
Medical	I
Therapies	I
to	O
Improve	O
Cardiac	I
Function	I
Among	O
Patients	I
With	O
Exertional	O
Shortness	O
of	O
Breath	O
Due	O
to	O
Lung	I
Congestion	O
;	O
ACTRN12610001087044	O
)	O
.	O

Aldosterone	I
antagonism	I
in	O
heart	I
failure	I

Aldosterone	I
,	O
a	O
neurohormone	I
known	O
to	O
affect	O
electrolytes	I
,	O
has	O
recently	O
been	O
implicated	O
as	O
playing	O
a	O
major	O
role	O
in	O
the	O
progression	O
of	O
heart	I
failure	I
,	O
particularly	O
in	O
patients	I
with	O
systolic	I
dysfunction	I
.	O

Major	O
clinical	I
trials	O
designed	O
to	O
analyze	O
clinical	I
outcomes	I
using	O
an	O
aldosterone	I
antagonist	I
have	O
been	O
done	O
in	O
two	O
groups	O
with	O
heart	I
failure	I
.	O

The	O
first	O
was	O
the	O
Randomized	I
Aldactone	I
Evaluation	O
Study	O
,	O
which	O
was	O
done	O
in	O
symptomatic	I
chronic	I
advanced	I
heart	I
failure	I
patients	I
and	O
showed	O
that	O
an	O
aldosterone	I
antagonist	I
,	O
spironolactone	I
,	O
reduced	O
mortality	I
significantly	I
compared	O
with	O
placebo	I
.	O

Very	O
few	O
of	O
these	O
patients	I
were	O
on	O
standard	O
therapy	I
with	O
beta	I
blockade	I
.	O

Another	O
study	O
,	O
the	O
Eplerenone	I
Post	O
myocardial	I
infarction	I
Heart	I
failure	I
Efficacy	O
and	O
SUrvival	O
Study	O
(	O
EPHESUS	O
)	O
,	O
done	O
in	O
post-myocardial	I
infarction	I
patients	I
with	O
heart	I
failure	I
,	O
demonstrated	O
a	O
significant	I
reduction	O
in	O
mortality	I
and	O
hospitalizations	I
for	O
patients	I
randomized	I
to	O
the	O
aldosterone	I
antagonist	I
eplerenone	I
.	O

These	O
trial	O
results	O
provide	O
the	O
background	O
for	O
aldosterone	I
antagonist	I
therapy	I
in	O
chronic	I
advanced	I
heart	I
failure	I
patients	I
as	O
well	O
as	O
post-myocardial	I
infarction	I
heart	I
failure	I
patients	I
with	O
reduced	O
ejection	O
.	O

Pharmacological	I
treatment	O
of	O
acute	I
heart	I
failure	I
:	O
current	O
treatment	O
and	O
new	O
targets	O
.	O

Acute	I
heart	I
failure	I
(	O
AHF	I
)	O
is	O
defined	O
as	O
the	O
rapid	O
onset	O
of	O
,	O
or	O
changes	O
in	O
,	O
the	O
symptoms	I
and	O
signs	O
of	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

It	O
is	O
a	O
life-threatening	O
situation	O
in	O
which	O
diagnosis	I
and	O
initiation	O
of	O
therapy	I
are	O
crucial	O
.	O

The	O
treatment	O
aims	O
are	O
to	O
stabilize	O
the	O
patient	I
,	O
improve	O
clinical	I
symptoms	I
,	O
and	O
increase	O
long-term	O
survival	O
rates	O
.	O

Few	O
treatments	O
have	O
been	O
investigated	O
in	O
clinical	I
trials	O
.	O

This	O
review	O
summarizes	O
the	O
principles	O
of	O
pharmacologic	I
treatment	O
,	O
the	O
underlying	O
clinical	I
trials	O
,	O
and	O
new	O
pharmacologic	I
targets	O
.	O

Risk	I
stratification	I
for	O
death	I
and	O
all-cause	I
hospitalization	I
in	O
heart	I
failure	I
clinic	I
outpatients	I
.	O

BACKGROUND	O
:	O

Most	O
heart	I
failure	I
(	O
HF	I
)	O
risk	I
stratification	I
models	O
were	O
developed	O
for	O
inpatient	I
use	O
,	O
and	O
available	O
outpatient	I
models	O
use	O
a	O
complex	O
set	O
of	O
variables	O
.	O

We	O
hypothesized	O
that	O
routinely	O
collected	O
clinical	I
data	O
could	O
predict	O
the	O
6-month	O
risk	O
of	O
death	I
and	O
all-cause	O
medical	I
hospitalization	I
in	O
HF	I
clinic	I
outpatients	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Using	O
a	O
quality	O
improvement	O
database	O
and	O
multivariable	O
Cox	I
modeling	I
,	O
we	O
derived	O
the	O
Heart	I
Failure	I
Patient	I
Severity	O
Index	O
(	O
HFPSI	O
)	O
in	O
the	O
University	O
of	O
Michigan	O
HF	I
clinic	I
(	O
UM	O
cohort	O
,	O
n	O
=	O
1,536	O
;	O
314	O
reached	O
primary	I
outcome	I
)	O
.	O

We	O
externally	O
validated	O
the	O
HFPSI	O
in	O
the	O
Ann	O
Arbor	O
Veterans	O
'	O
Affairs	O
HF	I
clinic	I
(	O
VA	O
cohort	O
,	O
n	O
=	O
445	O
;	O
106	O
outcomes	I
)	O
and	O
explored	O
real-time	O
HFPSI	O
use	O
(	O
VA-RT	O
cohort	O
,	O
n	O
=	O
486	O
;	O
141	O
outcomes	I
)	O
by	O
tracking	O
VA	O
patients	I
for	O
6	O
months	O
from	O
their	O
most	O
recently	O
calculated	O
HFPSI	O
,	O
rather	O
than	O
using	O
an	O
arbitrary	O
start	O
date	O
for	O
the	O
cohort	O
.	O

The	O
HFPSI	O
model	O
included	O
blood	I
urea	I
nitrogen	I
,	O
B-type	I
natriuretic	I
peptide	I
,	O
New	I
York	I
Heart	I
Association	I
class	I
,	O
diabetes	I
status	O
,	O
history	O
of	O
atrial	I
fibrillation	I
/	O
flutter	I
,	O
and	O
all-cause	I
hospitalization	I
within	O
the	O
prior	O
1	O
and	O
2	O
to	O
6	O
months	O
.	O

The	O
concordance	O
c	I
statistics	I
in	O
the	O
UM	O
/	O
VA	O
/	O
VA-RT	O
cohorts	O
were	O
0.71	O
/	O
0.68	O
/	O
0.74	O
.	O

Kaplan-Meier	I
curves	I
and	O
log-rank	I
testing	I
demonstrated	O
excellent	O
risk	I
stratification	I
,	O
particularly	O
between	O
a	O
large	O
,	O
low-risk	O
group	O
(	O
40	O
%	O
of	O
patients	I
,	O
6-month	O
event	O
rates	O
in	O
the	O
UM	O
/	O
VA	O
/	O
VA-RT	O
cohorts	O
8	O
%	O
/	O
12	O
%	O
/	O
12	O
%	O
)	O
and	O
a	O
small	O
,	O
high-risk	O
group	O
(	O
10	O
%	O
of	O
patients	I
,	O
6-month	O
event	O
rates	O
in	O
the	O
UM	O
/	O
VA	O
/	O
VA-RT	O
cohorts	O
57	O
%	O
/	O
58	O
%	O
/	O
79	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
HFPSI	O
uses	O
readily	O
available	O
data	O
to	O
predict	O
the	O
6-month	O
risk	O
of	O
death	I
and	O
/	O
or	O
all-cause	O
medical	I
hospitalization	I
in	O
HF	I
clinic	I
outpatients	I
and	O
could	O
potentially	O
help	O
allocate	O
specialized	O
HF	I
resources	O
within	O
health	I
systems	O
.	O

Uptitration	I
of	O
renin-angiotensin	I
system	I
blocker	I
and	O
beta-blocker	I
therapy	I
in	O
patients	I
hospitalized	I
for	O
heart	I
failure	I
with	O
reduced	I
versus	O
preserved	I
left	I
ventricular	I
ejection	I
fractions	I
.	O

In	O
ambulatory	I
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
and	O
reduced	I
ejection	I
fraction	I
(	O
rEF	I
)	O
,	O
renin-angiotensin	I
system	I
(	O
RAS	I
)	O
and	O
β-blockers	I
at	O
guideline-recommended	O
target	O
dose	O
reduce	O
all-cause	I
mortality	I
and	O
readmissions	I
.	O

Benefits	O
in	O
HF	I
with	I
preserved	I
ejection	I
fraction	I
(	O
pEF	I
)	O
,	O
as	O
well	O
as	O
uptitration	I
after	O
a	O
hospitalization	I
,	O
remain	O
uncertain	O
.	O

This	O
study	O
assesses	O
the	O
impact	O
of	O
RAS	I
-	I
and	O
β-blocker	I
uptitrations	I
in	O
patients	I
with	O
HFrEF	I
versus	O
HFpEF	I
during	O
and	O
immediately	O
after	O
a	O
hospital	I
admission	I
.	O

In	O
consecutive	O
patients	I
(	O
209	O
HFrEF	I
with	O
left	I
ventricular	I
ejection	I
fraction	I
<	O
40	O
%	O
and	O
108	O
HFpEF	I
with	O
left	I
ventricular	I
ejection	I
fraction	I
≥40	O
%	O
)	O
,	O
RAS	I
-	I
and	O
β-blocker	I
dose	O
changes	O
were	O
followed	O
during	O
6	O
months	O
after	O
an	O
index	O
HF	I
hospitalization	I
.	O

Patients	I
with	O
a	O
RAS	I
-	O
and	O
β-blocker	I
dose	O
increase	O
of	O
≥10	O
%	O
of	O
the	O
recommended	O
target	O
dose	O
were	O
compared	O
with	O
patients	I
without	O
uptitration	I
.	O

Patients	I
who	O
received	O
uptitration	I
were	O
significantly	I
younger	O
,	O
with	O
a	O
higher	O
heart	I
rate	I
and	O
better	O
renal	I
function	I
,	O
and	O
received	O
spironolactone	I
more	O
often	O
.	O

Both	O
RAS	I
-	I
and	O
β-blocker	I
uptitrations	I
were	O
associated	O
with	O
significant	I
reductions	O
in	O
the	O
composite	I
end-point	I
of	O
all-cause	I
mortality	I
or	O
HF	I
readmissions	I
in	O
HFrEF	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
0.36	O
,	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
0.22	O
to	O
0.60	O
and	O
HR	I
0.51	O
,	O
95	O
%	O
CI	I
0.32	O
to	O
0.81	O
,	O
respectively	O
)	O
.	O

After	O
correction	O
for	O
age	O
,	O
heart	I
rate	I
,	O
blood	I
pressure	I
,	O
renal	I
function	I
,	O
and	O
spironolactone	I
use	O
,	O
this	O
association	O
remained	O
significant	I
for	O
RAS	I
blockers	I
(	O
HR	I
0.54	O
,	O
95	O
%	O
CI	I
0.31	O
to	O
0.93	O
,	O
p	I
=	O
0.027	O
)	O
but	O
not	O
for	O
β-blockers	I
(	O
HR	I
0.65	O
,	O
95	O
%	O
CI	I
0.39	O
to	O
1.09	O
,	O
p	I
=	O
0.101	O
)	O
.	O

No	O
benefit	O
of	O
RAS	I
-	I
or	O
β-blocker	I
uptitration	I
was	O
observed	O
in	O
HFpEF	I
.	O

In	O
conclusion	O
,	O
uptitration	I
of	O
neurohumoral	I
blockers	I
after	O
an	O
HF	I
hospitalization	I
is	O
more	O
frequently	O
performed	O
in	O
younger	O
patients	I
with	O
low	O
co-morbidity	I
burden	O
.	O

RAS-blocker	I
uptitration	I
independently	O
predicts	O
clinical	I
outcome	I
in	O
patients	I
with	O
HFrEF	I
but	O
not	O
in	O
those	O
with	O
HFpEF	I
.	O

Comparative	O
effects	O
of	O
ventricular	I
assist	I
device	I
and	O
extracorporeal	I
membrane	I
oxygenation	I
on	O
renal	I
function	I
in	O
pediatric	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Effects	O
of	O
mechanical	I
cardiac	I
support	I
on	O
renal	I
function	I
in	O
children	O
with	O
end-stage	I
heart	I
failure	I
are	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
ventricular	I
assist	I
device	I
(	O
VAD	I
)	O
and	O
extracorporeal	I
membrane	I
oxygenation	I
(	O
ECMO	I
)	O
on	O
renal	I
function	I
in	O
children	O
.	O

METHODS	O
:	O

We	O
performed	O
a	O
single	O
center	O
retrospective	O
observational	O
study	O
in	O
children	O
with	O
end-stage	I
heart	I
failure	I
supported	O
on	O
pediatric	O
mechanical	I
cardiac	I
support	I
.	O

The	O
patient	I
population	O
was	O
divided	O
into	O
three	O
groups	O
:	O
the	O
VAD	I
group	O
included	O
patients	I
receiving	O
ventricular	I
assist	I
device	I
support	O
;	O
the	O
ECMO	I
group	O
included	O
patients	I
receiving	O
extracorporeal	I
membrane	I
oxygenation	I
membrane	O
support	O
for	O
more	O
than	O
14	O
days	O
;	O
and	O
the	O
ECMO+VAD	I
group	O
included	O
patients	I
receiving	O
ECMO	I
followed	O
by	O
VAD	I
support	O
.	O

Comparison	O
of	O
baseline	I
characteristics	O
,	O
duration	O
of	O
mechanical	I
cardiac	I
support	I
,	O
and	O
renal	I
function	I
was	O
made	O
between	O
the	O
three	O
groups	O
.	O

RESULTS	O
:	O

During	O
the	O
study	O
period	O
,	O
there	O
were	O
23	O
patients	I
in	O
the	O
VAD	I
group	O
,	O
16	O
patients	I
in	O
the	O
ECMO+VAD	I
group	O
,	O
and	O
37	O
patients	I
in	O
the	O
ECMO	I
group	O
.	O

The	O
patients	I
in	O
the	O
ECMO	I
group	O
were	O
significantly	I
younger	O
and	O
smaller	O
than	O
the	O
patients	I
in	O
the	O
VAD	I
and	O
ECMO+VAD	I
groups	O
.	O

There	O
was	O
a	O
steady	O
improvement	O
in	O
eGFR	I
in	O
the	O
VAD	I
group	O
and	O
the	O
ECMO+VAD	I
group	O
until	O
day	O
7	O
after	O
which	O
there	O
was	O
a	O
decline	O
in	O
renal	I
function	I
.	O

In	O
the	O
ECMO	I
group	O
,	O
the	O
improvement	O
in	O
eGFR	I
continued	O
until	O
day	O
28	O
after	O
which	O
there	O
was	O
a	O
steady	O
decline	O
in	O
eGFR	I
.	O

Improvement	O
in	O
eGFR	I
in	O
the	O
VAD	I
group	O
and	O
the	O
ECMO+VAD	I
group	O
was	O
much	O
higher	O
than	O
in	O
the	O
ECMO	I
group	O
in	O
the	O
first	O
7	O
days	O
.	O

CONCLUSIONS	O
:	O

On	O
the	O
basis	O
of	O
these	O
data	O
,	O
we	O
demonstrate	O
that	O
renal	I
dysfunction	I
improves	O
early	O
after	O
mechanical	I
cardiac	I
support	I
.	O

Does	O
reducing	O
length	O
of	O
stay	O
increase	O
rehospitalization	I
of	O
medicare	O
fee-for-service	O
beneficiaries	O
discharged	I
to	O
skilled	O
nursing	I
facilities	O
?	O

OBJECTIVES	O
:	O

To	O
analyze	O
the	O
relationship	O
between	O
length	O
of	O
stay	O
and	O
rehospitalization	I
.	O

DESIGN	O
:	O

Retrospective	I
cohort	I
study	I
.	O

SETTING	O
:	O

Six	O
thousand	O
five	O
hundred	O
thirty-seven	O
hospitals	I
nationwide	O
from	O
January	O
1999	O
through	O
September	O
2005	O
.	O

PARTICIPANTS	O
:	O

Medicare	O
fee-for-service	O
beneficiaries	O
associated	O
with	O
2,101,481	O
hospitalizations	I
.	O

MEASUREMENTS	O
:	O

Thirty-day	O
rehospitalization	I
derived	O
from	O
Medicare	O
hospital	I
claims	O
using	O
the	O
implementation	O
of	O
Medicare	O
's	O
post-acute	I
care	O
transfer	O
policy	O
as	O
a	O
quasi-experiment	O
.	O

RESULTS	O
:	O

Medicare	O
's	O
post-acute	I
care	O
transfer	O
policy	O
led	O
to	O
immediate	O
declines	O
in	O
length	O
of	O
stay	O
.	O

A	O
1-day	O
decrease	O
in	O
length	O
of	O
stay	O
was	O
associated	O
with	O
an	O
absolute	O
increase	O
in	O
30-day	O
rehospitalization	I
of	O
1.56	O
percentage	O
points	O
(	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
=	O
0.30	O
-	O
2.82	O
)	O
for	O
acute	I
myocardial	I
infarction	I
(	O
AMI	I
)	O
with	O
major	O
complications	I
and	O
0.81	O
percentage	O
points	O
(	O
95	O
%	O
CI	I
=	O
0.03	O
-	O
1.60	O
)	O
for	O
kidney	I
infection	I
or	O
urinary	I
tract	I
infection	I
(	O
UTI	I
)	O
without	O
major	O
complications	I
.	O

Individuals	O
hospitalized	I
for	O
AMI	I
without	O
major	O
complications	I
,	O
heart	I
failure	I
,	O
or	O
kidney	I
infection	I
or	O
UTI	I
with	O
major	O
complications	I
had	O
no	O
increase	O
in	O
30-day	O
rehospitalization	I
.	O

CONCLUSION	O
:	O

A	O
1-day	O
reduction	O
in	O
hospital	I
length	O
of	O
stay	O
was	O
not	O
consistently	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
rehospitalization	I
.	O

Cardiorespiratory	I
fitness	I
,	O
body	I
mass	I
index	I
,	O
and	O
heart	I
failure	I
mortality	I
in	O
men	O
:	O
Cooper	O
Center	O
Longitudinal	I
Study	O
.	O

BACKGROUND	O
:	O

We	O
evaluated	O
the	O
individual	O
and	O
joint	O
associations	O
among	O
cardiorespiratory	I
fitness	I
(	O
CRF	I
)	O
,	O
body	I
mass	I
index	I
,	O
and	O
heart	I
failure	I
(	O
HF	I
)	O
mortality	I
,	O
as	O
well	O
as	O
the	O
additive	O
effect	O
of	O
an	O
increasing	O
number	O
of	O
cardiovascular	I
risk	O
factors	O
on	O
HF	I
mortality	I
in	O
fit	O
versus	O
unfit	O
men	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

A	O
total	O
of	O
44	O
674	O
men	O
without	O
a	O
history	O
of	O
cardiovascular	I
disease	I
underwent	O
a	O
baseline	I
examination	O
between	O
1971	O
and	O
2010	O
.	O

Measures	O
included	O
body	I
mass	I
index	I
and	O
CRF	I
quantified	O
as	O
duration	O
of	O
maximal	O
treadmill	O
exercise	O
testing	O
.	O

Participants	O
were	O
divided	O
into	O
age-specific	O
low	O
,	O
moderate	O
,	O
and	O
high	O
CRF	I
categories	O
.	O

Hazard	I
ratios	I
were	O
computed	O
with	O
Cox	I
regression	I
analysis	I
.	O

During	O
a	O
mean	O
follow-up	I
of	O
19.8±10.4	O
years	O
,	O
153	O
HF	I
deaths	I
occurred	O
.	O

Adjusted	O
hazard	I
ratios	I
across	O
high	O
,	O
moderate	O
,	O
and	O
low	O
CRF	I
categories	O
were	O
1.0	O
,	O
1.63	O
,	O
and	O
3.97	O
,	O
respectively	O
,	O
whereas	O
those	O
of	O
normal	O
,	O
overweight	O
,	O
and	O
obese	I
body	I
mass	I
index	I
categories	O
were	O
1.0	O
,	O
1.56	O
,	O
and	O
3.71	O
,	O
respectively	O
(	O
P	I
for	O
trend	O
<	O
0.0001	O
for	O
each	O
)	O
.	O

When	O
grouped	O
into	O
categories	O
of	O
fit	O
and	O
unfit	O
(	O
upper	O
80	O
%	O
and	O
lower	O
20	O
%	O
of	O
CRF	I
distribution	O
,	O
respectively	O
)	O
,	O
hazard	I
ratios	I
were	O
significantly	I
lower	O
in	O
fit	O
compared	O
with	O
unfit	O
men	O
in	O
normal	O
and	O
overweight	O
body	I
mass	I
index	I
strata	O
(	O
P	I
<	O
0.002	O
)	O
but	O
not	O
in	O
obese	I
men	O
.	O

Within	O
men	O
matched	O
for	O
the	O
same	O
number	O
of	O
HF	I
risk	O
factors	O
,	O
fit	O
men	O
had	O
significantly	I
lower	O
HF	I
mortality	I
than	O
unfit	O
men	O
(	O
P≤0.02	I
)	O
.	O

CONCLUSIONS	O
:	O

Higher	O
baseline	I
CRF	I
is	O
associated	O
with	O
lower	O
HF	I
mortality	I
risk	O
in	O
men	O
,	O
regardless	O
of	O
the	O
number	O
of	O
HF	I
risk	O
factors	O
present	O
.	O

Men	O
should	O
be	O
counseled	O
on	O
physical	I
activity	O
with	O
the	O
goal	O
of	O
achieving	O
at	O
least	O
a	O
moderate	O
level	O
of	O
CRF	I
,	O
thereby	O
presumably	O
decreasing	O
their	O
risk	O
of	O
HF	I
mortality	I
.	O

Mediterranean	O
and	O
DASH	O
diet	O
scores	O
and	O
mortality	I
in	O
women	O
with	O
heart	I
failure	I
:	O
The	O
Women	O
's	O
Health	I
Initiative	O
.	O

BACKGROUND	O
:	O

Current	O
dietary	O
recommendations	O
for	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
are	O
largely	O
based	O
on	O
data	O
from	O
non-HF	I
populations	O
;	O
evidence	O
on	O
associations	O
of	O
dietary	O
patterns	O
with	O
outcomes	I
in	O
HF	I
is	O
limited	O
.	O

We	O
therefore	O
evaluated	O
associations	O
of	O
Mediterranean	O
and	O
Dietary	O
Approaches	O
to	O
Stop	O
Hypertension	I
(	O
DASH	O
)	O
diet	O
scores	O
with	O
mortality	I
among	O
postmenopausal	I
women	O
with	O
HF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Women	O
's	O
Health	I
Initiative	O
participants	O
were	O
followed	I
up	I
from	O
the	O
date	O
of	O
HF	I
hospitalization	I
through	O
the	O
date	O
of	O
death	I
or	O
last	O
participant	O
contact	O
before	O
August	O
2009	O
.	O

Mediterranean	O
and	O
DASH	O
diet	O
scores	O
were	O
calculated	O
from	O
food-frequency	O
questionnaires	O
.	O

Cox	I
proportional	I
hazards	I
models	I
adjusted	O
for	O
demographics	O
,	O
health	I
behaviors	O
,	O
and	O
health	I
status	O
were	O
used	O
to	O
calculate	O
hazard	I
ratios	I
and	O
95	O
%	O
confidence	I
intervals	I
(	O
CI	I
)	O
.	O

For	O
a	O
median	O
of	O
4.6	O
years	O
of	O
follow-up	I
,	O
1385	O
of	O
3215	O
(	O
43.1	O
%	O
)	O
participants	O
who	O
experienced	O
a	O
HF	I
hospitalization	I
died	O
.	O

Multivariable-adjusted	I
hazard	I
ratios	I
were	O
1	O
(	O
reference	O
)	O
,	O
1.05	O
(	O
95	O
%	O
CI	I
,	O
0.89	O
-	O
1.24	O
)	O
,	O
0.97	O
(	O
95	O
%	O
CI	I
,	O
0.81	O
-	O
1.17	O
)	O
,	O
and	O
0.85	O
(	O
95	O
%	O
CI	I
,	O
0.70	O
-	O
1.02	O
)	O
across	O
quartiles	O
of	O
the	O
Mediterranean	O
diet	O
score	O
(	O
P	I
trend=0.08	O
)	O
and	O
1	O
(	O
reference	O
)	O
,	O
1.04	O
(	O
95	O
%	O
CI	I
,	O
0.89	O
-	O
1.21	O
)	O
,	O
0.83	O
(	O
95	O
%	O
CI	I
,	O
0.70	O
-	O
0.98	O
)	O
,	O
and	O
0.84	O
(	O
95	O
%	O
CI	I
,	O
0.70	O
-	O
1.00	O
)	O
across	O
quartiles	O
of	O
the	O
DASH	O
diet	O
score	O
(	O
P	I
trend=0.01	O
)	O
.	O

Diet	O
score	O
components	O
,	O
vegetables	O
,	O
nuts	O
,	O
and	O
whole	O
grain	O
intake	O
,	O
were	O
inversely	O
associated	O
with	O
mortality	I
.	O

CONCLUSIONS	O
:	O

Higher	O
DASH	O
diet	O
scores	O
were	O
associated	O
with	O
modestly	O
lower	O
mortality	I
in	O
women	O
with	O
HF	I
,	O
and	O
there	O
was	O
a	O
nonsignificant	I
trend	O
toward	O
an	O
inverse	O
association	O
with	O
Mediterranean	O
diet	O
scores	O
.	O

These	O
data	O
provide	O
support	O
for	O
the	O
concept	O
that	O
dietary	O
recommendations	O
developed	O
for	O
other	O
cardiovascular	I
conditions	I
or	O
general	O
populations	O
may	O
also	O
be	O
appropriate	O
in	O
patients	I
with	O
HF	I
.	O

Measuring	O
frailty	I
in	O
heart	I
failure	I
:	O
a	O
community	O
perspective	O
.	O

BACKGROUND	O
:	O

Frailty	I
,	O
an	O
important	O
prognostic	I
indicator	O
in	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
may	O
be	O
defined	O
as	O
a	O
biological	I
phenotype	I
or	O
an	O
accumulation	O
of	O
deficits	O
.	O

Each	O
method	O
has	O
strengths	O
and	O
limitations	O
,	O
but	O
their	O
utility	O
has	O
never	O
been	O
evaluated	O
in	O
the	O
same	O
community	O
HF	I
cohort	O
.	O

METHODS	O
:	O

Southeastern	O
Minnesota	O
residents	O
with	O
HF	I
were	O
recruited	O
from	O
2007	O
to	O
2011	O
.	O

Frailty	I
according	O
to	O
the	O
biological	I
phenotype	I
was	O
defined	O
as	O
3	O
or	O
more	O
of	O
:	O
weak	O
grip	O
strength	O
,	O
physical	I
exhaustion	O
,	O
slowness	O
,	O
low	O
activity	O
and	O
unintentional	O
weight	O
loss	O
>	O
10	O
lb	O
in	O
1	O
year	O
.	O

Intermediate	O
frailty	I
was	O
defined	O
as	O
1	O
to	O
2	O
.	O

The	O
deficit	I
index	I
was	O
defined	O
as	O
the	O
proportion	O
of	O
deficits	O
present	O
out	O
of	O
32	O
deficits	O
.	O

RESULTS	O
:	O

Among	O
223	O
patients	I
(	O
mean	O
age	O
71	O
±	O
14	O
,	O
61	O
%	O
male	O
)	O
,	O
21	O
%	O
were	O
frail	I
and	O
48	O
%	O
intermediate	O
frail	I
according	O
to	O
the	O
biological	I
phenotype	I
.	O

The	O
deficit	I
index	I
ranged	O
from	O
0.02	O
-	O
0.75	O
,	O
with	O
a	O
mean	O
(	O
SD	I
)	O
of	O
0.25	O
(	O
0.13	O
)	O
.	O

Over	O
a	O
mean	O
follow-up	I
of	O
2.4	O
years	O
,	O
63	O
patients	I
died	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
sex	O
and	O
ejection	I
fraction	I
,	O
patients	I
categorized	O
as	O
frail	I
by	O
the	O
biological	I
phenotype	I
had	O
a	O
2-fold	O
increased	O
risk	O
of	O
death	I
compared	O
to	O
those	O
with	O
no	O
frailty	I
,	O
whereas	O
a	O
0.1	O
unit	O
increase	O
in	O
the	O
deficit	I
index	I
was	O
associated	O
with	O
a	O
44	O
%	O
increased	O
risk	O
of	O
death	I
.	O

Both	O
measures	O
predicted	O
death	I
equally	O
(	O
C-statistics	I
:	O
0.687	O
for	O
biological	I
phenotype	I
and	O
0.700	O
for	O
deficit	I
index	I
)	O
.	O

CONCLUSION	O
:	O

The	O
deficit	I
index	I
and	O
the	O
biological	I
phenotype	I
equally	O
predict	O
mortality	I
.	O

As	O
the	O
biological	I
phenotype	I
is	O
not	O
routinely	O
assessed	O
clinically	I
,	O
the	O
deficit	I
index	I
,	O
which	O
can	O
be	O
ascertained	O
from	O
medical	I
records	O
,	O
is	O
a	O
feasible	O
alternative	O
to	O
ascertain	O
frailty	I
.	O

Trends	O
from	O
1996	O
to	O
2007	O
in	O
incidence	I
and	O
mortality	I
outcomes	I
of	O
heart	I
failure	I
after	O
acute	I
myocardial	I
infarction	I
:	O
a	O
population-based	O
study	O
of	O
20,812	O
patients	I
with	O
first	O
acute	I
myocardial	I
infarction	I
in	O
Western	O
Australia	O
.	O

BACKGROUND	O
:	O

Advances	O
in	O
treatment	O
for	O
acute	I
myocardial	I
infarction	I
(	O
AMI	I
)	O
are	O
likely	O
to	O
have	O
had	O
a	O
beneficial	O
impact	O
on	O
the	O
incidence	I
of	O
and	O
deaths	I
attributable	O
to	O
heart	I
failure	I
(	O
HF	I
)	O
complicating	O
AMI	I
,	O
although	O
limited	O
data	O
are	O
available	O
to	O
support	O
this	O
contention	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Western	O
Australian	O
linked	O
administrative	O
health	I
data	O
were	O
used	O
to	O
identify	O
20	O
812	O
consecutive	O
patients	I
,	O
aged	O
40	O
to	O
84	O
years	O
,	O
without	O
prior	O
HF	I
hospitalized	I
with	O
an	O
index	O
(	O
first	O
)	O
AMI	I
between	O
1996	O
and	O
2007	O
.	O

We	O
assessed	O
the	O
temporal	O
incidence	I
of	O
and	O
adjusted	I
odds	I
ratio	I
/	O
hazard	I
ratio	I
for	O
death	I
associated	O
with	O
HF	I
concurrent	O
with	O
AMI	I
admission	I
and	O
within	O
1	O
year	O
after	O
discharge	I
.	O

Concurrent	O
HF	I
comprised	O
75	O
%	O
of	O
incident	O
HF	I
cases	O
.	O

Between	O
the	O
periods	O
1996	O
-	O
1998	O
and	O
2005	O
-	O
2007	O
,	O
the	O
prevalence	I
of	O
HF	I
after	O
AMI	I
declined	O
from	O
28.1	O
%	O
to	O
16.5	O
%	O
,	O
with	O
an	O
adjusted	I
odds	I
ratio	I
of	O
0.50	O
(	O
95	O
%	O
CI	I
,	O
0.44	O
to	O
0.55	O
)	O
.	O

The	O
crude	O
28-day	O
case-fatality	I
rate	I
for	O
patients	I
with	O
concurrent	O
HF	I
declined	O
marginally	O
from	O
20.5	O
%	O
to	O
15.9	O
%	O
(	O
P	I
<	O
0.05	O
)	O
compared	O
with	O
those	O
without	O
concurrent	O
HF	I
,	O
in	O
whom	O
the	O
case-fatality	I
rate	I
declined	O
from	O
11.0	O
%	O
to	O
4.8	O
%	O
(	O
P	I
<	O
0.001	O
)	O
.	O

Concurrent	O
HF	I
was	O
associated	O
with	O
a	O
multivariate-adjusted	I
odds	I
ratio	I
of	O
2.2	O
for	O
28-day	O
mortality	I
and	O
a	O
hazard	I
ratio	I
of	O
2.2	O
for	O
1-year	O
mortality	I
in	O
28-day	O
survivors	O
.	O

Occurrence	O
of	O
HF	I
within	O
90	O
days	O
of	O
the	O
index	O
AMI	I
was	O
associated	O
with	O
an	O
adjusted	O
hazard	I
ratio	I
of	O
2.7	O
for	O
1-year	O
mortality	I
in	O
90-day	O
survivors	O
.	O

CONCLUSIONS	O
:	O

Despite	O
encouraging	O
declines	O
in	O
the	O
incidence	I
of	O
HF	I
complicating	O
AMI	I
,	O
it	O
remains	O
a	O
common	O
problem	O
with	O
high	O
mortality	I
.	O

Increased	O
attention	O
to	O
these	O
high-risk	O
patients	I
is	O
needed	O
given	O
the	O
lack	O
of	O
improvement	O
in	O
their	O
long-term	O
prognosis	I
.	O

Potent	O
inhibition	O
of	O
L-type	I
Ca2	I
+	I
currents	I
by	O
a	O
Rad	I
variant	I
associated	O
with	O
congestive	I
heart	I
failure	I
.	O

Ca	I
(	I
2	I
+	I
)	I
influx	O
via	O
L-type	I
voltage-gated	I
Ca	I
(	I
2	I
+	I
)	I
channels	I
supports	O
the	O
plateau	O
phase	O
of	O
ventricular	I
action	I
potentials	I
and	O
is	O
the	O
trigger	O
for	O
excitation-contraction	I
(	O
EC	I
)	O
coupling	O
in	O
the	O
myocardium	I
.	O

Rad	I
,	O
a	O
member	O
of	O
the	O
RGK	I
(	O
Rem	I
,	O
Rem2	I
,	O
Rad	I
,	O
Gem	I
/	I
Kir	I
)	O
family	O
of	O
monomeric	I
G	I
proteins	I
,	O
regulates	O
ventricular	I
action	I
potential	I
duration	O
and	O
EC	I
coupling	O
gain	O
through	O
its	O
ability	O
to	O
inhibit	O
cardiac	I
L-type	I
channel	I
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
potential	O
dysfunction	I
of	O
a	O
naturally	O
occurring	O
Rad	I
variant	I
(	O
Q66P	I
)	O
that	O
has	O
been	O
associated	O
with	O
congestive	I
heart	I
failure	I
in	O
humans	O
.	O

Specifically	O
,	O
we	O
have	O
tested	O
whether	O
Rad	I
Q66P	I
limits	O
,	O
or	O
even	O
eliminates	O
,	O
the	O
inhibitory	O
actions	O
of	O
Rad	I
on	O
CaV1.2	I
and	O
CaV1.3	I
,	O
the	O
two	O
L-type	I
channel	I
isoforms	I
known	O
to	O
be	O
expressed	O
in	O
the	O
heart	I
.	O

We	O
have	O
found	O
that	O
mouse	O
Rad	I
Q65P	I
(	O
the	O
murine	I
equivalent	O
of	O
human	O
Rad	I
Q66P	I
)	O
inhibits	O
L-type	I
currents	I
conducted	O
by	O
CaV1.2	I
or	O
CaV1.3	I
channels	O
as	O
potently	O
as	O
wild-type	I
Rad	I
(	O
>	O
95	O
%	O
inhibition	O
of	O
both	O
channels	O
)	O
.	O

In	O
addition	O
,	O
Rad	I
Q65P	I
attenuates	O
the	O
gating	O
movement	O
of	O
both	O
channels	O
as	O
effectively	O
as	O
wild-type	I
Rad	I
,	O
indicating	O
that	O
the	O
Q65P	I
substitution	O
does	O
not	O
differentially	O
impair	O
any	O
of	O
the	O
three	O
described	O
modes	O
of	O
L-type	I
channel	I
inhibition	O
by	O
RGK	I
proteins	I
.	O

Thus	O
,	O
we	O
conclude	O
that	O
if	O
Rad	I
Q66P	I
contributes	O
to	O
cardiomyopathy	I
,	O
it	O
does	O
so	O
via	O
a	O
mechanism	O
that	O
is	O
not	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
L-type	I
channel-dependent	I
processes	O
per	O
se	O
.	O

However	O
,	O
our	O
results	O
do	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
decreased	O
expression	I
,	O
mistargeting	O
or	O
altered	O
regulation	O
of	O
Rad	I
Q66P	I
may	O
reduce	O
the	O
RGK	I
protein	I
's	O
efficacy	O
in	I
vivo	I
.	O

Impact	O
of	O
QRS	I
morphology	I
and	O
duration	I
on	O
outcomes	I
after	O
cardiac	I
resynchronization	I
therapy	I
:	O
Results	O
from	O
the	O
Resynchronization-Defibrillation	I
for	O
Ambulatory	I
Heart	I
Failure	I
Trial	O
(	O
RAFT	O
)	O
.	O

BACKGROUND	O
:	O

The	O
impact	O
of	O
QRS	I
morphology	I
and	O
duration	I
on	O
the	O
effectiveness	O
of	O
cardiac	I
resynchronization	I
therapy	I
(	O
CRT	I
)	O
has	O
been	O
usually	O
assessed	O
separately	O
.	O

The	O
interaction	O
between	O
these	O
2	O
simple	O
ECG	I
parameters	O
and	O
their	O
effect	O
on	O
CRT	I
has	O
not	O
been	O
systematically	O
assessed	O
in	O
a	O
large-scale	O
clinical	I
trial	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

The	O
Resynchronization-Defibrillation	I
for	O
Ambulatory	I
Heart	I
Failure	I
Trial	O
showed	O
that	O
implantable	I
cardioverter	I
defibrillator-CRT	I
was	O
associated	O
with	O
a	O
significant	I
reduction	O
in	O
the	O
primary	I
end	I
point	I
of	O
all-cause	I
mortality	I
or	O
heart	I
failure	I
hospitalization	I
.	O

For	O
this	O
substudy	O
,	O
we	O
excluded	O
patients	I
in	O
atrial	I
fibrillation	I
and	O
those	O
with	O
a	O
previous	O
pacemaker	I
.	O

All	O
baseline	I
ECGs	I
were	O
reviewed	O
by	O
a	O
panel	O
of	O
3	O
experienced	O
electrocardiographers	I
.	O

A	O
total	O
of	O
1483	O
patients	I
were	O
included	O
in	O
this	O
study	O
.	O

Of	O
these	O
,	O
1175	O
had	O
left	I
bundle-branch	I
block	I
(	O
LBBB	I
)	O
and	O
308	O
had	O
non-LBBB	I
.	O

In	O
patients	I
with	O
LBBB	I
receiving	O
implantable	I
cardioverter	I
defibrillator-CRT	I
,	O
there	O
was	O
a	O
reduction	O
in	O
the	O
primary	I
outcome	I
and	O
in	O
each	O
individual	O
component	O
of	O
the	O
primary	I
outcome	I
.	O

Furthermore	O
,	O
there	O
was	O
continuous	O
relationship	O
between	O
QRS	I
duration	I
and	O
extent	O
of	O
benefit	O
.	O

In	O
patients	I
with	O
non-LBBB	I
and	O
QRS	I
≥160	O
ms	O
,	O
the	O
hazard	I
ratio	I
for	O
the	O
primary	I
outcome	I
was	O
0.52	O
(	O
0.29	O
-	O
0.96	O
;	O
P=0.033	I
)	O
;	O
in	O
patients	I
with	O
QRS	I
<	O
160	O
ms	O
,	O
the	O
hazard	I
ratio	I
was	O
1.38	O
(	O
0.88	O
-	O
2.14	O
;	O
P=0.155	I
)	O
.	O

CONCLUSIONS	O
:	O

In	O
patients	I
with	O
LBBB	I
,	O
there	O
was	O
a	O
continuous	O
relationship	O
between	O
broader	O
QRS	I
and	O
greater	O
benefit	O
from	O
implantable	I
cardioverter	I
defibrillator-CRT	I
.	O

However	O
,	O
our	O
data	O
do	O
not	O
support	O
the	O
use	O
of	O
implantable	I
cardioverter	I
defibrillator-CRT	I
in	O
patients	I
with	O
non-LBBB	I
,	O
especially	O
when	O
the	O
QRS	I
duration	I
is	O
<	O
160	O
ms	O
.	O

There	O
may	O
be	O
some	O
delayed	O
benefit	O
when	O
the	O
QRS	I
is	O
≥160	O
ms	O
,	O
but	O
this	O
needs	O
further	O
investigation	O
.	O

A	O
novel	O
heart	I
failure	I
mice	O
model	O
of	O
hypertensive	I
heart	I
disease	I
by	O
angiotensin	I
II	I
infusion	I
,	O
nephrectomy	I
,	O
and	O
salt	I
loading	I
.	O

Although	O
the	O
mouse	O
heart	I
failure	I
(	O
HF	I
)	O
model	O
of	O
hypertensive	I
heart	I
disease	I
(	O
HHD	I
)	O
is	O
useful	O
to	O
investigate	O
the	O
pathophysiology	I
and	O
new	O
therapeutic	I
targets	O
for	O
HHD	I
,	O
the	O
model	O
using	O
simple	O
experimental	O
procedures	O
and	O
stable	O
phenotypes	I
has	O
not	O
been	O
established	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
novel	O
mouse	O
HF	I
model	O
of	O
HHD	I
by	O
combining	O
salt	I
loading	I
and	O
uninephrectomy	I
with	O
ANG	I
II	I
infusion	I
.	O

Eight-week-old	O
C57BL	O
/	O
6	O
male	O
mice	O
were	O
treated	O
with	O
ANG	I
II	I
infusion	I
(	O
AT	O
)	O
,	O
ANG	I
II	I
infusion	I
and	O
uninephrectomy	I
(	O
AN	O
)	O
,	O
ANG	I
II	I
infusion	I
and	O
salt	I
loading	I
(	O
AS	O
)	O
,	O
or	O
ANG	I
II	I
infusion	I
,	O
uninephrectomy	I
,	O
and	O
salt	I
loading	I
(	O
ANS	O
)	O
.	O

Systolic	I
blood	I
pressure	I
was	O
significantly	I
elevated	O
and	O
left	I
ventricular	I
(	O
LV	I
)	O
hypertrophy	I
was	O
found	O
in	O
AT	O
,	O
AN	O
,	O
AS	O
,	O
and	O
ANS	O
mice	O
,	O
and	O
there	O
were	O
no	O
significant	I
differences	O
in	O
those	O
parameters	O
between	O
the	O
four	O
groups	O
.	O

At	O
6	O
wk	O
after	O
the	O
procedures	O
,	O
only	O
ANS	O
mice	O
showed	O
significant	I
decreases	O
in	O
LV	I
fractional	I
shortening	I
and	O
increases	O
in	O
lung	I
weight	O
with	O
a	O
high	O
incidence	I
.	O

This	O
phenotype	I
was	O
reproducible	O
,	O
and	O
there	O
were	O
few	O
perioperative	I
or	O
early	O
deaths	I
in	O
the	O
experimental	O
procedures	O
.	O

Severe	O
LV	I
fibrosis	I
was	O
found	O
in	O
ANS	O
mice	O
.	O

Oxidative	I
stress	I
was	O
enhanced	O
and	O
small	O
GTPase	I
Rac1	I
activity	O
was	O
upregulated	O
in	O
the	O
hearts	I
of	O
ANS	O
mice	O
.	O

After	O
the	O
addition	O
of	O
salt	I
loading	I
and	O
uninephrectomy	I
to	O
the	O
ANG	I
II	I
infusion	I
mouse	O
model	O
,	O
cardiac	I
function	I
was	O
significantly	I
impaired	O
,	O
and	O
mice	O
developed	O
HF	I
.	O

This	O
might	O
be	O
a	O
novel	O
and	O
useful	O
mouse	O
HF	I
model	O
to	O
study	O
the	O
transition	O
from	O
compensated	I
LV	I
hypertrophy	I
to	O
HF	I
in	O
HHD	I
.	O

Patient	I
perceptions	O
of	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
discussions	O
:	O
A	O
qualitative	O
study	O
.	O

BACKGROUND	O
:	O

There	O
is	O
a	O
class	O
I	O
recommendation	O
for	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
discussions	O
to	O
occur	O
between	O
physicians	I
and	O
heart	I
failure	I
patients	I
.	O

Few	O
studies	O
have	O
reported	O
the	O
patient	I
's	O
perspective	O
on	O
the	O
timing	O
of	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
discussions	O
.	O

AIM	O
:	O

To	O
determine	O
patient	I
awareness	O
,	O
preferences	O
and	O
timing	O
of	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
discussions	O
.	O

DESIGN	O
:	O

Grounded	O
theory	O
was	O
used	O
to	O
collect	O
and	O
analyze	O
interview	O
data	O
from	O
25	O
heart	I
failure	I
patients	I
with	O
an	O
implantable	I
cardioverter-defibrillator	I
.	O

SETTING	O
AND	O
PARTICIPANTS	O
:	O

Patients	I
with	O
an	O
implantable	I
cardioverter-defibrillator	I
,	O
from	O
the	O
Heart	I
Function	O
Clinic	I
at	O
University	O
Health	I
Network	O
(	O
Toronto	O
,	O
Canada	O
)	O
.	O

RESULTS	O
:	O

The	O
sample	O
(	O
n	O
=	O
25	O
)	O
was	O
predominately	O
male	O
(	O
76	O
%	O
)	O
with	O
an	O
average	O
age	O
of	O
62	O
years	O
.	O

Patients	I
identified	O
three	O
stages	O
where	O
they	O
felt	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
should	O
be	O
discussed	O
:	O
(	O
1	O
)	O
prior	O
to	O
implantation	I
,	O
(	O
2	O
)	O
with	O
any	O
significant	O
deterioration	O
but	O
while	O
they	O
were	O
of	O
sound	O
mind	O
to	O
engage	O
in	O
and	O
communicate	O
their	O
preferences	O
and	O
(	O
3	O
)	O
at	O
end	O
of	O
life	O
,	O
where	O
patients	I
wished	O
further	O
review	O
of	O
their	O
previously	O
established	O
preferences	O
and	O
decisions	O
about	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
.	O

Most	O
patients	I
(	O
n	O
=	O
17	O
,	O
68	O
%	O
)	O
said	O
they	O
would	O
consider	O
deactivation	O
,	O
six	O
(	O
24	O
%	O
)	O
were	O
undecided	O
and	O
two	O
(	O
8	O
%	O
)	O
were	O
adamant	O
they	O
would	O
never	O
turn	O
it	O
off	O
.	O

CONCLUSION	O
:	O

The	O
patient	I
preferences	O
identified	O
in	O
this	O
study	O
support	O
the	O
need	O
to	O
include	O
information	O
on	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
at	O
implant	I
,	O
with	O
change	O
in	O
clinical	I
status	O
and	O
within	O
broader	O
discussions	O
about	O
end-of-life	O
treatment	O
preferences	O
.	O

Using	O
this	O
process	O
to	O
help	O
patients	I
determine	O
and	O
communicate	O
their	O
implantable	I
cardioverter-defibrillator	I
deactivation	O
preferences	O
may	O
reduce	O
the	O
number	O
of	O
patients	I
experiencing	O
distressing	O
implantable	I
cardioverter-defibrillator	I
shocks	O
at	O
end	O
of	O
life	O
.	O

Diuretic	I
use	O
in	O
heart	I
failure	I
and	O
outcomes	I
.	O

Diuretics	I
are	O
frequently	O
administered	O
to	O
relieve	O
congestive	O
symptoms	I
in	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

Despite	O
their	O
widespread	O
use	O
,	O
prospective	I
data	O
on	O
the	O
potential	O
of	O
diuretics	I
to	O
modulate	O
HF-related	I
morbidity	I
and	O
mortality	I
are	O
scarce	O
.	O

Diuretic	I
efficacy	O
may	O
be	O
limited	O
by	O
adverse	O
neurohormonal	I
activation	O
and	O
by	O
congestion-like	O
symptoms	I
that	O
may	O
occur	O
in	O
the	O
absence	O
of	O
fluid	I
overload	I
.	O

Herein	O
,	O
we	O
review	O
the	O
current	O
knowledge	O
on	O
diuretic	I
use	O
and	O
outcomes	I
in	O
HF	I
.	O

Left	I
ventricular	I
ejection	I
time	I
in	O
acute	I
heart	I
failure	I
complicating	O
precapillary	I
pulmonary	I
hypertension	I
.	O

BACKGROUND	O
:	O

Novel	O
noninvasive	I
tools	O
may	O
improve	O
the	O
management	O
of	O
patients	I
with	O
pulmonary	I
hypertension	I
(	O
PH	I
)	O
experiencing	O
heart	I
failure	I
.	O

Major	O
right	I
ventricle	I
overload	O
leads	O
to	O
decreased	O
stroke	I
volume	I
,	O
which	O
shortens	O
left	I
ventricular	I
ejection	I
time	I
(	O
LVET	I
)	O
.	O

Our	O
arterial	I
tonometry	I
study	O
tested	O
the	O
hypothesis	O
that	O
LVET	I
carries	O
prognostic	I
value	O
in	O
patients	I
with	O
precapillary	I
PH	I
with	O
heart	I
failure	I
.	O

METHODS	O
:	O

Clinical	I
,	O
biologic	O
,	O
and	O
radial	O
artery	I
tonometry	I
variables	O
were	O
prospectively	I
obtained	O
at	O
admission	I
and	O
at	O
day	O
3	O
to	O
5	O
in	O
53	O
consecutive	O
patients	I
with	O
PH	I
admitted	O
to	O
our	O
ICU	I
for	O
clinical	I
deterioration	O
.	O

LVET	I
was	O
measured	O
from	O
the	O
reconstructed	O
aortic	I
pressure	I
curve	O
.	O

RESULTS	O
:	O

Overall	O
ICU	I
mortality	I
(	O
median	O
stay	O
,	O
5	O
days	O
)	O
was	O
17	O
%	O
.	O

At	O
admission	I
,	O
the	O
LVET	I
was	O
shorter	O
in	O
patients	I
with	O
unfavorable	O
outcome	I
(	O
median	O
,	O
228	O
milliseconds	O
[	O
25th-75th	O
percentiles	O
,	O
212	O
-	O
278	O
milliseconds	O
]	O
vs	O
257	O
milliseconds	O
[	O
237	O
-	O
277	O
milliseconds	O
]	O
,	O
P	I
=	O
.032	O
)	O
,	O
whereas	O
other	O
tonometric	I
indices	O
were	O
similar	O
.	O

The	O
LVET	I
at	O
entry	O
(	O
237	O
milliseconds	O
)	O
had	O
73	O
%	O
sensitivity	I
and	O
89	O
%	O
specificity	I
for	O
identifying	O
death	I
in	O
the	O
ICU	I
.	O

Other	O
prognostic	I
factors	O
at	O
admission	I
were	O
higher	O
serum	O
levels	O
of	O
brain	I
natriuretic	I
peptide	I
(	O
BNP	I
)	O
and	O
creatinine	I
and	O
lower	O
natremia	I
.	O

Dobutamine	I
requirement	O
,	O
higher	O
furosemide	I
dose	O
,	O
and	O
higher	O
oxygen	O
flow	O
were	O
associated	O
with	O
unfavorable	O
outcome	I
.	O

At	O
the	O
second	O
evaluation	O
,	O
higher	O
serum	O
levels	O
of	O
creatinine	I
and	O
BNP	I
,	O
higher	O
furosemide	I
dose	O
and	O
oxygen	O
flow	O
,	O
and	O
dobutamine	I
or	O
norepinephrine	I
requirement	O
were	O
associated	O
with	O
poor	O
outcome	I
.	O

The	O
change	O
in	O
LVET	I
between	O
admission	I
and	O
follow-up	I
measurement	O
was	O
not	O
associated	O
with	O
outcome	I
.	O

The	O
90-day	O
mortality	I
was	O
28	O
%	O
.	O

CONCLUSIONS	O
:	O

Shortened	O
LVET	I
at	O
ICU	I
admission	I
was	O
a	O
prognostic	I
factor	O
in	O
patients	I
with	O
precapillary	I
PH	I
with	O
heart	I
failure	I
.	O

Previously	O
documented	O
prognostic	I
factors	O
were	O
also	O
confirmed	O
in	O
this	O
cohort	O
.	O

A	O
young	O
adult	O
Jehovah	O
's	O
Witness	O
with	O
severe	O
anemia	I
.	O

Two	O
of	O
the	O
most	O
ethically	O
complex	O
situations	O
in	O
pediatrics	O
are	O
those	O
involving	O
families	O
whose	O
religious	O
beliefs	O
preclude	O
the	O
provision	O
of	O
life-sustaining	O
treatment	O
and	O
those	O
involving	O
young	O
adults	O
who	O
have	O
reached	O
the	O
age	O
of	O
legal	O
majority	O
and	O
who	O
face	O
decisions	O
about	O
life-sustaining	O
treatment	O
.	O

This	O
month	O
's	O
Ethics	O
Rounds	O
presents	O
a	O
case	O
in	O
which	O
these	O
2	O
complexities	O
overlapped	O
.	O

An	O
18-year-old	O
Jehovah	O
's	O
Witness	O
with	O
sickle	I
cell	I
disease	I
has	O
life-threatening	O
anemia	I
.	O

She	O
is	O
going	O
into	O
heart	I
failure	I
.	O

Her	O
doctors	I
urgently	O
recommend	O
blood	I
transfusions	I
.	O

The	O
young	O
woman	O
and	O
her	O
family	O
adamantly	O
refuse	O
.	O

Should	O
the	O
doctors	I
let	O
her	O
die	O
?	O

Is	O
there	O
any	O
alternative	O
?	O

Treatment	O
of	O
anemia	I
in	O
patients	I
with	O
heart	I
disease	I
:	O
a	O
systematic	O
review	O
.	O

Background	O
:	O
The	O
benefits	O
of	O
anemia	I
treatment	O
in	O
patients	I
with	O
heart	I
disease	I
are	O
uncertain	O
.	O

Purpose	O
:	O
To	O
evaluate	O
the	O
benefits	O
and	O
harms	O
of	O
treatments	O
for	O
anemia	I
in	O
adults	O
with	O
heart	I
disease	I
.	O

Data	O
Sources	O
:	O
MEDLINE	O
,	O
EMBASE	O
,	O
and	O
Cochrane	O
databases	O
;	O
clinical	I
trial	O
registries	O
;	O
reference	O
lists	O
;	O
and	O
technical	O
advisors	O
.	O

Study	O
Selection	O
:	O
English-language	O
trials	O
of	O
blood	I
transfusions	I
,	O
iron	O
,	O
or	O
erythropoiesis-stimulating	I
agents	I
in	O
adults	O
with	O
anemia	I
and	O
congestive	I
heart	I
failure	I
or	O
coronary	I
heart	I
disease	I
and	O
observational	O
studies	O
of	O
transfusion	I
.	O

Data	O
Extraction	O
:	O
Data	O
on	O
study	O
design	O
,	O
population	O
characteristics	O
,	O
hemoglobin	I
levels	O
,	O
and	O
health	I
outcomes	I
were	O
extracted	O
.	O

Trials	O
were	O
assessed	O
for	O
quality	O
.	O

Data	O
Synthesis	O
:	O
Low-strength	O
evidence	O
from	O
6	O
trials	O
and	O
26	O
observational	O
studies	O
suggests	O
that	O
liberal	O
transfusion	I
protocols	O
do	O
not	O
improve	O
short-term	O
mortality	I
rates	O
compared	O
with	O
less	O
aggressive	O
protocols	O
(	O
combined	O
relative	I
risk	I
among	O
trials	O
,	O
0.94	O
[	O
95	O
%	O
CI	I
,	O
0.61	O
to	O
1.42	O
]	O
;	O
I2	O
=	O
16.8	O
%	O
)	O
,	O
although	O
decreased	O
mortality	I
rates	O
occurred	O
in	O
a	O
small	O
trial	O
of	O
patients	I
with	O
the	O
acute	I
coronary	I
syndrome	I
(	O
1.8	O
%	O
vs.	O
13.0	O
%	O
;	O
P	I
=	O
0.032	O
)	O
.	O

Moderate-strength	O
evidence	O
from	O
3	O
trials	O
of	O
intravenous	I
iron	O
found	O
improved	O
short-term	O
exercise	I
tolerance	I
and	O
quality	I
of	I
life	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

Moderate	O
-	O
to	O
high-strength	O
evidence	O
from	O
17	O
trials	O
of	O
erythropoiesis-stimulating	I
agent	I
therapy	I
found	O
they	O
offered	O
no	O
consistent	O
benefits	O
,	O
but	O
their	O
use	O
may	O
be	O
associated	O
with	O
harms	O
,	O
such	O
as	O
venous	I
thromboembolism	I
.	O

Limitations	O
:	O
Few	O
trials	O
have	O
examined	O
transfusions	I
in	O
patients	I
with	O
heart	I
disease	I
,	O
and	O
observational	O
studies	O
are	O
potentially	O
confounded	O
by	O
indication	O
.	O

Data	O
supporting	O
iron	O
use	O
come	O
mainly	O
from	O
1	O
large	O
trial	O
,	O
and	O
long-term	O
effects	O
are	O
unknown	O
.	O

Conclusion	O
:	O
Higher	O
transfusion	I
thresholds	O
do	O
not	O
consistently	O
improve	O
mortality	I
rates	O
,	O
but	O
large	O
trials	O
are	O
needed	O
.	O

Intravenous	I
iron	O
may	O
help	O
to	O
alleviate	O
symptoms	I
in	O
patients	I
with	O
heart	I
failure	I
and	O
iron	O
deficiency	O
and	O
also	O
warrants	O
further	O
study	O
.	O

Erythropoiesis-stimulating	I
agents	I
do	O
not	O
seem	O
to	O
benefit	O
patients	I
with	O
mild	O
to	O
moderate	O
anemia	I
and	O
heart	I
disease	I
and	O
may	O
be	O
associated	O
with	O
serious	O
harms	O
.	O

Survival	O
after	O
left	I
ventricular	I
assist	I
device	I
with	O
and	O
without	O
temporary	O
right	I
ventricular	I
support	I
.	O

BACKGROUND	O
:	O

Right	I
ventricular	I
(	O
RV	I
)	O
failure	I
after	O
the	O
insertion	O
of	O
a	O
left	I
ventricular	I
assist	I
device	I
(	O
LVAD	I
)	O
historically	O
results	O
in	O
poor	O
outcomes	I
.	O

Patients	I
requiring	O
temporary	O
RV	I
support	I
after	O
LVAD	I
insertion	O
are	O
a	O
heterogeneous	O
group	O
of	O
patients	I
consisting	O
of	O
those	O
in	O
cardiogenic	I
shock	I
after	O
myocardial	I
infarction	I
,	O
to	O
those	O
with	O
chronic	I
decompensated	I
heart	I
failure	I
.	O

For	O
patients	I
requiring	O
biventricular	I
support	I
,	O
we	O
have	O
used	O
a	O
hybrid	O
system	O
consisting	O
of	O
a	O
HeartMate	O
II	O
LVAD	I
and	O
CentriMag	O
right	I
ventricular	I
assist	I
device	I
(	O
RVAD	I
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
1-year	O
survival	O
in	O
patients	I
requiring	O
isolated	O
LVAD	I
and	O
patients	I
requiring	O
biventricular	I
support	I
.	O

METHODS	O
:	O

All	O
patients	I
who	O
underwent	O
HeartMate	O
II	O
LVAD	I
alone	O
or	O
in	O
conjunction	O
with	O
a	O
temporary	O
CentriMag	O
RVAD	I
were	O
examined	O
from	O
2006	O
to	O
2011	O
.	O

Preoperative	I
demographics	O
,	O
operative	I
outcomes	I
,	O
and	O
survival	O
were	O
analyzed	O
.	O

RESULTS	O
:	O

A	O
total	O
of	O
139	O
patients	I
required	O
HeartMate	O
II	O
insertion	O
;	O
34	O
(	O
24	O
%	O
)	O
required	O
biventricular	I
support	I
at	O
the	O
time	O
of	O
HeartMate	O
II	O
implantation	I
.	O

The	O
mean	O
duration	O
of	O
biventricular	I
support	I
was	O
17	O
±	O
11.9	O
days	O
(	O
range	O
,	O
6	O
to	O
56	O
days	O
)	O
with	O
91.8	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
RVADs	I
successfully	O
explanted	I
.	O

Survival	O
to	O
hospital	I
discharge	I
was	O
not	O
different	O
between	O
groups	O
(	O
95.2	O
versus	O
88.2	O
%	O
;	O
p	I
=	O
0.2	O
)	O
.	O

However	O
,	O
1-year	O
survival	O
was	O
significantly	I
greater	O
in	O
patients	I
who	O
required	O
isolated	O
HeartMate	O
II	O
LVAD	I
(	O
87	O
%	O
versus	O
77	O
%	O
;	O
p	I
=	O
0.03	O
)	O
.	O

CONCLUSIONS	O
:	O

Biventricular	I
support	I
using	O
a	O
HeartMate	O
II	O
LVAD	I
and	O
CentriMag	O
RVAD	I
resulted	O
in	O
limited	O
mortality	I
at	O
hospital	I
discharge	I
.	O

However	O
biventricular	I
dysfunction	I
does	O
not	O
have	O
a	O
favorable	O
outcome	I
at	O
1	O
year	O
when	O
compared	O
with	O
patients	I
requiring	O
isolated	O
HeartMate	O
II	O
.	O

Effectiveness	O
of	O
implementation	O
strategies	O
in	O
improving	O
physician	I
adherence	O
to	O
guideline	O
recommendations	O
in	O
heart	I
failure	I
:	O
a	O
systematic	O
review	O
protocol	O

Introduction	O
The	O
uptake	O
of	O
Clinical	I
Practice	I
Guideline	I
(	O
CPG	I
)	O
recommendations	O
that	O
improve	O
outcomes	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
remains	O
suboptimal	O
.	O

We	O
will	O
conduct	O
a	O
systematic	O
review	O
to	O
identify	O
implementation	O
strategies	O
that	O
improve	O
physician	I
adherence	O
to	O
class	O
I	O
recommendations	O
,	O
those	O
with	O
clear	O
evidence	O
that	O
benefits	O
outweigh	O
the	O
risks	O
.	O

We	O
will	O
use	O
American	O
,	O
Canadian	O
and	O
European	O
HF	I
guidelines	O
as	O
our	O
reference	O
.	O

Methods	O
and	O
analysis	O
We	O
will	O
conduct	O
a	O
literature	O
search	O
in	O
the	O
databases	O
of	O
MEDLINE	O
,	O
EMBASE	O
,	O
HEALTHSTAR	O
,	O
CINAHL	O
,	O
Cochrane	O
Library	O
,	O
Campbell	O
Collaboration	O
,	O
Joanna	O
Briggs	O
Institute	O
Evidence	O
Based	O
Practice	O
,	O
Centre	O
for	O
Reviews	O
and	O
Dissemination	O
and	O
Evidence	O
Based	O
Practice	O
Centres	O
.	O

We	O
will	O
include	O
prospective	I
studies	I
evaluating	O
implementation	O
interventions	O
aimed	O
at	O
improving	O
uptake	O
of	O
class	O
I	O
CPG	O
recommendations	O
in	O
HF	I
.	O

We	O
will	O
extract	O
data	O
in	O
duplicate	O
.	O

We	O
will	O
classify	O
interventions	O
according	O
to	O
their	O
level	O
of	O
application	O
(	O
ie	O
,	O
provider	O
,	O
organisation	O
,	O
systems	O
level	O
)	O
and	O
common	O
underlying	O
characteristics	O
(	O
eg	O
,	O
education	O
,	O
decision-support	O
,	O
financial	O
incentives	O
)	O
using	O
the	O
Cochrane	O
Effective	O
Practice	O
and	O
Organisation	O
of	O
Care	O
Taxonomy	O
.	O

We	O
will	O
assess	O
the	O
impact	O
of	O
the	O
intervention	O
on	O
adherence	O
to	O
the	O
CPGs	O
.	O

Outcomes	I
will	O
include	O
proportion	O
of	O
eligible	O
patients	I
who	O
were	O
:	O
prescribed	I
a	O
CPG-recommended	O
pharmacological	I
treatment	O
;	O
referred	O
for	O
device	O
consideration	O
;	O
provided	O
self-care	O
education	O
at	O
discharge	I
;	O
and	O
provided	O
left	I
ventricular	I
function	I
assessment	O
.	O

We	O
will	O
include	O
clinical	I
outcomes	I
such	O
as	O
hospitalisations	I
,	O
readmissions	I
and	O
mortality	I
,	O
if	O
data	O
is	O
available	O
.	O

We	O
will	O
identify	O
the	O
common	O
elements	O
of	O
successful	O
and	O
failing	O
interventions	O
,	O
and	O
examine	O
the	O
context	O
in	O
which	O
they	O
were	O
applied	O
,	O
using	O
the	O
Process	O
Redesign	O
contextual	O
framework	O
.	O

We	O
will	O
synthesise	O
the	O
results	O
narratively	O
and	O
,	O
if	O
appropriate	O
,	O
will	O
pool	O
results	O
for	O
meta-analysis	I
.	O

Discussion	O
and	O
dissemination	O
In	O
this	O
review	O
,	O
we	O
will	O
assess	O
the	O
impact	O
of	O
implementation	O
strategies	O
and	O
contextual	O
factors	O
on	O
physician	I
adherence	O
to	O
HF	I
CPGs	O
.	O

We	O
will	O
explore	O
why	O
some	O
interventions	O
may	O
succeed	O
in	O
one	O
setting	O
and	O
fail	O
in	O
another	O
.	O

We	O
will	O
disseminate	O
our	O
findings	O
through	O
briefing	O
reports	O
,	O
publications	O
and	O
presentations	O
.	O

Do	O
outcomes	I
for	O
patients	I
with	O
heart	I
failure	I
vary	O
by	O
emergency	I
department	I
volume	O
?	O

Background—Heart	I
failure	I
is	O
a	O
common	O
Emergency	I
Department	I
(	O
ED	I
)	O
presentation	O
but	O
whether	O
ED	I
volume	O
influences	O
patient	I
outcomes	I
is	O
unknown	O
.	O

Methods	O
and	O
Results—Retrospective	I
cohort	I
of	O
all	O
adults	O
presenting	O
to	O
93	O
EDs	I
between	O
1999	O
and	O
2009	O
with	O
a	O
most	O
responsible	O
diagnosis	I
of	O
heart	I
failure	I
(	O
n=44	O
925	O
ED	I
visits	O
;	O
mean	O
age	O
,	O
76.4	O
years	O
)	O
.	O

Cases	O
seen	O
in	O
low-volume	O
EDs	I
had	O
less	O
comorbidities	I
and	O
were	O
less	O
likely	O
to	O
be	O
hospitalized	I
(	O
54.5	O
%	O
)	O
than	O
those	O
seen	O
in	O
medium	O
(	O
61.8	O
%	O
;	O
adjusted	I
odds	I
ratio	I
[	O
aOR	I
]	O
1.16	O
,	O
[	O
95	O
%	O
confidence	I
interval	I
{	O
CI	I
}	O
1.10–1.23	O
]	O
)	O
or	O
high-volume	O
EDs	I
(	O
73.6	O
%	O
;	O
aOR	I
,	O
1.95	O
[	O
95	O
%	O
CI	I
,	O
1.83–2.07	O
]	O
)	O
.	O

Of	O
patients	I
treated	O
and	O
released	O
,	O
low-volume	O
ED	I
cases	O
exhibited	O
higher	O
risk	O
of	O
death	I
/	O
hospitalization	I
/	O
ED	I
visit	O
in	O
the	O
subsequent	O
7	O
(	O
22.0	O
%	O
)	O
and	O
30	O
days	O
(	O
44.9	O
%	O
)	O
than	O
medium	O
(	O
16.3	O
%	O
;	O
aOR	I
,	O
0.81	O
[	O
95	O
%	O
CI	I
,	O
0.73–0.90	O
]	O
,	O
and	O
35.3	O
%	O
;	O
aOR	I
,	O
0.79	O
[	O
95	O
%	O
CI	I
,	O
0.73–0.86	O
]	O
)	O
or	O
high-volume	O
ED	I
cases	O
(	O
13.0	O
%	O
;	O
aOR	I
,	O
0.69	O
[	O
95	O
%	O
CI	I
,	O
0.61–0.78	O
]	O
,	O
and	O
30.2	O
%	O
;	O
aOR	I
,	O
0.67	O
[	O
95	O
%	O
CI	I
,	O
0.61–0.74	O
]	O
)	O
.	O

Of	O
patients	I
hospitalized	I
at	O
the	O
time	O
of	O
their	O
index	O
ED	I
visit	O
,	O
low-volume	O
ED	I
cases	O
exhibited	O
a	O
higher	O
risk	O
of	O
30-day	O
death	I
/	O
all-cause	I
readmission	I
(	O
24.3	O
%	O
)	O
than	O
those	O
seen	O
in	O
medium	O
(	O
21.9	O
%	O
;	O
aOR	I
,	O
0.83	O
[	O
95	O
%	O
CI	I
,	O
0.76–0.91	O
]	O
)	O
or	O
high-volume	O
EDs	I
(	O
18.1	O
%	O
;	O
aOR	I
,	O
0.77	O
[	O
95	O
%	O
CI	I
,	O
0.70–0.85	O
]	O
)	O
.	O

Conclusions—Low-volume	O
EDs	I
were	O
more	O
likely	O
to	O
discharge	I
patients	I
with	O
heart	I
failure	I
home	O
,	O
but	O
low-volume	O
ED	I
cases	O
exhibited	O
worse	O
outcomes	I
(	O
driven	O
largely	O
by	O
readmissions	I
or	O
repeat	O
ED	I
visits	O
)	O
.	O

Interventions	O
to	O
improve	O
management	O
of	O
acute	I
heart	I
failure	I
are	O
required	O
at	O
low-volume	O
sites	O
.	O

Heart	I
failure	I
with	I
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
.	O

Half	O
of	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
have	O
a	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
.	O

Morbidity	I
and	O
mortality	I
in	O
HFpEF	I
are	O
similar	O
to	O
values	O
observed	O
in	O
patients	I
with	O
HF	I
and	O
reduced	I
EF	I
,	O
yet	O
no	O
effective	O
treatment	O
has	O
been	O
identified	O
.	O

While	O
early	O
research	O
focused	O
on	O
the	O
importance	O
of	O
diastolic	I
dysfunction	I
in	O
the	O
pathophysiology	I
of	O
HFpEF	I
,	O
recent	O
studies	O
have	O
revealed	O
that	O
multiple	O
non-diastolic	I
abnormalities	O
in	O
cardiovascular	I
function	I
also	O
contribute	O
.	O

Diagnosis	I
of	O
HFpEF	I
is	O
frequently	O
challenging	O
and	O
relies	O
upon	O
careful	O
clinical	I
evaluation	O
,	O
echo-Doppler	I
cardiography	I
,	O
and	O
invasive	I
haemodynamic	I
assessment	I
.	O

In	O
this	O
review	O
,	O
the	O
principal	O
mechanisms	O
,	O
diagnostic	I
approaches	O
,	O
and	O
clinical	I
trials	O
are	O
reviewed	O
,	O
along	O
with	O
a	O
discussion	O
of	O
novel	O
treatment	O
strategies	O
that	O
are	O
currently	O
under	O
investigation	O
or	O
hold	O
promise	O
for	O
the	O
future	O
.	O

Tools	O
for	O
Economic	O
Analysis	O
of	O
Patient	I
Management	O
Interventions	O
in	O
Heart	I
Failure	I
Cost-Effectiveness	O
Model	O
:	O
A	O
Web-based	O
program	O
designed	O
to	O
evaluate	O
the	O
cost-effectiveness	O
of	O
disease	I
management	O
programs	O
in	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Heart	I
failure	I
disease	I
management	O
programs	O
can	O
influence	O
medical	I
resource	O
use	O
and	O
quality-adjusted	O
survival	O
.	O

Because	O
projecting	O
long-term	O
costs	O
and	O
survival	O
is	O
challenging	O
,	O
a	O
consistent	O
and	O
valid	O
approach	O
to	O
extrapolating	O
short-term	O
outcomes	I
would	O
be	O
valuable	O
.	O

METHODS	O
:	O

We	O
developed	O
the	O
Tools	O
for	O
Economic	O
Analysis	O
of	O
Patient	I
Management	O
Interventions	O
in	O
Heart	I
Failure	I
Cost-Effectiveness	O
Model	O
,	O
a	O
Web-based	O
simulation	O
tool	O
designed	O
to	O
integrate	O
data	O
on	O
demographic	O
,	O
clinical	I
,	O
and	O
laboratory	O
characteristics	O
;	O
use	O
of	O
evidence-based	I
medications	I
;	O
and	O
costs	O
to	O
generate	O
predicted	O
outcomes	I
.	O

Survival	O
projections	O
are	O
based	O
on	O
a	O
modified	O
Seattle	O
Heart	I
Failure	I
Model	O
.	O

Projections	O
of	O
resource	O
use	O
and	O
quality	I
of	I
life	I
are	O
modeled	O
using	O
relationships	O
with	O
time-varying	O
Seattle	O
Heart	I
Failure	I
Model	O
scores	O
.	O

The	O
model	O
can	O
be	O
used	O
to	O
evaluate	O
parallel-group	O
and	O
single-cohort	I
study	I
designs	O
and	O
hypothetical	O
programs	O
.	O

Simulations	O
consist	O
of	O
10,000	O
pairs	O
of	O
virtual	O
cohorts	O
used	O
to	O
generate	O
estimates	O
of	O
resource	O
use	O
,	O
costs	O
,	O
survival	O
,	O
and	O
incremental	O
cost-effectiveness	O
ratios	O
from	O
user	O
inputs	O
.	O

RESULTS	O
:	O

The	O
model	O
demonstrated	O
acceptable	O
internal	O
and	O
external	O
validity	O
in	O
replicating	O
resource	O
use	O
,	O
costs	O
,	O
and	O
survival	O
estimates	O
from	O
3	O
clinical	I
trials	O
.	O

Simulations	O
to	O
evaluate	O
the	O
cost-effectiveness	O
of	O
heart	I
failure	I
disease	I
management	O
programs	O
across	O
3	O
scenarios	O
demonstrate	O
how	O
the	O
model	O
can	O
be	O
used	O
to	O
design	O
a	O
program	O
in	O
which	O
short-term	O
improvements	O
in	O
functioning	O
and	O
use	O
of	O
evidence-based	I
treatments	O
are	O
sufficient	O
to	O
demonstrate	O
good	O
long-term	O
value	O
to	O
the	O
health	I
care	I
system	O
.	O

CONCLUSION	O
:	O

The	O
Tools	O
for	O
Economic	O
Analysis	O
of	O
Patient	I
Management	O
Interventions	O
in	O
Heart	I
Failure	I
Cost-Effectiveness	O
Model	O
provides	O
researchers	O
and	O
providers	O
with	O
a	O
tool	O
for	O
conducting	O
long-term	O
cost-effectiveness	O
analyses	O
of	O
disease	I
management	O
programs	O
in	O
heart	I
failure	I
.	O

Nursing-sensitive	I
outcome	I
change	O
scores	O
for	O
hospitalized	I
older	O
adults	O
with	O
heart	I
failure	I
:	O
a	O
preliminary	O
descriptive	O
study	O
.	O

Nursing	I
has	O
a	O
social	O
mandate	O
to	O
ensure	O
effective	O
practice	O
within	O
its	O
domain	O
and	O
to	O
be	O
accountable	O
for	O
the	O
outcomes	I
of	O
nursing	I
care	O
.	O

Using	O
standardized	O
nursing	I
terminologies	O
makes	O
it	O
possible	O
to	O
measure	O
aspects	O
of	O
nursing	I
care	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
significant	I
difference	O
in	O
outcome	I
ratings	O
exists	O
from	O
admission	I
to	O
discharge	I
for	O
hospitalized	I
older	O
adults	O
with	O
heart	I
failure	I
(	O
HF	I
)	O
using	O
Nursing	I
Outcomes	I
Classification	O
(	O
NOC	O
)	O
.	O

A	O
retrospective	O
descriptive	O
research	O
design	O
was	O
used	O
.	O

Data	O
were	O
obtained	O
from	O
268	O
inpatient	I
records	O
of	O
patients	I
discharged	I
with	O
HF	I
during	O
a	O
1-year	O
period	O
.	O

All	O
top	O
10	O
NOC	O
outcomes	I
demonstrated	O
statistically	O
significant	I
improvement	O
in	O
outcome	I
ratings	O
from	O
admission	I
to	O
discharge	I
.	O

Findings	O
from	O
this	O
study	O
provide	O
insight	O
on	O
the	O
possible	O
contribution	O
of	O
nursing	I
to	O
outcomes	I
of	O
hospitalized	I
older	O
adults	O
with	O
HF	I
.	O

Validating	O
and	O
incorporating	O
nursing-sensitive	I
outcome	I
measures	O
in	O
future	O
prospective	I
experimental	O
research	O
can	O
contribute	O
to	O
the	O
advancement	O
of	O
science	O
regarding	O
effective	O
treatment	O
of	O
older	O
adults	O
hospitalized	I
with	O
HF	I
,	O
while	O
highlighting	O
the	O
contribution	O
of	O
nursing	I
care	O
to	O
outcomes	I
.	O

Psoriasis	I
is	O
not	O
associated	O
with	O
atherosclerosis	I
and	O
incident	O
cardiovascular	I
events	I
:	O
the	O
Rotterdam	O
Study	O
.	O

Psoriasis	I
has	O
been	O
suggested	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
cardiovascular	I
disease	I
(	O
CVD	I
)	O
;	O
however	O
,	O
available	O
studies	O
have	O
shown	O
inconsistent	O
results	O
.	O

In	O
this	O
study	O
,	O
embedded	O
within	O
the	O
population-based	O
Rotterdam	O
Study	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
psoriasis	I
and	O
cardiovascular	I
outcomes	I
.	O

Adjusted	O
means	O
were	O
calculated	O
for	O
subclinical	I
atherosclerosis	I
using	O
general	O
linear	I
models	I
.	O

Using	O
Cox	I
regression	I
,	O
the	O
hazards	O
of	O
cardiovascular	I
events	I
for	O
psoriasis	I
,	O
as	O
a	O
time-dependent	O
variable	O
,	O
were	O
calculated	O
.	O

A	O
total	O
of	O
262	O
psoriasis	I
(	O
24	O
%	O
systemic	I
/	O
UV	O
treatment	O
)	O
and	O
8,009	O
reference	O
subjects	O
were	O
followed	I
up	I
for	O
a	O
mean	O
of	O
11	O
years	O
.	O

Psoriasis	I
patients	I
were	O
significantly	I
younger	O
,	O
smoked	O
more	O
,	O
and	O
had	O
higher	O
diastolic	I
blood	I
pressure	I
and	O
body	I
mass	I
index	I
levels	O
.	O

The	O
adjusted	O
carotid	I
intima-media	I
thickness	I
was	O
1.02±0.18	O
mm	O
for	O
psoriasis	I
and	O
1.02±0.16	O
mm	O
for	O
reference	O
subjects	O
.	O

Similarly	O
,	O
crude	O
and	O
adjusted	O
ankle-brachial	I
index	I
,	O
pulse-wave	I
velocity	O
,	O
and	O
coronary	I
artery	I
calcium	I
scores	I
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

The	O
risk	O
of	O
incident	O
CVD	I
was	O
not	O
increased	O
in	O
psoriasis	I
(	O
adjusted	O
hazard	I
ratio	I
0.73	O
,	O
95	O
%	O
confidence	I
interval	I
0.50	O
-	O
1.06	O
)	O
.	O

The	O
results	O
were	O
similar	O
when	O
coronary	I
heart	I
disease	I
,	O
stroke	I
,	O
and	O
heart	I
failure	I
were	O
analyzed	O
separately	O
.	O

Psoriasis	I
patients	I
with	O
predominantly	O
mild	O
disease	I
from	O
the	O
general	O
population	O
are	O
as	O
likely	O
to	O
develop	O
atherosclerosis	I
and	O
cardiovascular	I
events	I
as	O
subjects	O
without	O
psoriasis	I
.	O

Baseline	I
and	O
6-Week	O
follow-up	I
levels	O
of	O
PAF	I
and	O
activity	O
of	O
its	O
metabolic	I
enzymes	I
in	O
patients	I
with	O
heart	I
failure	I
and	O
healthy	I
volunteers--a	O
pilot	O
study	O
.	O

This	O
study	O
aimed	O
at	O
evaluating	O
the	O
changes	O
in	O
platelet-activating	I
factor	I
(	O
PAF	I
)	O
and	O
its	O
metabolic	I
enzymes	I
over	O
a	O
6-week	O
follow-up	I
period	O
in	O
patients	I
with	O
newly	O
diagnosed	I
heart	I
failure	I
(	O
[	O
HF	I
]	O
n	O
=	O
12	O
)	O
compared	O
with	O
age-	O
,	O
sex-	O
,	O
and	O
BMI-matched	I
apparently	O
healthy	I
volunteers	O
(	O
n	O
=	O
10	O
)	O
.	O

The	O
PAF	I
,	O
its	O
key	O
biosynthetic	I
enzymes	I
(	O
lyso-PAF	I
acetyltransferase	I
[	O
lyso-PAF-AT	I
]	O
and	O
dithiothreitol	I
[	O
DTT]-insensitive	I
CDP	I
choline	I
:	O
1-alkyl-2-acetyl-sn-glycerol	I
cholinephosphotransferase	I
[	O
PAF-CPT	I
]	O
)	O
,	O
and	O
its	O
catabolic	I
isoenzymes	I
(	O
PAF-acetylhydrolase	I
[	O
PAF-AH	I
]	O
and	O
lipoprotein-associated	I
phospholipase	I
A2	I
[	O
Lp-PLA2	I
]	O
)	O
were	O
measured	O
in	O
serum	O
and	O
leukocytes	I
of	O
participants	O
.	O

At	O
baseline	I
,	O
patients	I
with	O
HF	I
had	O
lower	O
median	O
activities	O
of	O
lyso-PAF-AT	I
(	O
P	I
<	O
.001	O
)	O
and	O
PAF-CPT	I
(	O
P	I
=	O
.07	O
)	O
in	O
parallel	O
with	O
PAF	I
levels	O
(	O
P	I
=	O
.05	O
)	O
and	O
higher	O
activities	O
of	O
PAF-AH	I
(	O
P	I
=	O
.02	O
)	O
and	O
Lp-PLA2	I
(	O
P	I
<	O
.001	O
)	O
than	O
controls	O
.	O

At	O
follow-up	I
,	O
PAF-CPT	I
and	O
PAF	I
levels	O
marginally	O
increased	O
(	O
P	I
=	O
.1	O
)	O
,	O
lyso-PAF-AT	I
(	O
P	I
<	O
.001	O
)	O
remained	O
downregulated	I
,	O
while	O
PAF-AH	I
(	O
P	I
=	O
.004	O
)	O
and	O
Lp-PLA2	I
(	O
P	I
<	O
.001	O
)	O
remained	O
elevated	O
compared	O
with	O
the	O
controls	O
.	O

Newly	O
diagnosed	I
patients	I
with	O
HF	I
under	O
drug	I
treatment	I
have	O
an	O
affected	O
profile	O
of	O
PAF	I
biosynthetic	I
enzymes	I
and	O
especially	O
lyso-PAF-AT	I
.	O

Cardiac	I
insulin-resistance	I
and	O
decreased	O
mitochondrial	I
energy	I
production	I
precede	O
the	O
development	O
of	O
systolic	I
heart	I
failure	I
after	O
pressure-overload	I
hypertrophy	I
.	O

BACKGROUND	O
:	O

Cardiac	I
hypertrophy	I
is	O
accompanied	O
by	O
significant	O
alterations	O
in	O
energy	I
metabolism	I
.	O

Whether	O
these	O
changes	O
in	O
energy	I
metabolism	I
precede	O
and	O
contribute	O
to	O
the	O
development	O
of	O
heart	I
failure	I
in	O
the	O
hypertrophied	I
heart	I
is	O
not	O
clear	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Mice	O
were	O
subjected	O
to	O
cardiac	I
hypertrophy	I
secondary	O
to	O
pressure-overload	I
as	O
a	O
result	O
of	O
an	O
abdominal	I
aortic	I
constriction	I
(	O
AAC	I
)	O
.	O

The	O
rates	O
of	O
energy	I
substrate	I
metabolism	I
were	O
assessed	O
in	O
isolated	O
working	O
hearts	I
obtained	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
after	O
AAC	I
.	O

Mice	O
subjected	O
to	O
AAC	I
demonstrated	O
a	O
progressive	O
development	O
of	O
cardiac	I
hypertrophy	I
.	O

In	I
vivo	I
assessment	O
of	O
cardiac	I
function	I
(	O
via	O
echocardiography	I
)	O
demonstrated	O
diastolic	I
dysfunction	I
by	O
2	O
weeks	O
(	O
20	O
%	O
increase	O
in	O
E	I
/	I
E	I
'	I
)	O
,	O
and	O
systolic	I
dysfunction	I
by	O
3	O
weeks	O
(	O
16	O
%	O
decrease	O
in	O
%	O
ejection	I
fraction	I
)	O
.	O

Marked	O
cardiac	I
insulin-resistance	I
by	O
2	O
weeks	O
post-AAC	I
was	O
evidenced	O
by	O
a	O
significant	I
decrease	O
in	O
insulin-stimulated	I
rates	O
of	O
glycolysis	I
and	O
glucose	I
oxidation	I
,	O
and	O
plasma	I
membrane	I
translocation	I
of	O
glucose	I
transporter	O
4	O
.	O

Overall	O
ATP	I
production	O
rates	O
were	O
decreased	O
at	O
2	O
and	O
3	O
weeks	O
post-AAC	I
(	O
by	O
37	O
%	O
and	O
47	O
%	O
,	O
respectively	O
)	O
because	O
of	O
a	O
reduction	O
in	O
mitochondrial	I
oxidation	I
of	O
glucose	I
,	O
lactate	I
,	O
and	O
fatty	I
acids	I
that	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
in	O
myocardial	I
glycolysis	I
rates	O
.	O

Reduced	O
mitochondrial	I
complex	I
V	I
activity	I
was	O
evident	O
at	O
3	O
weeks	O
post-AAC	I
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
ratio	O
of	O
phosphocreatine	I
to	O
ATP	I
.	O

CONCLUSIONS	O
:	O

The	O
development	O
of	O
cardiac	I
insulin-resistance	I
and	O
decreased	O
mitochondrial	I
oxidative	I
metabolism	I
are	O
early	O
metabolic	I
changes	O
in	O
the	O
development	O
of	O
cardiac	I
hypertrophy	I
,	O
which	O
create	O
an	O
energy	O
deficit	O
that	O
may	O
contribute	O
to	O
the	O
progression	O
from	O
hypertrophy	I
to	O
heart	I
failure	I
.	O

Surgical	I
correction	O
of	O
aortic	I
valve	I
insufficiency	I
after	O
left	I
ventricular	I
assist	I
device	I
implantation	I
.	O

OBJECTIVES	O
:	O

New-onset	O
aortic	I
insufficiency	I
(	O
AI	I
)	O
can	O
be	O
encountered	O
after	O
instituting	O
mechanical	I
circulatory	I
support	I
and	O
seems	O
more	O
common	O
and	O
severe	O
with	O
continuous	I
flow	I
(	O
CF	I
)	O
left	I
ventricular	I
assist	I
devices	I
(	O
LVADs	I
)	O
compared	O
with	O
pulsatile	I
devices	I
.	O

Treatment	O
algorithms	O
for	O
de	O
novo	O
,	O
post-LVAD	I
AI	I
have	O
not	O
been	O
well	O
defined	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
have	O
described	O
6	O
patients	I
who	O
underwent	O
aortic	I
valve	I
surgery	I
for	O
new-onset	O
post-LVAD	I
AI	I
.	O

METHODS	O
:	O

From	O
2005	O
to	O
2011	O
,	O
271	O
patients	I
underwent	O
LVAD	I
implantation	I
.	O

Of	O
these	O
LVADs	I
,	O
225	O
were	O
CF	I
devices	O
(	O
203	O
HeartMate	O
II	O
devices	O
,	O
Thoratec	O
Corp	O
,	O
Pleasanton	O
,	O
Calif	O
;	O
and	O
22	O
HVAD	O
devices	O
,	O
HeartWare	O
Intl	O
,	O
Inc	O
,	O
Framingham	O
,	O
Mass	O
)	O
.	O

The	O
patients	I
were	O
examined	O
for	O
new-onset	O
severe	O
AI	I
requiring	O
surgical	I
intervention	O
.	O

RESULTS	O
:	O

During	O
follow-up	I
,	O
6	O
CF	I
LVAD	I
patients	I
developed	O
new	O
,	O
severe	O
AI	I
that	O
was	O
accompanied	O
by	O
heart	I
failure	I
.	O

After	O
medical	I
therapy	I
had	O
failed	O
,	O
4	O
patients	I
underwent	O
redo	I
sternotomy	I
for	O
aortic	I
valve	I
procedures	O
(	O
1	O
bioprosthetic	I
valve	I
replacement	I
,	O
1	O
Dacron	I
patch	I
closure	I
,	O
and	O
2	O
aortic	I
valve	I
repairs	O
)	O
,	O
and	O
2	O
patients	I
underwent	O
transcatheter	I
aortic	I
valve	I
procedure	I
,	O
with	O
1	O
requiring	O
revision	O
by	O
open	O
surgery	I
for	O
aortic	I
valve	I
replacement	O
.	O

Of	O
the	O
6	O
patients	I
,	O
5	O
experienced	O
significant	I
improvement	O
in	O
functional	I
capacity	I
and	O
symptoms	I
.	O

One	O
patient	I
died	O
postoperatively	I
secondary	O
to	O
multiorgan	I
failure	I
and	O
sepsis	I
.	O

CONCLUSIONS	O
:	O

Surgical	I
treatment	O
of	O
post-LVAD	I
AI	I
with	O
aortic	I
valve	I
oversewing	O
or	O
leaflet	I
repair	O
or	O
by	O
bioprosthetic	I
aortic	I
valve	I
replacement	I
is	O
effective	O
at	O
restoring	O
functional	I
capacity	I
for	O
CF	I
LVAD	I
patients	I
who	O
develop	O
symptomatic	I
,	O
severe	O
AI	I
and	O
can	O
be	O
performed	O
safely	O
with	O
good	O
results	O
.	O

Various	O
transcatheter	I
approaches	O
to	O
these	O
difficult	O
problems	O
are	O
also	O
available	O
and	O
offer	O
less	O
invasive	I
alternatives	O
to	O
conventional	O
surgery	I
.	O

Human	O
heart	I
failure	I
is	O
accompanied	O
by	O
altered	O
protein	I
kinase	I
A	I
subunit	O
expression	I
and	O
post-translational	O
state	O
.	O

β-Adrenergic	I
receptor	I
blockade	I
reduces	O
total	O
mortality	I
and	O
all-cause	I
hospitalizations	I
in	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

Nonetheless	O
,	O
β-blockade	I
does	O
not	O
halt	O
disease	I
progression	O
,	O
suggesting	O
that	O
cAMP-dependent	I
protein	I
kinase	I
(	O
PKA	I
)	O
signaling	O
downstream	O
of	O
β-adrenergic	I
receptor	I
activation	O
may	O
persist	O
through	O
unique	O
post-translational	O
states	O
.	O

In	O
this	O
study	O
,	O
human	O
myocardial	I
tissue	I
was	O
used	O
to	O
examine	O
the	O
state	O
of	O
PKA	I
subunits	O
.	O

As	O
expected	O
,	O
total	O
myosin	I
binding	O
protein-C	I
phosphorylation	I
and	O
Ser23	O
/	O
24	O
troponin	I
I	I
phosphorylation	I
significantly	I
decreased	O
in	O
HF	I
.	O

Examination	O
of	O
PKA	I
subunits	O
demonstrated	O
no	O
change	O
in	O
type	I
II	I
regulatory	I
(	O
RIIα	I
)	O
or	O
catalytic	I
(	O
Cα	I
)	O
subunit	I
expression	I
,	O
although	O
site	O
specific	O
RIIα	I
(	O
Ser96	I
)	O
and	O
Cα	I
(	O
Thr197	I
)	O
phosphorylation	I
were	O
increased	O
in	O
HF	I
.	O

Further	O
,	O
the	O
expression	I
of	O
type	I
I	I
regulatory	I
subunit	I
(	O
RI	I
)	O
was	O
increased	O
in	O
HF	I
.	O

Isoelectric	I
focusing	I
of	O
RIα	I
demonstrated	O
up	O
to	O
three	O
variants	O
,	O
consistent	O
with	O
reports	O
that	O
Ser77	I
and	O
Ser83	I
are	O
in	I
vivo	I
phosphorylation	I
sites	O
.	O

Western	I
blots	I
with	O
site-specific	O
monoclonal	I
antibodies	I
showed	O
increased	O
Ser83	I
phosphorylation	I
in	O
HF	I
.	O

8-fluo-cAMP	I
binding	O
by	O
wild	O
type	O
and	O
phosphomimic	I
Ser77	I
and	O
Ser83	I
mutant	O
RIα	I
proteins	I
demonstrated	O
reduced	O
Kd	O
for	O
the	O
double	O
mutant	O
as	O
compared	O
to	O
WT	O
RIα	I
.	O

Therefore	O
,	O
failing	O
myocardium	I
displays	O
altered	O
expression	I
and	O
post-translational	O
modification	O
of	O
PKA	I
subunits	O
that	O
may	O
impact	O
downstream	I
signaling	I
.	O

Nutrition	O
in	O
heart	I
failure	I
:	O
an	O
update	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O

Chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
is	O
increasingly	O
recognized	O
as	O
a	O
multisystem	I
disease	I
with	O
important	O
comorbidities	I
such	O
as	O
anemia	I
,	O
insulin	I
resistance	I
,	O
autonomic	I
dysbalance	I
,	O
or	O
cardiac	I
cachexia	I
.	O

RECENT	O
FINDINGS	O
:	O

Apart	O
from	O
these	O
perturbations	O
,	O
increasing	O
evidence	O
points	O
to	O
alterations	O
in	O
intestinal	I
morphology	O
,	O
permeability	O
,	O
and	O
absorption	O
function	O
in	O
patients	I
with	O
CHF	I
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
sonographic	I
,	O
histological	I
,	O
and	O
functional	O
abnormalities	O
of	O
different	O
gastrointestinal	I
regions	O
.	O

This	O
intestinal	I
dysfunction	I
and	O
disturbed	O
intestinal	I
barrier	O
may	O
lead	O
to	O
both	O
the	O
chronic	I
inflammatory	I
state	O
and	O
catabolic	I
/	O
anabolic	I
imbalance	O
as	O
seen	O
in	O
cardiac	I
cachexia	I
,	O
as	O
a	O
terminal	I
stage	O
of	O
CHF	I
,	O
which	O
carries	O
a	O
particularly	O
poor	O
prognosis	I
.	O

This	O
review	O
highlights	O
the	O
current	O
knowledge	O
of	O
nutritional	O
abnormalities	O
that	O
may	O
occur	O
in	O
CHF	I
,	O
including	O
fat	O
,	O
carbohydrates	O
,	O
proteins	I
,	O
water	O
,	O
and	O
micronutrients	O
.	O

The	O
regulation	O
of	O
feeding	O
is	O
discussed	O
,	O
as	O
are	O
nutritional	O
strategies	O
with	O
potentially	O
anti-inflammatory	I
effects	O
in	O
the	O
treatment	O
of	O
CHF	I
.	O

SUMMARY	O
:	O

The	O
gut	I
and	O
its	O
role	O
for	O
inflammation	I
and	O
dietary	O
interventions	O
in	O
heart	I
failure	I
patients	I
are	O
a	O
crucial	O
target	O
of	O
further	O
heart	I
failure	I
research	O
.	O

Circulating	O
fragments	O
of	O
N-terminal	I
pro-B-type	I
natriuretic	I
peptides	I
in	O
plasma	I
of	O
heart	I
failure	I
patients	I
.	O

BACKGROUND	O
:	O

The	O
use	O
of	O
nonstandardized	O
N-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
(	O
NT-proBNP	I
)	O
assays	O
can	O
contribute	O
to	O
the	O
misdiagnosis	I
of	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

Moreover	O
,	O
there	O
is	O
yet	O
to	O
be	O
established	O
a	O
common	O
consensus	O
regarding	O
the	O
circulating	O
forms	O
of	O
NT-proBNP	I
being	O
used	O
in	O
current	O
assays	O
.	O

We	O
aimed	O
to	O
characterize	O
and	O
quantify	O
the	O
various	O
forms	O
of	O
NT-proBNP	I
in	O
the	O
circulation	I
of	O
HF	I
patients	I
.	O

METHODS	O
:	O

Plasma	I
samples	O
were	O
collected	O
from	O
HF	I
patients	I
(	O
n	O
=	O
20	O
)	O
at	O
rest	O
and	O
stored	O
at	O
-	O
80	O
°C	O
.	O

NT-proBNP	I
was	O
enriched	O
from	O
HF	I
patient	I
plasma	I
by	O
use	O
of	O
immunoprecipitation	I
followed	O
by	O
mass	I
spectrometric	I
analysis	I
.	O

Customized	O
homogeneous	O
sandwich	O
AlphaLISA®	O
immunoassays	I
were	O
developed	O
and	O
validated	O
to	O
quantify	O
6	O
fragments	O
of	O
NT-proBNP	I
.	O

RESULTS	O
:	O

Mass	I
spectrometry	I
identified	O
the	O
presence	O
of	O
several	O
N	I
-	O
and	O
C-terminally	I
processed	O
forms	O
of	O
circulating	O
NT-proBNP	I
,	O
with	O
physiological	I
proteolysis	I
between	O
Pro2-Leu3	I
,	O
Leu3-Gly4	I
,	O
Pro6-Gly7	I
,	O
and	O
Pro75-Arg76	I
.	O

Consistent	O
with	O
this	O
result	O
,	O
AlphaLISA	O
immunoassays	I
demonstrated	O
that	O
antibodies	I
targeting	O
the	O
extreme	O
N	I
or	O
C	I
termini	I
measured	O
a	O
low	O
apparent	O
concentration	O
of	O
circulating	O
NT-proBNP	I
.	O

The	O
apparent	O
circulating	O
NT-proBNP	I
concentration	O
was	O
increased	O
with	O
antibodies	I
targeting	O
nonglycosylated	I
and	O
nonterminal	I
epitopes	I
(	O
P	I
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O

In	O
plasma	I
collected	O
from	O
HF	I
patients	I
,	O
immunoreactive	I
NT-proBNP	I
was	O
present	O
as	O
multiple	O
N	I
-	O
and	O
C-terminally	I
truncated	O
fragments	O
of	O
the	O
full	O
length	O
NT-proBNP	I
molecule	O
.	O

Immunodetection	I
of	O
NT-proBNP	I
was	O
significantly	I
improved	O
with	O
the	O
use	O
of	O
antibodies	I
that	O
did	O
not	O
target	O
these	O
terminal	O
regions	O
.	O

These	O
findings	O
support	O
the	O
development	O
of	O
a	O
next	O
generation	O
NT-proBNP	I
assay	O
targeting	O
nonterminal	I
epitopes	I
as	O
well	O
as	O
avoiding	O
the	O
central	I
glycosylated	I
region	I
of	O
this	O
molecule	O
.	O

Acute	I
right	I
heart	I
failure	I
in	O
pulmonary	I
hypertension	I
.	O

The	O
right	I
ventricle	I
(	O
RV	I
)	O
is	O
integral	O
to	O
normal	O
cardiac	I
function	I
,	O
but	O
receives	O
little	O
attention	O
in	O
the	O
medical	I
literature	O
.	O

The	O
etiologic	I
causes	O
of	O
acute	I
RV	I
failure	I
often	O
differ	O
from	O
those	O
encountered	O
in	O
left	I
ventricular	I
dysfunction	I
.	O

Thus	O
,	O
RV	I
failure	I
frequently	O
requires	O
diagnostic	I
procedures	O
and	O
management	O
strategies	O
that	O
differ	O
from	O
those	O
routinely	O
used	O
in	O
the	O
management	O
of	O
intrinsic	O
left	I
ventricular	I
dysfunction	I
.	O

In	O
this	O
summary	O
,	O
the	O
structure	O
and	O
function	O
of	O
the	O
RV	I
will	O
be	O
reviewed	O
,	O
concentrating	O
on	O
the	O
pathophysiologic	I
mechanisms	O
behind	O
the	O
development	O
of	O
RV	I
dysfunction	I
.	O

We	O
will	O
then	O
focus	O
on	O
two	O
distinct	O
populations	O
of	O
patients	I
who	O
are	O
at	O
risk	O
for	O
acute	I
RV	I
failure	I
:	O
those	O
with	O
chronic	I
pulmonary	I
arterial	I
hypertension	I
(	O
PAH	I
)	O
and	O
those	O
with	O
acute	I
pulmonary	I
embolism	I
.	O

In	O
chronic	I
PAH	I
,	O
we	O
will	O
examine	O
clinical	I
circumstances	O
common	O
to	O
hospitalized	I
patients	I
that	O
may	O
provoke	O
acute	I
RV	I
decompensation	I
,	O
as	O
well	O
as	O
pharmacologic	I
therapies	I
that	O
are	O
unique	O
to	O
RV	I
failure	I
management	O
in	O
PAH	I
.	O

Individuals	O
with	O
acute	I
RV	I
failure	I
in	O
the	O
setting	O
of	O
pulmonary	I
embolism	I
represent	O
a	O
group	O
with	O
particularly	O
high	O
mortality	I
,	O
and	O
the	O
specific	O
diagnostic	I
and	O
management	O
strategies	O
that	O
are	O
important	O
for	O
improved	O
survival	O
will	O
be	O
discussed	O
.	O

Impact	O
of	O
heart	I
magnetic	I
resonance	I
imaging	I
on	O
chelation	I
choices	O
,	O
compliance	I
with	O
treatment	O
and	O
risk	O
of	O
heart	I
disease	I
in	O
patients	I
with	O
thalassaemia	I
major	I
.	O

This	O
study	O
aimed	O
to	O
verify	O
the	O
impact	O
of	O
heart	I
magnetic	I
resonance	I
imaging	I
on	O
chelation	I
choices	O
and	O
patient	I
compliance	I
in	O
a	O
single-institution	O
cohort	O
as	O
well	O
as	O
its	O
predictive	O
value	O
for	O
heart	I
failure	I
and	O
arrhythmias	I
.	O

Abnormal	O
cardiac	I
T2	I
*	I
values	O
determined	O
changes	O
in	O
treatment	O
in	O
most	O
subjects	O
.	O

Heart	I
T2	I
*	I
was	O
confirmed	O
to	O
be	O
highly	O
predictive	O
over	O
1	O
year	O
for	O
heart	I
failure	I
and	O
arrhythmias	I
.	O

The	O
choice	O
of	O
chelation	I
regimens	O
known	O
to	O
remove	O
heart	I
iron	I
efficiently	O
was	O
not	O
sufficient	O
by	O
itself	O
to	O
influence	O
the	O
risk	O
.	O

Compliance	I
with	O
treatment	O
had	O
a	O
more	O
remarkable	O
role	O
.	O

Heart	I
failure	I
and	O
cognitive	O
impairment	O
:	O
relationships	O
with	O
mortality	I
.	O

We	O
read	O
the	O
article	O
by	O
Dodson	O
et	O
al	O
with	O
interest	O
.	O

The	O
authors	O
evaluated	O
how	O
often	O
the	O
nurse	I
assessment	O
of	O
cognitive	O
impairment	O
at	O
hospitalization	I
was	O
documented	O
by	O
the	O
physician	I
at	O
the	O
time	O
of	O
discharge	I
in	O
a	O
cohort	O
of	O
elderly	O
patients	I
hospitalized	I
for	O
heart	I
failure	I
.	O

Subsequently	O
,	O
the	O
authors	O
analyzed	O
the	O
association	O
of	O
cognitive	O
impairment	O
with	O
6-month	O
mortality	I
or	O
readmission	I
.	O

Cardiac-resynchronization	I
therapy	I
in	O
heart	I
failure	I
with	O
a	O
narrow	I
QRS	I
complex	I
.	O

BACKGROUND	O
:	O

Cardiac-resynchronization	I
therapy	I
(	O
CRT	I
)	O
reduces	O
morbidity	I
and	O
mortality	I
in	O
chronic	I
systolic	I
heart	I
failure	I
with	O
a	O
wide	I
QRS	I
complex	I
.	O

Mechanical	O
dyssynchrony	O
also	O
occurs	O
in	O
patients	I
with	O
a	O
narrow	I
QRS	I
complex	I
,	O
which	O
suggests	O
the	O
potential	O
usefulness	O
of	O
CRT	I
in	O
such	O
patients	I
.	O

METHODS	O
:	O

We	O
conducted	O
a	O
randomized	I
trial	O
involving	O
115	O
centers	O
to	O
evaluate	O
the	O
effect	O
of	O
CRT	I
in	O
patients	I
with	O
New	I
York	I
Heart	I
Association	I
class	I
III	I
or	O
IV	I
heart	I
failure	I
,	O
a	O
left	I
ventricular	I
ejection	I
fraction	I
of	O
35	O
%	O
or	O
less	O
,	O
a	O
QRS	I
duration	I
of	O
less	O
than	O
130	O
msec	O
,	O
and	O
echocardiographic	I
evidence	O
of	O
left	I
ventricular	I
dyssynchrony	I
.	O

All	O
patients	I
underwent	O
device	O
implantation	I
and	O
were	O
randomly	O
assigned	O
to	O
have	O
CRT	I
capability	O
turned	O
on	O
or	O
off	O
.	O

The	O
primary	O
efficacy	O
outcome	I
was	O
the	O
composite	O
of	O
death	I
from	O
any	O
cause	O
or	O
first	O
hospitalization	I
for	O
worsening	O
heart	I
failure	I
.	O

RESULTS	O
:	O

On	O
March	O
13	O
,	O
2013	O
,	O
the	O
study	O
was	O
stopped	O
for	O
futility	O
on	O
the	O
recommendation	O
of	O
the	O
data	O
and	O
safety	O
monitoring	O
board	O
.	O

At	O
study	O
closure	O
,	O
the	O
809	O
patients	I
who	O
had	O
undergone	O
randomization	I
had	O
been	O
followed	O
for	O
a	O
mean	O
of	O
19.4	O
months	O
.	O

The	O
primary	I
outcome	I
occurred	O
in	O
116	O
of	O
404	O
patients	I
in	O
the	O
CRT	I
group	O
,	O
as	O
compared	O
with	O
102	O
of	O
405	O
in	O
the	O
control	O
group	O
(	O
28.7	O
%	O
vs.	O
25.2	O
%	O
;	O
hazard	I
ratio	I
,	O
1.20	O
;	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
,	O
0.92	O
to	O
1.57	O
;	O
P=0.15	I
)	O
.	O

There	O
were	O
45	O
deaths	I
in	O
the	O
CRT	I
group	O
and	O
26	O
in	O
the	O
control	O
group	O
(	O
11.1	O
%	O
vs.	O
6.4	O
%	O
;	O
hazard	I
ratio	I
,	O
1.81	O
;	O
95	O
%	O
CI	I
,	O
1.11	O
to	O
2.93	O
;	O
P=0.02	I
)	O
.	O

CONCLUSIONS	O
:	O

In	O
patients	I
with	O
systolic	I
heart	I
failure	I
and	O
a	O
QRS	I
duration	I
of	O
less	O
than	O
130	O
msec	O
,	O
CRT	I
does	O
not	O
reduce	O
the	O
rate	O
of	O
death	I
or	O
hospitalization	I
for	O
heart	I
failure	I
and	O
may	O
increase	O
mortality	I
.	O

Efficacy	O
,	O
safety	O
,	O
and	O
outcomes	I
of	O
catheter	I
ablation	I
of	O
atrial	I
fibrillation	I
in	O
patients	I
with	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
.	O

OBJECTIVES	O
:	O

This	O
study	O
sought	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
catheter	I
ablation	I
for	O
atrial	I
fibrillation	I
(	O
AF	I
)	O
in	O
patients	I
with	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFPEF	I
)	O
.	O

BACKGROUND	O
:	O

AF	I
is	O
a	O
precipitating	O
factor	O
for	O
clinical	I
deterioration	O
of	O
HFPEF	I
.	O

METHODS	O
:	O

Catheter	I
ablation	I
for	O
AF	I
was	O
performed	O
in	O
a	O
consecutive	O
74	O
patients	I
with	O
compensated	I
HFPEF	I
(	O
left	I
ventricular	I
[	O
LV	I
]	O
ejection	I
fraction	I
>	O
50	O
%	O
)	O
.	O

AF-free	I
probability	O
after	O
catheter	I
ablation	I
and	O
factors	O
relating	O
to	O
maintenance	O
of	O
sinus	I
rhythm	I
were	O
investigated	O
.	O

LV	I
strain	I
and	O
strain	I
rate	I
were	O
assessed	O
by	O
echocardiography	I
at	O
baseline	I
and	O
over	O
12	O
months	O
after	O
ablation	I
.	O

RESULTS	O
:	O

During	O
a	O
34	O
±	O
16-month	O
follow-up	I
period	O
,	O
single	O
-	O
and	O
multiple-procedure	O
drug-free	I
success	O
rates	O
were	O
27	O
%	O
(	O
n	O
=	O
20	O
)	O
and	O
45	O
%	O
(	O
n	O
=	O
33	O
)	O
,	O
respectively	O
.	O

Multiple	O
procedures	O
and	O
pharmaceutically	I
assisted	O
success	O
rate	O
was	O
73	O
%	O
(	O
n	O
=	O
54	O
)	O
.	O

No	O
major	O
complications	I
occurred	O
during	O
follow-up	I
.	O

Multivariate	I
Cox	I
regression	I
analyses	I
revealed	O
that	O
AF	I
type	O
(	O
other	O
than	O
long-standing	O
persistent	O
AF	I
)	O
and	O
lack	O
of	O
hypertension	I
were	O
independently	O
associated	O
with	O
maintenance	O
of	O
sinus	I
rhythm	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
:	O
1.81	O
,	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
:	O
1.03	O
to	O
3.17	O
,	O
p	I
=	O
0.04	O
;	O
HR	I
:	O
0.49	O
,	O
95	O
%	O
CI	I
:	O
0.24	O
to	O
0.96	O
,	O
p	I
=	O
0.04	O
,	O
respectively	O
)	O
.	O

LV	I
systolic	I
indices	O
(	O
LV	I
ejection	I
fraction	I
,	O
LV	I
strain	I
/	O
strain	I
rate	I
at	O
systole	I
)	O
and	O
diastolic	I
indices	O
(	O
E	I
/	I
E	I
'	I
,	O
ratio	O
of	O
LV	I
strain	I
rate	I
at	O
diastole	I
with	O
early	O
transmitral	I
flow	I
)	O
were	O
improved	O
only	O
in	O
patients	I
maintaining	O
sinus	I
rhythm	I
at	O
follow-up	I
.	O

CONCLUSIONS	O
:	O

Our	O
results	O
suggest	O
that	O
AF	I
can	O
be	O
effectively	O
and	O
safely	O
treated	O
with	O
a	O
composite	O
of	O
repeat	O
procedures	O
and	O
pharmaceuticals	I
in	O
patients	I
with	O
HFPEF	I
.	O

However	O
,	O
the	O
current	O
study	O
was	O
a	O
single-arm	O
analysis	O
;	O
therefore	O
,	O
larger	O
randomized	I
control	O
studies	O
are	O
needed	O
to	O
verify	O
the	O
benefit	O
of	O
AF	I
ablation	I
in	O
this	O
cohort	O
.	O

Participating	O
in	O
a	O
multihospital	O
study	O
to	O
promote	O
adoption	O
of	O
heart	I
failure	I
guidelines	O
:	O
lessons	O
for	O
nurse	I
leaders	O
.	O

Many	O
multisite	O
studies	O
in	O
practice	O
settings	O
focus	O
on	O
improving	O
processes	O
of	O
care	O
,	O
adopting	O
evidence-based	I
practices	O
,	O
and	O
improving	O
patient	I
outcomes	I
.	O

While	O
specific	O
research	O
questions	O
may	O
be	O
the	O
focus	O
,	O
it	O
is	O
the	O
implementation	O
issues	O
and	O
strategies	O
that	O
reveal	O
how	O
individuals	O
and	O
organizations	O
are	O
profoundly	O
transformed	O
.	O

Utilizing	O
voluntary	O
testimonies	O
and	O
conversations	O
with	O
participating	O
nurses	I
,	O
the	O
benefits	O
of	O
involvement	O
in	O
a	O
multisite	O
study	O
extend	O
beyond	O
meeting	O
Magnet(®)	O
research	O
requirements	O
.	O

Cardiac	I
amyloidosis	I
,	O
about	O
an	O
atypical	O
case	O
.	O

The	O
described	O
report	O
deals	O
with	O
the	O
case	O
of	O
a	O
patient	I
with	O
diagnosis	I
of	O
ischemic-hypertensive	I
cardiomyiopathy	I
based	O
on	O
the	O
history	O
of	O
angina	I
and	O
inducible	O
myocardial	I
ischemia	I
with	O
normal	O
coronary	I
arteries	I
.	O

However	O
,	O
after	O
cardiac	I
magnetic	I
resonance	I
,	O
the	O
typical	O
amyloidotic	I
pattern	O
is	O
found	O
and	O
the	O
final	O
diagnosis	I
of	O
multiple	I
myeloma	I
is	O
made	O
at	O
osteomedullary	I
biopsy	I
.	O

Management	O
of	O
end	I
stage	I
heart	I
failure	I

Heart	I
failure	I
is	O
a	O
major	O
public	O
health	I
problem	O
,	O
with	O
a	O
patient	I
population	O
of	O
at	O
least	O
10	O
million	O
in	O
Europe	O
and	O
approximately	O
5	O
million	O
in	O
North	O
America	O
.	O

Because	O
of	O
its	O
age-dependent	O
increase	O
in	O
incidence	I
and	O
prevalence	I
,	O
heart	I
failure	I
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	I
and	O
hospitalisation	I
among	O
the	O
elderly	O
.	O

As	O
a	O
consequence	O
of	O
the	O
worldwide	O
increase	O
in	O
life	I
expectancy	I
,	O
and	O
due	O
to	O
improvements	O
in	O
the	O
treatment	O
of	O
heart	I
failure	I
in	O
recent	O
years	O
,	O
the	O
proportion	O
of	O
patients	I
that	O
reach	O
an	O
advanced	O
phase	O
of	O
the	O
disease	I
,	O
so-called	O
end	O
stage	O
,	O
refractory	I
or	O
terminal	I
heart	I
failure	I
,	O
is	O
steadily	O
growing	O
.	O

Patients	I
with	O
end	I
stage	I
heart	I
failure	I
fall	O
into	O
stage	O
D	O
of	O
the	O
ABCD	I
classification	I
of	O
the	O
American	O
College	O
of	O
Cardiology	I
(	O
ACC	O
)	O
/	O
American	O
Heart	I
Association	O
(	O
AHA	O
)	O
,	O
and	O
class	O
III–IV	O
of	O
the	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	O
)	O
functional	O
classification	O
;	O
they	O
are	O
characterised	O
by	O
advanced	O
structural	O
heart	I
disease	I
and	O
pronounced	O
symptoms	I
of	O
heart	I
failure	I
at	O
rest	O
or	O
upon	O
minimal	O
physical	I
exertion	O
,	O
despite	O
maximal	O
medical	I
treatment	I
according	O
to	O
current	O
guidelines	O
.	O

This	O
patient	I
population	O
has	O
a	O
1-year	O
mortality	I
rate	O
of	O
approximately	O
50	O
%	O
and	O
requires	O
special	O
therapeutic	I
interventions	O
.	O

Every	O
attempt	O
should	O
be	O
made	O
to	O
identify	O
and	O
correct	O
reversible	O
causes	O
for	O
a	O
worsening	O
of	O
heart	I
failure	I
,	O
such	O
as	O
poor	O
patient	I
compliance	I
,	O
myocardial	I
ischaemia	I
,	O
tachy	I
-	O
or	O
bradyarrhythmias	I
,	O
valvular	I
regurgitation	I
,	O
pulmonary	I
embolism	I
,	O
infection	I
,	O
or	O
renal	I
dysfunction	I
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
current	O
strategies	O
for	O
the	O
treatment	O
of	O
end	I
stage	I
heart	I
failure	I
.	O

Assessment	O
and	O
prognostic	I
relevance	O
of	O
right	I
ventricular	I
contractile	I
reserve	I
in	O
patients	I
with	O
severe	O
pulmonary	I
hypertension	I
.	O

BACKGROUND	O
:	O

This	O
study	O
sought	O
to	O
analyze	O
a	O
new	O
approach	O
to	O
assess	O
exercise-induced	I
pulmonary	I
artery	I
systolic	I
pressure	I
(	O
PASP	I
)	O
increase	O
by	O
means	O
of	O
stress	I
Doppler	I
echocardiography	I
as	O
a	O
possible	O
measure	O
of	O
right	I
ventricular	I
contractile	I
reserve	I
in	O
patients	I
with	O
severe	O
pulmonary	I
hypertension	I
and	O
right	I
heart	I
failure	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

In	O
this	O
prospective	I
study	I
,	O
patients	I
with	O
invasively	I
diagnosed	I
pulmonary	I
arterial	I
hypertension	I
or	O
inoperable	I
chronic	I
thromboembolic	I
pulmonary	I
hypertension	I
and	O
impaired	O
right	I
ventricular	I
pump	O
function	O
despite	O
a	O
stable	I
targeted	O
pulmonary	I
arterial	I
hypertension	I
medication	I
underwent	O
a	O
broad	O
panel	O
of	O
noninvasive	I
assessments	O
,	O
including	O
stress	I
echocardiography	I
and	O
cardiopulmonary	I
exercise	I
testing	I
.	O

On	O
the	O
basis	O
of	O
the	O
assumption	O
that	O
exercise-induced	I
PASP	I
is	O
a	O
measure	O
of	O
right	I
ventricular	I
contractile	I
reserve	I
,	O
patients	I
were	O
classified	O
into	O
2	O
groups	O
according	O
to	O
an	O
exercise-induced	I
PASP	I
increase	O
above	O
or	O
below	O
the	O
median	O
.	O

Patients	I
were	O
followed	I
up	I
for	O
3.0	O
±	O
1.8	O
years	O
.	O

Univariate	I
and	O
multivariate	I
analyses	I
were	O
used	O
for	O
factors	O
predicting	O
survival	O
.	O

Of	O
124	O
patients	I
,	O
66	O
were	O
below	O
the	O
median	O
exercise-induced	I
PASP	I
increase	O
of	O
30	O
mm	O
Hg	O
(	O
low	O
PASP	I
)	O
,	O
and	O
58	O
patients	I
were	O
above	O
the	O
median	O
(	O
high	O
PASP	I
)	O
.	O

These	O
groups	O
were	O
not	O
significantly	I
different	O
in	O
terms	O
of	O
medication	I
and	O
resting	I
hemodynamics	I
.	O

Low	O
PASP	I
was	O
associated	O
with	O
a	O
significantly	I
lower	O
6-minute	I
walking	I
distance	I
,	O
peak	I
o2	I
per	O
kilogram	O
,	O
and	O
1-	O
,	O
3-	O
,	O
and	O
4-year	O
survival	O
rates	O
(	O
92	O
%	O
,	O
69	O
%	O
,	O
and	O
48	O
%	O
,	O
respectively	O
,	O
versus	O
96	O
%	O
,	O
92	O
%	O
,	O
and	O
89	O
%	O
)	O
.	O

In	O
the	O
multivariate	I
Cox	I
model	I
analysis	O
adjusted	O
for	O
age	O
and	O
sex	O
,	O
PASP	I
increase	O
during	O
exercise	O
and	O
peak	I
o2	I
per	O
kilogram	O
remained	O
independent	O
prognostic	I
markers	O
(	O
hazard	I
ratio	I
,	O
2.56	O
for	O
peak	I
o2	I
per	O
kilogram	O
and	O
2.84	O
for	O
PASP	I
increase	O
)	O
.	O

CONCLUSIONS	O
:	O

Exercise-induced	I
PASP	I
increase	O
is	O
of	O
high	O
clinical	I
and	O
prognostic	I
relevance	O
in	O
pulmonary	I
hypertension	I
patients	I
and	O
may	O
indicate	O
right	I
ventricular	I
contractile	I
reserve	I
.	O

Stress	I
Doppler	I
echocardiography	I
may	O
be	O
a	O
useful	O
tool	O
for	O
prognostic	I
assessment	O
in	O
pulmonary	I
hypertension	I
patients	I
.	O

Incidence	I
and	O
predictors	O
of	O
end-stage	I
renal	I
disease	I
in	O
outpatients	I
with	O
systolic	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Renal	I
dysfunction	I
is	O
an	O
important	O
prognostic	I
factor	O
in	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
but	O
whether	O
this	O
dysfunction	I
progresses	O
to	O
end-stage	I
renal	I
disease	I
(	O
ESRD	I
)	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
examined	O
incidence	I
and	O
predictors	O
of	O
ESRD	I
in	O
outpatients	I
with	O
HF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Patients	I
with	O
systolic	I
HF	I
were	O
identified	O
in	O
The	O
Danish	O
Heart	I
Failure	I
database	O
and	O
new-onset	O
ESRD	I
from	O
the	O
Danish	O
Registry	O
on	O
Dialysis	I
.	O

Renal	I
function	I
was	O
estimated	O
by	O
The	O
Chronic	I
Kidney	I
Disease	I
Epidemiology	I
Collaboration	O
equation	O
and	O
patients	I
grouped	O
by	O
estimated	I
glomerular	I
filtration	I
rate	I
(eGFR)-group	I
I	O
:	O
≥60	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
group	O
II	O
:	O
30	O
to	O
59	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
group	O
III	O
:	O
15	O
to	O
29	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
group	O
IV	O
:	O
<	O
15	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
.	O

Cox	I
hazard	I
models	I
for	O
time	O
to	O
ESRD	I
,	O
to	O
death	I
,	O
and	O
the	O
composite	I
end	I
point	I
of	O
ESRD	I
or	O
death	I
were	O
constructed	O
and	O
predictors	O
of	O
ESRD	I
identified	O
.	O

A	O
total	O
of	O
8204	O
patients	I
were	O
included	O
in	O
the	O
analyses	O
.	O

Median	O
age	O
was	O
70	O
years	O
(	O
Q	O
,	O
61	O
-	O
77	O
)	O
,	O
28	O
%	O
were	O
women	O
,	O
median	O
left	I
ventricular	I
ejection	I
fraction	I
was	O
30	O
%	O
(	O
Q	O
,	O
24	O
-	O
40	O
)	O
,	O
and	O
median	O
eGFR	I
was	O
68	O
(	O
Q	O
,	O
51	O
-	O
85	O
)	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
.	O

Forty-one	O
patients	I
developed	O
ESRD	I
(	O
1.3	O
/	O
1000	O
patient-years	I
)	O
.	O

Baseline	I
eGFR	I
group	O
II	O
(	O
P	I
<	O
0.001	O
)	O
,	O
eGFR	I
group	O
III	O
(	O
P	I
<	O
0.001	O
)	O
,	O
eGFR	I
group	O
IV	O
(	O
P	I
<	O
0.001	O
)	O
,	O
uncontrolled	O
hypertension	I
(	O
P=0.049	I
)	O
,	O
need	O
of	O
diuretics	I
,	O
and	O
age	O
<	O
60	O
years	O
(	O
P=0.016	I
)	O
were	O
associated	O
with	O
time	O
to	O
ESRD	I
.	O

CONCLUSIONS	O
:	O

ESRD	I
is	O
rare	O
in	O
outpatients	I
with	O
systolic	I
HF	I
and	O
is	O
mainly	O
observed	O
in	O
patients	I
with	O
an	O
eGFR	I
<	O
30	O
mL	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
.	O

A	O
low	O
eGFR	I
,	O
age	O
<	O
60	O
years	O
,	O
need	O
of	O
diuretics	I
,	O
and	O
uncontrolled	O
hypertension	I
identify	O
patients	I
with	O
an	O
increased	O
risk	O
for	O
ESRD	I
.	O

Measurement	O
of	O
natriuretic	I
peptides	I
at	O
the	O
point	I
of	I
care	I
in	O
the	O
emergency	O
and	O
ambulatory	I
setting	O
:	O
current	O
status	O
and	O
future	O
perspectives	O
.	O

The	O
measurement	O
of	O
natriuretic	I
peptides	I
(	O
NPs	I
)	O
,	O
B-type	I
NP	I
or	O
N-terminal	I
pro-B-type	I
NP	I
,	O
can	O
be	O
an	O
important	O
tool	O
in	O
the	O
diagnosis	I
of	O
acute	I
heart	I
failure	I
in	O
patients	I
presenting	O
to	O
an	O
Emergency	I
Department	I
(	O
ED	I
)	O
with	O
acute	I
dyspnea	I
,	O
according	O
to	O
international	O
guidelines	O
.	O

Studies	O
and	O
subsequent	O
meta-analyses	I
are	O
mixed	O
on	O
the	O
absolute	O
value	O
of	O
routine	O
NP	I
assessment	O
of	O
ED	I
patients	I
.	O

However	O
,	O
levels	O
of	O
NPs	I
are	O
likely	O
to	O
be	O
used	O
also	O
to	O
guide	O
treatment	O
and	O
to	O
assess	O
risk	O
of	O
adverse	I
outcomes	I
in	O
other	O
patients	I
at	O
risk	O
of	O
developing	O
heart	I
failure	I
,	O
including	O
those	O
with	O
pulmonary	I
embolism	I
or	O
diabetes	I
,	O
or	O
receiving	O
chemotherapy	I
.	O

Natriuretic	I
peptide	I
levels	O
,	O
like	O
other	O
biomarkers	I
,	O
can	O
now	O
be	O
measured	O
at	O
the	O
point	I
of	I
care	I
(	O
POC	I
)	O
.	O

We	O
have	O
reviewed	O
the	O
current	O
status	O
of	O
NP	I
measurement	O
together	O
with	O
the	O
potential	O
contribution	O
of	O
POC	I
measurement	O
of	O
NPs	I
to	O
clinical	I
care	O
delivery	O
in	O
the	O
emergency	O
and	O
other	O
settings	O
.	O

Several	O
POC	I
systems	O
for	O
measuring	O
NP	I
levels	O
are	O
now	O
available	O
:	O
these	O
produce	O
test	O
results	O
within	O
15	O
minutes	O
and	O
appear	O
sufficiently	O
sensitive	O
and	O
robust	O
to	O
be	O
used	O
routinely	O
in	O
diagnostic	I
evaluations	O
.	O

Point-of-care	I
systems	O
could	O
be	O
used	O
to	O
assess	O
NP	I
levels	O
in	O
the	O
ED	I
and	O
community	O
outpatient	I
settings	O
to	O
monitor	O
the	O
risk	O
of	O
acute	I
heart	I
failure	I
.	O

Furthermore	O
,	O
the	O
use	O
of	O
protocol-driven	O
POC	I
testing	O
of	O
NP	I
within	O
the	O
time	O
frame	O
of	O
a	O
patient	I
consultation	I
in	O
the	O
ED	I
may	O
facilitate	O
and	O
accelerate	O
the	O
throughput	O
and	O
disposition	O
of	O
at-risk	O
patients	I
.	O

Appropriately	O
designed	O
clinical	I
trials	O
will	O
be	O
needed	O
to	O
confirm	O
these	O
potential	O
benefits	O
.	O

It	O
is	O
also	O
important	O
that	O
processes	O
of	O
care	O
delivery	O
are	O
redesigned	O
to	O
take	O
full	O
advantage	O
of	O
the	O
faster	O
turnaround	O
times	O
provided	O
by	O
POC	I
technology	O
.	O

Preliminary	O
report	O
of	O
using	O
cardiopulmonary	I
exercise	I
testing	I
guide	O
exercise	I
rehabilitation	I
in	O
patients	I
with	O
chronic	I
heart	I
failure	I

OBJECTIVE	O
:	O

The	O
exercise	I
rehabilitation	I
in	O
patient	I
with	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
is	O
standard	O
clinical	I
practice	O
,	O
but	O
it	O
is	O
rare	O
using	O
CardioPulmonary	I
Exercise	I
Testing	I
(	O
CPET	I
)	O
guide	O
to	O
prescribe	O
exercise	I
rehabilitation	I
in	O
China	O
.	O

METHODS	O
:	O

We	O
performed	O
symptom	I
limited	O
maximal	O
CPET	I
in	O
10	O
patients	I
with	O
CHF	I
,	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
5	O
patients	I
as	O
control	O
without	O
exercise	O
and	O
5	O
exercise	O
patients	I
used	O
Δ50%W	O
intensity	O
to	O
exercise	O
30	O
min	O
/	O
d	O
,	O
5	O
d	O
/	O
w	O
,	O
x12	O
w	O
.	O

Before	O
and	O
after	O
12	O
w	O
rehabilitation	I
,	O
we	O
evaluated	O
functions	O
.	O

RESULTS	O
:	O

There	O
were	O
no	O
significant	I
difference	O
between	O
two	O
groups	O
patients	I
(	O
P	I
>	O
0.05	O
)	O
.	O

The	O
exercise	O
duration	O
was	O
increased	O
from	O
8	O
min	O
to	O
23	O
min	O
after	O
rehabilitation	I
(	O
P	I
<	O
0.001	O
)	O
;	O
distance	O
6	O
minutes	O
walking	O
was	O
increased	O
from	O
394	O
m	O
to	O
470	O
m	O
(	O
P	I
<	O
0.05	O
)	O
;	O
score	O
of	O
Minnesota	O
quality	I
of	I
life	I
was	O
decreased	O
from	O
25	O
to	O
3	O
in	O
exercise	O
group	O
(	O
P	I
<	O
0.01	O
)	O
.	O

However	O
,	O
there	O
were	O
nosignificant	I
changes	O
in	O
control	O
group	O
(	O
P	I
>	O
0.05	O
)	O
and	O
their	O
changes	O
were	O
smaller	O
than	O
those	O
in	O
exercise	O
group	O
(	O
P	I
<	O
0.01	O
)	O
.	O

CONCLUSION	O
:	O

The	O
CPET	I
guiding	O
exercise	I
rehabilitation	I
is	O
safe	O
and	O
effective	O
for	O
patients	I
with	O
CHF	I
.	O

The	O
bottleneck	I
stent	I
model	O
for	O
chronic	I
myocardial	I
ischemia	I
and	O
heart	I
failure	I
in	O
pigs	O
.	O

A	O
large	O
animal	O
model	O
of	O
chronic	I
myocardial	I
ischemia	I
and	O
heart	I
failure	I
is	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	I
approaches	O
.	O

In	O
this	O
study	O
we	O
developed	O
a	O
novel	O
percutaneous	I
one	O
-	O
and	O
two-vessel	O
model	O
for	O
chronic	I
myocardial	I
ischemia	I
using	O
a	O
stent	I
coated	O
with	O
a	O
polytetrafluoroethylene	I
tube	O
formed	O
in	O
a	O
bottleneck	O
shape	O
.	O

The	O
bottleneck	I
stent	I
was	O
implanted	I
in	O
the	O
proximal	O
left	I
anterior	I
descending	I
(	O
LAD	I
)	O
or	O
proximal	O
circumflex	I
artery	I
(	O
LCX	I
)	O
,	O
or	O
in	O
both	O
proximal	O
LCX	I
and	O
mid	O
LAD	I
1	O
wk	O
later	O
(	O
2-vessel	O
model	O
)	O
,	O
and	O
pigs	O
were	O
followed	O
for	O
4	O
-	O
5	O
wk	O
.	O

Ejection	I
fraction	I
(	O
EF	I
)	O
,	O
infarct	I
size	O
,	O
collateral	I
growth	I
,	O
and	O
myocardial	I
perfusion	I
were	O
assessed	O
.	O

Pigs	O
were	O
given	O
antiarrhythmic	I
medication	I
to	O
prevent	O
sudden	O
death	I
.	O

The	O
occlusion	O
time	O
of	O
the	O
bottleneck	I
stent	I
and	O
the	O
timing	O
of	O
myocardial	I
infarction	I
could	O
be	O
modulated	O
by	O
the	O
duration	O
of	O
antiplatelet	I
medication	I
.	O

Fractional	I
flow	I
reserve	I
measurements	O
and	O
positron	I
emission	I
tomography	I
imaging	O
showed	O
severe	O
ischemia	I
after	O
bottleneck	I
stenting	I
covering	O
over	O
50	O
%	O
of	O
the	O
left	I
ventricle	I
in	O
the	O
proximal	O
LAD	I
model	O
.	O

Complete	O
coronary	I
occlusion	I
was	O
necessary	O
for	O
significant	O
collateral	I
growth	I
,	O
which	O
mostly	O
had	O
occurred	O
already	O
during	O
the	O
first	O
wk	O
after	O
the	O
stent	I
occlusion	O
.	O

Dynamic	O
and	O
competitive	O
collateral	I
growth	I
patterns	O
were	O
observed	O
.	O

EF	I
declined	O
from	O
64	O
to	O
41	O
%	O
in	O
the	O
LCX	I
model	O
and	O
to	O
44	O
%	O
in	O
the	O
LAD	I
model	O
4	O
wk	O
after	O
stenting	I
with	O
12	O
and	O
21	O
%	O
infarcted	I
left	I
ventricle	I
in	O
the	O
LCX	I
and	O
LAD	I
models	O
,	O
respectively	O
.	O

The	O
mortality	I
was	O
32	O
and	O
37	O
%	O
in	O
the	O
LCX	I
and	O
LAD	I
models	O
but	O
very	O
(	O
71	O
%	O
)	O
high	O
in	O
the	O
two-vessel	O
disease	I
model	O
.	O

The	O
implantation	I
of	O
a	O
novel	O
bottleneck	I
stent	I
in	O
the	O
proximal	O
LAD	I
or	O
LCX	I
is	O
a	O
novel	O
porcine	O
model	O
of	O
reversible	O
myocardial	I
ischemia	I
(	O
open	O
stent	I
)	O
and	O
ischemic	I
heart	I
failure	I
(	O
occluded	O
stent	I
)	O
and	O
is	O
feasible	O
for	O
the	O
development	O
of	O
new	O
therapeutic	I
approaches	O
.	O

Relation	O
of	O
preoperative	I
serum	I
albumin	I
levels	O
to	O
survival	O
in	O
patients	I
undergoing	O
left	I
ventricular	I
assist	I
device	I
implantation	I
.	O

Hypoalbuminemia	I
has	O
been	O
recognized	O
as	O
a	O
prognostic	I
indicator	O
in	O
patients	I
with	O
heart	I
failure	I
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
of	O
hypoalbuminemia	I
with	O
postoperative	I
mortality	I
in	O
patients	I
undergoing	O
left	I
ventricular	I
assist	I
device	I
(	O
LVAD	I
)	O
implantation	I
.	O

We	O
studied	O
272	O
consecutive	O
patients	I
undergoing	O
LVAD	I
implantation	I
from	O
2000	O
to	O
2010	O
at	O
our	O
institution	O
.	O

Preoperative	I
clinical	I
characteristics	O
and	O
laboratory	O
variables	O
associated	O
with	O
mortality	I
were	O
analyzed	O
.	O

Postoperative	I
survival	O
of	O
patients	I
with	O
preoperative	I
hypoalbuminemia	I
(	O
<	O
3.5	O
g	O
/	O
dl	O
,	O
n	O
=	O
125	O
)	O
and	O
those	O
with	O
normal	O
albumin	I
concentration	O
(	O
≥3.5	O
g	O
/	O
dl	O
,	O
n	O
=	O
147	O
)	O
was	O
compared	O
.	O

Survival	O
after	O
LVAD	I
surgery	I
was	O
better	O
in	O
patients	I
with	O
normal	O
albumin	I
levels	O
compared	O
with	O
those	O
with	O
hypoalbuminemia	I
before	O
surgery	I
(	O
3	O
and	O
12	O
months	O
:	O
93.2	O
%	O
vs	O
82.4	O
%	O
and	O
88.4	O
%	O
vs	O
75.2	O
%	O
,	O
respectively	O
,	O
p	I
<	O
0.001	O
)	O
.	O

Multivariate	I
analysis	I
revealed	O
that	O
preoperative	I
albumin	I
was	O
independently	O
associated	O
with	O
mortality	I
after	O
LVAD	I
implantation	I
(	O
hazard	I
ratio	I
0.521	O
,	O
95	O
%	O
confidence	I
interval	I
0.290	O
to	O
0.934	O
;	O
p	I
=	O
0.029	O
.	O
)	O

Furthermore	O
,	O
the	O
impact	O
of	O
normalization	O
of	O
albumin	I
levels	O
during	O
LVAD	I
support	O
on	O
postoperative	I
survival	O
was	O
analyzed	O
in	O
both	O
groups	O
.	O

Subgroup	O
analysis	O
of	O
patients	I
with	O
preoperative	I
hypoalbuminemia	I
and	O
postoperative	I
normalization	O
of	O
albumin	I
levels	O
(	O
n	O
=	O
81	O
)	O
showed	O
improved	O
survival	O
compared	O
with	O
those	O
who	O
remained	O
hypoalbuminemia	I
(	O
n	O
=	O
44	O
)	O
or	O
those	O
who	O
had	O
decreasing	O
albumin	I
levels	O
during	O
LVAD	I
support	O
(	O
n	O
=	O
40	O
;	O
3-month	O
survival	O
:	O
92.6	O
%	O
vs	O
63.6	O
%	O
and	O
65.0	O
%	O
;	O
p	I
<	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
preoperative	I
hypoalbuminemia	I
is	O
associated	O
with	O
poor	O
prognosis	I
after	O
LVAD	I
surgery	I
.	O

Postoperative	I
normalization	O
of	O
albumin	I
level	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Attention	O
to	O
albumin	I
levels	O
by	O
correcting	O
nutrition	O
,	O
inflammation	I
,	O
and	O
hepatic	I
function	O
could	O
be	O
an	O
effective	O
way	O
to	O
improve	O
prognosis	I
in	O
patients	I
evaluated	O
for	O
LVAD	I
implantation	I
.	O

Autonomic	O
modulation	O
of	O
repolarization	I
instability	O
in	O
patients	I
with	O
heart	I
failure	I
prone	O
to	O
ventricular	I
tachycardia	I
.	O

QT	I
variability	I
(	O
QTV	I
)	O
signifies	O
repolarization	I
lability	O
,	O
and	O
increased	O
QTV	I
is	O
a	O
risk	O
predictor	O
for	O
sudden	O
cardiac	I
death	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
autonomic	I
nervous	I
system	I
activity	O
on	O
QTV	I
.	O

This	O
study	O
was	O
performed	O
in	O
29	O
subjects	O
:	O
10	O
heart	I
failure	I
(	O
HF	I
)	O
patients	I
with	O
spontaneous	I
ventricular	I
tachycardia	I
[	O
HFVT(+)	O
]	O
,	O
10	O
HF	I
patients	I
without	O
spontaneous	I
VT	I
[	O
HFVT(-)	O
]	O
,	O
and	O
9	O
subjects	O
with	O
structurally	O
normal	O
hearts	I
(	O
HNorm	O
)	O
.	O

The	O
beat-to-beat	O
QT	I
interval	I
was	O
measured	O
on	O
3-min	O
records	O
of	O
surface	O
ECGs	I
at	O
baseline	I
and	O
during	O
interventions	O
(	O
atrial	I
pacing	I
and	O
esmolol	I
,	O
isoprenaline	I
,	O
and	O
atropine	I
infusion	I
)	O
.	O

Variability	O
in	O
QT	I
intervals	I
was	O
expressed	O
as	O
the	O
SD	I
of	I
all	I
QT	I
intervals	I
(	O
SDQT	I
)	O
.	O

The	O
ratio	O
of	O
the	O
SDQT	I
to	O
SD	I
of	I
RR	I
intervals	I
(	O
SDRR	I
)	O
was	O
calculated	O
as	O
an	O
index	O
of	O
QTV	I
normalized	O
to	O
heart	I
rate	I
variability	I
.	O

There	O
was	O
a	O
trend	O
toward	O
a	O
higher	O
baseline	I
SDQT-to-SDRR	I
ratio	O
in	O
the	O
HFVT(+)	O
group	O
compared	O
with	O
the	O
HFVT(-)	O
and	O
HNorm	O
groups	O
(	O
P	I
=	O
0.09	O
)	O
.	O

SDQT	I
increased	O
significantly	I
in	O
the	O
HFVT(+)	O
and	O
HFVT(-)	O
groups	O
compared	O
with	O
the	O
HNorm	O
group	O
during	O
fixed-rate	O
atrial	I
pacing	I
(	O
P	I
=	O
0.008	O
)	O
.	O

Compared	O
with	O
baseline	I
,	O
isoprenaline	I
infusion	I
increased	O
SDQT	I
in	O
HNorm	O
subjects	O
(	O
P	I
=	O
0.02	O
)	O
but	O
not	O
in	O
HF	I
patients	I
.	O

SDQT	I
remained	O
elevated	O
in	O
the	O
HFVT(+)	O
group	O
relative	O
to	O
the	O
HNorm	O
group	O
despite	O
acute	I
β-adrenoceptor	I
blockade	I
with	O
esmolol	I
(	O
P	I
=	O
0.02	O
)	O
.	O

In	O
conclusion	O
,	O
patients	I
with	O
HF	I
and	O
spontaneous	I
VT	I
have	O
larger	O
fluctuations	O
in	O
beat-to-beat	O
QT	I
intervals	I
.	O

This	O
appears	O
to	O
be	O
a	O
genuine	O
effect	O
that	O
is	O
not	O
solely	O
a	O
consequence	O
of	O
heart	I
rate	I
variation	O
.	O

The	O
effect	O
of	O
acute	I
autonomic	I
nervous	I
system	I
modulation	O
on	O
QTV	I
appears	O
to	O
be	O
limited	O
in	O
HF	I
patients	I
.	O

Selective	O
heart	I
rate	I
reduction	I
with	O
ivabradine	I
unloads	O
the	O
left	I
ventricle	I
in	O
heart	I
failure	I
patients	I
.	O

OBJECTIVES	O
:	O

The	O
study	O
aimed	O
to	O
determine	O
whether	O
isolated	O
heart	I
rate	I
(	O
HR	I
)	O
reduction	I
with	O
ivabradine	I
reduces	O
afterload	I
of	O
patients	I
with	O
systolic	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

The	O
effective	O
arterial	I
elastance	I
(	O
Ea	I
)	O
represents	O
resistive	I
and	O
pulsatile	I
afterload	I
of	O
the	O
heart	I
derived	O
from	O
the	O
pressure	I
volume	I
relation	I
.	O

HR	I
modulates	O
Ea	I
,	O
and	O
,	O
therefore	O
,	O
afterload	I
burden	O
.	O

METHODS	O
:	O

Among	O
the	O
patients	I
with	O
systolic	I
heart	I
failure	I
(	O
ejection	I
fraction	I
≤35	O
%	O
)	O
randomized	I
to	O
either	O
placebo	I
or	O
ivabradine	I
in	O
the	O
SHIFT	O
(	O
Systolic	I
Heart	I
Failure	I
Treatment	O
With	O
the	O
If	O
Inhibitor	O
Ivabradine	I
Trial	O
)	O
,	O
275	O
patients	I
(	O
n	O
=	O
132	O
,	O
placebo	I
;	O
n	O
=	O
143	O
,	O
ivabradine	I
7.5	O
mg	O
twice	O
a	O
day	O
)	O
were	O
included	O
in	O
the	O
echocardiographic	I
substudy	O
.	O

Ea	I
,	O
total	I
arterial	I
compliance	I
(	O
TAC	I
)	O
,	O
and	O
end-systolic	I
elastance	I
(	O
Ees	I
)	O
were	O
calculated	O
at	O
baseline	I
and	O
after	O
8	O
months	O
of	O
treatment	O
.	O

Blood	I
pressure	I
was	O
measured	O
by	O
arm	I
cuff	I
;	O
stroke	I
volume	I
(	O
SV	I
)	O
,	O
ejection	I
fraction	I
,	O
and	O
end-diastolic	I
volume	I
were	O
assessed	O
by	O
echocardiography	I
.	O

RESULTS	O
:	O

At	O
baseline	I
Ea	I
,	O
TAC	I
,	O
HR	I
,	O
and	O
Ees	I
did	O
not	O
differ	O
significantly	I
between	O
ivabradine	I
-	O
and	O
placebo-treated	I
patients	I
.	O

After	O
8	O
months	O
of	O
treatment	O
,	O
HR	I
was	O
significantly	I
reduced	O
in	O
the	O
ivabradine	I
group	O
(	O
p	I
<	O
0.0001	O
)	O
and	O
was	O
accompanied	O
by	O
marked	O
reduction	O
in	O
Ea	I
(	O
p	I
<	O
0.0001	O
)	O
and	O
improved	O
TAC	I
(	O
p	I
=	O
0.004	O
)	O
compared	O
with	O
placebo	I
.	O

Although	O
contractility	I
remained	O
unchanged	O
,	O
ventricular-arterial	I
coupling	I
was	O
markedly	O
improved	O
(	O
p	I
=	O
0.002	O
)	O
,	O
resulting	O
in	O
a	O
higher	O
SV	I
(	O
p	I
<	O
0.0001	O
)	O
in	O
the	O
ivabradine-treated	I
patients	I
.	O

CONCLUSIONS	O
:	O

Isolated	O
HR	I
reduction	I
by	O
ivabradine	I
improves	O
TAC	I
,	O
thus	O
reducing	O
Ea	I
.	O

Because	O
Ees	I
is	O
unaltered	O
,	O
improved	O
ventricular-arterial	I
coupling	I
is	O
responsible	O
for	O
increased	O
SV	I
.	O

Therefore	O
,	O
unloading	O
of	O
the	O
heart	I
may	O
contribute	O
to	O
the	O
beneficial	O
effect	O
of	O
isolated	O
HR	I
reduction	I
in	O
patients	I
with	O
systolic	I
heart	I
failure	I
.	O

Safety	O
and	O
efficacy	O
of	O
eplerenone	I
in	O
patients	I
at	O
high	O
risk	O
for	O
hyperkalemia	I
and	O
/	O
or	O
worsening	O
renal	I
function	I
:	O
analyses	O
of	O
the	O
EMPHASIS-HF	I
study	O
subgroups	O
(	O
Eplerenone	I
in	O
Mild	O
Patients	I
Hospitalization	I
And	O
SurvIval	O
Study	O
in	O
Heart	I
Failure	I
)	O
.	O

OBJECTIVES	O
:	O

The	O
study	O
sought	O
to	O
investigate	O
the	O
safety	O
and	O
efficacy	O
of	O
eplerenone	I
in	O
patients	I
at	O
high	O
risk	O
for	O
hyperkalemia	I
or	O
worsening	O
renal	I
function	I
(	O
WRF	O
)	O
in	O
EMPHASIS-HF	I
,	O
a	O
trial	O
that	O
enrolled	O
patients	I
at	O
least	O
55	O
years	O
old	O
with	O
heart	I
failure	I
and	I
reduced	I
ejection	I
fraction	I
(	O
HF-REF	I
)	O
,	O
in	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	O
)	O
functional	I
class	I
II	O
and	O
with	O
an	O
estimated	I
glomerular	I
filtration	I
rate	I
(	O
eGFR	I
)	O
>	O
30	O
ml	O
/	O
min	O
/	O
1.73	O
m	O
(	O
2	O
)	O
and	O
serum	I
potassium	I
<	O
5.0	O
mmol	O
/	O
l	O
.	O

Patients	I
were	O
receiving	O
optimal	O
therapy	I
and	O
most	O
had	O
been	O
hospitalized	I
for	O
a	O
cardiovascular	I
reason	O
within	O
180	O
days	O
of	O
inclusion	O
.	O

BACKGROUND	O
:	O

Underuse	O
of	O
eplerenone	I
in	O
patients	I
with	O
HF-REF	I
may	O
be	O
due	O
to	O
fear	O
of	O
inducing	O
hyperkalemia	I
or	O
WRF	O
in	O
high-risk	O
patients	I
.	O

METHODS	O
:	O

This	O
was	O
a	O
pre-specified	O
analysis	O
of	O
subgroups	O
of	O
patients	I
at	O
high	O
risk	O
of	O
hyperkalemia	I
or	O
WRF	O
(	O
patients	I
≥	O
75	O
years	O
of	O
age	O
,	O
with	O
diabetes	I
,	O
with	O
eGFR	I
<	O
60	O
ml	O
/	O
min	O
/	O
1.73	O
m	O
(	O
2	O
)	O
,	O
and	O
with	O
systolic	I
blood	I
pressure	I
<	O
median	O
of	O
123	O
mm	O
Hg	O
)	O
,	O
examining	O
the	O
major	O
safety	O
measures	O
(	O
potassium	I
>	O
5.5	O
,	O
>	O
6.0	O
,	O
and	O
<	O
3.5	O
mmol	O
/	O
l	O
;	O
hyperkalemia	I
leading	O
to	O
study-drug	I
discontinuation	O
or	O
hospitalization	I
;	O
and	O
hospitalization	I
for	O
WRF	O
)	O
as	O
well	O
as	O
the	O
primary	I
outcome	I
(	O
hospitalization	I
for	O
HF	I
or	O
cardiovascular	I
mortality	I
)	O
.	O

RESULTS	O
:	O

In	O
all	O
high-risk	O
subgroups	O
,	O
patients	I
treated	O
with	O
eplerenone	I
had	O
an	O
increased	O
risk	O
of	O
potassium	I
>	O
5.5	O
mmol	O
/	O
l	O
but	O
not	O
of	O
potassium	I
>	O
6.0	O
mmol	O
/	O
l	O
,	O
and	O
of	O
hospitalization	I
for	O
hyperkalemia	I
or	O
discontinuation	O
of	O
study	O
medication	I
due	O
to	O
adverse	I
events	I
.	O

Eplerenone	I
was	O
effective	O
in	O
reducing	O
the	O
primary	I
composite	I
endpoint	I
in	O
all	O
subgroups	O
.	O

CONCLUSIONS	O
:	O

In	O
patients	I
with	O
chronic	I
HF-REF	I
,	O
in	O
NYHA	I
functional	I
class	I
II	I
,	O
and	O
meeting	O
specific	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
including	O
an	O
eGFR	I
>	O
30	O
ml	O
/	O
min	O
/	O
1.73	O
m	O
(	O
2	O
)	O
and	O
potassium	I
<	O
5.0	O
mmol	O
/	O
l	O
,	O
eplerenone	I
was	O
both	O
efficacious	O
and	O
safe	O
when	O
carefully	O
monitored	O
,	O
even	O
in	O
subgroups	O
at	O
high	O
risk	O
of	O
developing	O
hyperkalemia	I
or	O
WRF	O
.	O

(	O
A	O
Comparison	O
Of	O
Outcomes	I
In	O
Patients	I
In	O
New	O
York	O
Heart	I
Association	O
[	O
NYHA	O
]	O
Class	O
II	O
Heart	I
Failure	I
When	O
Treated	O
With	O
Eplerenone	I
Or	O
Placebo	I
In	O
Addition	O
To	O
Standard	O
Heart	I
Failure	I
Medicines	I
[	O
EMPHASIS-HF	I
Study	O
]	O
;	O
NCT00232180	O
)	O
.	O

Key	O
role	O
of	O
ERK1	I
/	I
2	I
molecular	I
scaffolds	I
in	O
heart	I
pathology	I
.	O

The	O
ability	O
of	O
cardiomyocytes	I
to	O
detect	O
mechanical	O
and	O
humoral	O
stimuli	O
is	O
critical	O
for	O
adaptation	O
of	O
the	O
myocardium	I
in	O
response	O
to	O
new	O
conditions	O
and	O
for	O
sustaining	O
the	O
increased	O
workload	O
during	O
stress	O
.	O

While	O
certain	O
stimuli	O
mediate	O
a	O
beneficial	O
adaptation	O
to	O
stress	O
conditions	O
,	O
others	O
result	O
in	O
maladaptive	O
remodelling	I
,	O
ultimately	O
leading	O
to	O
heart	I
failure	I
.	O

Specific	O
signalling	I
pathways	I
activating	O
either	O
adaptive	O
or	O
maladaptive	O
cardiac	I
remodelling	I
have	O
been	O
identified	O
.	O

Paradoxically	O
,	O
however	O
,	O
in	O
a	O
number	O
of	O
cases	O
,	O
the	O
transduction	I
pathways	I
involved	O
in	O
such	O
opposing	O
responses	O
engage	O
the	O
same	O
signalling	I
proteins	I
.	O

A	O
notable	O
example	O
is	O
the	O
Raf-MEK1	I
/	I
2-ERK1	I
/	I
2	I
signalling	I
pathway	I
that	O
can	O
control	O
both	O
adaptive	O
and	O
maladaptive	O
remodelling	I
.	O

ERK1	I
/	I
2	I
signalling	O
requires	O
a	O
signalosome	I
complex	I
where	O
a	O
scaffold	I
protein	I
drives	O
the	O
assembly	O
of	O
these	O
three	O
kinases	I
into	O
a	O
linear	O
pathway	O
to	O
facilitate	O
their	O
sequential	O
phosphorylation	I
,	O
ultimately	O
targeting	O
specific	O
effector	I
molecules	I
.	O

Interestingly	O
,	O
a	O
number	O
of	O
different	O
Raf-MEK1	I
/	I
2-ERK1	I
/	I
2	I
scaffold	I
proteins	I
have	O
been	O
identified	O
,	O
and	O
their	O
role	O
in	O
determining	O
the	O
adaptive	O
or	O
maladaptive	O
cardiac	I
remodelling	I
is	O
a	O
promising	O
field	O
of	O
investigation	O
for	O
the	O
development	O
of	O
therapeutic	I
strategies	O
capable	O
of	O
selectively	O
potentiating	O
the	O
adaptive	O
response	O
.	O

Fat	O
,	O
cachexia	I
,	O
and	O
the	O
right	I
ventricle	I
in	O
heart	I
failure	I
:	O
a	O
web	O
of	O
complicity	O
.	O

In	O
this	O
guideline	O
,	O
the	O
International	O
Right	O
Heart	I
Foundation	O
Working	O
Group	O
moves	O
a	O
step	O
forward	O
to	O
develop	O
a	O
common	O
language	O
to	O
describe	O
the	O
development	O
and	O
defects	O
that	O
exemplify	O
the	O
common	O
syndrome	I
of	O
right	I
heart	I
failure	I
.	O

We	O
first	O
propose	O
fundamental	O
definitions	O
of	O
the	O
distinctive	O
components	O
of	O
the	O
right	I
heart	I
circulation	I
and	O
provide	O
consensus	O
on	O
a	O
universal	O
definition	O
of	O
right	I
heart	I
failure	I
.	O

These	O
definitions	O
will	O
form	O
the	O
foundation	O
for	O
describing	O
a	O
uniform	O
nomenclature	O
for	O
right	I
heart	I
circulatory	I
failure	I
with	O
a	O
view	O
to	O
foster	O
collaborative	O
research	O
initiatives	O
and	O
conjoint	O
education	O
in	O
an	O
effort	O
to	O
provide	O
insight	O
into	O
mechanisms	O
of	O
disease	I
unique	O
to	O
the	O
right	I
heart	I
.	O

Gastrointestinal	I
bleeding	I
in	O
patients	I
with	O
ventricular	I
assist	I
devices	I
:	O
what	O
every	O
cardiac	I
nurse	I
should	O
know	O
.	O

Patients	I
with	O
end-stage	I
heart	I
failure	I
are	O
increasingly	O
being	O
treated	O
with	O
implantation	I
of	O
a	O
long-term	O
ventricular	I
assist	I
device	I
.	O

As	O
the	O
use	O
of	O
these	O
devices	O
has	O
grown	O
,	O
health	I
care	I
providers	O
have	O
been	O
faced	O
with	O
managing	O
clinically	I
significant	O
gastrointestinal	I
bleeding	I
in	O
this	O
population	O
.	O

Gastrointestinal	I
bleeding	I
is	O
not	O
uncommon	O
and	O
is	O
reported	O
to	O
occur	O
in	O
13	O
%	O
to	O
44	O
%	O
of	O
patients	I
treated	O
with	O
ventricular	I
assist	I
devices	I
.	O

Interestingly	O
,	O
because	O
patients	I
with	O
ventricular	I
assist	I
devices	I
are	O
housed	O
on	O
units	O
accustomed	O
to	O
managing	O
the	O
device	O
,	O
cardiac	I
nurses	I
are	O
often	O
asked	O
about	O
the	O
management	O
of	O
gastrointestinal	I
bleeding	I
.	O

This	O
article	O
describes	O
the	O
possible	O
causes	O
of	O
,	O
the	O
array	O
of	O
diagnostic	I
procedures	O
for	O
,	O
and	O
treatments	O
for	O
this	O
complication	I
.	O

It	O
is	O
critical	O
to	O
develop	O
an	O
understanding	O
of	O
this	O
topic	O
so	O
cardiac	I
nurses	I
can	O
partner	O
with	O
other	O
subspecialty	O
groups	O
to	O
manage	O
this	O
population	O
.	O

Heart	I
rate	I
variability	I
in	O
risk	I
stratification	I
of	O
cardiac	I
patients	I
.	O

Heart	I
rate	I
(	O
HR	I
)	O
variability	I
has	O
been	O
extensively	O
studied	O
in	O
cardiac	I
patients	I
,	O
especially	O
in	O
patients	I
surviving	O
an	O
acute	I
myocardial	I
infarction	I
(	O
AMI	I
)	O
and	O
also	O
in	O
patients	I
with	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
or	O
left	I
ventricular	I
(	O
LV	I
)	O
dysfunction	I
.	O

The	O
majority	O
of	O
studies	O
have	O
shown	O
that	O
patients	I
with	O
reduced	O
or	O
abnormal	O
HR	I
variability	I
have	O
an	O
increased	O
risk	O
of	O
mortality	I
within	O
a	O
few	O
years	O
after	O
an	O
AMI	I
or	O
after	O
a	O
diagnosis	I
of	O
CHF	I
/	O
LV	I
dysfunction	I
.	O

Various	O
measures	O
of	O
HR	I
dynamics	O
,	O
such	O
as	O
time-domain	O
,	O
spectral	O
,	O
and	O
non-linear	O
measures	O
of	O
HR	I
variability	I
have	O
been	O
used	O
in	O
risk	I
stratification	I
.	O

The	O
prognostic	I
power	O
of	O
various	O
measures	O
,	O
except	O
of	O
those	O
reflecting	O
rapid	O
R-R	I
interval	I
oscillations	O
,	O
has	O
been	O
almost	O
identical	O
,	O
albeit	O
some	O
non-linear	O
HR	I
variability	I
measures	O
,	O
such	O
as	O
short-term	I
fractal	I
scaling	I
exponent	I
have	O
provided	O
somewhat	O
better	O
prognostic	I
information	O
than	O
the	O
others	O
.	O

Abnormal	O
HR	I
variability	I
predicts	O
both	O
sudden	O
and	O
non-sudden	O
cardiac	I
death	I
.	O

Because	O
of	O
remodeling	I
of	O
the	O
arrhythmia	I
substrate	O
after	O
AMI	I
,	O
early	O
measurement	O
of	O
HR	I
variability	I
to	O
identify	O
those	O
at	O
high	O
risk	O
should	O
likely	O
be	O
repeated	O
later	O
in	O
order	O
to	O
assess	O
the	O
risk	O
of	O
fatal	O
arrhythmia	I
events	O
.	O

Future	O
randomized	I
trials	O
using	O
HR	I
variability	I
/	O
turbulence	O
as	O
one	O
of	O
the	O
pre-defined	O
inclusion	O
criteria	O
will	O
show	O
whether	O
routine	O
measurement	O
of	O
HR	I
variability	I
/	O
turbulence	O
will	O
become	O
a	O
routine	O
clinical	I
tool	O
for	O
risk	I
stratification	I
of	O
cardiac	I
patients	I
.	O

Exercise	O
training	O
in	O
patients	I
with	O
chronic	I
heart	I
failure	I
promotes	O
restoration	O
of	O
high-density	I
lipoprotein	I
functional	O
properties	O
.	O

RATIONALE	O
:	O

High-density	I
lipoprotein	I
(	O
HDL	I
)	O
exerts	O
endothelial-protective	I
effects	O
via	O
stimulation	O
of	O
endothelial	I
cell	I
(	O
EC	I
)	O
nitric	I
oxide	I
(	O
NO	I
)	O
production	O
.	O

This	O
function	O
is	O
impaired	O
in	O
patients	I
with	O
cardiovascular	I
disease	I
.	O

Protective	O
effects	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
on	O
endothelial	I
function	I
have	O
been	O
demonstrated	O
.	O

OBJECTIVE	O
:	O

This	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
impact	O
of	O
ET	O
on	O
HDL-mediated	I
protective	O
effects	O
and	O
the	O
respective	O
molecular	I
pathways	I
in	O
patients	I
with	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

HDL	I
was	O
isolated	O
from	O
16	O
healthy	I
controls	O
(	O
HDL	I
(	O
healthy	I
)	O
)	O
and	O
16	O
patients	I
with	O
CHF-NYHA-III	I
(	O
HDL	I
(	O
NYHA-IIIb	I
)	O
)	O
before	O
and	O
after	O
ET	O
,	O
as	O
well	O
as	O
from	O
8	O
patients	I
with	O
CHF-NYHA-II	I
(	O
HDL	I
(	O
NYHA-II	I
)	O
)	O
.	O

ECs	I
were	O
incubated	O
with	O
HDL	I
,	O
and	O
phosphorylation	I
of	O
eNOS-Ser	I
(	I
1177	I
)	I
,	O
eNOS-Thr	I
(	I
495	I
)	I
,	O
PKC-βII-Ser	I
(	I
660	I
)	I
,	O
and	O
p70S6K-Ser	I
(	I
411	I
)	I
was	O
evaluated	O
.	O

HDL-bound	I
malondialdehyde	I
and	O
HDL-induced	I
NO	I
production	O
by	O
EC	I
were	O
quantified	O
.	O

Endothelial	I
function	I
was	O
assessed	O
by	O
flow-mediated	I
dilatation	I
.	O

The	O
proteome	I
of	O
HDL	I
particles	O
was	O
profiled	O
by	O
shotgun	I
LC-MS	I
/	I
MS	I
.	O

Incubation	O
of	O
EC	I
with	O
HDL	I
(	O
NYHA-IIIb	I
)	O
triggered	O
a	O
lower	O
stimulation	O
of	O
phosphorylation	I
at	O
eNOS-Ser	I
(	I
1177	I
)	I
and	O
a	O
higher	O
phosphorylation	I
at	O
eNOS-Thr	I
(	I
495	I
)	I
when	O
compared	O
with	O
HDL	I
(	O
healthy	I
)	O
.	O

This	O
was	O
associated	O
with	O
lower	O
NO	I
production	O
of	O
EC	I
.	O

In	O
addition	O
,	O
an	O
elevated	O
activation	O
of	O
p70S6K	I
,	O
PKC-βII	I
by	O
HDL	I
(	O
NYHA-IIIb	I
)	O
,	O
and	O
a	O
higher	O
amount	O
of	O
malondialdehyde	I
bound	O
to	O
HDL	I
(	O
NYHA-IIIb	I
)	O
compared	O
with	O
HDL	I
(	O
healthy	I
)	O
was	O
measured	O
.	O

In	O
healthy	I
individuals	O
,	O
ET	O
had	O
no	O
effect	O
on	O
HDL	I
function	O
,	O
whereas	O
ET	O
of	O
CHF-NYHA-IIIb	I
significantly	I
improved	O
HDL	I
function	O
.	O

A	O
correlation	I
between	O
changes	O
in	O
HDL-induced	I
NO	I
production	O
and	O
flow-mediated	I
dilatation	I
improvement	O
by	O
ET	O
was	O
evident	O
.	O

CONCLUSIONS	O
:	O

These	O
results	O
demonstrate	O
that	O
HDL	I
function	O
is	O
impaired	O
in	O
CHF	I
and	O
that	O
ET	O
improved	O
the	O
HDL-mediated	I
vascular	I
effects	O
.	O

This	O
may	O
be	O
one	O
mechanism	O
how	O
ET	O
exerts	O
beneficial	O
effects	O
in	O
CHF	I
.	O

Cardiac	I
overexpression	I
of	O
Mammalian	I
enabled	I
(	O
Mena	I
)	O
exacerbates	O
heart	I
failure	I
in	O
mice	O
.	O

Mammalian	I
enabled	I
(	O
Mena	I
)	O
is	O
a	O
key	O
regulator	O
of	O
cytoskeletal	I
actin	I
dynamics	I
,	O
which	O
has	O
been	O
implicated	O
in	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
cardiac	I
Mena	I
deletion	I
produced	O
cardiac	I
dysfunction	I
with	O
conduction	O
abnormalities	O
and	O
hypertrophy	I
.	O

Moreover	O
,	O
elevated	O
Mena	I
expression	I
correlates	I
with	O
HF	I
in	O
human	O
and	O
animal	O
models	O
,	O
yet	O
the	O
precise	O
role	O
of	O
Mena	I
in	O
cardiac	I
pathophysiology	I
is	O
unclear	O
.	O

In	O
these	O
studies	O
,	O
we	O
evaluated	O
mice	O
with	O
cardiac	I
myocyte-specific	I
Mena	I
overexpression	I
(	O
TTA	I
/	I
TgTetMena	I
)	O
comparable	O
to	O
that	O
observed	O
in	O
cardiac	I
pathology	I
.	O

We	O
found	O
that	O
the	O
hearts	I
of	O
TTA	I
/	I
TgTetMena	I
mice	O
were	O
functionally	O
and	O
morphologically	O
comparable	O
to	O
wild-type	O
littermates	O
,	O
except	O
for	O
mildly	O
increased	O
heart	I
mass	I
in	O
the	O
transgenic	I
mice	O
.	O

Interestingly	O
,	O
TTA	I
/	I
TgTetMena	I
mice	O
were	O
particularly	O
susceptible	O
to	O
cardiac	I
injury	I
,	O
as	O
these	O
animals	O
experienced	O
pronounced	O
decreases	O
in	O
ejection	I
fraction	I
and	O
fractional	I
shortening	I
as	O
well	O
as	O
heart	I
dilatation	I
and	O
hypertrophy	I
after	O
transverse	I
aortic	I
constriction	I
(	O
TAC	I
)	O
.	O

By	O
turning	O
off	O
Mena	I
overexpression	I
in	O
TTA	I
/	I
TgTetMena	I
mice	O
either	O
immediately	O
prior	O
to	O
or	O
immediately	O
after	O
TAC	I
surgery	I
,	O
we	O
discovered	O
that	O
normalizing	O
Mena	I
levels	O
eliminated	O
cardiac	I
hypertrophy	I
in	O
TTA	I
/	I
TgTetMena	I
animals	O
but	O
did	O
not	O
preclude	O
post-TAC	I
cardiac	I
functional	O
deterioration	O
.	O

These	O
findings	O
indicate	O
that	O
hearts	I
with	O
increased	O
levels	O
of	O
Mena	I
fare	O
worse	O
when	O
subjected	O
to	O
cardiac	I
injury	I
and	O
suggest	O
that	O
Mena	I
contributes	O
to	O
HF	I
pathophysiology	I
.	O

Improving	O
survival	O
rates	O
of	O
patients	I
with	O
idiopathic	I
dilated	I
cardiomyopathy	I
in	O
Tuscany	O
over	O
3	O
decades	O
:	O
impact	O
of	O
evidence-based	I
management	O
.	O

BACKGROUND	O
:	O

Contemporary	O
therapeutic	I
options	O
have	O
led	O
to	O
substantial	O
improvement	O
in	O
survival	O
of	O
patients	I
with	O
heart	I
failure	I
.	O

However	O
,	O
limited	O
evidence	O
is	O
available	O
specifically	O
on	O
idiopathic	I
dilated	I
cardiomyopathy	I
.	O

We	O
thus	O
examined	O
changes	O
in	O
prognosis	I
of	O
a	O
large	O
idiopathic	I
dilated	I
cardiomyopathy	I
cohort	O
systematically	O
followed	O
during	O
the	O
past	O
30	O
years	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

From	O
1977	O
to	O
2011	O
,	O
603	O
consecutive	O
patients	I
(	O
age	O
,	O
53±12	O
years	O
;	O
73	O
%	O
men	O
;	O
left	I
ventricular	I
ejection	I
fraction	I
,	O
32±10	O
%	O
)	O
fulfilling	O
World	O
Health	I
Organization	O
criteria	O
for	O
idiopathic	I
dilated	I
cardiomyopathy	I
,	O
including	O
negative	O
coronary	I
angiography	I
,	O
were	O
followed	I
up	I
for	O
8.8±6.3	O
years	O
.	O

Patients	I
were	O
subdivided	O
in	O
4	O
enrollment	O
periods	O
on	O
the	O
basis	O
of	O
heart	I
failure	I
treatment	O
eras	O
:	O
(	O
1	O
)	O
1977	O
-	O
1984	O
(	O
n=66	O
)	O
;	O
(	O
2	O
)	O
1985	O
-	O
1990	O
(	O
n=102	O
)	O
;	O
(	O
3	O
)	O
1991	O
-	O
2000	O
(	O
n=197	O
)	O
;	O
(	O
4	O
)	O
2001	O
-	O
2011	O
(	O
n=238	O
)	O
.	O

Rates	O
of	O
patients	I
receiving	O
angiotensin-converting	I
enzyme	I
inhibitors	I
/	O
angiotensin	I
receptors	I
blockers	I
,	O
β-blockers	I
,	O
and	O
devices	O
at	O
final	O
evaluation	O
increased	O
from	O
56	O
%	O
,	O
12	O
%	O
,	O
8	O
%	O
(	O
period	O
1	O
)	O
to	O
97	O
%	O
,	O
86	O
%	O
,	O
17	O
%	O
(	O
period	O
4	O
)	O
,	O
respectively	O
(	O
P	I
<	O
0.05	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
enrollment	O
of	O
older	O
patients	I
with	O
less	O
severe	O
left	I
ventricular	I
dilatation	I
and	O
dysfunction	I
during	O
the	O
years	O
.	O

During	O
follow-up	I
,	O
271	O
patients	I
(	O
45	O
%	O
)	O
reached	O
a	O
combined	I
end	I
point	I
including	O
death	I
(	O
heart	I
failure	I
related	O
,	O
n=142	O
;	O
sudden	O
death	I
,	O
n=71	O
;	O
and	O
noncardiac	O
,	O
n=22	O
)	O
or	O
cardiac	I
transplant	I
(	O
n=36	O
)	O
.	O

A	O
more	O
recent	O
enrollment	O
period	O
represented	O
the	O
most	O
powerful	O
independent	O
predictor	O
of	O
favorable	O
outcome	I
{	O
period	O
2	O
versus	O
1	O
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
,	O
0.64	O
;	O
P=0.04	I
)	O
,	O
period	O
3	O
versus	O
1	O
(	O
HR	I
,	O
0.35	O
;	O
P	I
<	O
0.001	O
)	O
,	O
period	O
4	O
versus	O
1	O
(	O
HR	I
,	O
0.14	O
;	O
P	I
<	O
001	O
)	O
}	O
.	O

Each	O
period	O
was	O
associated	O
with	O
a	O
42	O
%	O
risk	O
reduction	O
versus	O
the	O
previous	O
one	O
(	O
HR	I
,	O
0.58	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.50	O
-	O
0.67	O
;	O
P	I
<	O
0.001	O
)	O
,	O
reflecting	O
marked	O
decreases	O
in	O
heart	I
failure-related	I
mortality	I
and	O
sudden	O
death	I
(	O
period	O
4	O
versus	O
1	O
:	O
HR	I
,	O
0.10	O
;	O
P	I
<	O
001	O
and	O
HR	I
,	O
0.13	O
;	O
P	I
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O

Evidence-based	I
treatment	O
has	O
led	O
to	O
dramatic	O
improvement	O
in	O
the	O
prognosis	I
of	O
idiopathic	I
dilated	I
cardiomyopathy	I
during	O
the	O
past	O
3	O
decades	O
.	O

The	O
benefits	O
of	O
controlled	O
randomized	I
trials	O
can	O
be	O
replicated	O
in	O
the	O
real	O
world	O
,	O
emphasizing	O
the	O
importance	O
of	O
tailored	O
follow-up	I
and	O
long-term	O
continuity	O
of	O
care	O
.	O

Usefulness	O
and	O
consequences	O
of	O
cardiac	I
resynchronization	I
therapy	I
in	O
dialysis-dependent	I
patients	I
with	O
heart	I
failure	I
.	O

Cardiac	I
resynchronization	I
therapy	I
(	O
CRT	I
)	O
is	O
often	O
deferred	O
in	O
dialysis-dependent	I
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
because	O
of	O
a	O
perceived	O
lack	O
of	O
benefit	O
and	O
potentially	O
higher	O
risks	O
,	O
although	O
the	O
outcomes	I
associated	O
with	O
CRT	I
in	O
dialysis	I
have	O
not	O
been	O
reported	O
.	O

We	O
therefore	O
studied	O
our	O
center	O
's	O
experience	O
with	O
CRT	I
in	O
dialysis-dependent	I
patients	I
.	O

We	O
constructed	O
a	O
descriptive	O
assessment	O
of	O
these	O
patients	I
(	O
n	O
=	O
15	O
)	O
and	O
performed	O
a	O
case-control	O
analysis	O
matching	O
for	O
age	O
,	O
gender	O
,	O
bundle	I
branch	I
morphology	I
,	O
diabetes	I
mellitus	I
,	O
cardiomyopathy	I
origin	O
,	O
and	O
β-blocker	I
and	O
angiotensin-converting	I
enzyme	I
inhibitor	I
or	O
angiotensin	I
II	I
receptor	I
blocker	I
use	O
.	O

Baseline	I
and	O
6-month	O
echocardiograms	I
were	O
assessed	O
for	O
evidence	O
of	O
reverse	I
remodeling	I
.	O

No	O
periprocedural	O
or	O
long-term	O
complications	I
were	O
observed	O
among	O
dialysis	I
patients	I
.	O

Heterogenous	O
improvement	O
in	O
ejection	I
fraction	I
(	O
+	O
3.1	O
±	O
9.2	O
%	O
)	O
was	O
noted	O
and	O
2	O
patients	I
derived	O
absolute	O
improvements	O
of	O
8	O
%	O
and	O
22	O
%	O
,	O
respectively	O
.	O

Dialysis	I
patients	I
demonstrated	O
the	O
following	O
3-year	O
event	O
rates	O
:	O
HF	I
hospitalization	I
,	O
31	O
%	O
;	O
all-cause	I
hospitalization	I
,	O
100	O
%	O
;	O
mortality	I
,	O
73	O
%	O
;	O
and	O
HF	I
hospitalization	I
or	O
death	I
,	O
82	O
%	O
.	O

In	O
the	O
case-control	O
analysis	O
,	O
controls	O
demonstrated	O
superior	O
reverse	I
remodeling	I
(	O
+	O
9.2	O
±	O
9.5	O
%	O
increase	O
in	O
ejection	I
fraction	I
)	O
,	O
decreased	O
mortality	I
(	O
73	O
%	O
vs	O
44	O
%	O
,	O
p	I
=	O
0.038	O
)	O
,	O
and	O
all-cause	I
hospitalizations	I
(	O
76	O
%	O
vs	O
100	O
%	O
,	O
p	I
=	O
0.047	O
)	O
,	O
with	O
no	O
difference	O
in	O
HF	I
hospitalizations	I
(	O
p	I
=	O
0.39	O
)	O
,	O
compared	O
with	O
dialysis	I
patients	I
.	O

In	O
conclusion	O
,	O
at	O
our	O
center	O
,	O
the	O
dialysis-dependent	I
patients	I
with	O
HF	I
who	O
underwent	O
CRT	I
implantation	I
did	O
so	O
safely	O
and	O
no	O
serious	O
complications	I
were	O
observed	O
.	O

Certain	O
dialysis	I
patients	I
demonstrated	O
compelling	O
improvement	O
after	O
device	O
implantation	I
.	O

Compared	O
with	O
matched	O
controls	O
,	O
dialysis	I
patients	I
were	O
at	O
increased	O
risk	O
for	O
adverse	I
events	I
and	O
worsened	O
echocardiographic	I
outcomes	I
.	O

